US20070185311A1 - Peptide-Based Multimeric Targeted Contrast Agents - Google Patents
Peptide-Based Multimeric Targeted Contrast Agents Download PDFInfo
- Publication number
- US20070185311A1 US20070185311A1 US11/564,648 US56464806A US2007185311A1 US 20070185311 A1 US20070185311 A1 US 20070185311A1 US 56464806 A US56464806 A US 56464806A US 2007185311 A1 US2007185311 A1 US 2007185311A1
- Authority
- US
- United States
- Prior art keywords
- peptide
- group
- moiety
- linker
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000002872 contrast media Substances 0.000 title abstract description 88
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 189
- 150000001875 compounds Chemical class 0.000 claims description 70
- 108010073385 Fibrin Proteins 0.000 claims description 55
- 102000009123 Fibrin Human genes 0.000 claims description 55
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 claims description 54
- 229950003499 fibrin Drugs 0.000 claims description 54
- 150000001413 amino acids Chemical class 0.000 claims description 38
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 18
- 229960000103 thrombolytic agent Drugs 0.000 claims description 16
- 239000003527 fibrinolytic agent Substances 0.000 claims description 14
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims description 13
- 230000009870 specific binding Effects 0.000 claims description 10
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 claims description 9
- 102000003990 Urokinase-type plasminogen activator Human genes 0.000 claims description 9
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims description 9
- COLNVLDHVKWLRT-QMMMGPOBSA-N phenylalanine group Chemical group N[C@@H](CC1=CC=CC=C1)C(=O)O COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims description 9
- 229960005356 urokinase Drugs 0.000 claims description 9
- 108010023197 Streptokinase Proteins 0.000 claims description 3
- 239000012190 activator Substances 0.000 claims description 3
- 229960005202 streptokinase Drugs 0.000 claims description 3
- 108010058207 Anistreplase Proteins 0.000 claims description 2
- 241000288900 Desmodus rotundus Species 0.000 claims description 2
- 101710145796 Staphylokinase Proteins 0.000 claims description 2
- 102000003978 Tissue Plasminogen Activator Human genes 0.000 claims description 2
- 108090000373 Tissue Plasminogen Activator Proteins 0.000 claims description 2
- 229960000983 anistreplase Drugs 0.000 claims description 2
- 108010073863 saruplase Proteins 0.000 claims description 2
- 238000000034 method Methods 0.000 abstract description 54
- 102000004196 processed proteins & peptides Human genes 0.000 abstract description 53
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 108
- 239000002243 precursor Substances 0.000 description 105
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 84
- 125000005647 linker group Chemical group 0.000 description 82
- 239000012216 imaging agent Substances 0.000 description 77
- 150000007942 carboxylates Chemical class 0.000 description 73
- 239000013522 chelant Substances 0.000 description 71
- 239000000203 mixture Substances 0.000 description 64
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 62
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 61
- 239000011347 resin Substances 0.000 description 54
- 229920005989 resin Polymers 0.000 description 54
- 229910001868 water Inorganic materials 0.000 description 52
- 239000000243 solution Substances 0.000 description 50
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 42
- 108091005601 modified peptides Proteins 0.000 description 42
- 125000003277 amino group Chemical group 0.000 description 41
- 230000027455 binding Effects 0.000 description 41
- 229910021645 metal ion Inorganic materials 0.000 description 41
- 230000015572 biosynthetic process Effects 0.000 description 40
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 37
- 235000001014 amino acid Nutrition 0.000 description 37
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 36
- 230000005298 paramagnetic effect Effects 0.000 description 36
- 239000000126 substance Substances 0.000 description 34
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 33
- 238000003786 synthesis reaction Methods 0.000 description 33
- 230000008685 targeting Effects 0.000 description 33
- -1 2-Thioxothiazolidin-1yl Chemical group 0.000 description 32
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 31
- 235000019439 ethyl acetate Nutrition 0.000 description 30
- 230000002829 reductive effect Effects 0.000 description 30
- 0 Cc(cc1C(O)=O)ccc1C(c(ccc(*)c1)c1O1)=C(C=C2)C1=CC2=O Chemical compound Cc(cc1C(O)=O)ccc1C(c(ccc(*)c1)c1O1)=C(C=C2)C1=CC2=O 0.000 description 29
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 29
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 28
- 210000004899 c-terminal region Anatomy 0.000 description 27
- 229910052739 hydrogen Inorganic materials 0.000 description 27
- 238000003384 imaging method Methods 0.000 description 27
- 150000002148 esters Chemical class 0.000 description 25
- 239000003921 oil Substances 0.000 description 25
- 208000007536 Thrombosis Diseases 0.000 description 24
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 24
- 125000001931 aliphatic group Chemical group 0.000 description 23
- 125000000217 alkyl group Chemical group 0.000 description 23
- 125000006239 protecting group Chemical group 0.000 description 23
- VNWKTOKETHGBQD-UHFFFAOYSA-N C Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 22
- 210000004369 blood Anatomy 0.000 description 21
- 239000008280 blood Substances 0.000 description 21
- 230000003287 optical effect Effects 0.000 description 21
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 20
- 238000006243 chemical reaction Methods 0.000 description 20
- 239000001257 hydrogen Substances 0.000 description 20
- 239000003446 ligand Substances 0.000 description 20
- 238000002595 magnetic resonance imaging Methods 0.000 description 20
- 239000002904 solvent Substances 0.000 description 20
- 229910052731 fluorine Inorganic materials 0.000 description 19
- 125000003118 aryl group Chemical group 0.000 description 18
- 239000007787 solid Substances 0.000 description 18
- 239000003795 chemical substances by application Substances 0.000 description 16
- 239000000975 dye Substances 0.000 description 16
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 15
- 229910052740 iodine Inorganic materials 0.000 description 15
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical group [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 14
- 125000003342 alkenyl group Chemical group 0.000 description 14
- 230000000536 complexating effect Effects 0.000 description 14
- 150000004820 halides Chemical class 0.000 description 14
- 229910052751 metal Inorganic materials 0.000 description 14
- 239000002184 metal Substances 0.000 description 14
- 239000012044 organic layer Substances 0.000 description 14
- 239000011541 reaction mixture Substances 0.000 description 14
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 14
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 14
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 13
- 239000002616 MRI contrast agent Substances 0.000 description 13
- 150000008064 anhydrides Chemical class 0.000 description 13
- 229910052794 bromium Inorganic materials 0.000 description 13
- 229910052801 chlorine Inorganic materials 0.000 description 13
- 230000002537 thrombolytic effect Effects 0.000 description 13
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical group CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 12
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 12
- 102000008100 Human Serum Albumin Human genes 0.000 description 12
- 108091006905 Human Serum Albumin Proteins 0.000 description 12
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 12
- 125000004432 carbon atom Chemical group C* 0.000 description 12
- 229910052757 nitrogen Inorganic materials 0.000 description 12
- 102000004169 proteins and genes Human genes 0.000 description 12
- 108090000623 proteins and genes Proteins 0.000 description 12
- DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Substances OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 12
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 11
- QPCDCPDFJACHGM-UHFFFAOYSA-N N,N-bis{2-[bis(carboxymethyl)amino]ethyl}glycine Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(=O)O)CCN(CC(O)=O)CC(O)=O QPCDCPDFJACHGM-UHFFFAOYSA-N 0.000 description 11
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 11
- 125000000304 alkynyl group Chemical group 0.000 description 11
- 150000001412 amines Chemical class 0.000 description 11
- 239000000047 product Substances 0.000 description 11
- 210000001519 tissue Anatomy 0.000 description 11
- 238000005160 1H NMR spectroscopy Methods 0.000 description 10
- PLSKJURUWGHSLI-CFDBANIYSA-N CCC(C)[C@H](NC(=O)[C@H](CC1=CNC=N1)NC(=O)[C@@H]1CSSC[C@H](C)C(=O)N2CC(O)C[C@H]2C(=O)N[C@@H](CC2=CC=C(O)C(I)=C2)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC(C)C)C(=O)N1)C(=O)N[C@@H](CC(C)C)C(N)=O Chemical compound CCC(C)[C@H](NC(=O)[C@H](CC1=CNC=N1)NC(=O)[C@@H]1CSSC[C@H](C)C(=O)N2CC(O)C[C@H]2C(=O)N[C@@H](CC2=CC=C(O)C(I)=C2)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC(C)C)C(=O)N1)C(=O)N[C@@H](CC(C)C)C(N)=O PLSKJURUWGHSLI-CFDBANIYSA-N 0.000 description 10
- 229910052688 Gadolinium Inorganic materials 0.000 description 10
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 10
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 10
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 10
- 150000002500 ions Chemical class 0.000 description 10
- 239000010410 layer Substances 0.000 description 10
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 10
- 235000018102 proteins Nutrition 0.000 description 10
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 9
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 9
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 9
- 125000000753 cycloalkyl group Chemical group 0.000 description 9
- 239000000706 filtrate Substances 0.000 description 9
- 239000012634 fragment Substances 0.000 description 9
- 125000000524 functional group Chemical group 0.000 description 9
- UIWYJDYFSGRHKR-UHFFFAOYSA-N gadolinium atom Chemical compound [Gd] UIWYJDYFSGRHKR-UHFFFAOYSA-N 0.000 description 9
- 238000001802 infusion Methods 0.000 description 9
- JCXJVPUVTGWSNB-UHFFFAOYSA-N nitrogen dioxide Inorganic materials O=[N]=O JCXJVPUVTGWSNB-UHFFFAOYSA-N 0.000 description 9
- 239000011780 sodium chloride Substances 0.000 description 9
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 9
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 8
- 102000004190 Enzymes Human genes 0.000 description 8
- 108090000790 Enzymes Proteins 0.000 description 8
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 8
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 8
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 8
- 239000003153 chemical reaction reagent Substances 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 229940088598 enzyme Drugs 0.000 description 8
- 239000000463 material Substances 0.000 description 8
- 125000001424 substituent group Chemical group 0.000 description 8
- 229910052717 sulfur Inorganic materials 0.000 description 8
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 8
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical group CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 7
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 7
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 7
- 125000003668 acetyloxy group Chemical group [H]C([H])([H])C(=O)O[*] 0.000 description 7
- 239000003146 anticoagulant agent Substances 0.000 description 7
- 239000008367 deionised water Substances 0.000 description 7
- 229910021641 deionized water Inorganic materials 0.000 description 7
- 150000004985 diamines Chemical class 0.000 description 7
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 7
- 229960002591 hydroxyproline Drugs 0.000 description 7
- 238000002347 injection Methods 0.000 description 7
- 239000007924 injection Substances 0.000 description 7
- 210000004731 jugular vein Anatomy 0.000 description 7
- 238000004519 manufacturing process Methods 0.000 description 7
- 150000003839 salts Chemical class 0.000 description 7
- 238000010898 silica gel chromatography Methods 0.000 description 7
- 239000011734 sodium Substances 0.000 description 7
- 238000010532 solid phase synthesis reaction Methods 0.000 description 7
- 230000001131 transforming effect Effects 0.000 description 7
- SNDPXSYFESPGGJ-UHFFFAOYSA-N L-norVal-OH Natural products CCCC(N)C(O)=O SNDPXSYFESPGGJ-UHFFFAOYSA-N 0.000 description 6
- LRQKBLKVPFOOQJ-YFKPBYRVSA-N L-norleucine Chemical compound CCCC[C@H]([NH3+])C([O-])=O LRQKBLKVPFOOQJ-YFKPBYRVSA-N 0.000 description 6
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical class [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 6
- 239000012043 crude product Substances 0.000 description 6
- 238000003818 flash chromatography Methods 0.000 description 6
- 239000006260 foam Substances 0.000 description 6
- 238000001727 in vivo Methods 0.000 description 6
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 6
- 239000008194 pharmaceutical composition Substances 0.000 description 6
- 239000000523 sample Substances 0.000 description 6
- 229920006395 saturated elastomer Polymers 0.000 description 6
- 229910052938 sodium sulfate Inorganic materials 0.000 description 6
- 235000011152 sodium sulphate Nutrition 0.000 description 6
- 239000006228 supernatant Substances 0.000 description 6
- AQRLNPVMDITEJU-UHFFFAOYSA-N triethylsilane Chemical compound CC[SiH](CC)CC AQRLNPVMDITEJU-UHFFFAOYSA-N 0.000 description 6
- 229910052727 yttrium Inorganic materials 0.000 description 6
- XBNGYFFABRKICK-UHFFFAOYSA-N 2,3,4,5,6-pentafluorophenol Chemical compound OC1=C(F)C(F)=C(F)C(F)=C1F XBNGYFFABRKICK-UHFFFAOYSA-N 0.000 description 5
- SLXKOJJOQWFEFD-UHFFFAOYSA-N 6-aminohexanoic acid Chemical compound NCCCCCC(O)=O SLXKOJJOQWFEFD-UHFFFAOYSA-N 0.000 description 5
- BQXUPNKLZNSUMC-YUQWMIPFSA-N CCN(CCCCCOCC(=O)N[C@H](C(=O)N1C[C@H](O)C[C@H]1C(=O)N[C@@H](C)c1ccc(cc1)-c1scnc1C)C(C)(C)C)CCOc1ccc(cc1)C(=O)c1c(sc2cc(O)ccc12)-c1ccc(O)cc1 Chemical compound CCN(CCCCCOCC(=O)N[C@H](C(=O)N1C[C@H](O)C[C@H]1C(=O)N[C@@H](C)c1ccc(cc1)-c1scnc1C)C(C)(C)C)CCOc1ccc(cc1)C(=O)c1c(sc2cc(O)ccc12)-c1ccc(O)cc1 BQXUPNKLZNSUMC-YUQWMIPFSA-N 0.000 description 5
- 102000001938 Plasminogen Activators Human genes 0.000 description 5
- 239000004793 Polystyrene Substances 0.000 description 5
- 229920001222 biopolymer Polymers 0.000 description 5
- 239000003054 catalyst Substances 0.000 description 5
- 238000003776 cleavage reaction Methods 0.000 description 5
- 125000000392 cycloalkenyl group Chemical group 0.000 description 5
- 239000000284 extract Substances 0.000 description 5
- 150000002430 hydrocarbons Chemical group 0.000 description 5
- 210000004185 liver Anatomy 0.000 description 5
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 5
- 238000012634 optical imaging Methods 0.000 description 5
- 238000007254 oxidation reaction Methods 0.000 description 5
- IZUPBVBPLAPZRR-UHFFFAOYSA-N pentachloro-phenol Natural products OC1=C(Cl)C(Cl)=C(Cl)C(Cl)=C1Cl IZUPBVBPLAPZRR-UHFFFAOYSA-N 0.000 description 5
- 229940127126 plasminogen activator Drugs 0.000 description 5
- 239000002244 precipitate Substances 0.000 description 5
- 229940080818 propionamide Drugs 0.000 description 5
- 230000007017 scission Effects 0.000 description 5
- 239000002002 slurry Substances 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 238000002560 therapeutic procedure Methods 0.000 description 5
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 5
- 229910052721 tungsten Inorganic materials 0.000 description 5
- HHLZCENAOIROSL-UHFFFAOYSA-N 2-[4,7-bis(carboxymethyl)-1,4,7,10-tetrazacyclododec-1-yl]acetic acid Chemical compound OC(=O)CN1CCNCCN(CC(O)=O)CCN(CC(O)=O)CC1 HHLZCENAOIROSL-UHFFFAOYSA-N 0.000 description 4
- YQOUWOJPPGRPPW-UHFFFAOYSA-N 2-bis(4-methylphenyl)phosphanylethyl-bis(4-methylphenyl)phosphane Chemical compound C1=CC(C)=CC=C1P(C=1C=CC(C)=CC=1)CCP(C=1C=CC(C)=CC=1)C1=CC=C(C)C=C1 YQOUWOJPPGRPPW-UHFFFAOYSA-N 0.000 description 4
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 4
- PECYZEOJVXMISF-UHFFFAOYSA-N 3-aminoalanine Chemical compound [NH3+]CC(N)C([O-])=O PECYZEOJVXMISF-UHFFFAOYSA-N 0.000 description 4
- 108010049003 Fibrinogen Proteins 0.000 description 4
- 102000008946 Fibrinogen Human genes 0.000 description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- NYHBQMYGNKIUIF-UUOKFMHZSA-N Guanosine Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NYHBQMYGNKIUIF-UUOKFMHZSA-N 0.000 description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 4
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 4
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 4
- 125000000729 N-terminal amino-acid group Chemical group 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 4
- 108010001014 Plasminogen Activators Proteins 0.000 description 4
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical class [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 4
- WDLRUFUQRNWCPK-UHFFFAOYSA-N Tetraxetan Chemical compound OC(=O)CN1CCN(CC(O)=O)CCN(CC(O)=O)CCN(CC(O)=O)CC1 WDLRUFUQRNWCPK-UHFFFAOYSA-N 0.000 description 4
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 4
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 4
- RDOXTESZEPMUJZ-UHFFFAOYSA-N anisole Chemical compound COC1=CC=CC=C1 RDOXTESZEPMUJZ-UHFFFAOYSA-N 0.000 description 4
- 210000001367 artery Anatomy 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 4
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 4
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 4
- 229940125904 compound 1 Drugs 0.000 description 4
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 4
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 4
- 229940012952 fibrinogen Drugs 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- 125000005842 heteroatom Chemical group 0.000 description 4
- 238000004128 high performance liquid chromatography Methods 0.000 description 4
- 238000001990 intravenous administration Methods 0.000 description 4
- 229920002223 polystyrene Polymers 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 238000002953 preparative HPLC Methods 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- 238000004007 reversed phase HPLC Methods 0.000 description 4
- RPENMORRBUTCPR-UHFFFAOYSA-M sodium;1-hydroxy-2,5-dioxopyrrolidine-3-sulfonate Chemical compound [Na+].ON1C(=O)CC(S([O-])(=O)=O)C1=O RPENMORRBUTCPR-UHFFFAOYSA-M 0.000 description 4
- 239000007858 starting material Substances 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- 238000006467 substitution reaction Methods 0.000 description 4
- 230000002194 synthesizing effect Effects 0.000 description 4
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 4
- UMGDCJDMYOKAJW-UHFFFAOYSA-N thiourea Chemical compound NC(N)=S UMGDCJDMYOKAJW-UHFFFAOYSA-N 0.000 description 4
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 4
- BDNKZNFMNDZQMI-UHFFFAOYSA-N 1,3-diisopropylcarbodiimide Chemical compound CC(C)N=C=NC(C)C BDNKZNFMNDZQMI-UHFFFAOYSA-N 0.000 description 3
- XXJGBENTLXFVFI-UHFFFAOYSA-N 1-amino-methylene Chemical group N[CH2] XXJGBENTLXFVFI-UHFFFAOYSA-N 0.000 description 3
- FUOOLUPWFVMBKG-UHFFFAOYSA-N 2-Aminoisobutyric acid Chemical compound CC(C)(N)C(O)=O FUOOLUPWFVMBKG-UHFFFAOYSA-N 0.000 description 3
- JHALWMSZGCVVEM-UHFFFAOYSA-N 2-[4,7-bis(carboxymethyl)-1,4,7-triazonan-1-yl]acetic acid Chemical compound OC(=O)CN1CCN(CC(O)=O)CCN(CC(O)=O)CC1 JHALWMSZGCVVEM-UHFFFAOYSA-N 0.000 description 3
- JMTMSDXUXJISAY-UHFFFAOYSA-N 2H-benzotriazol-4-ol Chemical compound OC1=CC=CC2=C1N=NN2 JMTMSDXUXJISAY-UHFFFAOYSA-N 0.000 description 3
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 3
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- OBMZMSLWNNWEJA-XNCRXQDQSA-N C1=CC=2C(C[C@@H]3NC(=O)[C@@H](NC(=O)[C@H](NC(=O)N(CC#CCN(CCCC[C@H](NC(=O)[C@@H](CC4=CC=CC=C4)NC3=O)C(=O)N)CC=C)NC(=O)[C@@H](N)C)CC3=CNC4=C3C=CC=C4)C)=CNC=2C=C1 Chemical compound C1=CC=2C(C[C@@H]3NC(=O)[C@@H](NC(=O)[C@H](NC(=O)N(CC#CCN(CCCC[C@H](NC(=O)[C@@H](CC4=CC=CC=C4)NC3=O)C(=O)N)CC=C)NC(=O)[C@@H](N)C)CC3=CNC4=C3C=CC=C4)C)=CNC=2C=C1 OBMZMSLWNNWEJA-XNCRXQDQSA-N 0.000 description 3
- UVUCVWQYMGWCHS-UJVRUJOSSA-N CCC(C)[C@H](NC(=O)[C@H](CC1=CNC2C=CC=CC12)NC(=O)[C@@H]1CSSC[C@H](C)C(=O)N2CCC[C@H]2C(=O)N[C@@H](CC2=CC=C(O)C=C2)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N1)C(=O)N[C@@H](CCC(N)=O)C(N)=O Chemical compound CCC(C)[C@H](NC(=O)[C@H](CC1=CNC2C=CC=CC12)NC(=O)[C@@H]1CSSC[C@H](C)C(=O)N2CCC[C@H]2C(=O)N[C@@H](CC2=CC=C(O)C=C2)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N1)C(=O)N[C@@H](CCC(N)=O)C(N)=O UVUCVWQYMGWCHS-UJVRUJOSSA-N 0.000 description 3
- 241000700199 Cavia porcellus Species 0.000 description 3
- JPVYNHNXODAKFH-UHFFFAOYSA-N Cu2+ Chemical compound [Cu+2] JPVYNHNXODAKFH-UHFFFAOYSA-N 0.000 description 3
- RPNUMPOLZDHAAY-UHFFFAOYSA-N Diethylenetriamine Chemical compound NCCNCCN RPNUMPOLZDHAAY-UHFFFAOYSA-N 0.000 description 3
- VTLYFUHAOXGGBS-UHFFFAOYSA-N Fe3+ Chemical compound [Fe+3] VTLYFUHAOXGGBS-UHFFFAOYSA-N 0.000 description 3
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 3
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 3
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 3
- 238000005481 NMR spectroscopy Methods 0.000 description 3
- 101710176384 Peptide 1 Proteins 0.000 description 3
- 102000013566 Plasminogen Human genes 0.000 description 3
- 108010051456 Plasminogen Proteins 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 3
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 3
- 108010003205 Vasoactive Intestinal Peptide Proteins 0.000 description 3
- 102400000015 Vasoactive intestinal peptide Human genes 0.000 description 3
- UJUPBNMOPOYXHW-UHFFFAOYSA-N [2-(2-aminoethylamino)ethylamino]methanol Chemical compound NCCNCCNCO UJUPBNMOPOYXHW-UHFFFAOYSA-N 0.000 description 3
- 239000002253 acid Chemical class 0.000 description 3
- 238000010976 amide bond formation reaction Methods 0.000 description 3
- 150000003862 amino acid derivatives Chemical class 0.000 description 3
- 125000000539 amino acid group Chemical group 0.000 description 3
- MDFFNEOEWAXZRQ-UHFFFAOYSA-N aminyl Chemical group [NH2] MDFFNEOEWAXZRQ-UHFFFAOYSA-N 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- DCVBSDISYDCFMT-UHFFFAOYSA-N benzyl 4-amino-5-(2-aminoethylamino)pentanoate Chemical compound C(C1=CC=CC=C1)OC(=O)CCC(N)CNCCN DCVBSDISYDCFMT-UHFFFAOYSA-N 0.000 description 3
- AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical compound BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 3
- GCTPMLUUWLLESL-UHFFFAOYSA-N benzyl prop-2-enoate Chemical compound C=CC(=O)OCC1=CC=CC=C1 GCTPMLUUWLLESL-UHFFFAOYSA-N 0.000 description 3
- 230000017531 blood circulation Effects 0.000 description 3
- 239000012267 brine Substances 0.000 description 3
- 229910000024 caesium carbonate Inorganic materials 0.000 description 3
- FFGPTBGBLSHEPO-UHFFFAOYSA-N carbamazepine Chemical compound C1=CC2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 FFGPTBGBLSHEPO-UHFFFAOYSA-N 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 150000004697 chelate complex Chemical class 0.000 description 3
- BFGKITSFLPAWGI-UHFFFAOYSA-N chromium(3+) Chemical compound [Cr+3] BFGKITSFLPAWGI-UHFFFAOYSA-N 0.000 description 3
- 238000010276 construction Methods 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- UAOMVDZJSHZZME-UHFFFAOYSA-N diisopropylamine Chemical compound CC(C)NC(C)C UAOMVDZJSHZZME-UHFFFAOYSA-N 0.000 description 3
- BGRWYRAHAFMIBJ-UHFFFAOYSA-N diisopropylcarbodiimide Natural products CC(C)NC(=O)NC(C)C BGRWYRAHAFMIBJ-UHFFFAOYSA-N 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 3
- 125000001072 heteroaryl group Chemical group 0.000 description 3
- 125000000623 heterocyclic group Chemical group 0.000 description 3
- 150000002431 hydrogen Chemical group 0.000 description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 3
- 238000004949 mass spectrometry Methods 0.000 description 3
- GDOPTJXRTPNYNR-UHFFFAOYSA-N methyl-cyclopentane Natural products CC1CCCC1 GDOPTJXRTPNYNR-UHFFFAOYSA-N 0.000 description 3
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 3
- 230000003647 oxidation Effects 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 239000008363 phosphate buffer Substances 0.000 description 3
- 125000004437 phosphorous atom Chemical group 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000002285 radioactive effect Effects 0.000 description 3
- 238000004366 reverse phase liquid chromatography Methods 0.000 description 3
- 239000000741 silica gel Substances 0.000 description 3
- 229910002027 silica gel Inorganic materials 0.000 description 3
- 229960001866 silicon dioxide Drugs 0.000 description 3
- UKLNMMHNWFDKNT-UHFFFAOYSA-M sodium chlorite Chemical compound [Na+].[O-]Cl=O UKLNMMHNWFDKNT-UHFFFAOYSA-M 0.000 description 3
- 229960002218 sodium chlorite Drugs 0.000 description 3
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 3
- 239000007790 solid phase Substances 0.000 description 3
- 125000006850 spacer group Chemical group 0.000 description 3
- 239000011593 sulfur Substances 0.000 description 3
- WGTODYJZXSJIAG-UHFFFAOYSA-N tetramethylrhodamine chloride Chemical compound [Cl-].C=12C=CC(N(C)C)=CC2=[O+]C2=CC(N(C)C)=CC=C2C=1C1=CC=CC=C1C(O)=O WGTODYJZXSJIAG-UHFFFAOYSA-N 0.000 description 3
- MPLHNVLQVRSVEE-UHFFFAOYSA-N texas red Chemical compound [O-]S(=O)(=O)C1=CC(S(Cl)(=O)=O)=CC=C1C(C1=CC=2CCCN3CCCC(C=23)=C1O1)=C2C1=C(CCC1)C3=[N+]1CCCC3=C2 MPLHNVLQVRSVEE-UHFFFAOYSA-N 0.000 description 3
- 229910052716 thallium Inorganic materials 0.000 description 3
- BKVIYDNLLOSFOA-UHFFFAOYSA-N thallium Chemical compound [Tl] BKVIYDNLLOSFOA-UHFFFAOYSA-N 0.000 description 3
- 239000003656 tris buffered saline Substances 0.000 description 3
- 238000000108 ultra-filtration Methods 0.000 description 3
- 229910052720 vanadium Inorganic materials 0.000 description 3
- 230000002792 vascular Effects 0.000 description 3
- 210000003462 vein Anatomy 0.000 description 3
- 210000001631 vena cava inferior Anatomy 0.000 description 3
- 239000003643 water by type Substances 0.000 description 3
- OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 description 2
- IYKLZBIWFXPUCS-VIFPVBQESA-N (2s)-2-(naphthalen-1-ylamino)propanoic acid Chemical compound C1=CC=C2C(N[C@@H](C)C(O)=O)=CC=CC2=C1 IYKLZBIWFXPUCS-VIFPVBQESA-N 0.000 description 2
- UQWNNUPJBDWRHC-UWVGGRQHSA-N (3s,4s)-4-amino-5-cyclohexyl-3-hydroxypentanoic acid Chemical compound OC(=O)C[C@H](O)[C@@H](N)CC1CCCCC1 UQWNNUPJBDWRHC-UWVGGRQHSA-N 0.000 description 2
- LTRDBICHBYDAKU-UHFFFAOYSA-N 1,3,6,9-tetrazacyclododecane Chemical compound C1CNCCNCCNCNC1 LTRDBICHBYDAKU-UHFFFAOYSA-N 0.000 description 2
- PAJPWUMXBYXFCZ-UHFFFAOYSA-N 1-aminocyclopropanecarboxylic acid Chemical compound OC(=O)C1(N)CC1 PAJPWUMXBYXFCZ-UHFFFAOYSA-N 0.000 description 2
- FCEHBMOGCRZNNI-UHFFFAOYSA-N 1-benzothiophene Chemical compound C1=CC=C2SC=CC2=C1 FCEHBMOGCRZNNI-UHFFFAOYSA-N 0.000 description 2
- PBLZLIFKVPJDCO-UHFFFAOYSA-N 12-aminododecanoic acid Chemical compound NCCCCCCCCCCCC(O)=O PBLZLIFKVPJDCO-UHFFFAOYSA-N 0.000 description 2
- IYOCAGBMCLTMJS-UHFFFAOYSA-N 2,3-diaminopropanoic acid;trihydrochloride Chemical compound Cl.Cl.Cl.NCC(N)C(O)=O IYOCAGBMCLTMJS-UHFFFAOYSA-N 0.000 description 2
- FBTSQILOGYXGMD-LURJTMIESA-N 3-nitro-L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C([N+]([O-])=O)=C1 FBTSQILOGYXGMD-LURJTMIESA-N 0.000 description 2
- QXZBMSIDSOZZHK-DOPDSADYSA-N 31362-50-2 Chemical class C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(N)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1NC(=O)CC1)C(C)C)C1=CNC=N1 QXZBMSIDSOZZHK-DOPDSADYSA-N 0.000 description 2
- ALYNCZNDIQEVRV-UHFFFAOYSA-N 4-aminobenzoic acid Chemical compound NC1=CC=C(C(O)=O)C=C1 ALYNCZNDIQEVRV-UHFFFAOYSA-N 0.000 description 2
- DFVFTMTWCUHJBL-UHFFFAOYSA-N 4-azaniumyl-3-hydroxy-6-methylheptanoate Chemical compound CC(C)CC(N)C(O)CC(O)=O DFVFTMTWCUHJBL-UHFFFAOYSA-N 0.000 description 2
- MLCMXDYMSAZNPC-UHFFFAOYSA-N 4-methoxychromen-2-one Chemical compound C1=CC=CC2=C1OC(=O)C=C2OC MLCMXDYMSAZNPC-UHFFFAOYSA-N 0.000 description 2
- MOGYDGWJQMYRDO-UHFFFAOYSA-N 4-o-benzyl 1-o-tert-butyl 2-amino-3-[[(2-methylpropan-2-yl)oxycarbonylamino]methyl]butanedioate Chemical compound CC(C)(C)OC(=O)NCC(C(N)C(=O)OC(C)(C)C)C(=O)OCC1=CC=CC=C1 MOGYDGWJQMYRDO-UHFFFAOYSA-N 0.000 description 2
- JJMDCOVWQOJGCB-UHFFFAOYSA-N 5-aminopentanoic acid Chemical compound [NH3+]CCCCC([O-])=O JJMDCOVWQOJGCB-UHFFFAOYSA-N 0.000 description 2
- ODHCTXKNWHHXJC-VKHMYHEASA-N 5-oxo-L-proline Chemical compound OC(=O)[C@@H]1CCC(=O)N1 ODHCTXKNWHHXJC-VKHMYHEASA-N 0.000 description 2
- ZHGNHOOVYPHPNJ-UHFFFAOYSA-N Amigdalin Chemical compound FC(F)(F)C(=O)OCC1OC(OCC2OC(OC(C#N)C3=CC=CC=C3)C(OC(=O)C(F)(F)F)C(OC(=O)C(F)(F)F)C2OC(=O)C(F)(F)F)C(OC(=O)C(F)(F)F)C(OC(=O)C(F)(F)F)C1OC(=O)C(F)(F)F ZHGNHOOVYPHPNJ-UHFFFAOYSA-N 0.000 description 2
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- VHOMAPWVLKRQAZ-UHFFFAOYSA-N Benzyl propionate Chemical compound CCC(=O)OCC1=CC=CC=C1 VHOMAPWVLKRQAZ-UHFFFAOYSA-N 0.000 description 2
- 102000004506 Blood Proteins Human genes 0.000 description 2
- 108010017384 Blood Proteins Proteins 0.000 description 2
- 125000001433 C-terminal amino-acid group Chemical group 0.000 description 2
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 2
- YVEUILGEDYVSQQ-UHFFFAOYSA-N CC(=O)C(C)C.CC(=O)C1CCCC1.CCC(C)C(C)=O.CCC(CC)C(C)=O.CCCCN(CCCC)CC(C)=O.CCCN(CCC)CC(C)=O.CCCN(CCC)CC(C)=O Chemical compound CC(=O)C(C)C.CC(=O)C1CCCC1.CCC(C)C(C)=O.CCC(CC)C(C)=O.CCCCN(CCCC)CC(C)=O.CCCN(CCC)CC(C)=O.CCCN(CCC)CC(C)=O YVEUILGEDYVSQQ-UHFFFAOYSA-N 0.000 description 2
- FJQAIPXYZPOQQE-QBLFRENUSA-N CC(=O)C[C@H](NC(=O)[C@@H](C)CC1=CC=C(C2=CC=CC=C2)C=C1)C(=O)NCC1=CC=CC(CNC(C2=CC=CC=C2)(C2=CC=CC=C2)C2=CC=C(C)C=C2)=C1.CC1=CC=C(C(NCC2=CC(CN)=CC=C2)(C2=CC=CC=C2)C2=CC=CC=C2)C=C1.CC[C@H](NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC1=CC=C(C)C=C1)NC(=O)[C@H](CC1=CC=C(C)C=C1)NC(=O)[C@H](CC(C)=O)NC(=O)[C@H](CC)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)CC(C)C)C(C)C)C(=O)NC Chemical compound CC(=O)C[C@H](NC(=O)[C@@H](C)CC1=CC=C(C2=CC=CC=C2)C=C1)C(=O)NCC1=CC=CC(CNC(C2=CC=CC=C2)(C2=CC=CC=C2)C2=CC=C(C)C=C2)=C1.CC1=CC=C(C(NCC2=CC(CN)=CC=C2)(C2=CC=CC=C2)C2=CC=CC=C2)C=C1.CC[C@H](NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC1=CC=C(C)C=C1)NC(=O)[C@H](CC1=CC=C(C)C=C1)NC(=O)[C@H](CC(C)=O)NC(=O)[C@H](CC)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)CC(C)C)C(C)C)C(=O)NC FJQAIPXYZPOQQE-QBLFRENUSA-N 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- MIKUYHXYGGJMLM-GIMIYPNGSA-N Crotonoside Natural products C1=NC2=C(N)NC(=O)N=C2N1[C@H]1O[C@@H](CO)[C@H](O)[C@@H]1O MIKUYHXYGGJMLM-GIMIYPNGSA-N 0.000 description 2
- NYHBQMYGNKIUIF-UHFFFAOYSA-N D-guanosine Natural products C1=2NC(N)=NC(=O)C=2N=CN1C1OC(CO)C(O)C1O NYHBQMYGNKIUIF-UHFFFAOYSA-N 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- 102400000921 Gastrin Human genes 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- 108090000288 Glycoproteins Proteins 0.000 description 2
- 102000003886 Glycoproteins Human genes 0.000 description 2
- 239000007821 HATU Substances 0.000 description 2
- 208000032843 Hemorrhage Diseases 0.000 description 2
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 2
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 2
- 102100025306 Integrin alpha-IIb Human genes 0.000 description 2
- 101710149643 Integrin alpha-IIb Proteins 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 244000137850 Marrubium vulgare Species 0.000 description 2
- SFURNQDSNNZBMA-UHFFFAOYSA-N NCC1=CC(CNC(C2=CC=CC=C2)(C2=CC=CC=C2)C2=CC=C(C(=O)NCC[SH]=P)C=C2)=CC=C1.NCC1=CC=CC(CN)=C1.O=C(NCC[SH]=P)C1=CC=C(C(Cl)(C2=CC=CC=C2)C2=CC=CC=C2)C=C1 Chemical compound NCC1=CC(CNC(C2=CC=CC=C2)(C2=CC=CC=C2)C2=CC=C(C(=O)NCC[SH]=P)C=C2)=CC=C1.NCC1=CC=CC(CN)=C1.O=C(NCC[SH]=P)C1=CC=C(C(Cl)(C2=CC=CC=C2)C2=CC=CC=C2)C=C1 SFURNQDSNNZBMA-UHFFFAOYSA-N 0.000 description 2
- UFWIBTONFRDIAS-UHFFFAOYSA-N Naphthalene Chemical compound C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 208000031481 Pathologic Constriction Diseases 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- 101000781681 Protobothrops flavoviridis Disintegrin triflavin Proteins 0.000 description 2
- KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 2
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 2
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 239000005708 Sodium hypochlorite Substances 0.000 description 2
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 2
- 108090000190 Thrombin Proteins 0.000 description 2
- 108010075974 Vasoactive Intestinal Peptide Receptors Proteins 0.000 description 2
- 102000012088 Vasoactive Intestinal Peptide Receptors Human genes 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 2
- 239000012346 acetyl chloride Substances 0.000 description 2
- 125000004442 acylamino group Chemical group 0.000 description 2
- 229960005305 adenosine Drugs 0.000 description 2
- 125000002723 alicyclic group Chemical group 0.000 description 2
- 125000003545 alkoxy group Chemical group 0.000 description 2
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 2
- 125000005194 alkoxycarbonyloxy group Chemical group 0.000 description 2
- 125000004457 alkyl amino carbonyl group Chemical group 0.000 description 2
- 125000003282 alkyl amino group Chemical group 0.000 description 2
- 125000004947 alkyl aryl amino group Chemical group 0.000 description 2
- 125000002877 alkyl aryl group Chemical group 0.000 description 2
- 125000003806 alkyl carbonyl amino group Chemical group 0.000 description 2
- 125000004448 alkyl carbonyl group Chemical group 0.000 description 2
- 125000005196 alkyl carbonyloxy group Chemical group 0.000 description 2
- 125000004644 alkyl sulfinyl group Chemical group 0.000 description 2
- 125000004691 alkyl thio carbonyl group Chemical group 0.000 description 2
- 125000004414 alkyl thio group Chemical group 0.000 description 2
- 230000029936 alkylation Effects 0.000 description 2
- 238000005804 alkylation reaction Methods 0.000 description 2
- QWCKQJZIFLGMSD-UHFFFAOYSA-N alpha-aminobutyric acid Chemical compound CCC(N)C(O)=O QWCKQJZIFLGMSD-UHFFFAOYSA-N 0.000 description 2
- 239000003708 ampul Substances 0.000 description 2
- RWZYAGGXGHYGMB-UHFFFAOYSA-N anthranilic acid Chemical compound NC1=CC=CC=C1C(O)=O RWZYAGGXGHYGMB-UHFFFAOYSA-N 0.000 description 2
- 239000012062 aqueous buffer Substances 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 125000001769 aryl amino group Chemical group 0.000 description 2
- 125000004658 aryl carbonyl amino group Chemical group 0.000 description 2
- 125000005129 aryl carbonyl group Chemical group 0.000 description 2
- 125000005199 aryl carbonyloxy group Chemical group 0.000 description 2
- 125000005110 aryl thio group Chemical group 0.000 description 2
- 125000005200 aryloxy carbonyloxy group Chemical group 0.000 description 2
- 235000003704 aspartic acid Nutrition 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 239000012298 atmosphere Substances 0.000 description 2
- 125000000852 azido group Chemical group *N=[N+]=[N-] 0.000 description 2
- RFRXIWQYSOIBDI-UHFFFAOYSA-N benzarone Chemical compound CCC=1OC2=CC=CC=C2C=1C(=O)C1=CC=C(O)C=C1 RFRXIWQYSOIBDI-UHFFFAOYSA-N 0.000 description 2
- IOJUPLGTWVMSFF-UHFFFAOYSA-N benzothiazole Chemical compound C1=CC=C2SC=NC2=C1 IOJUPLGTWVMSFF-UHFFFAOYSA-N 0.000 description 2
- WRYMOMRCZGXGFV-UHFFFAOYSA-N benzyl 2,3-bis[(2-methylpropan-2-yl)oxycarbonylamino]propanoate Chemical compound CC(C)(C)OC(=O)NCC(NC(=O)OC(C)(C)C)C(=O)OCC1=CC=CC=C1 WRYMOMRCZGXGFV-UHFFFAOYSA-N 0.000 description 2
- WGQKYBSKWIADBV-UHFFFAOYSA-N benzylamine Chemical compound NCC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 description 2
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 2
- 208000034158 bleeding Diseases 0.000 description 2
- 230000000740 bleeding effect Effects 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 125000001951 carbamoylamino group Chemical group C(N)(=O)N* 0.000 description 2
- 210000001715 carotid artery Anatomy 0.000 description 2
- 230000003197 catalytic effect Effects 0.000 description 2
- 150000001768 cations Chemical class 0.000 description 2
- AOXOCDRNSPFDPE-UKEONUMOSA-N chembl413654 Chemical compound C([C@H](C(=O)NCC(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](C)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)CNC(=O)[C@@H](N)CCC(O)=O)C1=CC=C(O)C=C1 AOXOCDRNSPFDPE-UKEONUMOSA-N 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- 230000001268 conjugating effect Effects 0.000 description 2
- 229940039231 contrast media Drugs 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 239000010779 crude oil Substances 0.000 description 2
- 125000004093 cyano group Chemical group *C#N 0.000 description 2
- 125000004122 cyclic group Chemical group 0.000 description 2
- 230000009089 cytolysis Effects 0.000 description 2
- 229940104302 cytosine Drugs 0.000 description 2
- 238000002059 diagnostic imaging Methods 0.000 description 2
- 125000004663 dialkyl amino group Chemical group 0.000 description 2
- 125000004473 dialkylaminocarbonyl group Chemical group 0.000 description 2
- 125000004986 diarylamino group Chemical group 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 2
- 229910000397 disodium phosphate Inorganic materials 0.000 description 2
- 238000006073 displacement reaction Methods 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 239000003480 eluent Substances 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- DQYBDCGIPTYXML-UHFFFAOYSA-N ethoxyethane;hydrate Chemical compound O.CCOCC DQYBDCGIPTYXML-UHFFFAOYSA-N 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 230000003480 fibrinolytic effect Effects 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 2
- 229940029575 guanosine Drugs 0.000 description 2
- 229910052736 halogen Inorganic materials 0.000 description 2
- 150000002367 halogens Chemical class 0.000 description 2
- 229960002897 heparin Drugs 0.000 description 2
- 229920000669 heparin Polymers 0.000 description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 2
- 238000005984 hydrogenation reaction Methods 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 238000001095 inductively coupled plasma mass spectrometry Methods 0.000 description 2
- 239000000543 intermediate Substances 0.000 description 2
- 238000002075 inversion recovery Methods 0.000 description 2
- 239000012948 isocyanate Substances 0.000 description 2
- 150000002513 isocyanates Chemical class 0.000 description 2
- AWJUIBRHMBBTKR-UHFFFAOYSA-N isoquinoline Chemical compound C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 description 2
- 229910052747 lanthanoid Inorganic materials 0.000 description 2
- 150000002602 lanthanoids Chemical class 0.000 description 2
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 2
- 230000005291 magnetic effect Effects 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- UZKWTJUDCOPSNM-UHFFFAOYSA-N methoxybenzene Substances CCCCOC=C UZKWTJUDCOPSNM-UHFFFAOYSA-N 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 238000001208 nuclear magnetic resonance pulse sequence Methods 0.000 description 2
- 230000000269 nucleophilic effect Effects 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 108010011903 peptide receptors Proteins 0.000 description 2
- 102000014187 peptide receptors Human genes 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 210000002381 plasma Anatomy 0.000 description 2
- CHKVPAROMQMJNQ-UHFFFAOYSA-M potassium bisulfate Chemical compound [K+].OS([O-])(=O)=O CHKVPAROMQMJNQ-UHFFFAOYSA-M 0.000 description 2
- 229910000343 potassium bisulfate Inorganic materials 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 150000003147 proline derivatives Chemical class 0.000 description 2
- 235000019260 propionic acid Nutrition 0.000 description 2
- 238000000159 protein binding assay Methods 0.000 description 2
- 239000012264 purified product Substances 0.000 description 2
- 239000012217 radiopharmaceutical Substances 0.000 description 2
- 229940121896 radiopharmaceutical Drugs 0.000 description 2
- 230000002799 radiopharmaceutical effect Effects 0.000 description 2
- 238000006268 reductive amination reaction Methods 0.000 description 2
- FSYKKLYZXJSNPZ-UHFFFAOYSA-N sarcosine Chemical compound C[NH2+]CC([O-])=O FSYKKLYZXJSNPZ-UHFFFAOYSA-N 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 description 2
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 2
- SUKJFIGYRHOWBL-UHFFFAOYSA-N sodium hypochlorite Chemical compound [Na+].Cl[O-] SUKJFIGYRHOWBL-UHFFFAOYSA-N 0.000 description 2
- 229910000162 sodium phosphate Inorganic materials 0.000 description 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
- 230000000087 stabilizing effect Effects 0.000 description 2
- 230000036262 stenosis Effects 0.000 description 2
- 208000037804 stenosis Diseases 0.000 description 2
- 125000005017 substituted alkenyl group Chemical group 0.000 description 2
- 125000000547 substituted alkyl group Chemical group 0.000 description 2
- 238000000967 suction filtration Methods 0.000 description 2
- 125000005420 sulfonamido group Chemical group S(=O)(=O)(N*)* 0.000 description 2
- 150000003467 sulfuric acid derivatives Chemical group 0.000 description 2
- 238000001308 synthesis method Methods 0.000 description 2
- 125000004213 tert-butoxy group Chemical group [H]C([H])([H])C(O*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 229960004072 thrombin Drugs 0.000 description 2
- 229960003766 thrombin (human) Drugs 0.000 description 2
- 229940113082 thymine Drugs 0.000 description 2
- FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 2
- GECIDMICWWDIBO-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 3',6'-dihydroxy-3-oxospiro[2-benzofuran-1,9'-xanthene]-5-carboxylate Chemical group C=1C(O)=CC=C2C=1OC1=CC(O)=CC=C1C2(C1=CC=2)OC(=O)C1=CC=2C(=O)ON1C(=O)CCC1=O GECIDMICWWDIBO-UHFFFAOYSA-N 0.000 description 1
- FQRURPFZTFUXEZ-MRVPVSSYSA-N (2s)-2,3,3,3-tetrafluoro-2-(n-fluoroanilino)propanoic acid Chemical compound OC(=O)[C@](F)(C(F)(F)F)N(F)C1=CC=CC=C1 FQRURPFZTFUXEZ-MRVPVSSYSA-N 0.000 description 1
- BVAUMRCGVHUWOZ-ZETCQYMHSA-N (2s)-2-(cyclohexylazaniumyl)propanoate Chemical compound OC(=O)[C@H](C)NC1CCCCC1 BVAUMRCGVHUWOZ-ZETCQYMHSA-N 0.000 description 1
- NRCSJHVDTAAISV-QMMMGPOBSA-N (2s)-2-amino-3-(3,4-dichlorophenyl)propanoic acid Chemical compound OC(=O)[C@@H](N)CC1=CC=C(Cl)C(Cl)=C1 NRCSJHVDTAAISV-QMMMGPOBSA-N 0.000 description 1
- WAMWSIDTKSNDCU-ZETCQYMHSA-N (2s)-2-azaniumyl-2-cyclohexylacetate Chemical compound OC(=O)[C@@H](N)C1CCCCC1 WAMWSIDTKSNDCU-ZETCQYMHSA-N 0.000 description 1
- GTVVZTAFGPQSPC-QMMMGPOBSA-N (2s)-2-azaniumyl-3-(4-nitrophenyl)propanoate Chemical compound OC(=O)[C@@H](N)CC1=CC=C([N+]([O-])=O)C=C1 GTVVZTAFGPQSPC-QMMMGPOBSA-N 0.000 description 1
- LJRDOKAZOAKLDU-UDXJMMFXSA-N (2s,3s,4r,5r,6r)-5-amino-2-(aminomethyl)-6-[(2r,3s,4r,5s)-5-[(1r,2r,3s,5r,6s)-3,5-diamino-2-[(2s,3r,4r,5s,6r)-3-amino-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-hydroxycyclohexyl]oxy-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl]oxyoxane-3,4-diol;sulfuric ac Chemical compound OS(O)(=O)=O.N[C@@H]1[C@@H](O)[C@H](O)[C@H](CN)O[C@@H]1O[C@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](N)C[C@@H](N)[C@@H]2O)O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)N)O[C@@H]1CO LJRDOKAZOAKLDU-UDXJMMFXSA-N 0.000 description 1
- DEQANNDTNATYII-OULOTJBUSA-N (4r,7s,10s,13r,16s,19r)-10-(4-aminobutyl)-19-[[(2r)-2-amino-3-phenylpropanoyl]amino]-16-benzyl-n-[(2r,3r)-1,3-dihydroxybutan-2-yl]-7-[(1r)-1-hydroxyethyl]-13-(1h-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxa Chemical compound C([C@@H](N)C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](CC=2C3=CC=CC=C3NC=2)NC(=O)[C@H](CC=2C=CC=CC=2)NC1=O)C(=O)N[C@H](CO)[C@H](O)C)C1=CC=CC=C1 DEQANNDTNATYII-OULOTJBUSA-N 0.000 description 1
- VMSLCPKYRPDHLN-UHFFFAOYSA-N (R)-Humulone Chemical compound CC(C)CC(=O)C1=C(O)C(CC=C(C)C)=C(O)C(O)(CC=C(C)C)C1=O VMSLCPKYRPDHLN-UHFFFAOYSA-N 0.000 description 1
- NQRKYASMKDDGHT-UHFFFAOYSA-N (aminooxy)acetic acid Chemical compound NOCC(O)=O NQRKYASMKDDGHT-UHFFFAOYSA-N 0.000 description 1
- NYPYHUZRZVSYKL-UHFFFAOYSA-N -3,5-Diiodotyrosine Natural products OC(=O)C(N)CC1=CC(I)=C(O)C(I)=C1 NYPYHUZRZVSYKL-UHFFFAOYSA-N 0.000 description 1
- BWKMGYQJPOAASG-UHFFFAOYSA-N 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid Chemical compound C1=CC=C2CNC(C(=O)O)CC2=C1 BWKMGYQJPOAASG-UHFFFAOYSA-N 0.000 description 1
- BCMCBBGGLRIHSE-UHFFFAOYSA-N 1,3-benzoxazole Chemical compound C1=CC=C2OC=NC2=C1 BCMCBBGGLRIHSE-UHFFFAOYSA-N 0.000 description 1
- ITWBWJFEJCHKSN-UHFFFAOYSA-N 1,4,7-triazonane Chemical compound C1CNCCNCCN1 ITWBWJFEJCHKSN-UHFFFAOYSA-N 0.000 description 1
- JFLSOKIMYBSASW-UHFFFAOYSA-N 1-chloro-2-[chloro(diphenyl)methyl]benzene Chemical compound ClC1=CC=CC=C1C(Cl)(C=1C=CC=CC=1)C1=CC=CC=C1 JFLSOKIMYBSASW-UHFFFAOYSA-N 0.000 description 1
- FPIRBHDGWMWJEP-UHFFFAOYSA-N 1-hydroxy-7-azabenzotriazole Chemical compound C1=CN=C2N(O)N=NC2=C1 FPIRBHDGWMWJEP-UHFFFAOYSA-N 0.000 description 1
- GUOSQNAUYHMCRU-UHFFFAOYSA-N 11-Aminoundecanoic acid Chemical compound NCCCCCCCCCCC(O)=O GUOSQNAUYHMCRU-UHFFFAOYSA-N 0.000 description 1
- HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical compound C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 description 1
- UDZLUXXCXDIIOK-UHFFFAOYSA-N 2,3-bis[(2-methylpropan-2-yl)oxycarbonylamino]propanoic acid Chemical compound CC(C)(C)OC(=O)NCC(C(O)=O)NC(=O)OC(C)(C)C UDZLUXXCXDIIOK-UHFFFAOYSA-N 0.000 description 1
- TXHAHOVNFDVCCC-UHFFFAOYSA-N 2-(tert-butylazaniumyl)acetate Chemical compound CC(C)(C)NCC(O)=O TXHAHOVNFDVCCC-UHFFFAOYSA-N 0.000 description 1
- VWFRSNKRTNUMET-UHFFFAOYSA-N 2-[3-(dimethylamino)-6-dimethylazaniumylidenexanthen-9-yl]-5-(2,5-dioxopyrrolidin-1-yl)oxycarbonylbenzoate Chemical compound C=12C=CC(=[N+](C)C)C=C2OC2=CC(N(C)C)=CC=C2C=1C(C(=C1)C([O-])=O)=CC=C1C(=O)ON1C(=O)CCC1=O VWFRSNKRTNUMET-UHFFFAOYSA-N 0.000 description 1
- SGPXHPCSEYUXPA-UHFFFAOYSA-K 2-[4,7-bis(carboxylatomethyl)-1,4,7,10-tetrazacyclododec-1-yl]acetate;gadolinium(3+) Chemical compound [Gd+3].[O-]C(=O)CN1CCNCCN(CC([O-])=O)CCN(CC([O-])=O)CC1 SGPXHPCSEYUXPA-UHFFFAOYSA-K 0.000 description 1
- VHPXSBIFWDAFMB-UHFFFAOYSA-N 2-amino-Delta(2)-thiazoline-4-carboxylic acid Chemical compound NC1=[NH+]C(C([O-])=O)CS1 VHPXSBIFWDAFMB-UHFFFAOYSA-N 0.000 description 1
- CDULPPOISZOUTK-UHFFFAOYSA-N 2-azaniumyl-3,4-dihydro-1h-naphthalene-2-carboxylate Chemical compound C1=CC=C2CC(N)(C(O)=O)CCC2=C1 CDULPPOISZOUTK-UHFFFAOYSA-N 0.000 description 1
- NYCRCTMDYITATC-UHFFFAOYSA-N 2-fluorophenylalanine Chemical compound OC(=O)C(N)CC1=CC=CC=C1F NYCRCTMDYITATC-UHFFFAOYSA-N 0.000 description 1
- NYPYHUZRZVSYKL-ZETCQYMHSA-N 3,5-diiodo-L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC(I)=C(O)C(I)=C1 NYPYHUZRZVSYKL-ZETCQYMHSA-N 0.000 description 1
- AJHPGXZOIAYYDW-UHFFFAOYSA-N 3-(2-cyanophenyl)-2-[(2-methylpropan-2-yl)oxycarbonylamino]propanoic acid Chemical compound CC(C)(C)OC(=O)NC(C(O)=O)CC1=CC=CC=C1C#N AJHPGXZOIAYYDW-UHFFFAOYSA-N 0.000 description 1
- FWJRAUZFJSYARZ-UHFFFAOYSA-N 3-amino-4-[(2-methylpropan-2-yl)oxy]-2-[[(2-methylpropan-2-yl)oxycarbonylamino]methyl]-4-oxobutanoic acid Chemical compound CC(C)(C)OC(=O)NCC(C(O)=O)C(N)C(=O)OC(C)(C)C FWJRAUZFJSYARZ-UHFFFAOYSA-N 0.000 description 1
- ACWBBAGYTKWBCD-ZETCQYMHSA-N 3-chloro-L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(Cl)=C1 ACWBBAGYTKWBCD-ZETCQYMHSA-N 0.000 description 1
- BXRLWGXPSRYJDZ-UHFFFAOYSA-N 3-cyanoalanine Chemical compound OC(=O)C(N)CC#N BXRLWGXPSRYJDZ-UHFFFAOYSA-N 0.000 description 1
- UQTZMGFTRHFAAM-ZETCQYMHSA-N 3-iodo-L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(I)=C1 UQTZMGFTRHFAAM-ZETCQYMHSA-N 0.000 description 1
- MQHLULPKDLJASZ-QMMMGPOBSA-N 3-methyl-L-tyrosine zwitterion Chemical compound CC1=CC(C[C@H](N)C(O)=O)=CC=C1O MQHLULPKDLJASZ-QMMMGPOBSA-N 0.000 description 1
- PEPBFCOIJRULGJ-UHFFFAOYSA-N 3h-1,2,3-benzodioxazole Chemical compound C1=CC=C2NOOC2=C1 PEPBFCOIJRULGJ-UHFFFAOYSA-N 0.000 description 1
- HXOYWJCDYVODON-UHFFFAOYSA-N 4-[4-(hydroxymethyl)-3-methoxyphenoxy]butanoic acid Chemical compound COC1=CC(OCCCC(O)=O)=CC=C1CO HXOYWJCDYVODON-UHFFFAOYSA-N 0.000 description 1
- CMUHFUGDYMFHEI-QMMMGPOBSA-N 4-amino-L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N)C=C1 CMUHFUGDYMFHEI-QMMMGPOBSA-N 0.000 description 1
- 125000004800 4-bromophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Br 0.000 description 1
- NIGWMJHCCYYCSF-QMMMGPOBSA-N 4-chloro-L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(Cl)C=C1 NIGWMJHCCYYCSF-QMMMGPOBSA-N 0.000 description 1
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 description 1
- PZNQZSRPDOEBMS-QMMMGPOBSA-N 4-iodo-L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(I)C=C1 PZNQZSRPDOEBMS-QMMMGPOBSA-N 0.000 description 1
- 125000006306 4-iodophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1I 0.000 description 1
- LDCYZAJDBXYCGN-VIFPVBQESA-N 5-hydroxy-L-tryptophan Chemical compound C1=C(O)C=C2C(C[C@H](N)C(O)=O)=CNC2=C1 LDCYZAJDBXYCGN-VIFPVBQESA-N 0.000 description 1
- 229940000681 5-hydroxytryptophan Drugs 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- UQXNEWQGGVUVQA-UHFFFAOYSA-N 8-aminooctanoic acid Chemical compound NCCCCCCCC(O)=O UQXNEWQGGVUVQA-UHFFFAOYSA-N 0.000 description 1
- 241000271510 Agkistrodon contortrix Species 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 108090001008 Avidin Proteins 0.000 description 1
- GAMJRWJLGJWKPE-KDMRLUGVSA-N BC(=O)NC(CNB(C)O)C(=O)O.BC(=O)NC(CNB(C)O)C(=O)OCC1=CC=CC=C1.CCN(CC)CCN(CC)CC(C(=O)NC[C@@H](NC(=O)[C@H](CN(CC)CCN(CC)CC)N(CC)CC)C(=O)O)N(CC)CC.CCN(CC)CCN(CC)CC(C(=O)O)N(CC)CC.Cl.O=C(OCC1=CC=CC=C1)C(CNCl)N=Cl Chemical compound BC(=O)NC(CNB(C)O)C(=O)O.BC(=O)NC(CNB(C)O)C(=O)OCC1=CC=CC=C1.CCN(CC)CCN(CC)CC(C(=O)NC[C@@H](NC(=O)[C@H](CN(CC)CCN(CC)CC)N(CC)CC)C(=O)O)N(CC)CC.CCN(CC)CCN(CC)CC(C(=O)O)N(CC)CC.Cl.O=C(OCC1=CC=CC=C1)C(CNCl)N=Cl GAMJRWJLGJWKPE-KDMRLUGVSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N Benzoic acid Natural products OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 108010051479 Bombesin Proteins 0.000 description 1
- 102000013585 Bombesin Human genes 0.000 description 1
- 108010073466 Bombesin Receptors Proteins 0.000 description 1
- YBOMNKBURGSZDR-UHFFFAOYSA-N C.C.CCC.CCCCCN.CCCCCNC.CCCCCNC Chemical compound C.C.CCC.CCCCCN.CCCCCNC.CCCCCNC YBOMNKBURGSZDR-UHFFFAOYSA-N 0.000 description 1
- HFFYWTMMBRQCIA-UHFFFAOYSA-N C.CC(C)(C)OC(=O)NCCN(CC(CO)NC(=O)OC(C)(C)C)C(=O)OC(C)(C)C.CC(C)(C)OC(=O)NCCN(CC(NC(=O)OC(C)(C)C)C(=O)O)C(=O)OC(C)(C)C Chemical compound C.CC(C)(C)OC(=O)NCCN(CC(CO)NC(=O)OC(C)(C)C)C(=O)OC(C)(C)C.CC(C)(C)OC(=O)NCCN(CC(NC(=O)OC(C)(C)C)C(=O)O)C(=O)OC(C)(C)C HFFYWTMMBRQCIA-UHFFFAOYSA-N 0.000 description 1
- MQDYLIRYEBZJNO-GXXQEZFJSA-N C=C(CBr)C(=O)OC.CCN(CC)CCN(CC)C[C@@H](C(=O)NCC(CNC(=O)[C@H](CN(CC)CCN(CC)CC)N(CC)CC)C(=O)O)N(CC)CC.CCN(CC)CCN(CC)C[C@@H](C(=O)NCC(CNC(=O)[C@H](CN(CC)CCN(CC)CC)N(CC)CC)C(=O)OCC1=CC=CC=C1)N(CC)CC.COC(=O)C(CBr)CBr.COC(=O)C(CN)CN.COC(=O)C(CNCC1=CC=CC=C1)CNCC1=CC=CC=C1.NCC(CN)C(=O)OCC1=CC=CC=C1.NCC1=CC=CC=C1 Chemical compound C=C(CBr)C(=O)OC.CCN(CC)CCN(CC)C[C@@H](C(=O)NCC(CNC(=O)[C@H](CN(CC)CCN(CC)CC)N(CC)CC)C(=O)O)N(CC)CC.CCN(CC)CCN(CC)C[C@@H](C(=O)NCC(CNC(=O)[C@H](CN(CC)CCN(CC)CC)N(CC)CC)C(=O)OCC1=CC=CC=C1)N(CC)CC.COC(=O)C(CBr)CBr.COC(=O)C(CN)CN.COC(=O)C(CNCC1=CC=CC=C1)CNCC1=CC=CC=C1.NCC(CN)C(=O)OCC1=CC=CC=C1.NCC1=CC=CC=C1 MQDYLIRYEBZJNO-GXXQEZFJSA-N 0.000 description 1
- VMGBWMOHSCQEFR-UHFFFAOYSA-N C=CC(=O)NCC1CN(CC(C)=O)CCN(CC(C)=O)CCN(CC(C)=O)CCN1CC(C)=O.CC(=O)CN1CCN(CC(C)=O)CCN(CC(C)=O)C(CNC(=O)CBr)CN(CC(C)=O)CC1.CCC1CN(CC(C)=O)CCN(CC(C)=O)CCN(CC(C)=O)CCN1CC(C)=O Chemical compound C=CC(=O)NCC1CN(CC(C)=O)CCN(CC(C)=O)CCN(CC(C)=O)CCN1CC(C)=O.CC(=O)CN1CCN(CC(C)=O)CCN(CC(C)=O)C(CNC(=O)CBr)CN(CC(C)=O)CC1.CCC1CN(CC(C)=O)CCN(CC(C)=O)CCN(CC(C)=O)CCN1CC(C)=O VMGBWMOHSCQEFR-UHFFFAOYSA-N 0.000 description 1
- UCVTVPMXLVNKDE-UHFFFAOYSA-N C=CC(=O)OCC1=CC=CC=C1.CC(C)(C)OC(=O)NCCN(CCNC(=O)OC(C)(C)C)CCC(=O)OCC1=CC=CC=C1.CC(C)(C)OC(=O)NCCNCCNC(=O)OC(C)(C)C.CC(C)(C)OC(=O)ON.CCCN(CCC)CCC(=O)O.CCCN(CCC)CCC(=O)OCC1=CC=CC=C1.NCCN(CCN)CCC(=O)OCC1=CC=CC=C1.NCCNCCN Chemical compound C=CC(=O)OCC1=CC=CC=C1.CC(C)(C)OC(=O)NCCN(CCNC(=O)OC(C)(C)C)CCC(=O)OCC1=CC=CC=C1.CC(C)(C)OC(=O)NCCNCCNC(=O)OC(C)(C)C.CC(C)(C)OC(=O)ON.CCCN(CCC)CCC(=O)O.CCCN(CCC)CCC(=O)OCC1=CC=CC=C1.NCCN(CCN)CCC(=O)OCC1=CC=CC=C1.NCCNCCN UCVTVPMXLVNKDE-UHFFFAOYSA-N 0.000 description 1
- ORVJKDLMMYXHJC-VFECSPBCSA-N C=NOCC(=O)NCCN(CCCCCNC(=O)CONC(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(=O)NC)C(=O)C(C)CC.CC(O)[C@@H]1NC(=O)CNC(=O)[C@H](CC2=CC=C(O)C=C2)NC(=O)[C@H](CC2=CC=C(O)C=C2)NC(=O)[C@H](CC(=O)O)NC(=O)[C@@H](C)CSSC[C@@H](C(=O)N[C@@H](CC2=CC=C(C3=CC=CC=C3)C=C2)C(=O)N[C@H](CC(=O)O)C(N)=O)NC1=O Chemical compound C=NOCC(=O)NCCN(CCCCCNC(=O)CONC(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(=O)NC)C(=O)C(C)CC.CC(O)[C@@H]1NC(=O)CNC(=O)[C@H](CC2=CC=C(O)C=C2)NC(=O)[C@H](CC2=CC=C(O)C=C2)NC(=O)[C@H](CC(=O)O)NC(=O)[C@@H](C)CSSC[C@@H](C(=O)N[C@@H](CC2=CC=C(C3=CC=CC=C3)C=C2)C(=O)N[C@H](CC(=O)O)C(N)=O)NC1=O ORVJKDLMMYXHJC-VFECSPBCSA-N 0.000 description 1
- OHPMISQPXQRUSG-UHFFFAOYSA-N CC(=O)CCCC(=O)O.O=C1CCCC(=O)O1 Chemical compound CC(=O)CCCC(=O)O.O=C1CCCC(=O)O1 OHPMISQPXQRUSG-UHFFFAOYSA-N 0.000 description 1
- ZPMUXYFVJKXMLA-OXYZELJTSA-N CC(=O)CN1CCN(CC(C)=O)CCN(C(CCC(=O)NCC[C@H](NC(=O)CCC(C(C)=O)N2CCN(CC(C)=O)CCN(CC(C)=O)CCN(CC(C)=O)CC2)C(C)=O)C(C)=O)CCN(CC(C)=O)CC1.CC(=O)CN1CCN(CC(C)=O)CCN(C(CCC(=O)NC[C@H](NC(=O)CCC(C(C)=O)N2CCN(CC(C)=O)CCN(CC(C)=O)CCN(CC(C)=O)CC2)C(C)=O)C(C)=O)CCN(CC(C)=O)CC1 Chemical compound CC(=O)CN1CCN(CC(C)=O)CCN(C(CCC(=O)NCC[C@H](NC(=O)CCC(C(C)=O)N2CCN(CC(C)=O)CCN(CC(C)=O)CCN(CC(C)=O)CC2)C(C)=O)C(C)=O)CCN(CC(C)=O)CC1.CC(=O)CN1CCN(CC(C)=O)CCN(C(CCC(=O)NC[C@H](NC(=O)CCC(C(C)=O)N2CCN(CC(C)=O)CCN(CC(C)=O)CCN(CC(C)=O)CC2)C(C)=O)C(C)=O)CCN(CC(C)=O)CC1 ZPMUXYFVJKXMLA-OXYZELJTSA-N 0.000 description 1
- WLDMKJCGHAQYET-UHFFFAOYSA-N CC(=O)CN1CCN(CC(C)=O)CCN(C(CCC(=O)O)C(C)=O)CCN(CC(C)=O)CC1.CC(=O)CN1CCN(CC(C)=O)CCN(C(CCN=C=O)C(C)=O)CCN(CC(C)=O)CC1.CC(=O)CN1CCN(CC(C)=O)CCN(C(CCN=C=S)C(C)=O)CCN(CC(C)=O)CC1 Chemical compound CC(=O)CN1CCN(CC(C)=O)CCN(C(CCC(=O)O)C(C)=O)CCN(CC(C)=O)CC1.CC(=O)CN1CCN(CC(C)=O)CCN(C(CCN=C=O)C(C)=O)CCN(CC(C)=O)CC1.CC(=O)CN1CCN(CC(C)=O)CCN(C(CCN=C=S)C(C)=O)CCN(CC(C)=O)CC1 WLDMKJCGHAQYET-UHFFFAOYSA-N 0.000 description 1
- ALQXTEDQCKNXHZ-UHFFFAOYSA-N CC(=O)CN1CCN(CC(C)=O)CCN(C(CCNC(=O)N2C=CN=C2)C(C)=O)CCN(CC(C)=O)CC1.CC(=O)CN1CCN(CC(C)=O)CCN(C(CCOC(=O)N2C=CN=C2)C(C)=O)CCN(CC(C)=O)CC1.[H]C(=O)CCC(C(C)=O)N1CCN(CC(C)=O)CCN(CC(C)=O)CCN(CC(C)=O)CC1 Chemical compound CC(=O)CN1CCN(CC(C)=O)CCN(C(CCNC(=O)N2C=CN=C2)C(C)=O)CCN(CC(C)=O)CC1.CC(=O)CN1CCN(CC(C)=O)CCN(C(CCOC(=O)N2C=CN=C2)C(C)=O)CCN(CC(C)=O)CC1.[H]C(=O)CCC(C(C)=O)N1CCN(CC(C)=O)CCN(CC(C)=O)CCN(CC(C)=O)CC1 ALQXTEDQCKNXHZ-UHFFFAOYSA-N 0.000 description 1
- OSGOVRDIEDYKJT-UHFFFAOYSA-N CC(=O)CN1CCN(CC(C)=O)CCN(CC(C)=O)C(C(=O)O)CN(CC(C)=O)CC1.CC(=O)CN1CCN(CC(C)=O)CCN(CC(C)=O)C(CN=C=O)CN(CC(C)=O)CC1.CC(=O)CN1CCN(CC(C)=O)CCN(CC(C)=O)C(CN=C=S)CN(CC(C)=O)CC1 Chemical compound CC(=O)CN1CCN(CC(C)=O)CCN(CC(C)=O)C(C(=O)O)CN(CC(C)=O)CC1.CC(=O)CN1CCN(CC(C)=O)CCN(CC(C)=O)C(CN=C=O)CN(CC(C)=O)CC1.CC(=O)CN1CCN(CC(C)=O)CCN(CC(C)=O)C(CN=C=S)CN(CC(C)=O)CC1 OSGOVRDIEDYKJT-UHFFFAOYSA-N 0.000 description 1
- JWGFQWUKAWPYFB-UHFFFAOYSA-M CC(=O)CN1CCN(CC(C)=O)CCN(CC(C)=O)C(CN)CN(CC(C)=O)CC1.CC(=O)CN1CCN(CC(C)=O)CCN(CC(C)=O)C(COP(=O)([O-])OCC(=O)O)CN(CC(C)=O)CC1 Chemical compound CC(=O)CN1CCN(CC(C)=O)CCN(CC(C)=O)C(CN)CN(CC(C)=O)CC1.CC(=O)CN1CCN(CC(C)=O)CCN(CC(C)=O)C(COP(=O)([O-])OCC(=O)O)CN(CC(C)=O)CC1 JWGFQWUKAWPYFB-UHFFFAOYSA-M 0.000 description 1
- GNBNCZGGIFHSJO-UHFFFAOYSA-N CC(=O)CN1CCN(CC(C)=O)CCN(CC(C)=O)C(CNC(=O)N2C=CN=C2)CN(CC(C)=O)CC1.CC(=O)CN1CCN(CC(C)=O)CCN(CC(C)=O)C(COC(=O)N2C=CN=C2)CN(CC(C)=O)CC1.[H]C(=O)C1CN(CC(C)=O)CCN(CC(C)=O)CCN(CC(C)=O)CCN1CC(C)=O Chemical compound CC(=O)CN1CCN(CC(C)=O)CCN(CC(C)=O)C(CNC(=O)N2C=CN=C2)CN(CC(C)=O)CC1.CC(=O)CN1CCN(CC(C)=O)CCN(CC(C)=O)C(COC(=O)N2C=CN=C2)CN(CC(C)=O)CC1.[H]C(=O)C1CN(CC(C)=O)CCN(CC(C)=O)CCN(CC(C)=O)CCN1CC(C)=O GNBNCZGGIFHSJO-UHFFFAOYSA-N 0.000 description 1
- AOUHSUWJKDGIOI-UHFFFAOYSA-N CC(=O)CN1CCN(CC(C)=O)CCN(CC(C)=O)CC1 Chemical compound CC(=O)CN1CCN(CC(C)=O)CCN(CC(C)=O)CC1 AOUHSUWJKDGIOI-UHFFFAOYSA-N 0.000 description 1
- BMGPITILIHECBL-SZMZYLLISA-N CC(=O)C[C@H](NC(=O)[C@@H](C)CC1=CC=C(C2=CC=CC=C2)C=C1)C(=O)NCC1=CC=CC(CNC(C2=CC=CC=C2)(C2=CC=CC=C2)C2=CC=C(C)C=C2)=C1.CC(=O)C[C@H](NC(=O)[C@H](CC1=CC=C(C2=CC=CC=C2)C=C1)NC(=O)[C@@H]1CSSC[C@H](NC(=O)[C@@H]2CCCN2C(=O)[C@@H](N)CC(C)C)C(=O)N[C@@H](CC(C)=O)C(=O)N[C@@H](CC2=CC=C(C)C=C2)C(=O)N[C@@H](CC2=CC=C(C)C=C2)C(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N1)C(=O)NCC1=CC=CC(CN)=C1.CNC(=O)[C@@H]1CSSC[C@H](NC(=O)[C@@H]2CCCN2C(=O)[C@@H](N)CC(C)C)C(=O)N[C@@H](CC(C)=O)C(=O)N[C@@H](CC2=CC=C(C)C=C2)C(=O)N[C@@H](CC2=CC=C(C)C=C2)C(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N1 Chemical compound CC(=O)C[C@H](NC(=O)[C@@H](C)CC1=CC=C(C2=CC=CC=C2)C=C1)C(=O)NCC1=CC=CC(CNC(C2=CC=CC=C2)(C2=CC=CC=C2)C2=CC=C(C)C=C2)=C1.CC(=O)C[C@H](NC(=O)[C@H](CC1=CC=C(C2=CC=CC=C2)C=C1)NC(=O)[C@@H]1CSSC[C@H](NC(=O)[C@@H]2CCCN2C(=O)[C@@H](N)CC(C)C)C(=O)N[C@@H](CC(C)=O)C(=O)N[C@@H](CC2=CC=C(C)C=C2)C(=O)N[C@@H](CC2=CC=C(C)C=C2)C(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N1)C(=O)NCC1=CC=CC(CN)=C1.CNC(=O)[C@@H]1CSSC[C@H](NC(=O)[C@@H]2CCCN2C(=O)[C@@H](N)CC(C)C)C(=O)N[C@@H](CC(C)=O)C(=O)N[C@@H](CC2=CC=C(C)C=C2)C(=O)N[C@@H](CC2=CC=C(C)C=C2)C(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N1 BMGPITILIHECBL-SZMZYLLISA-N 0.000 description 1
- WZDAMLHVZVQDTE-LOJKLJCLSA-N CC(=O)C[C@H](NC(=O)[C@H](CC1=CC=C(C2=CC=CC=C2)C=C1)NC(=O)[C@@H]1CSSC[C@H](NC(=O)[C@@H]2CCCN2C(=O)[C@@H](N)CC(C)C)C(=O)N[C@@H](CC(C)=O)C(=O)N[C@@H](CC2=CC=C(C)C=C2)C(=O)N[C@@H](CC2=CC=C(C)C=C2)C(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N1)C(=O)NCC1=CC=CC(CN)=C1.CC[C@H](NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC1=CC=C(C)C=C1)NC(=O)[C@H](CC1=CC=C(C)C=C1)NC(=O)[C@H](CC(C)=O)NC(=O)[C@H](CC)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)CC(C)C)C(C)C)C(=O)N[C@@H](CC1=CC=C(C2=CC=CC=C2)C=C1)C(=O)N[C@@H](CC(C)=O)C(=O)NCC1=CC=CC(CN)=C1.CNCCN(CCNC)CC(=O)O Chemical compound CC(=O)C[C@H](NC(=O)[C@H](CC1=CC=C(C2=CC=CC=C2)C=C1)NC(=O)[C@@H]1CSSC[C@H](NC(=O)[C@@H]2CCCN2C(=O)[C@@H](N)CC(C)C)C(=O)N[C@@H](CC(C)=O)C(=O)N[C@@H](CC2=CC=C(C)C=C2)C(=O)N[C@@H](CC2=CC=C(C)C=C2)C(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N1)C(=O)NCC1=CC=CC(CN)=C1.CC[C@H](NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC1=CC=C(C)C=C1)NC(=O)[C@H](CC1=CC=C(C)C=C1)NC(=O)[C@H](CC(C)=O)NC(=O)[C@H](CC)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)CC(C)C)C(C)C)C(=O)N[C@@H](CC1=CC=C(C2=CC=CC=C2)C=C1)C(=O)N[C@@H](CC(C)=O)C(=O)NCC1=CC=CC(CN)=C1.CNCCN(CCNC)CC(=O)O WZDAMLHVZVQDTE-LOJKLJCLSA-N 0.000 description 1
- BWAQADJLAQLBLO-UHFFFAOYSA-N CC(=O)Cl.O=C(NCC[SH]=P)C1=CC=C(C(Cl)(C2=CC=CC=C2)C2=CC=CC=C2)C=C1.O=C(NCC[SH]=P)C1=CC=C(C(O)(C2=CC=CC=C2)C2=CC=CC=C2)C=C1 Chemical compound CC(=O)Cl.O=C(NCC[SH]=P)C1=CC=C(C(Cl)(C2=CC=CC=C2)C2=CC=CC=C2)C=C1.O=C(NCC[SH]=P)C1=CC=C(C(O)(C2=CC=CC=C2)C2=CC=CC=C2)C=C1 BWAQADJLAQLBLO-UHFFFAOYSA-N 0.000 description 1
- CDXYBVDXTRAFFC-HDXCKNHGSA-N CC(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@H]1CSSC[C@@H](C(=O)N[C@@H](CC2=CNC=N2)C(C)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC2=CC(Cl)=C(O)C=C2)NC(=O)C2CC(O)CN2C1=O.CCC.CCC(C)[C@H](NC)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)NCC(=O)ON1C(=O)CCC1=O.CCCCCN.CCCCCN.CCCCCN Chemical compound CC(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@H]1CSSC[C@@H](C(=O)N[C@@H](CC2=CNC=N2)C(C)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC2=CC(Cl)=C(O)C=C2)NC(=O)C2CC(O)CN2C1=O.CCC.CCC(C)[C@H](NC)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)NCC(=O)ON1C(=O)CCC1=O.CCCCCN.CCCCCN.CCCCCN CDXYBVDXTRAFFC-HDXCKNHGSA-N 0.000 description 1
- GRKKDFSEIIQIGB-SVSBDMTBSA-N CC(=O)N[C@H](CC1=CC=CC=C1)C(=O)N[C@H](CC1=CNC=N1)C(=O)N[C@@H]1CSSC[C@H](C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](CC(=O)O)NC(=O)[C@@H](CC2=CC(Cl)=C(O)C=C2)NC(=O)[C@H]2CC(O)CN2C1=O.CCC.CCCCCN.CCCCCN.CCCCCNC(=O)CNC(=O)CNC(=O)[C@@H](CC(C)C)NC(=O)[C@H](NC(=O)[C@@H](CC1=CNC=N1)NC(C)=O)C(C)CC Chemical compound CC(=O)N[C@H](CC1=CC=CC=C1)C(=O)N[C@H](CC1=CNC=N1)C(=O)N[C@@H]1CSSC[C@H](C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](CC(=O)O)NC(=O)[C@@H](CC2=CC(Cl)=C(O)C=C2)NC(=O)[C@H]2CC(O)CN2C1=O.CCC.CCCCCN.CCCCCN.CCCCCNC(=O)CNC(=O)CNC(=O)[C@@H](CC(C)C)NC(=O)[C@H](NC(=O)[C@@H](CC1=CNC=N1)NC(C)=O)C(C)CC GRKKDFSEIIQIGB-SVSBDMTBSA-N 0.000 description 1
- YATDCPCBJYNULJ-UHFFFAOYSA-N CC(C)(C)NCC(=O)NCC(=O)C(C)(C)C Chemical compound CC(C)(C)NCC(=O)NCC(=O)C(C)(C)C YATDCPCBJYNULJ-UHFFFAOYSA-N 0.000 description 1
- XGSXYPLTBHTMGC-UHFFFAOYSA-N CC(C)(C)OC(=O)NCCN(CC(CO)NC(=O)OC(C)(C)C)C(=O)OC(C)(C)C.CC(C)(C)OC(=O)OC(=O)OC(C)(C)C.Cl.Cl.Cl.NCCNCC(N)CO Chemical compound CC(C)(C)OC(=O)NCCN(CC(CO)NC(=O)OC(C)(C)C)C(=O)OC(C)(C)C.CC(C)(C)OC(=O)OC(=O)OC(C)(C)C.Cl.Cl.Cl.NCCNCC(N)CO XGSXYPLTBHTMGC-UHFFFAOYSA-N 0.000 description 1
- NDBJUPQAKUNKFG-UHFFFAOYSA-N CC(C)(C)OC(=O)NCCN(CC(NC(=O)OC(C)(C)C)C(=O)O)C(=O)OC(C)(C)C.CC(C)(C)OC(=O)NCCN(CC(NC(=O)OC(C)(C)C)C(=O)OCC1=CC=CC=C1)C(=O)OC(C)(C)C Chemical compound CC(C)(C)OC(=O)NCCN(CC(NC(=O)OC(C)(C)C)C(=O)O)C(=O)OC(C)(C)C.CC(C)(C)OC(=O)NCCN(CC(NC(=O)OC(C)(C)C)C(=O)OCC1=CC=CC=C1)C(=O)OC(C)(C)C NDBJUPQAKUNKFG-UHFFFAOYSA-N 0.000 description 1
- GTRIWSTWFZIZCU-UXCSQNNLSA-J CC(C)C[C@@H]1NC(=O)CNC(=O)[C@H](CC2=CC(Cl)=C(O)C=C2)NC(=O)C2C[C@@H](O)CN2C(=O)[C@@H](NC(=O)[C@@H](CCC(=O)O)NC(=O)[C@H](CC2=CNC3=C2C=CC=C3)NC(=O)[C@H](CCNC(=O)CCC(C(=O)O)N2CCN(CC(=O)[O-])CCN(CC(=O)[O-])CCN(CC(=O)O)CC2)N[C-](=O)CCC(C(=O)[O-])N2CCN(CC(=O)[O-])CCN(CC(=O)O)CCN(CC(=O)O)CC2)CSSC[C@@H](C)NC1=O.CNCCN(CCNC)CC(=O)NCC1=CC(CNC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC2=CC=C(C3=CC=CC=C3)C=C2)NC(C)=O)=CC=C1.CNCCN(CCNC)CC(=O)N[C@@H](CC(C)C)C(=O)N1CCCC1C(=O)N[C@H]1CSSC[C@@H](C)NC(=O)[C@H](C(C)O)NC(=O)CNC(=O)[C@H](CC2=CC=C(O)C=C2)NC(=O)[C@H](CC2=CC=C(O)C=C2)NC(=O)[C@H](CC(=O)O)NC1=O.[Gd].[Gd] Chemical compound CC(C)C[C@@H]1NC(=O)CNC(=O)[C@H](CC2=CC(Cl)=C(O)C=C2)NC(=O)C2C[C@@H](O)CN2C(=O)[C@@H](NC(=O)[C@@H](CCC(=O)O)NC(=O)[C@H](CC2=CNC3=C2C=CC=C3)NC(=O)[C@H](CCNC(=O)CCC(C(=O)O)N2CCN(CC(=O)[O-])CCN(CC(=O)[O-])CCN(CC(=O)O)CC2)N[C-](=O)CCC(C(=O)[O-])N2CCN(CC(=O)[O-])CCN(CC(=O)O)CCN(CC(=O)O)CC2)CSSC[C@@H](C)NC1=O.CNCCN(CCNC)CC(=O)NCC1=CC(CNC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC2=CC=C(C3=CC=CC=C3)C=C2)NC(C)=O)=CC=C1.CNCCN(CCNC)CC(=O)N[C@@H](CC(C)C)C(=O)N1CCCC1C(=O)N[C@H]1CSSC[C@@H](C)NC(=O)[C@H](C(C)O)NC(=O)CNC(=O)[C@H](CC2=CC=C(O)C=C2)NC(=O)[C@H](CC2=CC=C(O)C=C2)NC(=O)[C@H](CC(=O)O)NC1=O.[Gd].[Gd] GTRIWSTWFZIZCU-UXCSQNNLSA-J 0.000 description 1
- RCJAASSKGPTCBM-RQKCAMDLSA-J CC(C)C[C@@H]1NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC2=CC(Cl)=C(O)C=C2)NC(=O)C2CC(O)CN2C(=O)[C@@H](NC(=O)[C@H](CC2=CNC=N2)NC(=O)[C@@H](C)CC2=CC=CC=C2)CSSC[C@@H](C)NC1=O.CCC(C)[C@H](NC(=O)[C@H](CC1=CNC=N1)NC(C)=O)C(=O)N[C@@H](CC(C)C)C(=O)NCC1=CC=C(CNC(=O)CN(CCNC(=O)CCC(C(=O)[O-])N2CCN(CC(=O)[O-])CCN(CC(=O)O)CCN(CC(=O)O)CC2)CCNC(=O)CCC(C(=O)[O-])N2CCN(CC(=O)[O-])CCN(CC(=O)O)CCN(CC(=O)O)CC2)C=C1.[Gd].[Gd] Chemical compound CC(C)C[C@@H]1NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC2=CC(Cl)=C(O)C=C2)NC(=O)C2CC(O)CN2C(=O)[C@@H](NC(=O)[C@H](CC2=CNC=N2)NC(=O)[C@@H](C)CC2=CC=CC=C2)CSSC[C@@H](C)NC1=O.CCC(C)[C@H](NC(=O)[C@H](CC1=CNC=N1)NC(C)=O)C(=O)N[C@@H](CC(C)C)C(=O)NCC1=CC=C(CNC(=O)CN(CCNC(=O)CCC(C(=O)[O-])N2CCN(CC(=O)[O-])CCN(CC(=O)O)CCN(CC(=O)O)CC2)CCNC(=O)CCC(C(=O)[O-])N2CCN(CC(=O)[O-])CCN(CC(=O)O)CCN(CC(=O)O)CC2)C=C1.[Gd].[Gd] RCJAASSKGPTCBM-RQKCAMDLSA-J 0.000 description 1
- YJERVXSVYPXUIF-FXNIIUOHSA-H CC(C)C[C@@H]1NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC2=CC(Cl)=C(O)C=C2)NC(=O)C2CC(O)CN2C(=O)[C@@H](NC(=O)[C@H](CC2=CNC=N2)NC(=O)[C@@H](C)CC2=CC=CC=C2)CSSC[C@@H](C)NC1=O.CNC(=O)CN(CCNC(=O)[C@H](CCNC(=O)CCC(C(=O)O)N1CCN(CC(=O)[O-])CCN(CC(=O)[O-])CCN(CC(=O)O)CC1)NC(=O)CCC(C(=O)O)N1CCN(CC(=O)[O-])CCN(CC(=O)[O-])CCN(CC(=O)O)CC1)CCNC(=O)[C@H](CCNC(=O)CCC(C(=O)O)N1CCN(CC(=O)[O-])CCN(CC(=O)[O-])CCN(CC(=O)O)CC1)NC(=O)CCC(C(=O)O)N1CCN(CC(=O)O)CCN(CC(=O)O)CCN(CC(=O)O)CC1.[Gd].[Gd].[Gd].[Gd] Chemical compound CC(C)C[C@@H]1NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC2=CC(Cl)=C(O)C=C2)NC(=O)C2CC(O)CN2C(=O)[C@@H](NC(=O)[C@H](CC2=CNC=N2)NC(=O)[C@@H](C)CC2=CC=CC=C2)CSSC[C@@H](C)NC1=O.CNC(=O)CN(CCNC(=O)[C@H](CCNC(=O)CCC(C(=O)O)N1CCN(CC(=O)[O-])CCN(CC(=O)[O-])CCN(CC(=O)O)CC1)NC(=O)CCC(C(=O)O)N1CCN(CC(=O)[O-])CCN(CC(=O)[O-])CCN(CC(=O)O)CC1)CCNC(=O)[C@H](CCNC(=O)CCC(C(=O)O)N1CCN(CC(=O)[O-])CCN(CC(=O)[O-])CCN(CC(=O)O)CC1)NC(=O)CCC(C(=O)O)N1CCN(CC(=O)O)CCN(CC(=O)O)CCN(CC(=O)O)CC1.[Gd].[Gd].[Gd].[Gd] YJERVXSVYPXUIF-FXNIIUOHSA-H 0.000 description 1
- XEGSXFXPVREAFZ-UMNXTKDQSA-B CC(C)C[C@@H]1NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC2=CC(Cl)=C(O)C=C2)NC(=O)C2CC(O)CN2C(=O)[C@@H](NC(=O)[C@H](CC2=CNC=N2)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CNC(=O)[C@H](CCNC(=O)CCC(C(=O)O)N2CCN(CC(=O)[O-])CCN(CC(=O)[O-])CCN(CC(=O)O)CC2)NC(=O)C(C(=O)[O-])N2CCN(CC(=O)[O-])CCN(CC(=O)O)CCN(CC(=O)O)CC2)NC(=O)[C@H](CCNC(=O)CCC(C(=O)O)N2CCN(CC(=O)[O-])CCN(CC(=O)[O-])CCN(CC(=O)O)CC2)NC(=O)CCC(C(=O)O)N2CCN(CC(=O)[O-])CCN(CC(=O)[O-])CCN(CC(=O)O)CC2)CSSC[C@@H](C)NC1=O.CCC(C)[C@H](NC(=O)[C@H](CC1=CNC=N1)NC(C)=O)C(=O)N[C@@H](CC(C)C)C(=O)NCC1=CC=C(CNC(=O)[C@H](CCNC(=O)CCC(C(=O)[O-])N2CCN(CC(=O)[O-])CCN(CC(=O)O)CCN(CC(=O)O)CC2)NC(=O)CCC(C(=O)[O-])N2CCN(CC(=O)[O-])CCN(CC(=O)O)CCN(CC(=O)O)CC2)C=C1.[Gd].[Gd].[Gd].[Gd].[Gd].[Gd] Chemical compound CC(C)C[C@@H]1NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC2=CC(Cl)=C(O)C=C2)NC(=O)C2CC(O)CN2C(=O)[C@@H](NC(=O)[C@H](CC2=CNC=N2)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CNC(=O)[C@H](CCNC(=O)CCC(C(=O)O)N2CCN(CC(=O)[O-])CCN(CC(=O)[O-])CCN(CC(=O)O)CC2)NC(=O)C(C(=O)[O-])N2CCN(CC(=O)[O-])CCN(CC(=O)O)CCN(CC(=O)O)CC2)NC(=O)[C@H](CCNC(=O)CCC(C(=O)O)N2CCN(CC(=O)[O-])CCN(CC(=O)[O-])CCN(CC(=O)O)CC2)NC(=O)CCC(C(=O)O)N2CCN(CC(=O)[O-])CCN(CC(=O)[O-])CCN(CC(=O)O)CC2)CSSC[C@@H](C)NC1=O.CCC(C)[C@H](NC(=O)[C@H](CC1=CNC=N1)NC(C)=O)C(=O)N[C@@H](CC(C)C)C(=O)NCC1=CC=C(CNC(=O)[C@H](CCNC(=O)CCC(C(=O)[O-])N2CCN(CC(=O)[O-])CCN(CC(=O)O)CCN(CC(=O)O)CC2)NC(=O)CCC(C(=O)[O-])N2CCN(CC(=O)[O-])CCN(CC(=O)O)CCN(CC(=O)O)CC2)C=C1.[Gd].[Gd].[Gd].[Gd].[Gd].[Gd] XEGSXFXPVREAFZ-UMNXTKDQSA-B 0.000 description 1
- QCPRXXRGUNRGNC-PJOBQMEGSA-J CC(C)C[C@@H]1NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC2=CC(Cl)=C(O)C=C2)N[C@H](O)C2CC(O)CN2C(=O)[C@@H](NC(=O)[C@H](CC2=CNC=N2)NC(=O)[C@@H](C)CC2=CC=CC=C2)CSSC[C@@H](C)NC1=O.CCC(C)[C@H](NC(=O)[C@H](CC1=CNC=N1)NC(C)=O)C(=O)N[C@@H](CC(C)C)C(=O)NCC1=CC=C(CNC(=O)[C@H](CNC(=O)CCC(C(=O)[O-])N2CCN(CC(=O)[O-])CCN(CC(=O)O)CCN(CC(=O)O)CC2)NC(=O)CCC(C(=O)[O-])N2CCN(CC(=O)[O-])CCN(CC(=O)O)CCN(CC(=O)O)CC2)C=C1.[Gd].[Gd] Chemical compound CC(C)C[C@@H]1NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC2=CC(Cl)=C(O)C=C2)N[C@H](O)C2CC(O)CN2C(=O)[C@@H](NC(=O)[C@H](CC2=CNC=N2)NC(=O)[C@@H](C)CC2=CC=CC=C2)CSSC[C@@H](C)NC1=O.CCC(C)[C@H](NC(=O)[C@H](CC1=CNC=N1)NC(C)=O)C(=O)N[C@@H](CC(C)C)C(=O)NCC1=CC=C(CNC(=O)[C@H](CNC(=O)CCC(C(=O)[O-])N2CCN(CC(=O)[O-])CCN(CC(=O)O)CCN(CC(=O)O)CC2)NC(=O)CCC(C(=O)[O-])N2CCN(CC(=O)[O-])CCN(CC(=O)O)CCN(CC(=O)O)CC2)C=C1.[Gd].[Gd] QCPRXXRGUNRGNC-PJOBQMEGSA-J 0.000 description 1
- BQZJQYIBZKVCJO-JYKBTEBVSA-F CC(C)C[C@@H]1NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC2=CC(Cl)=C(O)C=C2)N[C@H](O)C2CC(O)CN2C(=O)[C@@H](NC(=O)[C@H](CC2=CNC=N2)NC(=O)[C@@H](C)CC2=CC=CC=C2)CSSC[C@@H](C)NC1=O.CNC(=O)[C@H](CNC(=O)[C@H](CCNC(=O)CCC(C(=O)O)N1CCN(CC(=O)[O-])CCN(CC(=O)[O-])CCN(CC(=O)O)CC1)NC(=O)CCC(C(=O)[O-])N1CCN(CC(=O)[O-])CCN(CC(=O)O)CCN(CC(=O)O)CC1)NC(=O)[C@H](CNC(=O)CCC(C(=O)O)N1CCN(CC(=O)[O-])CCN(CC(=O)[O-])CCN(CC(=O)O)CC1)NC(=O)CCC(C(=O)O)N1CCN(CC(=O)[O-])CCN(CC(=O)[O-])CCN(CC(=O)O)CC1.[Gd].[Gd].[Gd].[Gd] Chemical compound CC(C)C[C@@H]1NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC2=CC(Cl)=C(O)C=C2)N[C@H](O)C2CC(O)CN2C(=O)[C@@H](NC(=O)[C@H](CC2=CNC=N2)NC(=O)[C@@H](C)CC2=CC=CC=C2)CSSC[C@@H](C)NC1=O.CNC(=O)[C@H](CNC(=O)[C@H](CCNC(=O)CCC(C(=O)O)N1CCN(CC(=O)[O-])CCN(CC(=O)[O-])CCN(CC(=O)O)CC1)NC(=O)CCC(C(=O)[O-])N1CCN(CC(=O)[O-])CCN(CC(=O)O)CCN(CC(=O)O)CC1)NC(=O)[C@H](CNC(=O)CCC(C(=O)O)N1CCN(CC(=O)[O-])CCN(CC(=O)[O-])CCN(CC(=O)O)CC1)NC(=O)CCC(C(=O)O)N1CCN(CC(=O)[O-])CCN(CC(=O)[O-])CCN(CC(=O)O)CC1.[Gd].[Gd].[Gd].[Gd] BQZJQYIBZKVCJO-JYKBTEBVSA-F 0.000 description 1
- RDLHBAHBOKUYKL-FBXLYHSKSA-N CC(C)C[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@H]1CSSC[C@@H]([C@@H](O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(=O)O)C(N)=O)NC(=O)[C@H](C(C)O)NC(=O)CNC(=O)[C@H](CC2=CC=C(O)C=C2)NC(=O)[C@H](CC2=CC=C(O)C=C2)NC(=O)[C@H](CC(=O)O)N[C@@H]1O Chemical compound CC(C)C[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@H]1CSSC[C@@H]([C@@H](O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(=O)O)C(N)=O)NC(=O)[C@H](C(C)O)NC(=O)CNC(=O)[C@H](CC2=CC=C(O)C=C2)NC(=O)[C@H](CC2=CC=C(O)C=C2)NC(=O)[C@H](CC(=O)O)N[C@@H]1O RDLHBAHBOKUYKL-FBXLYHSKSA-N 0.000 description 1
- FPEFVFJHEXSRKB-CMEHWHEOSA-N CC(C)C[C@H](NC(=O)C1=CC=C(C2=CC=CC=C2)C=C1)C(=O)N1CCC[C@H]1[C@H](O)N[C@H]1CSSC[C@@H](C)NC(=O)[C@H](C(C)O)NC(=O)CNC(=O)[C@H](CC2=CC=C(O)C=C2)NC(=O)[C@H](CC2=CC=C(O)C=C2)NC(=O)[C@H](CC(=O)O)NC1=O.CCC(C)C(=O)N(CCN)CCN(CCNC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(C)C)NC(C)=O)C(=O)C(C)CC Chemical compound CC(C)C[C@H](NC(=O)C1=CC=C(C2=CC=CC=C2)C=C1)C(=O)N1CCC[C@H]1[C@H](O)N[C@H]1CSSC[C@@H](C)NC(=O)[C@H](C(C)O)NC(=O)CNC(=O)[C@H](CC2=CC=C(O)C=C2)NC(=O)[C@H](CC2=CC=C(O)C=C2)NC(=O)[C@H](CC(=O)O)NC1=O.CCC(C)C(=O)N(CCN)CCN(CCNC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(C)C)NC(C)=O)C(=O)C(C)CC FPEFVFJHEXSRKB-CMEHWHEOSA-N 0.000 description 1
- CTZAOBLPOQNTTD-MQNIXKLBSA-N CC(C)C[C@H](NC(=O)[C@@H]1CSSC[C@H](C)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC2=CC=C(O)C=C2)C(=O)N[C@@H](CC2=CC=C(O)C=C2)C(=O)NCC(=O)N[C@@H](C(C)O)C(=O)N1)C(=O)N[C@@H](CC(=O)O)C(N)=O Chemical compound CC(C)C[C@H](NC(=O)[C@@H]1CSSC[C@H](C)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC2=CC=C(O)C=C2)C(=O)N[C@@H](CC2=CC=C(O)C=C2)C(=O)NCC(=O)N[C@@H](C(C)O)C(=O)N1)C(=O)N[C@@H](CC(=O)O)C(N)=O CTZAOBLPOQNTTD-MQNIXKLBSA-N 0.000 description 1
- QCVBMRYWSLKCPU-UHFFFAOYSA-N CC(C)NCCN(CCNC(C)C)C(=O)CNC(C)C Chemical compound CC(C)NCCN(CCNC(C)C)C(=O)CNC(C)C QCVBMRYWSLKCPU-UHFFFAOYSA-N 0.000 description 1
- ZMBVQHHPIWZBSB-UHFFFAOYSA-N CC(C)NCCN(CCNC(C)C)CC(=O)C(C)C Chemical compound CC(C)NCCN(CCNC(C)C)CC(=O)C(C)C ZMBVQHHPIWZBSB-UHFFFAOYSA-N 0.000 description 1
- AZBAZRSRYCINIR-YVZDRHRBSA-N CC(O)[C@@H]1NC(=O)CNC(=O)[C@H](CC2=CC=C(O)C=C2)NC(=O)[C@H](CC2=CC=C(O)C=C2)NC(=O)[C@H](CC(=O)O)NC(=O)[C@@H](N[C@@H](O)C2CCCN2C)CSSC[C@@H](C)NC1=O.CNCCN(CCNC)CC(=O)NCC(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N1CCCC1C(=O)N[C@H]1CSSC[C@@H](C)N[C@@H](O)[C@H](C(C)O)NC(=O)CNC(=O)[C@H](CC2=CC=C(O)C=C2)NC(=O)[C@H](CC2=CC=C(O)C=C2)NC(=O)[C@H](CC(=O)O)NC1=O.CNCCN(CCNC)CC(=O)NCCOCCOCCNC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC1=CC=C(C2=CC=CC=C2)C=C1)N[C@@H](C)O.CNCCN(CCNC)CC(=O)NCCOCCOC[C@H](O)N[C@@H](CC(C)C)C(C)=O.CNCCN(CCNC)C[C@H](O)NCC1=CC(CNC(=O)[C@H](CC(=O)O)N[C@@H](O)[C@H](CC2=CC=C(C3=CC=CC=C3)C=C2)NC(C)=O)=CC=C1 Chemical compound CC(O)[C@@H]1NC(=O)CNC(=O)[C@H](CC2=CC=C(O)C=C2)NC(=O)[C@H](CC2=CC=C(O)C=C2)NC(=O)[C@H](CC(=O)O)NC(=O)[C@@H](N[C@@H](O)C2CCCN2C)CSSC[C@@H](C)NC1=O.CNCCN(CCNC)CC(=O)NCC(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N1CCCC1C(=O)N[C@H]1CSSC[C@@H](C)N[C@@H](O)[C@H](C(C)O)NC(=O)CNC(=O)[C@H](CC2=CC=C(O)C=C2)NC(=O)[C@H](CC2=CC=C(O)C=C2)NC(=O)[C@H](CC(=O)O)NC1=O.CNCCN(CCNC)CC(=O)NCCOCCOCCNC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC1=CC=C(C2=CC=CC=C2)C=C1)N[C@@H](C)O.CNCCN(CCNC)CC(=O)NCCOCCOC[C@H](O)N[C@@H](CC(C)C)C(C)=O.CNCCN(CCNC)C[C@H](O)NCC1=CC(CNC(=O)[C@H](CC(=O)O)N[C@@H](O)[C@H](CC2=CC=C(C3=CC=CC=C3)C=C2)NC(C)=O)=CC=C1 AZBAZRSRYCINIR-YVZDRHRBSA-N 0.000 description 1
- NSDDJQCJALYCHO-UHFFFAOYSA-N CC1=CN(CC(=O)N(CCN)CC(=O)C(C)(C)C)C(=O)NC1=O.CCC Chemical compound CC1=CN(CC(=O)N(CCN)CC(=O)C(C)(C)C)C(=O)NC1=O.CCC NSDDJQCJALYCHO-UHFFFAOYSA-N 0.000 description 1
- JQPIJDSGXWELMX-OOYSOWLQSA-B CCC(=O)CN(CCNC(=O)CN(CCNC(=O)CCC(C(=O)[O-])N1CCN(CC(=O)[O-])CCN(CC(=O)O)CCN(CC(=O)O)CC1)CCNC(=O)CCC(C(=O)O)N1CCN(CC(=O)[O-])CCN(CC(=O)[O-])CCN(CC(=O)O)CC1)CCNC(=O)CN(CCNC(=O)CCC(C(=O)O)N1CCN(CC(=O)[O-])CCN(CC(=O)[O-])CCN(CC(=O)O)CC1)CCNC(=O)CCC(C(=O)O)N1CCN(CC(=O)[O-])CCN(CC(=O)[O-])CCN(CC(=O)O)CC1.CCC(C)[C@H](NC(=O)[C@H](CC1=CNC=N1)NC(C)=O)C(=O)N[C@@H](CC(C)C)C(=O)NCC1=CC=C(CNC(=O)[C@H](CCNC(=O)CCC(C(=O)[O-])N2CCN(CC(=O)[O-])CCN(CC(=O)O)CCN(CC(=O)O)CC2)NC(=O)CCC(C(=O)[O-])N2CCN(CC(=O)[O-])CCN(CC(=O)O)CCN(CC(=O)O)CC2)C=C1.[Gd].[Gd].[Gd].[Gd].[Gd].[Gd] Chemical compound CCC(=O)CN(CCNC(=O)CN(CCNC(=O)CCC(C(=O)[O-])N1CCN(CC(=O)[O-])CCN(CC(=O)O)CCN(CC(=O)O)CC1)CCNC(=O)CCC(C(=O)O)N1CCN(CC(=O)[O-])CCN(CC(=O)[O-])CCN(CC(=O)O)CC1)CCNC(=O)CN(CCNC(=O)CCC(C(=O)O)N1CCN(CC(=O)[O-])CCN(CC(=O)[O-])CCN(CC(=O)O)CC1)CCNC(=O)CCC(C(=O)O)N1CCN(CC(=O)[O-])CCN(CC(=O)[O-])CCN(CC(=O)O)CC1.CCC(C)[C@H](NC(=O)[C@H](CC1=CNC=N1)NC(C)=O)C(=O)N[C@@H](CC(C)C)C(=O)NCC1=CC=C(CNC(=O)[C@H](CCNC(=O)CCC(C(=O)[O-])N2CCN(CC(=O)[O-])CCN(CC(=O)O)CCN(CC(=O)O)CC2)NC(=O)CCC(C(=O)[O-])N2CCN(CC(=O)[O-])CCN(CC(=O)O)CCN(CC(=O)O)CC2)C=C1.[Gd].[Gd].[Gd].[Gd].[Gd].[Gd] JQPIJDSGXWELMX-OOYSOWLQSA-B 0.000 description 1
- YINOURAHCVMGFH-GOUSUKRASA-N CCC(C)C(=O)NCC1=CC=C(CNC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(C)C)NC(C)=O)C=C1.CCC(C)C(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@H]1CSSC[C@@H](C)NC(=O)[C@H](C(C)O)NC(=O)CNC(=O)[C@H](CC2=CC=C(O)C=C2)NC(=O)[C@H](CC2=CC=C(O)C=C2)NC(=O)[C@H](CC(=O)O)NC1=O Chemical compound CCC(C)C(=O)NCC1=CC=C(CNC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(C)C)NC(C)=O)C=C1.CCC(C)C(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@H]1CSSC[C@@H](C)NC(=O)[C@H](C(C)O)NC(=O)CNC(=O)[C@H](CC2=CC=C(O)C=C2)NC(=O)[C@H](CC2=CC=C(O)C=C2)NC(=O)[C@H](CC(=O)O)NC1=O YINOURAHCVMGFH-GOUSUKRASA-N 0.000 description 1
- PDZBAGREZACATG-KVFWDTBASA-N CCC(C)[C@H](NC(=O)[C@H](CC1=CNC2=C1C=CC=C2)NC(C)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC1=CC=CC(CNC(=O)CN(CCNC)CCNC)=C1.CCC(C)[C@H](NC(=O)[C@H](CC1=CNC2=C1C=CC=C2)NC(C)=O)C(=O)N[C@@H](CCC(N)=O)[C@H](O)NCCOCCN[C@@H](O)CN(CCNC)CCNC.CNCCN(CCNC)CC(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@H]1CSSC[C@@H](C)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](CC2=CC=C(O)C=C2)NC(=O)C2CCCN2C1=O.CNCCN(CCNC)CC(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)[C@H](O)N[C@@H](CCC(=O)O)C(=O)N[C@H]1CSSC[C@@H](C)N[C@@H](O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](CC2=CC=C(O)C=C2)NC(=O)C2CCCN2C1=O Chemical compound CCC(C)[C@H](NC(=O)[C@H](CC1=CNC2=C1C=CC=C2)NC(C)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC1=CC=CC(CNC(=O)CN(CCNC)CCNC)=C1.CCC(C)[C@H](NC(=O)[C@H](CC1=CNC2=C1C=CC=C2)NC(C)=O)C(=O)N[C@@H](CCC(N)=O)[C@H](O)NCCOCCN[C@@H](O)CN(CCNC)CCNC.CNCCN(CCNC)CC(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@H]1CSSC[C@@H](C)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](CC2=CC=C(O)C=C2)NC(=O)C2CCCN2C1=O.CNCCN(CCNC)CC(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)[C@H](O)N[C@@H](CCC(=O)O)C(=O)N[C@H]1CSSC[C@@H](C)N[C@@H](O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](CC2=CC=C(O)C=C2)NC(=O)C2CCCN2C1=O PDZBAGREZACATG-KVFWDTBASA-N 0.000 description 1
- FCIVBNOKEROJKJ-OMZRKMDQSA-N CCC(C)[C@H](NC(=O)[C@H](CC1=CNC2=C1C=CC=C2)NC(C)=O)C(=O)N[C@@H](CCC(N)=O)[C@H](O)NCC1=CC=C(CN[C@@H](O)CN(CCNC)CCNC)C=C1.CCC(C)[C@H](NC(=O)[C@H](CC1=CNC=N1)NC(C)=O)C(=O)N[C@@H](CC(C)C)C(=O)NCCN[C@@H](O)CN(CCNC)CCNC.CNCCN(CCNC)CC(=O)NCC(=O)NCC(=O)N[C@@H](CC1=CC=CC=C1)[C@H](O)N[C@@H](CC1=CNC=N1)C(=O)N[C@H]1CSSC[C@@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC2=CC=C(O)C=C2)NC(=O)C2CCCN2C1=O.CNCCN(CCNC)C[C@H](O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@H]1CSSC[C@@H](C)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](CC2=CC=C(O)C=C2)NC(=O)C2CCCN2C1=O Chemical compound CCC(C)[C@H](NC(=O)[C@H](CC1=CNC2=C1C=CC=C2)NC(C)=O)C(=O)N[C@@H](CCC(N)=O)[C@H](O)NCC1=CC=C(CN[C@@H](O)CN(CCNC)CCNC)C=C1.CCC(C)[C@H](NC(=O)[C@H](CC1=CNC=N1)NC(C)=O)C(=O)N[C@@H](CC(C)C)C(=O)NCCN[C@@H](O)CN(CCNC)CCNC.CNCCN(CCNC)CC(=O)NCC(=O)NCC(=O)N[C@@H](CC1=CC=CC=C1)[C@H](O)N[C@@H](CC1=CNC=N1)C(=O)N[C@H]1CSSC[C@@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC2=CC=C(O)C=C2)NC(=O)C2CCCN2C1=O.CNCCN(CCNC)C[C@H](O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@H]1CSSC[C@@H](C)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](CC2=CC=C(O)C=C2)NC(=O)C2CCCN2C1=O FCIVBNOKEROJKJ-OMZRKMDQSA-N 0.000 description 1
- PKHYWJCHYFSKAA-ZUCKGXLUSA-N CCC(C)[C@H](NC(=O)[C@H](CC1=CNC=N1)NC(=O)[C@@H]1CSSC[C@H](C)C(=O)N2CCC[C@H]2C(=O)N[C@@H](CC2=CC=C(O)C=C2)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC(C)C)C(=O)N1)C(=O)N[C@@H](CC(C)C)C(N)=O Chemical compound CCC(C)[C@H](NC(=O)[C@H](CC1=CNC=N1)NC(=O)[C@@H]1CSSC[C@H](C)C(=O)N2CCC[C@H]2C(=O)N[C@@H](CC2=CC=C(O)C=C2)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC(C)C)C(=O)N1)C(=O)N[C@@H](CC(C)C)C(N)=O PKHYWJCHYFSKAA-ZUCKGXLUSA-N 0.000 description 1
- CQOUXUTVLVFOLW-FLWUDXLZSA-N CCC(C)[C@H](NC(=O)[C@H](CC1=CNC=N1)NC(C)=O)C(=O)N[C@@H](CC(C)C)C(=O)NCC1=CC=C(CNC(=O)CN(CCNC)CCNC)C=C1.CCC(C)[C@H](NC(=O)[C@H](CC1=CNC=N1)NC(C)=O)C(=O)N[C@@H](CC(C)C)C(=O)NCCCCCNC(=O)CN(CCNC)CCNC.CNCCN(CCNC)CC(=O)N[C@@H](CC1=CC=CC=C1)[C@H](O)N[C@@H](CC1=CNC=N1)C(=O)N[C@H]1CSSC[C@@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC2=CC(Cl)=C(O)C=C2)NC(=O)[C@@H]2CC(O)CN2C1=O.CNCCN(CCNC)CC(=O)N[C@@H](CC1=CC=CC=C1)[C@H](O)N[C@@H](CC1=CNC=N1)C(=O)N[C@H]1CSSC[C@@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC2=CC=C(O)C=C2)NC(=O)[C@@H]2CCCN2C1=O Chemical compound CCC(C)[C@H](NC(=O)[C@H](CC1=CNC=N1)NC(C)=O)C(=O)N[C@@H](CC(C)C)C(=O)NCC1=CC=C(CNC(=O)CN(CCNC)CCNC)C=C1.CCC(C)[C@H](NC(=O)[C@H](CC1=CNC=N1)NC(C)=O)C(=O)N[C@@H](CC(C)C)C(=O)NCCCCCNC(=O)CN(CCNC)CCNC.CNCCN(CCNC)CC(=O)N[C@@H](CC1=CC=CC=C1)[C@H](O)N[C@@H](CC1=CNC=N1)C(=O)N[C@H]1CSSC[C@@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC2=CC(Cl)=C(O)C=C2)NC(=O)[C@@H]2CC(O)CN2C1=O.CNCCN(CCNC)CC(=O)N[C@@H](CC1=CC=CC=C1)[C@H](O)N[C@@H](CC1=CNC=N1)C(=O)N[C@H]1CSSC[C@@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC2=CC=C(O)C=C2)NC(=O)[C@@H]2CCCN2C1=O CQOUXUTVLVFOLW-FLWUDXLZSA-N 0.000 description 1
- HSCAXEHIUZYMNP-CNZGLVFKSA-B CCC(C)[C@H](NC(=O)[C@H](CC1=CNC=N1)NC(C)=O)C(=O)N[C@@H](CC(C)C)C(=O)NCC1=CC=C(CNC(=O)[C@H](CNC(=O)CCC(C(=O)[O-])N2CCN(CC(=O)[O-])CCN(CC(=O)O)CCN(CC(=O)O)CC2)NC(=O)CCC(C(=O)[O-])N2CCN(CC(=O)[O-])CCN(CC(=O)O)CCN(CC(=O)O)CC2)C=C1.CNC(=O)CN(CCNC(=O)[C@H](CNC(=O)CCC(C(=O)O)N1CCN(CC(=O)[O-])CCN(CC(=O)[O-])CCN(CC(=O)O)CC1)NC(=O)CCC(C(=O)[O-])N1CCN(CC(=O)[O-])CCN(CC(=O)O)CCN(CC(=O)O)CC1)CCNC(=O)[C@H](CNC(=O)CCC(C(=O)O)N1CCN(CC(=O)[O-])CCN(CC(=O)[O-])CCN(CC(=O)O)CC1)NC(=O)CCC(C(=O)O)N1CCN(CC(=O)[O-])CCN(CC(=O)[O-])CCN(CC(=O)O)CC1.[Gd].[Gd].[Gd].[Gd].[Gd].[Gd] Chemical compound CCC(C)[C@H](NC(=O)[C@H](CC1=CNC=N1)NC(C)=O)C(=O)N[C@@H](CC(C)C)C(=O)NCC1=CC=C(CNC(=O)[C@H](CNC(=O)CCC(C(=O)[O-])N2CCN(CC(=O)[O-])CCN(CC(=O)O)CCN(CC(=O)O)CC2)NC(=O)CCC(C(=O)[O-])N2CCN(CC(=O)[O-])CCN(CC(=O)O)CCN(CC(=O)O)CC2)C=C1.CNC(=O)CN(CCNC(=O)[C@H](CNC(=O)CCC(C(=O)O)N1CCN(CC(=O)[O-])CCN(CC(=O)[O-])CCN(CC(=O)O)CC1)NC(=O)CCC(C(=O)[O-])N1CCN(CC(=O)[O-])CCN(CC(=O)O)CCN(CC(=O)O)CC1)CCNC(=O)[C@H](CNC(=O)CCC(C(=O)O)N1CCN(CC(=O)[O-])CCN(CC(=O)[O-])CCN(CC(=O)O)CC1)NC(=O)CCC(C(=O)O)N1CCN(CC(=O)[O-])CCN(CC(=O)[O-])CCN(CC(=O)O)CC1.[Gd].[Gd].[Gd].[Gd].[Gd].[Gd] HSCAXEHIUZYMNP-CNZGLVFKSA-B 0.000 description 1
- GXGHKJIFOQRNCA-UFVPJUOXSA-N CCC(C)[C@H](NC(=O)[C@H](CC1=CNC=N1)NC(C)=O)C(=O)N[C@@H](CC(C)C)C(=O)NCC1=CC=C(CN[C@@H](O)CN(CCNC)CCNC)C=C1.CNCCN(CCNC)CC(=O)N[C@@H](CC1=CC=C(OC)C=C1)[C@H](O)N[C@@H](CC1=CNC=N1)C(=O)N[C@H]1CSSC[C@@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC2=CC(I)=C(O)C=C2)NC(=O)C2CC(O)CN2C1=O.CNCCN(CCNC)CC(=O)N[C@@H](CC1=CC=CC=C1)[C@H](O)N[C@@H](CC1=CNC=N1)C(=O)N[C@H]1CSSC[C@@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC2=CC(I)=C(O)C=C2)NC(=O)C2CC(O)CN2C1=O.CNCCN(CCNC)C[C@H](O)NCC1=CC=C(CNC(=O)[C@H](CC2=CC=CC3=CC=CC=C32)NC(=O)[C@H](CC2=CNC=N2)NC(C)=O)C=C1 Chemical compound CCC(C)[C@H](NC(=O)[C@H](CC1=CNC=N1)NC(C)=O)C(=O)N[C@@H](CC(C)C)C(=O)NCC1=CC=C(CN[C@@H](O)CN(CCNC)CCNC)C=C1.CNCCN(CCNC)CC(=O)N[C@@H](CC1=CC=C(OC)C=C1)[C@H](O)N[C@@H](CC1=CNC=N1)C(=O)N[C@H]1CSSC[C@@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC2=CC(I)=C(O)C=C2)NC(=O)C2CC(O)CN2C1=O.CNCCN(CCNC)CC(=O)N[C@@H](CC1=CC=CC=C1)[C@H](O)N[C@@H](CC1=CNC=N1)C(=O)N[C@H]1CSSC[C@@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC2=CC(I)=C(O)C=C2)NC(=O)C2CC(O)CN2C1=O.CNCCN(CCNC)C[C@H](O)NCC1=CC=C(CNC(=O)[C@H](CC2=CC=CC3=CC=CC=C32)NC(=O)[C@H](CC2=CNC=N2)NC(C)=O)C=C1 GXGHKJIFOQRNCA-UFVPJUOXSA-N 0.000 description 1
- SETNJSIDDPYXJI-ULFQOAFYSA-N CCC(C)[C@H](NC(=O)[C@H](CC1=CNC=N1)NC(C)=O)C(=O)N[C@@H](CC(C)C)C(=O)NCC1=CC=C(NC(=O)CN(CCNC)CCNC)C=C1.CCC(C)[C@H](NC(=O)[C@H](CC1=CNC=N1)NC(C)=O)C(=O)N[C@@H](CC(C)C)C(=O)NCC1=CC=CC(CNC(=O)CN(CCNC)CCNC)=C1.CNCCN(CCNC)CC(=O)NCC(=O)NCC(=O)N[C@@H](CC1=CC=CC=C1)[C@H](O)N[C@@H](CC1=CNC=N1)C(=O)N[C@H]1CSSC[C@@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC2=CC=C(O)C=C2)NC(=O)[C@@H]2CCCN2C1=O.CNCCN(CCNC)CC(=O)N[C@@H](CC1=CC=CC=C1)[C@H](O)N[C@@H](CC1=CNC=N1)C(=O)N[C@H]1CSSC[C@@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC2=CC=C(O)C=C2)NC(=O)[C@@H]2CCCN2C1=O Chemical compound CCC(C)[C@H](NC(=O)[C@H](CC1=CNC=N1)NC(C)=O)C(=O)N[C@@H](CC(C)C)C(=O)NCC1=CC=C(NC(=O)CN(CCNC)CCNC)C=C1.CCC(C)[C@H](NC(=O)[C@H](CC1=CNC=N1)NC(C)=O)C(=O)N[C@@H](CC(C)C)C(=O)NCC1=CC=CC(CNC(=O)CN(CCNC)CCNC)=C1.CNCCN(CCNC)CC(=O)NCC(=O)NCC(=O)N[C@@H](CC1=CC=CC=C1)[C@H](O)N[C@@H](CC1=CNC=N1)C(=O)N[C@H]1CSSC[C@@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC2=CC=C(O)C=C2)NC(=O)[C@@H]2CCCN2C1=O.CNCCN(CCNC)CC(=O)N[C@@H](CC1=CC=CC=C1)[C@H](O)N[C@@H](CC1=CNC=N1)C(=O)N[C@H]1CSSC[C@@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC2=CC=C(O)C=C2)NC(=O)[C@@H]2CCCN2C1=O SETNJSIDDPYXJI-ULFQOAFYSA-N 0.000 description 1
- VZBVQUXEMBDFQC-CGXPFTRXSA-N CCC(C)[C@H](NC(=O)[C@H](CC1=CNC=N1)NC(C)=O)C(=O)N[C@@H](CC(C)C)C(=O)NCCCCCNC(=O)CN(CCNC)CCNC.CNCCN(CCNC)CC(=O)NCC(=O)NCC(=O)N[C@@H](CC1=CC=CC=C1)[C@H](O)N[C@@H](CC1=CNC=N1)C(=O)N[C@H]1CSSC[C@@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC2=CC=C(O)C=C2)NC(=O)[C@@H]2CCCN2C1=O.CNCCN(CCNC)CC(=O)NCCN(CC(=O)N[C@@H](CC(C)C)[C@@H](O)N1CCCC1C(=O)N[C@H]1CSSC[C@@H](C)NC(=O)[C@H](C(C)O)NC(=O)CN[C@@H](O)[C@H](CC2=CC=C(O)C=C2)NC(=O)[C@H](CC2=CC=C(O)C=C2)NC(=O)[C@H](CC(=O)O)NC1=O)C(=O)CN1C=C(C)C(=O)NC1=O.CNCCN(CCNC)CC(=O)NCCNC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC1=CC=C(C2=CC=CC=C2)C=C1)NC(C)=O Chemical compound CCC(C)[C@H](NC(=O)[C@H](CC1=CNC=N1)NC(C)=O)C(=O)N[C@@H](CC(C)C)C(=O)NCCCCCNC(=O)CN(CCNC)CCNC.CNCCN(CCNC)CC(=O)NCC(=O)NCC(=O)N[C@@H](CC1=CC=CC=C1)[C@H](O)N[C@@H](CC1=CNC=N1)C(=O)N[C@H]1CSSC[C@@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC2=CC=C(O)C=C2)NC(=O)[C@@H]2CCCN2C1=O.CNCCN(CCNC)CC(=O)NCCN(CC(=O)N[C@@H](CC(C)C)[C@@H](O)N1CCCC1C(=O)N[C@H]1CSSC[C@@H](C)NC(=O)[C@H](C(C)O)NC(=O)CN[C@@H](O)[C@H](CC2=CC=C(O)C=C2)NC(=O)[C@H](CC2=CC=C(O)C=C2)NC(=O)[C@H](CC(=O)O)NC1=O)C(=O)CN1C=C(C)C(=O)NC1=O.CNCCN(CCNC)CC(=O)NCCNC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC1=CC=C(C2=CC=CC=C2)C=C1)NC(C)=O VZBVQUXEMBDFQC-CGXPFTRXSA-N 0.000 description 1
- SSFZBEBTFZEERL-SMUWUKPRSA-N CCC(C)[C@H](NC(=O)[C@H](CC1=CNC=N1)NC=O)C(=O)N[C@@H](CC(C)C)C(=O)NCC1=CC=C(CN[C@@H](O)CN(CCNC)CCNC)C=C1.CNCCN(CCNC)CC(=O)NCC(=O)NCC(=O)N[C@@H](CC1=CC=CC=C1)[C@H](O)N[C@@H](CC1=CNC=N1)C(=O)N[C@H]1CSSC[C@@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC2=CC=C(O)C=C2)NC(=O)C2CCCN2C1=O.CNCCN(CCNC)CC(=O)N[C@@H](CC1=CC=CC=C1)[C@H](O)N[C@@H](CC1=CNC=N1)C(=O)N[C@H]1CSSC[C@@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC2=CC(Cl)=C(O)C=C2)NC(=O)C2CC(O)CN2C1=O.CNCCN(CCNC)C[C@H](O)NCC1=CC=C(CNC(=O)[C@H](CC2=CC=CC3=CC=CC=C32)NC(=O)[C@H](CC2=CNC=N2)NC(C)=O)C=C1 Chemical compound CCC(C)[C@H](NC(=O)[C@H](CC1=CNC=N1)NC=O)C(=O)N[C@@H](CC(C)C)C(=O)NCC1=CC=C(CN[C@@H](O)CN(CCNC)CCNC)C=C1.CNCCN(CCNC)CC(=O)NCC(=O)NCC(=O)N[C@@H](CC1=CC=CC=C1)[C@H](O)N[C@@H](CC1=CNC=N1)C(=O)N[C@H]1CSSC[C@@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC2=CC=C(O)C=C2)NC(=O)C2CCCN2C1=O.CNCCN(CCNC)CC(=O)N[C@@H](CC1=CC=CC=C1)[C@H](O)N[C@@H](CC1=CNC=N1)C(=O)N[C@H]1CSSC[C@@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC2=CC(Cl)=C(O)C=C2)NC(=O)C2CC(O)CN2C1=O.CNCCN(CCNC)C[C@H](O)NCC1=CC=C(CNC(=O)[C@H](CC2=CC=CC3=CC=CC=C32)NC(=O)[C@H](CC2=CNC=N2)NC(C)=O)C=C1 SSFZBEBTFZEERL-SMUWUKPRSA-N 0.000 description 1
- VTCADXNWJSKFCZ-UHFFFAOYSA-N CCCCN(CCN(CCN(CCC)CC(O)=N)CC(O)=O)CC(N)=O Chemical compound CCCCN(CCN(CCN(CCC)CC(O)=N)CC(O)=O)CC(N)=O VTCADXNWJSKFCZ-UHFFFAOYSA-N 0.000 description 1
- OCYCZMKMMSVSRV-UHFFFAOYSA-N CCN(CC)CCN(CC)C(CN(CC)CC)C(C)=O.CCN(CC)CCN(CC)CC(C(C)=O)N(CC)CC.CCN(CC)CCN(CCN(CC)CC)C(C)C(C)=O Chemical compound CCN(CC)CCN(CC)C(CN(CC)CC)C(C)=O.CCN(CC)CCN(CC)CC(C(C)=O)N(CC)CC.CCN(CC)CCN(CCN(CC)CC)C(C)C(C)=O OCYCZMKMMSVSRV-UHFFFAOYSA-N 0.000 description 1
- PQVJVFVVFOHWRV-UHFFFAOYSA-N CCN(CC)CCN(CC)CC(C(=O)O)N(CC)CC.CCN(CC)CCN(CC)CC(CO)N(CC)CC Chemical compound CCN(CC)CCN(CC)CC(C(=O)O)N(CC)CC.CCN(CC)CCN(CC)CC(CO)N(CC)CC PQVJVFVVFOHWRV-UHFFFAOYSA-N 0.000 description 1
- NMBULAXVIHJCGP-UHFFFAOYSA-N CCN(CC)CCN(CC)CC(C(C)=O)N(CC)CC.CCN1CCN(CC)CCN(CC)C(C(C)=O)CN(CC)CC1 Chemical compound CCN(CC)CCN(CC)CC(C(C)=O)N(CC)CC.CCN1CCN(CC)CCN(CC)C(C(C)=O)CN(CC)CC1 NMBULAXVIHJCGP-UHFFFAOYSA-N 0.000 description 1
- RGAWJFFLDBWVJJ-UHFFFAOYSA-N CCN(CCN(CC(=O)OC(C)(C)C)CC(C(=O)NC(CNC(=O)C(CN(CCN(CC(=O)OC(C)(C)C)CC(=O)OC(C)(C)C)CC(=O)OC(C)(C)C)N(CC(=O)OC(C)(C)C)CC(=O)OC(C)(C)C)C(=O)O)N(CC(=O)OC(C)(C)C)CC(=O)OC(C)(C)C)CC(=O)OC(C)(C)C Chemical compound CCN(CCN(CC(=O)OC(C)(C)C)CC(C(=O)NC(CNC(=O)C(CN(CCN(CC(=O)OC(C)(C)C)CC(=O)OC(C)(C)C)CC(=O)OC(C)(C)C)N(CC(=O)OC(C)(C)C)CC(=O)OC(C)(C)C)C(=O)O)N(CC(=O)OC(C)(C)C)CC(=O)OC(C)(C)C)CC(=O)OC(C)(C)C RGAWJFFLDBWVJJ-UHFFFAOYSA-N 0.000 description 1
- VKSKCLCZYQVUQL-UHFFFAOYSA-N CCN(CCN(CC(=O)OC(C)(C)C)CC(C(=O)NCCN(C)(CCNC(=O)C(CN(CCN(CC(=O)OC(C)(C)C)CC(=O)OC(C)(C)C)CC(=O)OC(C)(C)C)N(CC(=O)OC(C)(C)C)CC(=O)OC(C)(C)C)C(=O)CN)N(CC(=O)OC(C)(C)C)CC(=O)OC(C)(C)C)CC(=O)OC(C)(C)C Chemical compound CCN(CCN(CC(=O)OC(C)(C)C)CC(C(=O)NCCN(C)(CCNC(=O)C(CN(CCN(CC(=O)OC(C)(C)C)CC(=O)OC(C)(C)C)CC(=O)OC(C)(C)C)N(CC(=O)OC(C)(C)C)CC(=O)OC(C)(C)C)C(=O)CN)N(CC(=O)OC(C)(C)C)CC(=O)OC(C)(C)C)CC(=O)OC(C)(C)C VKSKCLCZYQVUQL-UHFFFAOYSA-N 0.000 description 1
- XHORTNYAZTXLGQ-UHFFFAOYSA-N CCN(CCN(CC(=O)OC(C)(C)C)CC(C(=O)NCCN(CCNC(=O)C(CN(CCN(CC(=O)OC(C)(C)C)CC(=O)OC(C)(C)C)CC(=O)OC(C)(C)C)N(CC(=O)OC(C)(C)C)CC(=O)OC(C)(C)C)C(=O)CN)N(CC(=O)OC(C)(C)C)CC(=O)OC(C)(C)C)CC(=O)OC(C)(C)C Chemical compound CCN(CCN(CC(=O)OC(C)(C)C)CC(C(=O)NCCN(CCNC(=O)C(CN(CCN(CC(=O)OC(C)(C)C)CC(=O)OC(C)(C)C)CC(=O)OC(C)(C)C)N(CC(=O)OC(C)(C)C)CC(=O)OC(C)(C)C)C(=O)CN)N(CC(=O)OC(C)(C)C)CC(=O)OC(C)(C)C)CC(=O)OC(C)(C)C XHORTNYAZTXLGQ-UHFFFAOYSA-N 0.000 description 1
- NOOCJNPZJSGIQC-UHFFFAOYSA-N CCN(CCN(CC(=O)OC(C)(C)C)CC(C(=O)NCCN(CCNC(=O)C(CN(CCN(CC(=O)OC(C)(C)C)CC(=O)OC(C)(C)C)CC(=O)OC(C)(C)C)N(CC(=O)OC(C)(C)C)CC(=O)OC(C)(C)C)CC(C)=O)N(CC(=O)OC(C)(C)C)CC(=O)OC(C)(C)C)CC(=O)OC(C)(C)C Chemical compound CCN(CCN(CC(=O)OC(C)(C)C)CC(C(=O)NCCN(CCNC(=O)C(CN(CCN(CC(=O)OC(C)(C)C)CC(=O)OC(C)(C)C)CC(=O)OC(C)(C)C)N(CC(=O)OC(C)(C)C)CC(=O)OC(C)(C)C)CC(C)=O)N(CC(=O)OC(C)(C)C)CC(=O)OC(C)(C)C)CC(=O)OC(C)(C)C NOOCJNPZJSGIQC-UHFFFAOYSA-N 0.000 description 1
- HRQIGBGODHDDNB-JOCHJYFZSA-N CCN(CCN(CC(=O)OC(C)(C)C)C[C@H](C(=O)O)N(COC(=O)C(C)(C)C)CC(=O)OC(C)(C)C)CC(=O)OC(C)(C)C Chemical compound CCN(CCN(CC(=O)OC(C)(C)C)C[C@H](C(=O)O)N(COC(=O)C(C)(C)C)CC(=O)OC(C)(C)C)CC(=O)OC(C)(C)C HRQIGBGODHDDNB-JOCHJYFZSA-N 0.000 description 1
- XIKWMDUABOZZPS-UHFFFAOYSA-N CCN(CCN(CCN(COC(=O)C(C)(C)C)CC(=O)OC(C)(C)C)C(CC(=O)O)C(=O)OC(C)(C)C)CC(=O)OC(C)(C)C Chemical compound CCN(CCN(CCN(COC(=O)C(C)(C)C)CC(=O)OC(C)(C)C)C(CC(=O)O)C(=O)OC(C)(C)C)CC(=O)OC(C)(C)C XIKWMDUABOZZPS-UHFFFAOYSA-N 0.000 description 1
- IZNHTFSUHCZZRO-UHFFFAOYSA-N CCN1CCN(CC)CCN(C(C)CC(C)=O)CCN(CC)CC1.CCN1CCN(CC)CCN(C(C)CCC(C)=O)CCN(CC)CC1.CCN1CCN(CC)CCN(CC)C(C(C)=O)CN(CC)CC1 Chemical compound CCN1CCN(CC)CCN(C(C)CC(C)=O)CCN(CC)CC1.CCN1CCN(CC)CCN(C(C)CCC(C)=O)CCN(CC)CC1.CCN1CCN(CC)CCN(CC)C(C(C)=O)CN(CC)CC1 IZNHTFSUHCZZRO-UHFFFAOYSA-N 0.000 description 1
- KUDYJKMZBTVOHW-GOEPFKOCSA-N CC[C@H](NC(=O)[C@H](CC1=CCC=N1)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)CCN)C(=O)N1CC(C)C[C@H]1C(=O)N[C@@H](CC1=CC=C(O)C(I)=C1)C(=O)NC Chemical compound CC[C@H](NC(=O)[C@H](CC1=CCC=N1)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)CCN)C(=O)N1CC(C)C[C@H]1C(=O)N[C@@H](CC1=CC=C(O)C(I)=C1)C(=O)NC KUDYJKMZBTVOHW-GOEPFKOCSA-N 0.000 description 1
- WDOHERXYVJHTNC-GOTSBHOMSA-N CNC(=O)[C@@H]1CCCN1C(=O)[C@H](CC(C)C)NC(=O)CCCCCNC(=O)/C1=C/C2=CC=C(OC)C=C2OC1=O Chemical compound CNC(=O)[C@@H]1CCCN1C(=O)[C@H](CC(C)C)NC(=O)CCCCCNC(=O)/C1=C/C2=CC=C(OC)C=C2OC1=O WDOHERXYVJHTNC-GOTSBHOMSA-N 0.000 description 1
- HVMCCROPBFPNOF-ACHIHNKUSA-N CNC(=O)[C@H](CC1=CNC=N1)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)CCNC(=O)NC1=CC=C(C2=C3C=CC(=O)C=C3OC3=CC(O)=CC=C32)C(C(=O)O)=C1 Chemical compound CNC(=O)[C@H](CC1=CNC=N1)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)CCNC(=O)NC1=CC=C(C2=C3C=CC(=O)C=C3OC3=CC(O)=CC=C32)C(C(=O)O)=C1 HVMCCROPBFPNOF-ACHIHNKUSA-N 0.000 description 1
- QOOBLPHYVGATHO-SBVPHTNJSA-N CNC(=O)[C@H](CC1=NC=CN1)NC(=O)[C@@H](CC(=O)CNC(=O)CNC(=O)CCCCCNC(=O)NC1=CC=C(C2=C3C=CC(=O)C=C3OC3=CC(O)=CC=C32)C(C(=O)O)=C1)CC1=CC=CC=C1 Chemical compound CNC(=O)[C@H](CC1=NC=CN1)NC(=O)[C@@H](CC(=O)CNC(=O)CNC(=O)CCCCCNC(=O)NC1=CC=C(C2=C3C=CC(=O)C=C3OC3=CC(O)=CC=C32)C(C(=O)O)=C1)CC1=CC=CC=C1 QOOBLPHYVGATHO-SBVPHTNJSA-N 0.000 description 1
- RUAHOPJQKKBKAG-HEVIKAOCSA-N CNC(=O)[C@H](CC1=NC=CN1)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)CCCCCNC(=O)NC1=CC=C(C2=C3C=CC(=O)C=C3OC3=CC(O)=CC=C32)C(C(=O)O)=C1 Chemical compound CNC(=O)[C@H](CC1=NC=CN1)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)CCCCCNC(=O)NC1=CC=C(C2=C3C=CC(=O)C=C3OC3=CC(O)=CC=C32)C(C(=O)O)=C1 RUAHOPJQKKBKAG-HEVIKAOCSA-N 0.000 description 1
- HMGOWHFHHCWKRF-CONSDPRKSA-N CNC(=O)[C@H](CC1=NC=CN1)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)CCNC(=O)NC1=CC=C(C2=C3C=CC(=O)C=C3OC3=CC(O)=CC=C32)C(C(=O)O)=C1 Chemical compound CNC(=O)[C@H](CC1=NC=CN1)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)CCNC(=O)NC1=CC=C(C2=C3C=CC(=O)C=C3OC3=CC(O)=CC=C32)C(C(=O)O)=C1 HMGOWHFHHCWKRF-CONSDPRKSA-N 0.000 description 1
- MTVQBIGKVPKIBH-PXLJZGITSA-N CNC(=O)[C@H](CC1=NC=CN1)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)CNC(=O)CCCCCNC(=O)NC1=CC=C(C2=C3C=CC(=O)C=C3OC3=CC(O)=CC=C32)C(C(=O)O)=C1 Chemical compound CNC(=O)[C@H](CC1=NC=CN1)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)CNC(=O)CCCCCNC(=O)NC1=CC=C(C2=C3C=CC(=O)C=C3OC3=CC(O)=CC=C32)C(C(=O)O)=C1 MTVQBIGKVPKIBH-PXLJZGITSA-N 0.000 description 1
- OVJYWRYMYQKEPZ-SBPNQFBHSA-N CNC(=O)[C@H](CC1=NC=CN1)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)CNC(=O)CNC(=O)[C@H](N)CCCCNC(=O)NC1=CC=C(C2=C3C=CC(=O)C=C3OC3=CC(O)=CC=C32)C(C(=O)O)=C1 Chemical compound CNC(=O)[C@H](CC1=NC=CN1)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)CNC(=O)CNC(=O)[C@H](N)CCCCNC(=O)NC1=CC=C(C2=C3C=CC(=O)C=C3OC3=CC(O)=CC=C32)C(C(=O)O)=C1 OVJYWRYMYQKEPZ-SBPNQFBHSA-N 0.000 description 1
- BNMBCDOKNFAMSJ-PLJDCMBSSA-N CNC(=O)[C@H](CC1=NC=CN1)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)CNC(=O)[C@H](N)CCCCNC(=O)NC1=CC=C(C2=C3C=CC(=O)C=C3OC3=CC(O)=CC=C32)C(C(=O)O)=C1 Chemical compound CNC(=O)[C@H](CC1=NC=CN1)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)CNC(=O)[C@H](N)CCCCNC(=O)NC1=CC=C(C2=C3C=CC(=O)C=C3OC3=CC(O)=CC=C32)C(C(=O)O)=C1 BNMBCDOKNFAMSJ-PLJDCMBSSA-N 0.000 description 1
- ACZLEYAULGNYKP-KJFLPAQCSA-N CNC(=O)[C@H](CC1=NC=CN1)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC1=CNC2=C1C=CC=C2)NC(=O)CCCCCNC(=O)NC1=CC=C(C2=C3C=CC(=O)C=C3OC3=CC(O)=CC=C32)C(C(=O)O)=C1 Chemical compound CNC(=O)[C@H](CC1=NC=CN1)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC1=CNC2=C1C=CC=C2)NC(=O)CCCCCNC(=O)NC1=CC=C(C2=C3C=CC(=O)C=C3OC3=CC(O)=CC=C32)C(C(=O)O)=C1 ACZLEYAULGNYKP-KJFLPAQCSA-N 0.000 description 1
- ANDXMGCHKOTURB-KJFLPAQCSA-N CNC(=O)[C@H](CC1=NC=CN1)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC1=CNC2=C1C=CC=C2)NC(=O)CCCCCNC(=S)NC1=CC=C(C2=C3C=CC(=O)C=C3OC3=CC(O)=CC=C32)C(C(=O)O)=C1 Chemical compound CNC(=O)[C@H](CC1=NC=CN1)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC1=CNC2=C1C=CC=C2)NC(=O)CCCCCNC(=S)NC1=CC=C(C2=C3C=CC(=O)C=C3OC3=CC(O)=CC=C32)C(C(=O)O)=C1 ANDXMGCHKOTURB-KJFLPAQCSA-N 0.000 description 1
- CMIIBZZMEZZULG-NNNRABJASA-N CNC(=O)[C@H](CC1=NC=CN1)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC1=CNC2=C1C=CC=C2)NC(=O)[C@H](N)CCCCNC(=O)NC1=CC=C(C2=C3C=CC(=O)C=C3OC3=CC(O)=CC=C32)C(C(=O)O)=C1 Chemical compound CNC(=O)[C@H](CC1=NC=CN1)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC1=CNC2=C1C=CC=C2)NC(=O)[C@H](N)CCCCNC(=O)NC1=CC=C(C2=C3C=CC(=O)C=C3OC3=CC(O)=CC=C32)C(C(=O)O)=C1 CMIIBZZMEZZULG-NNNRABJASA-N 0.000 description 1
- BJVPCHNVALXVGL-WKNISULPSA-N CNC(=O)[C@H](CC1=NC=CN1)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](N)CCCCNC(=O)NC1=CC=C(C2=C3C=CC(=O)C=C3OC3=CC(O)=CC=C32)C(C(=O)O)=C1 Chemical compound CNC(=O)[C@H](CC1=NC=CN1)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](N)CCCCNC(=O)NC1=CC=C(C2=C3C=CC(=O)C=C3OC3=CC(O)=CC=C32)C(C(=O)O)=C1 BJVPCHNVALXVGL-WKNISULPSA-N 0.000 description 1
- LRYOZSHSPIPGAU-DTXPUJKBSA-N CNC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC1=CNC2=CC=CC=C12)NC(=O)[C@H](CCC(N)=O)NC(=O)CCCCCNC(=O)/C1=C/C2=CC=C(CO)C=C2OC1=O Chemical compound CNC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC1=CNC2=CC=CC=C12)NC(=O)[C@H](CCC(N)=O)NC(=O)CCCCCNC(=O)/C1=C/C2=CC=C(CO)C=C2OC1=O LRYOZSHSPIPGAU-DTXPUJKBSA-N 0.000 description 1
- KAHJZDNIWBFUTF-QXUSSCGESA-N CNC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC1=CNC2=CC=CC=C12)NC(=O)[C@H](CCC(N)=O)NC(=O)CCCCCNC(=S)NC1=CC=C(C2=C3C=CC(=O)C=C3OC3=CC(O)=CC=C32)C(C(=O)O)=C1 Chemical compound CNC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC1=CNC2=CC=CC=C12)NC(=O)[C@H](CCC(N)=O)NC(=O)CCCCCNC(=S)NC1=CC=C(C2=C3C=CC(=O)C=C3OC3=CC(O)=CC=C32)C(C(=O)O)=C1 KAHJZDNIWBFUTF-QXUSSCGESA-N 0.000 description 1
- OHYSZXQKDRXNOL-BJKOEGOMSA-N CNC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC1=CNC2=CC=CC=C12)NC(=O)[C@H](CCC(N)=O)NC(=O)CCCCCNC(=S)NC1=CC=C(C2=C3C=CC(=[N+](C)C)C=C3OC3=CC(N(C)C)=CC=C32)C(C(=O)[O-])=C1 Chemical compound CNC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC1=CNC2=CC=CC=C12)NC(=O)[C@H](CCC(N)=O)NC(=O)CCCCCNC(=S)NC1=CC=C(C2=C3C=CC(=[N+](C)C)C=C3OC3=CC(N(C)C)=CC=C32)C(C(=O)[O-])=C1 OHYSZXQKDRXNOL-BJKOEGOMSA-N 0.000 description 1
- UTBJPSCEDCZFTK-XJWIGURKSA-N CNCC(NC)C(=O)NCC1=CC=C(CNC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(C)C)NC(C)=O)C=C1.CNCC(NC)C(=O)NCCNC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(C)C)NC(C)=O.CNCC(NC)C(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@H]1CSSC[C@@H](C)NC(=O)[C@H](C(C)O)N[C@H](O)CNC(=O)[C@H](CC2=CC=C(O)C=C2)NC(=O)[C@H](CC2=CC=C(O)C=C2)NC(=O)[C@H](CC(=O)O)N[C@@H]1O.CNCC(NC)[C@@H](O)N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@H]1CSSC[C@@H](C)NC(=O)[C@H](C(C)O)NC(=O)CN[C@@H](O)[C@H](CC2=CC=C(O)C=C2)N[C@H](O)[C@H](CC2=CC=C(O)C=C2)NC(=O)[C@H](CC(=O)O)NC1=O Chemical compound CNCC(NC)C(=O)NCC1=CC=C(CNC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(C)C)NC(C)=O)C=C1.CNCC(NC)C(=O)NCCNC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(C)C)NC(C)=O.CNCC(NC)C(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@H]1CSSC[C@@H](C)NC(=O)[C@H](C(C)O)N[C@H](O)CNC(=O)[C@H](CC2=CC=C(O)C=C2)NC(=O)[C@H](CC2=CC=C(O)C=C2)NC(=O)[C@H](CC(=O)O)N[C@@H]1O.CNCC(NC)[C@@H](O)N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@H]1CSSC[C@@H](C)NC(=O)[C@H](C(C)O)NC(=O)CN[C@@H](O)[C@H](CC2=CC=C(O)C=C2)N[C@H](O)[C@H](CC2=CC=C(O)C=C2)NC(=O)[C@H](CC(=O)O)NC1=O UTBJPSCEDCZFTK-XJWIGURKSA-N 0.000 description 1
- XVHJHOFHOQCZNW-RGTMUZMFSA-N CNCC(NC)C(=O)NCCNC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC1=CC=C(C2=CC=CC=C2)C=C1)NC(C)=O.CNCC(NC)C(=O)N[C@@H](CC(C)C)C(=O)N1CCCC1C(=O)N[C@H]1CSSC[C@@H](C)NC(=O)[C@H](C(C)O)NC(=O)CNC(=O)[C@H](CC2=CC=C(O)C=C2)NC(=O)[C@H](CC2=CC=C(O)C=C2)NC(=O)[C@H](CC(=O)O)NC1=O.CNCCN(CCNC)CC(=O)NCCOCCOCCNC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC1=CC=C(C2=CC=CC=C2)C=C1)N[C@@H](C)O.CNCCN(CCNC)CC(=O)N[C@@H](CC(C)C)C(=O)N1CCCC1[C@H](O)N[C@H]1CSSC[C@@H](C)NC(=O)[C@H](C(C)O)N[C@H](O)CNC(=O)[C@H](CC2=CC=C(O)C=C2)NC(=O)[C@H](CC2=CC=C(O)C=C2)NC(=O)[C@H](CC(=O)O)NC1=O Chemical compound CNCC(NC)C(=O)NCCNC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC1=CC=C(C2=CC=CC=C2)C=C1)NC(C)=O.CNCC(NC)C(=O)N[C@@H](CC(C)C)C(=O)N1CCCC1C(=O)N[C@H]1CSSC[C@@H](C)NC(=O)[C@H](C(C)O)NC(=O)CNC(=O)[C@H](CC2=CC=C(O)C=C2)NC(=O)[C@H](CC2=CC=C(O)C=C2)NC(=O)[C@H](CC(=O)O)NC1=O.CNCCN(CCNC)CC(=O)NCCOCCOCCNC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC1=CC=C(C2=CC=CC=C2)C=C1)N[C@@H](C)O.CNCCN(CCNC)CC(=O)N[C@@H](CC(C)C)C(=O)N1CCCC1[C@H](O)N[C@H]1CSSC[C@@H](C)NC(=O)[C@H](C(C)O)N[C@H](O)CNC(=O)[C@H](CC2=CC=C(O)C=C2)NC(=O)[C@H](CC2=CC=C(O)C=C2)NC(=O)[C@H](CC(=O)O)NC1=O XVHJHOFHOQCZNW-RGTMUZMFSA-N 0.000 description 1
- VKYCYLIJGJATBL-LBLWJYMUSA-N CNCCC(CNC[C@H](O)NCCOCCOCCNC(=O)[C@H](CC1=CC=C(C2=CC=CC=C2)C=C1)NC(C)=O)NC.CNCCN(CCNC)CC(=O)NCC1=CC(CNC(C)=O)=CC=C1.CNCCN(CCNC)CC(=O)N[C@@H](CC(C)C)C(=O)N1CCCC1C(=O)N[C@H]1CSSC[C@@H](C)NC(=O)[C@H](C(C)O)NC(=O)CNC(=O)[C@H](CC2=CC=C(O)C=C2)NC(=O)[C@H](CC2=CC=C(O)C=C2)NC(=O)[C@H](CC(=O)O)N[C@@H]1O.CNCCN(CCNC)CC(=O)N[C@@H](CC(C)C)C(=O)N1CCCC1[C@H](O)N[C@H]1CSSC[C@@H](C)NC(=O)[C@H](C(C)O)NC(=O)CNC(=O)[C@H](CC2=CC=C(O)C=C2)NC(=O)[C@H](CC2=CC=C(O)C=C2)NC(=O)[C@H](CC(=O)O)NC1=O Chemical compound CNCCC(CNC[C@H](O)NCCOCCOCCNC(=O)[C@H](CC1=CC=C(C2=CC=CC=C2)C=C1)NC(C)=O)NC.CNCCN(CCNC)CC(=O)NCC1=CC(CNC(C)=O)=CC=C1.CNCCN(CCNC)CC(=O)N[C@@H](CC(C)C)C(=O)N1CCCC1C(=O)N[C@H]1CSSC[C@@H](C)NC(=O)[C@H](C(C)O)NC(=O)CNC(=O)[C@H](CC2=CC=C(O)C=C2)NC(=O)[C@H](CC2=CC=C(O)C=C2)NC(=O)[C@H](CC(=O)O)N[C@@H]1O.CNCCN(CCNC)CC(=O)N[C@@H](CC(C)C)C(=O)N1CCCC1[C@H](O)N[C@H]1CSSC[C@@H](C)NC(=O)[C@H](C(C)O)NC(=O)CNC(=O)[C@H](CC2=CC=C(O)C=C2)NC(=O)[C@H](CC2=CC=C(O)C=C2)NC(=O)[C@H](CC(=O)O)NC1=O VKYCYLIJGJATBL-LBLWJYMUSA-N 0.000 description 1
- UFEOGRUBLXBIER-UHFFFAOYSA-N CNCCN(CCNC)CC(=O)CNCC1=CC=CC(CNC(=O)CN(CCNC)CCNC)=C1 Chemical compound CNCCN(CCNC)CC(=O)CNCC1=CC=CC(CNC(=O)CN(CCNC)CCNC)=C1 UFEOGRUBLXBIER-UHFFFAOYSA-N 0.000 description 1
- GVPWPHCXJXMCNO-ZIOWWTGTSA-N CNCCN(CCNC)CC(=O)CN[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@H]1CSSC[C@@H](C(=O)N[C@@H](CC2=CC=C(C3=CC=CC=C3)C=C2)C(=O)N[C@@H](CC(=O)O)C(=O)NCC2=CC=CC(NC(=O)CN(CCNC)CCNC)=C2)NC(=O)[C@H](C(C)O)NC(=O)CNC(=O)[C@H](CC2=CC=C(O)C=C2)NC(=O)[C@H](CC2=CC=C(O)C=C2)NC(=O)[C@H](CC(=O)O)NC1=O Chemical compound CNCCN(CCNC)CC(=O)CN[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@H]1CSSC[C@@H](C(=O)N[C@@H](CC2=CC=C(C3=CC=CC=C3)C=C2)C(=O)N[C@@H](CC(=O)O)C(=O)NCC2=CC=CC(NC(=O)CN(CCNC)CCNC)=C2)NC(=O)[C@H](C(C)O)NC(=O)CNC(=O)[C@H](CC2=CC=C(O)C=C2)NC(=O)[C@H](CC2=CC=C(O)C=C2)NC(=O)[C@H](CC(=O)O)NC1=O GVPWPHCXJXMCNO-ZIOWWTGTSA-N 0.000 description 1
- YHHRQDPSOUDFKG-QXRSDBEBSA-N CNCCN(CCNC)CC(=O)NCC1=CC(CNC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC2=CC=C(C3=CC=CC=C3)C=C2)NC(C)=O)=CC=C1.CNCCN(CCNC)CC(=O)NCC1=CC(CNC(=O)[C@H](CC(C)=O)NC(=O)[C@H](CC2=CC=C(C3=CC=CC=C3)C=C2)NC(C)=O)=CC=C1.CNCCN(CCNC)CC(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@H]1CSSC[C@@H](C)NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CC2=CC=C(C)C=C2)NC(=O)[C@H](CC2=CC=C(C)C=C2)NC(=O)[C@H](CC(C)=O)NC1=O.CNCCN(CCNC)CC(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@H]1CSSC[C@@H](C)NC(=O)[C@H](C(C)O)NC(=O)CNC(=O)[C@H](CC2=CC=C(O)C=C2)NC(=O)[C@H](CC2=CC=C(O)C=C2)NC(=O)[C@H](CC(=O)O)NC1=O Chemical compound CNCCN(CCNC)CC(=O)NCC1=CC(CNC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC2=CC=C(C3=CC=CC=C3)C=C2)NC(C)=O)=CC=C1.CNCCN(CCNC)CC(=O)NCC1=CC(CNC(=O)[C@H](CC(C)=O)NC(=O)[C@H](CC2=CC=C(C3=CC=CC=C3)C=C2)NC(C)=O)=CC=C1.CNCCN(CCNC)CC(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@H]1CSSC[C@@H](C)NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CC2=CC=C(C)C=C2)NC(=O)[C@H](CC2=CC=C(C)C=C2)NC(=O)[C@H](CC(C)=O)NC1=O.CNCCN(CCNC)CC(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@H]1CSSC[C@@H](C)NC(=O)[C@H](C(C)O)NC(=O)CNC(=O)[C@H](CC2=CC=C(O)C=C2)NC(=O)[C@H](CC2=CC=C(O)C=C2)NC(=O)[C@H](CC(=O)O)NC1=O YHHRQDPSOUDFKG-QXRSDBEBSA-N 0.000 description 1
- BVPXAOWIZQLJII-MUDPPGKZSA-N CNCCN(CCNC)CC(=O)NCCN(CC(=O)N[C@@H](CC(C)C)C(=O)N1CCCC1C(=O)N[C@H]1CSSC[C@@H](C)NC(=O)[C@H](C(C)O)N[C@H](O)CNC(=O)[C@H](CC2=CC=C(O)C=C2)NC(=O)[C@H](CC2=CC=C(O)C=C2)N[C@@H](O)[C@H](CC(=O)O)N[C@@H]1O)C(=O)CN1C=C(C)C(=O)NC1=O.CNCCN(CCNC)CC(=O)NCCNC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC1=CC=C(C2=CC=CC=C2)C=C1)NC(C)=O.CNCCN(CCNC)CC(=O)N[C@@H](CC(C)C)C(=O)N1CCCC1C(=O)N[C@H]1CSSC[C@@H](C)NC(=O)[C@H](C(C)O)NC(=O)CNC(=O)[C@H](CC2=CC=C(O)C=C2)NC(=O)[C@H](CC2=CC=C(O)C=C2)NC(=O)[C@H](CC(=O)O)NC1=O.CNCCN(CCNC)C[C@H](O)NCC1=CC(CN[C@H](O)[C@H](CC(=O)O)NC(=O)[C@H](CC2=CC=C(C3=CC=CC=C3)C=C2)NC(C)=O)=CC=C1 Chemical compound CNCCN(CCNC)CC(=O)NCCN(CC(=O)N[C@@H](CC(C)C)C(=O)N1CCCC1C(=O)N[C@H]1CSSC[C@@H](C)NC(=O)[C@H](C(C)O)N[C@H](O)CNC(=O)[C@H](CC2=CC=C(O)C=C2)NC(=O)[C@H](CC2=CC=C(O)C=C2)N[C@@H](O)[C@H](CC(=O)O)N[C@@H]1O)C(=O)CN1C=C(C)C(=O)NC1=O.CNCCN(CCNC)CC(=O)NCCNC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC1=CC=C(C2=CC=CC=C2)C=C1)NC(C)=O.CNCCN(CCNC)CC(=O)N[C@@H](CC(C)C)C(=O)N1CCCC1C(=O)N[C@H]1CSSC[C@@H](C)NC(=O)[C@H](C(C)O)NC(=O)CNC(=O)[C@H](CC2=CC=C(O)C=C2)NC(=O)[C@H](CC2=CC=C(O)C=C2)NC(=O)[C@H](CC(=O)O)NC1=O.CNCCN(CCNC)C[C@H](O)NCC1=CC(CN[C@H](O)[C@H](CC(=O)O)NC(=O)[C@H](CC2=CC=C(C3=CC=CC=C3)C=C2)NC(C)=O)=CC=C1 BVPXAOWIZQLJII-MUDPPGKZSA-N 0.000 description 1
- YZNMOMRNEFWHMZ-TZKVPWIMSA-N CNCCN(CCNC)CC(=O)NCCNC(=O)[C@H](CC(O)O)NC(=O)[C@H](CC(C)C)N(C)[C@@H](C)O.CNCCN(CCNC)CC(=O)N[C@@H](CC(C)C)C(=O)N1CCCC1[C@H](O)N[C@H]1CSSC[C@@H](C)NC(=O)[C@H](C(C)O)NC(=O)CNC(=O)[C@H](CC2=CC=C(O)C=C2)NC(=O)[C@H](CC2=CC=C(O)C=C2)NC(=O)[C@H](CC(=O)O)NC1=O.CNCCN(CCNC)CC(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1[C@H](O)N[C@H]1CSSC[C@@H](C)NC(=O)[C@H](C(C)O)NC(=O)CNC(=O)[C@H](CC2=CC=C(O)C=C2)NC(=O)[C@H](CC2=CC=C(O)C=C2)NC(=O)[C@H](CC(=O)O)NC1=O.CNCCN(CNC)CC(=O)NCCOCCOCCNC(=O)[C@H](CC(O)O)NC(=O)[C@H](CC(C)C)N(C)[C@@H](C)O Chemical compound CNCCN(CCNC)CC(=O)NCCNC(=O)[C@H](CC(O)O)NC(=O)[C@H](CC(C)C)N(C)[C@@H](C)O.CNCCN(CCNC)CC(=O)N[C@@H](CC(C)C)C(=O)N1CCCC1[C@H](O)N[C@H]1CSSC[C@@H](C)NC(=O)[C@H](C(C)O)NC(=O)CNC(=O)[C@H](CC2=CC=C(O)C=C2)NC(=O)[C@H](CC2=CC=C(O)C=C2)NC(=O)[C@H](CC(=O)O)NC1=O.CNCCN(CCNC)CC(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1[C@H](O)N[C@H]1CSSC[C@@H](C)NC(=O)[C@H](C(C)O)NC(=O)CNC(=O)[C@H](CC2=CC=C(O)C=C2)NC(=O)[C@H](CC2=CC=C(O)C=C2)NC(=O)[C@H](CC(=O)O)NC1=O.CNCCN(CNC)CC(=O)NCCOCCOCCNC(=O)[C@H](CC(O)O)NC(=O)[C@H](CC(C)C)N(C)[C@@H](C)O YZNMOMRNEFWHMZ-TZKVPWIMSA-N 0.000 description 1
- KSSJBGNOJJETTC-UHFFFAOYSA-N COC1=C(C=CC=C1)N(C1=CC=2C3(C4=CC(=CC=C4C=2C=C1)N(C1=CC=C(C=C1)OC)C1=C(C=CC=C1)OC)C1=CC(=CC=C1C=1C=CC(=CC=13)N(C1=CC=C(C=C1)OC)C1=C(C=CC=C1)OC)N(C1=CC=C(C=C1)OC)C1=C(C=CC=C1)OC)C1=CC=C(C=C1)OC Chemical compound COC1=C(C=CC=C1)N(C1=CC=2C3(C4=CC(=CC=C4C=2C=C1)N(C1=CC=C(C=C1)OC)C1=C(C=CC=C1)OC)C1=CC(=CC=C1C=1C=CC(=CC=13)N(C1=CC=C(C=C1)OC)C1=C(C=CC=C1)OC)N(C1=CC=C(C=C1)OC)C1=C(C=CC=C1)OC)C1=CC=C(C=C1)OC KSSJBGNOJJETTC-UHFFFAOYSA-N 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 206010007688 Carotid artery thrombosis Diseases 0.000 description 1
- 101710091342 Chemotactic peptide Proteins 0.000 description 1
- 108010089448 Cholecystokinin B Receptor Proteins 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 206010011091 Coronary artery thrombosis Diseases 0.000 description 1
- 108010069514 Cyclic Peptides Proteins 0.000 description 1
- 102000001189 Cyclic Peptides Human genes 0.000 description 1
- 206010051055 Deep vein thrombosis Diseases 0.000 description 1
- XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical compound C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 description 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
- 108010016626 Dipeptides Proteins 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical group C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- 102000018389 Exopeptidases Human genes 0.000 description 1
- 108010091443 Exopeptidases Proteins 0.000 description 1
- 108010074860 Factor Xa Proteins 0.000 description 1
- NIGWMJHCCYYCSF-UHFFFAOYSA-N Fenclonine Chemical compound OC(=O)C(N)CC1=CC=C(Cl)C=C1 NIGWMJHCCYYCSF-UHFFFAOYSA-N 0.000 description 1
- 108010088842 Fibrinolysin Proteins 0.000 description 1
- 108010090109 Fibrolase Proteins 0.000 description 1
- 102000011652 Formyl peptide receptors Human genes 0.000 description 1
- 108010076288 Formyl peptide receptors Proteins 0.000 description 1
- 150000000921 Gadolinium Chemical class 0.000 description 1
- 108010052343 Gastrins Proteins 0.000 description 1
- 229910003317 GdCl3 Inorganic materials 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000605403 Homo sapiens Plasminogen Proteins 0.000 description 1
- PSCMQHVBLHHWTO-UHFFFAOYSA-K Indium trichloride Inorganic materials Cl[In](Cl)Cl PSCMQHVBLHHWTO-UHFFFAOYSA-K 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102100022337 Integrin alpha-V Human genes 0.000 description 1
- 108010047852 Integrin alphaVbeta3 Proteins 0.000 description 1
- 201000001429 Intracranial Thrombosis Diseases 0.000 description 1
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 1
- SNDPXSYFESPGGJ-BYPYZUCNSA-N L-2-aminopentanoic acid Chemical compound CCC[C@H](N)C(O)=O SNDPXSYFESPGGJ-BYPYZUCNSA-N 0.000 description 1
- LOOZZTFGSTZNRX-VIFPVBQESA-N L-Homotyrosine Chemical compound OC(=O)[C@@H](N)CCC1=CC=C(O)C=C1 LOOZZTFGSTZNRX-VIFPVBQESA-N 0.000 description 1
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
- ZGUNAGUHMKGQNY-ZETCQYMHSA-N L-alpha-phenylglycine zwitterion Chemical compound OC(=O)[C@@H](N)C1=CC=CC=C1 ZGUNAGUHMKGQNY-ZETCQYMHSA-N 0.000 description 1
- JTTHKOPSMAVJFE-VIFPVBQESA-N L-homophenylalanine Chemical compound OC(=O)[C@@H](N)CCC1=CC=CC=C1 JTTHKOPSMAVJFE-VIFPVBQESA-N 0.000 description 1
- UKAUYVFTDYCKQA-VKHMYHEASA-N L-homoserine Chemical compound OC(=O)[C@@H](N)CCO UKAUYVFTDYCKQA-VKHMYHEASA-N 0.000 description 1
- DGYHPLMPMRKMPD-UHFFFAOYSA-N L-propargyl glycine Natural products OC(=O)C(N)CC#C DGYHPLMPMRKMPD-UHFFFAOYSA-N 0.000 description 1
- DZLNHFMRPBPULJ-VKHMYHEASA-N L-thioproline Chemical compound OC(=O)[C@@H]1CSCN1 DZLNHFMRPBPULJ-VKHMYHEASA-N 0.000 description 1
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- RJUFJBKOKNCXHH-UHFFFAOYSA-N Methyl propionate Chemical compound CCC(=O)OC RJUFJBKOKNCXHH-UHFFFAOYSA-N 0.000 description 1
- IRZWHILMNSFEAF-UHFFFAOYSA-N O=C1C=CC2=C(C3=CC=C(N=C=S)C=C3C(=O)O)C3=CC=C(O)C=C3OC2=C1 Chemical compound O=C1C=CC2=C(C3=CC=C(N=C=S)C=C3C(=O)O)C3=CC=C(O)C=C3OC2=C1 IRZWHILMNSFEAF-UHFFFAOYSA-N 0.000 description 1
- 108010016076 Octreotide Proteins 0.000 description 1
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 description 1
- PEMUHKUIQHFMTH-UHFFFAOYSA-N P-Bromo-DL-phenylalanine Chemical compound OC(=O)C(N)CC1=CC=C(Br)C=C1 PEMUHKUIQHFMTH-UHFFFAOYSA-N 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 1
- 208000010378 Pulmonary Embolism Diseases 0.000 description 1
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 1
- ODHCTXKNWHHXJC-GSVOUGTGSA-N Pyroglutamic acid Natural products OC(=O)[C@H]1CCC(=O)N1 ODHCTXKNWHHXJC-GSVOUGTGSA-N 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 206010038563 Reocclusion Diseases 0.000 description 1
- 108010077895 Sarcosine Proteins 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 108050001286 Somatostatin Receptor Proteins 0.000 description 1
- 102000011096 Somatostatin receptor Human genes 0.000 description 1
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 1
- 208000001435 Thromboembolism Diseases 0.000 description 1
- 206010047249 Venous thrombosis Diseases 0.000 description 1
- 108010048673 Vitronectin Receptors Proteins 0.000 description 1
- FDLQZKYLHJJBHD-UHFFFAOYSA-N [3-(aminomethyl)phenyl]methanamine Chemical compound NCC1=CC=CC(CN)=C1 FDLQZKYLHJJBHD-UHFFFAOYSA-N 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- ODHCTXKNWHHXJC-UHFFFAOYSA-N acide pyroglutamique Natural products OC(=O)C1CCC(=O)N1 ODHCTXKNWHHXJC-UHFFFAOYSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 125000002015 acyclic group Chemical group 0.000 description 1
- 230000010933 acylation Effects 0.000 description 1
- 238000005917 acylation reaction Methods 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 150000001350 alkyl halides Chemical class 0.000 description 1
- 102000003801 alpha-2-Antiplasmin Human genes 0.000 description 1
- 108090000183 alpha-2-Antiplasmin Proteins 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- GYGBZPVYZIJYBM-UHFFFAOYSA-N amino(4-aminobutyl)carbamic acid Chemical compound NCCCCN(N)C(O)=O GYGBZPVYZIJYBM-UHFFFAOYSA-N 0.000 description 1
- 229960004050 aminobenzoic acid Drugs 0.000 description 1
- 229960002684 aminocaproic acid Drugs 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 238000002583 angiography Methods 0.000 description 1
- 210000002376 aorta thoracic Anatomy 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 150000001491 aromatic compounds Chemical class 0.000 description 1
- 125000003710 aryl alkyl group Chemical group 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- 230000001746 atrial effect Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- WXBLLCUINBKULX-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1.OC(=O)C1=CC=CC=C1 WXBLLCUINBKULX-UHFFFAOYSA-N 0.000 description 1
- JHVLLYQQQYIWKX-UHFFFAOYSA-N benzyl 2-bromoacetate Chemical compound BrCC(=O)OCC1=CC=CC=C1 JHVLLYQQQYIWKX-UHFFFAOYSA-N 0.000 description 1
- JWEDSLJYCYGJHO-UHFFFAOYSA-N benzyl 3-amino-2-(aminomethyl)propanoate;dihydrochloride Chemical compound Cl.Cl.NCC(CN)C(=O)OCC1=CC=CC=C1 JWEDSLJYCYGJHO-UHFFFAOYSA-N 0.000 description 1
- OGDYFFMGHCQHNS-UHFFFAOYSA-N benzyl 3-amino-4-(2-aminoethylamino)butanoate Chemical compound NCCNCC(N)CC(=O)OCC1=CC=CC=C1 OGDYFFMGHCQHNS-UHFFFAOYSA-N 0.000 description 1
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 description 1
- UCMIRNVEIXFBKS-UHFFFAOYSA-N beta-alanine Chemical compound NCCC(O)=O UCMIRNVEIXFBKS-UHFFFAOYSA-N 0.000 description 1
- 125000002619 bicyclic group Chemical group 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 125000006267 biphenyl group Chemical group 0.000 description 1
- 239000007844 bleaching agent Substances 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 210000000133 brain stem Anatomy 0.000 description 1
- 125000004369 butenyl group Chemical group C(=CCC)* 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000000480 butynyl group Chemical group [*]C#CC([H])([H])C([H])([H])[H] 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 150000001721 carbon Chemical group 0.000 description 1
- 150000001722 carbon compounds Chemical class 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000001311 chemical methods and process Methods 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 239000012230 colorless oil Substances 0.000 description 1
- 229940126214 compound 3 Drugs 0.000 description 1
- 229940125898 compound 5 Drugs 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 235000008504 concentrate Nutrition 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 150000004696 coordination complex Chemical class 0.000 description 1
- 208000002528 coronary thrombosis Diseases 0.000 description 1
- 239000007822 coupling agent Substances 0.000 description 1
- 125000001162 cycloheptenyl group Chemical group C1(=CCCCCC1)* 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000522 cyclooctenyl group Chemical group C1(=CCCCCCC1)* 0.000 description 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000298 cyclopropenyl group Chemical group [H]C1=C([H])C1([H])* 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 125000003493 decenyl group Chemical group [H]C([*])=C([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000005070 decynyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C#C* 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- 239000000032 diagnostic agent Substances 0.000 description 1
- 229940043279 diisopropylamine Drugs 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000005670 electromagnetic radiation Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000011067 equilibration Methods 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- 125000000816 ethylene group Chemical class [H]C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
- 125000005469 ethylenyl group Chemical group 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- MEANOSLIBWSCIT-UHFFFAOYSA-K gadolinium trichloride Chemical compound Cl[Gd](Cl)Cl MEANOSLIBWSCIT-UHFFFAOYSA-K 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 150000002332 glycine derivatives Chemical class 0.000 description 1
- YMAWOPBAYDPSLA-UHFFFAOYSA-N glycylglycine Chemical compound [NH3+]CC(=O)NCC([O-])=O YMAWOPBAYDPSLA-UHFFFAOYSA-N 0.000 description 1
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 150000002390 heteroarenes Chemical class 0.000 description 1
- 125000006038 hexenyl group Chemical group 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000005980 hexynyl group Chemical group 0.000 description 1
- LIAWOTKNAVAKCX-UHFFFAOYSA-N hydrazine;dihydrochloride Chemical class Cl.Cl.NN LIAWOTKNAVAKCX-UHFFFAOYSA-N 0.000 description 1
- 238000007327 hydrogenolysis reaction Methods 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000011503 in vivo imaging Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 1
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 1
- QNRXNRGSOJZINA-UHFFFAOYSA-N indoline-2-carboxylic acid Chemical compound C1=CC=C2NC(C(=O)O)CC2=C1 QNRXNRGSOJZINA-UHFFFAOYSA-N 0.000 description 1
- HOBCFUWDNJPFHB-UHFFFAOYSA-N indolizine Chemical compound C1=CC=CN2C=CC=C21 HOBCFUWDNJPFHB-UHFFFAOYSA-N 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 108010044426 integrins Proteins 0.000 description 1
- 102000006495 integrins Human genes 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- KQNPFQTWMSNSAP-UHFFFAOYSA-N isobutyric acid Chemical compound CC(C)C(O)=O KQNPFQTWMSNSAP-UHFFFAOYSA-N 0.000 description 1
- SRJOCJYGOFTFLH-UHFFFAOYSA-N isonipecotic acid Chemical compound OC(=O)C1CCNCC1 SRJOCJYGOFTFLH-UHFFFAOYSA-N 0.000 description 1
- 229940102253 isopropanolamine Drugs 0.000 description 1
- 150000002540 isothiocyanates Chemical class 0.000 description 1
- CTAPFRYPJLPFDF-UHFFFAOYSA-N isoxazole Chemical compound C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 description 1
- 229960003299 ketamine Drugs 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 229960004194 lidocaine Drugs 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- GLXDVVHUTZTUQK-UHFFFAOYSA-M lithium;hydroxide;hydrate Chemical compound [Li+].O.[OH-] GLXDVVHUTZTUQK-UHFFFAOYSA-M 0.000 description 1
- 239000003589 local anesthetic agent Substances 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 210000004324 lymphatic system Anatomy 0.000 description 1
- 239000008176 lyophilized powder Substances 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 230000005415 magnetization Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- OKKJLVBELUTLKV-VMNATFBRSA-N methanol-d1 Chemical compound [2H]OC OKKJLVBELUTLKV-VMNATFBRSA-N 0.000 description 1
- CFTUQSLVERGMHL-UHFFFAOYSA-N methyl 2-(bromomethyl)prop-2-enoate Chemical compound COC(=O)C(=C)CBr CFTUQSLVERGMHL-UHFFFAOYSA-N 0.000 description 1
- 150000004702 methyl esters Chemical class 0.000 description 1
- 229940017219 methyl propionate Drugs 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000002534 molecular mass spectrometry Methods 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 238000011587 new zealand white rabbit Methods 0.000 description 1
- FEMOMIGRRWSMCU-UHFFFAOYSA-N ninhydrin Chemical compound C1=CC=C2C(=O)C(O)(O)C(=O)C2=C1 FEMOMIGRRWSMCU-UHFFFAOYSA-N 0.000 description 1
- 125000005187 nonenyl group Chemical group C(=CCCCCCCC)* 0.000 description 1
- 125000001400 nonyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000005071 nonynyl group Chemical group C(#CCCCCCCC)* 0.000 description 1
- 239000012038 nucleophile Substances 0.000 description 1
- 238000010534 nucleophilic substitution reaction Methods 0.000 description 1
- CQYBNXGHMBNGCG-RNJXMRFFSA-N octahydroindole-2-carboxylic acid Chemical compound C1CCC[C@H]2N[C@H](C(=O)O)C[C@@H]21 CQYBNXGHMBNGCG-RNJXMRFFSA-N 0.000 description 1
- 125000004365 octenyl group Chemical group C(=CCCCCCC)* 0.000 description 1
- 229960002700 octreotide Drugs 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000005069 octynyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C#C* 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000013110 organic ligand Substances 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- LDCYZAJDBXYCGN-UHFFFAOYSA-N oxitriptan Natural products C1=C(O)C=C2C(CC(N)C(O)=O)=CNC2=C1 LDCYZAJDBXYCGN-UHFFFAOYSA-N 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000011236 particulate material Substances 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 229960001639 penicillamine Drugs 0.000 description 1
- 125000002255 pentenyl group Chemical group C(=CCCC)* 0.000 description 1
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 1
- 229960001412 pentobarbital Drugs 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 125000005981 pentynyl group Chemical group 0.000 description 1
- 238000010647 peptide synthesis reaction Methods 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- QJFMCHRSDOLMHA-UHFFFAOYSA-N phenylmethanamine;hydrobromide Chemical compound Br.NCC1=CC=CC=C1 QJFMCHRSDOLMHA-UHFFFAOYSA-N 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 229940012957 plasmin Drugs 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 150000004032 porphyrins Chemical class 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- 125000004368 propenyl group Chemical group C(=CC)* 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000002568 propynyl group Chemical group [*]C#CC([H])([H])[H] 0.000 description 1
- 235000019833 protease Nutrition 0.000 description 1
- 230000004224 protection Effects 0.000 description 1
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- IGFXRKMLLMBKSA-UHFFFAOYSA-N purine Chemical compound N1=C[N]C2=NC=NC2=C1 IGFXRKMLLMBKSA-UHFFFAOYSA-N 0.000 description 1
- PBMFSQRYOILNGV-UHFFFAOYSA-N pyridazine Chemical compound C1=CC=NN=C1 PBMFSQRYOILNGV-UHFFFAOYSA-N 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000005258 radioactive decay Effects 0.000 description 1
- 238000000163 radioactive labelling Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 239000004627 regenerated cellulose Substances 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 1
- 238000007363 ring formation reaction Methods 0.000 description 1
- DOSGOCSVHPUUIA-UHFFFAOYSA-N samarium(3+) Chemical compound [Sm+3] DOSGOCSVHPUUIA-UHFFFAOYSA-N 0.000 description 1
- 229940043230 sarcosine Drugs 0.000 description 1
- 150000003335 secondary amines Chemical class 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 235000010265 sodium sulphite Nutrition 0.000 description 1
- RZWQDAUIUBVCDD-UHFFFAOYSA-M sodium;benzenethiolate Chemical compound [Na+].[S-]C1=CC=CC=C1 RZWQDAUIUBVCDD-UHFFFAOYSA-M 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000000264 spin echo pulse sequence Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- DFVFTMTWCUHJBL-BQBZGAKWSA-N statine Chemical compound CC(C)C[C@H](N)[C@@H](O)CC(O)=O DFVFTMTWCUHJBL-BQBZGAKWSA-N 0.000 description 1
- 239000008227 sterile water for injection Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 125000004426 substituted alkynyl group Chemical group 0.000 description 1
- 125000005346 substituted cycloalkyl group Chemical group 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- BNWCETAHAJSBFG-UHFFFAOYSA-N tert-butyl 2-bromoacetate Chemical compound CC(C)(C)OC(=O)CBr BNWCETAHAJSBFG-UHFFFAOYSA-N 0.000 description 1
- QQWYQAQQADNEIC-RVDMUPIBSA-N tert-butyl [(z)-[cyano(phenyl)methylidene]amino] carbonate Chemical compound CC(C)(C)OC(=O)O\N=C(/C#N)C1=CC=CC=C1 QQWYQAQQADNEIC-RVDMUPIBSA-N 0.000 description 1
- 150000003536 tetrazoles Chemical class 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 231100001274 therapeutic index Toxicity 0.000 description 1
- 125000002813 thiocarbonyl group Chemical group *C(*)=S 0.000 description 1
- 229930192474 thiophene Natural products 0.000 description 1
- DZLNHFMRPBPULJ-UHFFFAOYSA-N thioproline Chemical compound OC(=O)C1CSCN1 DZLNHFMRPBPULJ-UHFFFAOYSA-N 0.000 description 1
- 230000009424 thromboembolic effect Effects 0.000 description 1
- 230000001732 thrombotic effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 150000003852 triazoles Chemical class 0.000 description 1
- LZTRCELOJRDYMQ-UHFFFAOYSA-N triphenylmethanol Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(O)C1=CC=CC=C1 LZTRCELOJRDYMQ-UHFFFAOYSA-N 0.000 description 1
- JBWKIWSBJXDJDT-UHFFFAOYSA-N triphenylmethyl chloride Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(Cl)C1=CC=CC=C1 JBWKIWSBJXDJDT-UHFFFAOYSA-N 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 229960000281 trometamol Drugs 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 230000002861 ventricular Effects 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
- A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
- A61K49/0039—Coumarin dyes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
- A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
- A61K49/0041—Xanthene dyes, used in vivo, e.g. administered to a mice, e.g. rhodamines, rose Bengal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
- A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
- A61K49/0041—Xanthene dyes, used in vivo, e.g. administered to a mice, e.g. rhodamines, rose Bengal
- A61K49/0043—Fluorescein, used in vivo
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
- A61K49/0056—Peptides, proteins, polyamino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
- A61K49/085—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier conjugated systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
- A61K49/10—Organic compounds
- A61K49/12—Macromolecular compounds
- A61K49/122—Macromolecular compounds dimers of complexes or complex-forming compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
- A61K49/10—Organic compounds
- A61K49/12—Macromolecular compounds
- A61K49/124—Macromolecular compounds dendrimers, dendrons, hyperbranched compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
- A61K49/10—Organic compounds
- A61K49/14—Peptides, e.g. proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
- C07K1/1072—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
- C07K1/1077—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups by covalent attachment of residues other than amino acids or peptide residues, e.g. sugars, polyols, fatty acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
Definitions
- This invention relates to contrast agents for diagnostic imaging, and more particularly to peptide-targeted, multimeric contrast agents, wherein a peptide functions as a targeting group and a point of attachment for one or more chelates at both the amino and carboxy termini of the peptide.
- Diagnostic imaging techniques such as magnetic resonance imaging (MRI), X-ray, nuclear radiopharmaceutical imaging, ultraviolet-visible-infrared light imaging, and ultrasound, have been used in medical diagnosis for a number of years. Contrast media additionally have been used to improve or increase the resolution of the image or to provide specific diagnostic information.
- MRI magnetic resonance imaging
- X-ray nuclear radiopharmaceutical imaging
- ultraviolet-visible-infrared light imaging and ultrasound
- Contrast media additionally have been used to improve or increase the resolution of the image or to provide specific diagnostic information.
- the contrast media must interfere with the wavelength of electromagnetic radiation used in the imaging technique, alter the physical properties of tissue to yield an altered signal, or, as in the case of radiopharmaceuticals, provide the source of radiation itself.
- MRI and optical methods are unique among imaging modalities in that they yield complex signals that are sensitive to the chemical environment. While the signal from X-ray or radionuclide agents remains the same whether agents are free in plasma, bound to proteins or other targets, or trapped inside bone, certain contrast agents for MRI and optical imaging will have different signal characteristics in differing physiological environments. It is important that the contrast agent be sufficiently sensitive and present at high enough concentration so that signal changes can be observed.
- Gadolinium complexes increase contrast by increasing the nuclear magnetic relaxation rates of protons found in the water molecules that are accessible to the contrast agents during MRI (Caravan, P., et al., R. B. Chem. Rev. 99, 2293 (1999)).
- the relaxation rate of the protons in these water molecules increases relative to protons in other water molecules that are not accessible to the contrast agent. This change in relaxation rate leads to improved contrast of the images.
- this increase in relaxivity within a specific population of water molecule protons can result in an ability to collect more image data in a given amount of time. This in turn results in an improved signal to noise ratio.
- Imaging may also be performed using light, in which case an optical dye is chosen to provide signal.
- an optical dye is chosen to provide signal.
- light in the 600-1300 nm (visible to near-infrared) range passes relatively easily through biological tissues and can be used for imaging purposes.
- the light that is transmitted through, or scattered by, reflected, or re-emitted (fluorescence), is detected and an image generated.
- Changes in the absorbance, reflectance, or fluorescence characteristics of a dye including an increase or decrease in the number of absorbance peaks or a change in their wavelength maxima, may occur upon binding to a biological target, thus providing additional tissue contrast.
- UV or visible light may also be used.
- the invention is based on peptides and peptide-targeted multimeric contrast agents for MR, optical, and radionuclide imaging, wherein a single peptide can function both as a targeting group and a point of attachment for one or more chelates at both the N- and C-termini, either directly or via an optional intervening linker.
- contrast agents of the invention maintain binding affinity for biological targets such as fibrin and high relaxivity.
- Agents of the invention have a sufficient half-life following in vivo administration such that effective imaging studies can be performed.
- the invention features purified peptides that include the amino acid sequence: P*-Y*-X 1 *-L* (SEQ ID NO:1), wherein P* is a proline or a non-natural derivative thereof, Y* is a tyrosine or a non-natural derivative thereof, X 1 * is G or D or a non-natural derivative of G or D; L* is a leucine or a non-natural derivative thereof, and wherein at least one of P*, Y*, X 1 *, and L* is a non-natural derivative of the respective amino acid.
- X 1 * can be G or D and L* can be leucine.
- P* is proline or 4-hydroxyproline
- Y* is tyrosine or a non-natural derivative of tyrosine substituted at the 3 position with a moiety selected from the group consisting of F, Cl, Br, I, and NO 2 .
- Compounds of the invention can include such peptides linked to a thrombolytic agent.
- the invention features purified peptides that include the amino acid sequence X 1 -X 2 -C-P*-Y*-X 3 -L-C-X 4 -X 5 -X 6 (SEQ ID NO:2), wherein: P* is a proline or a non-natural derivative thereof, Y* is a tyrosine or a non-natural derivative thereof, X 1 is selected from the group consisting of W, Y, F, S, Bip, Hx, Dpr, Cy, Gu, Ad, Hfe, 3-Pal, 4-Pal, DopaMe2, nTyr, dW, dF, F(3/4*), and Y(3*), wherein F(3/4*) is a phenylalanine substituted at either the 3 or the 4 position with a moiety selected from the group consisting of CH 3 , CF 3 , NH 2 , CH 2 NH 2 , CN, F, Cl, Br, I, Et,
- P* can be proline or 4-hydroxyproline
- Y* can be tyrosine or a non-natural derivative of tyrosine substituted at the 3 position with a moiety selected from the group consisting of F, Cl, Br, I, and NO 2 .
- the purified peptides can be capable of forming a disulfide bond under non-reducing conditions and can have specific binding affinity for fibrin.
- the peptides include a disulfide bond.
- Compounds of the invention can include such peptides linked to a thrombolytic agent.
- the invention also features purified peptides having an amino acid sequence selected from the group consisting of W-dE-C-P(4-OH)-Y(3-Cl)-G-L-C-W-I-Q (SEQ ID NO:4), Y-dE-C-P(4-OH)-Y(3-Cl)-G-L-C-Y-I-Q (SEQ ID NO:5), Y-dE-C-P(4-OH)-Y(3-Cl)-G-L-C-W-I-Q (SEQ ID NO:6), W-dE-C-P(4-OH)-Y(3-Cl)-G-L-C-Y-I-Q (SEQ ID NO:7), W-dE-C-P(4-OH)-Y(3-Cl)-D-L-C-W-I-Q (SEQ ID NO:8), Y-dE-C-P(4-OH)-Y(3-Cl)-D-
- the peptides can be capable of forming a disulfide bond under non-reducing conditions, and in some embodiments, the peptides include a disulfide bond.
- the peptides can have specific binding affinity for fibrin.
- Compounds of the invention can include such peptides linked to a thrombolytic agent.
- the invention features purified peptides that include the amino acid sequence: C-P*-Y*-X 1 -L-C (SEQ ID NO:3), wherein X 1 is G or D, P* is proline or its non-natural derivative 4-hydroxyproline; and Y* is tyrosine or a non-natural derivative of tyrosine substituted at the 3 position with a moiety selected from the group consisting of F, Cl, Br, I, and NO 2 ; provided that at least one of P* or Y* is a non-natural derivative of the respective amino acid.
- the purified peptides can be capable of forming a disulfide bond under non-reducing conditions and can have specific binding affinity for fibrin.
- the peptides include a disulfide bond.
- Compounds of the invention can include such peptides linked to a thrombolytic agent.
- the invention also features purified peptides that include the amino acid sequence: C-D-Y-Y-G-T-C-X 10 (SEQ ID. NO:17), wherein X 10 is selected from the group consisting of n(decyl)G, n(4-PhBu)G, MeL, Bpa, Bip, Me-Bip, F(4*), F(3-Me), F(3,4-difluoro), Amh, Hfe, Y(3,5-di-iodo), Pff, 1Nal, d1Nal, and MeL, wherein F(4*) is a phenylalanine substituted at the 4 position with a moiety selected from the group consisting of Et, CF 3 , I, and iPr.
- X 10 is selected from the group consisting of n(decyl)G, n(4-PhBu)G, MeL, Bpa, Bip, Me-Bip, F
- Purified peptides can include the amino acid sequence C-D-Y-Y-G-T-C-X 10 -X 11 (SEQ ID. NO:18), wherein X 11 is selected from the group consisting of D, dD, ⁇ D, Inp, Nip, Me-D, dC, Cop, and Cmp.
- a peptide can have the follow amino acid sequences: L-P-C-D-Y-Y-G-T-C-n(Decyl)G-dD (SEQ ID NO:19), L-P-C-D-Y-Y-G-T-C-n(Decyl)G-D (SEQ ID NO:20), L-P-C-D-Y-Y-G-T-C-Bip-D (SEQ ID NO:21), L-P-C-D-Y-Y-G-T-C-Bip-dD (SEQ ID NO:22), L-P-C-D-Y-Y-G-T-C-MeL-Inp (SEQ ID NO:23), L-P-C-D-Y-Y-G-T-C-MeL-Cmp (SEQ ID NO:24), or L-P-C-D-Y-Y-G-T-C-MeBip-D (SEQ ID NO:25).
- the purified peptides can be capable of forming a disulfide bond under non-reducing conditions and can have specific binding affinity for fibrin.
- the peptides include a disulfide bond.
- Compounds of the invention can include such peptides linked to a thrombolytic agent.
- the invention features a method of making an MR imaging agent.
- the method includes reacting a peptide having an N-terminal amine functional group with a linker-subunit moiety to form a modified peptide having both a C-terminal amine functional group and N-terminal amine functional group; covalently attaching a linker moiety to the C-terminal amine functional group and to the N-terminal amine functional group to form a precursor MR imaging agent; and converting the precursor MR imaging agent to the MR imaging agent.
- the linker-subunit moiety can be selected from the group consisting of: wherein n is an integer from 1 to 4; m is an integer selected 1 to 12; and R is an aliphatic or aromatic group.
- the linker moiety can be selected from the group consisting of wherein m is an integer from 1 to 4; n is an integer from 0 to 4; LG is a leaving group; and R′ and R′′ independently are selected from the group consisting of hydrogen and a chemical protecting group.
- the linker moiety also can be selected from the group consisting of: wherein LG is a leaving group; and R 1 and R 2 independently are selected from the group consisting of hydrogen and a chemical protecting group.
- the LG can be selected from the group consisting of —OH, activated ester, halide, and anhydride.
- the activated ester can be selected from the group consisting of pentafluorophenol (Pfp), N-hydroxysuccinimide (NHS), N-Hydroxysulfosuccinimide Sodium Salt (NHSS), 2-Thioxothiazolidin-1yl, and hydroxybenzotriazole (OBT).
- the halide can be selected from the group consisting of F, Cl, Br, and I.
- the chemical protecting group can be selected from the group consisting of Boc, Fmoc, CBZ, t-butyl, benzyl, and allyl.
- Converting the precursor MR imaging agent to the MR imaging agent can include reacting the precursor imaging agent with a precursor chelate moiety to form a covalent bond between the precursor chelate moiety and the linker moiety of the precursor MR imaging agent, the precursor chelate moiety comprising a plurality of carboxylate precursor groups, the carboxylate precursor groups capable of being transformed into carboxylate moieties; transforming a plurality of the carboxylate precursor groups of the bound precursor chelate moiety to a plurality of carboxylate moieties, the carboxylate moieties capable of complexing a paramagnetic metal ion; and complexing a paramagnetic metal ion to the plurality of carboxylate moieties to produce the MR imaging agent.
- the precursor chelate moiety can be selected from the group consisting of: wherein Y is a synthetic moiety capable of forming a covalent bond with the attached linker moiety, and wherein each X, independently, is an O ⁇ or an O ⁇ precursor so that X, upon conversion to O ⁇ , is capable of forming a carboxylate moiety with its adjacent carbonyl, and R 1 is an uncharged chemical moiety, an aliphatic, alkyl group, or cycloalkyl group, or uncharged substituted versions thereof.
- the synthetic moiety can be selected from the group consisting of a carboxylic acid, activated ester, acid halide, anhydride, alkyl halide, isocyanate, and isothiocyanate, and wherein the O ⁇ precursor is selected from the group consisting of —OH, —OMe, OEt, OtBu, Obenzyl, and O-allyl.
- the precursor chelate moiety also can be selected from the group consisting of: wherein LG is a leaving group selected from the group consisting of —OH, activated ester, halide, and anhydride, and wherein each R, independently, is an O ⁇ or an O ⁇ precursor selected from the group consisting of OH, —O-Me, O-Et, O-tBu, O-benzyl, and O-allyl, so that R, upon conversion to O ⁇ , is capable of forming a carboxylate moiety with its adjacent carbonyl.
- the precursor chelate moiety also can be selected from the group consisting of: wherein n is an integer from 1 to 4; R is selected from the group consisting of a negative charge and a negative charge precursor capable of being transformed into a negative charge; and X is a chemical leaving group selected from the group consisting of —Cl, —Br, —I, -MsO, -TsO, and -TfO.
- the percursor chelate moiety can be selected from the group consisting of: wherein R is selected from the group consisting of a negative charge and a negative charge precursor capable of being transformed into a negative charge; and X is a chemical leaving group selected from the group consisting of —Cl, —Br, —I, -MsO, -TsO, and -TfO.
- the negative charge precursor is selected from the group consisting of —H, -Me, -Et, -t-Bu, -benzyl, and -allyl.
- the linker moiety can be covalently conjugated to a precursor chelate moiety, the covalent conjugate comprising a plurality of carboxylate precursor groups, the carboxylate precursor groups capable of being transformed into carboxylate moieties.
- Converting the precursor MRI imaging agent to the MR imaging agent can include transforming a plurality of the covalent conjugate's carboxylate precursor groups into carboxylate moieties, the carboxylate moieties capable of complexing a paramagnetic metal ion; and complexing a paramagnetic metal ion to the plurality of carboxylate moieties to result in the MR imaging agent.
- the paramagnetic metal ion can be selected from the group consisting of: Gd(III), Fe(III), Mn(II and III), Cr(III), Cu(II), Dy(III), Tb(III and IV), Ho(III), Er(III), Pr(III), Eu(II) and Eu(III).
- Gd(III) is a particularly useful paramagnetic ion.
- the covalent conjugate can be selected from the group consisting of wherein n is an integer from 1 to 4; LG is a leaving group selected from the group consisting of —OH, activated ester, halide, and anhydride; and R 1 , R 2 , R 3 , R 4 , and R 5 are independently selected from the group consisting of an acetate moiety, a -Me, -Et, or -t-Bu protected acetate moiety, an acetamide moiety, and an acetoxy moiety.
- the covalent conjugate also can be selected from the group consisting of: wherein LG is a leaving group selected from the group consisting of —OH, activated ester, halide, and anhydride; and R 1 , R 2 , R 3 , and R 4 are selected from the group consisting of an acetate moiety, a -Me, -Et, or -t-Bu protected acetate moiety, an acetamide moiety, and an acetoxy moiety.
- the covalent conjugate can be selected from the group consisting of:
- the covalent conjugate also can be selected from the group consisting of: wherein:
- Methods of the invention further can include, before covalently attaching a linker moiety to the C- and N-terminal amine functional groups, reacting a linker-subunit with the N-terminal amine functional group of the peptide to produce a derivatized N-terminal amine functional group of the peptide.
- the linker-subunit can be selected from the group consisting of: wherein Base is selected from the group consisting of adenosine, guanosine, thymine, and cytosine; LG is a leaving group selected from the group consisting of OH, activated ester, halide, and anhydride; and R is an aliphatic or aromatic moiety.
- the linker-subunit also can be selected from the group consisting of: wherein n is independently an integer from 0 to 3; R is an aliphatic or aromatic group; and LG is a leaving group selected from the group consisting of: OH, activated ester, halide, and anhydride.
- the linker-subunit also can be selected from the group consisting of: wherein n is independently 1 or 2; R is an aliphatic or aromatic group; and LG is a leaving group selected from the group consisting of: OH, activated ester, halide, and anhydride.
- the invention features a method of making a MR imaging agent.
- the method includes covalently binding an amino acid residue to a linker-subunit moiety to form a C-terminal end of a peptide, wherein the linker-subunit moiety is covalently attached to a resin; synthesizing a peptide on the resin from the covalently bound C-terminal end to an N-terminal residue of the peptide, the N-terminal residue comprising an N-terminal amine functional group; cleaving the peptide from the resin to produce a peptide having a C-terminal amine functional group; covalently attaching a linker moiety to the peptide's C-terminal amine functional group and N-terminal amine functional group to form a precursor MR imaging agent; and converting the precursor MR imaging agent to the MR imaging agent.
- the method further can include before cleaving the peptide from the resin, covalently attaching a linker-subunit moiety to the N-terminal amino functional group to produce a derivatized N-terminal amine functional group.
- the linker moiety can be covalently conjugated to a precursor chelate moiety, the covalent conjugate comprising a plurality of carboxylate precursor groups, the carboxylate precursor groups capable of being transformed into carboxylate moieties.
- Converting the precursor MR imaging agent to the MR imaging agent can include reacting the precursor MR imaging agent with a precursor chelate moiety to form a covalent bond between the precursor chelate moiety and the linker moiety of the precursor MR imaging agent, the precursor chelate moiety comprising a plurality of carboxylate precursor groups, the carboxylate precursor groups capable of being transformed into carboxylate moieties; transforming a plurality of the carboxylate precursor groups of the bound precursor chelate moiety to a plurality of carboxylate moieties, the carboxylate moieties capable of complexing a paramagnetic metal ion; and complexing a paramagnetic metal ion to the plurality of carboxylate moieties to produce the MR imaging agent.
- Converting the precursor MRI imaging agent to the MR imaging agent also can include transforming a plurality of the covalent conjugate's carboxylate precursor groups into carboxylate moieties, the carboxylate moieties capable of complexing a paramagnetic metal ion; and complexing a paramagnetic metal ion to the plurality of carboxylate moieties to result in the MR imaging agent.
- the paramagnetic metal ion can be selected from the group consisting of: Gd(III), Fe(III), Mn(II and III), Cr(III), Cu(II), Dy(III), Tb(III and IV), Ho(III), Er(III), Pr(III), Eu(II) and Eu(III).
- Gd(III) is a particularly useful paramagnetic metal ion.
- the invention features a method of making a MR imaging agent that includes reacting a peptide having a C-terminal carboxylate functional group with a linker-subunit moiety to form a modified peptide having both a C-terminal carboxylate functional group and an N-terminal carboxylate functional group; covalently attaching a linker moiety to both the N-terminal and C-terminal carboxylate functional groups of the modified peptide to form a precursor MR imaging agent; and converting the precursor MR imaging agent to the MR imaging agent.
- the linker-subunit moiety can be selected from the group consisting of: wherein LG is a leaving group selected from the group consisting of OH, activated ester, halide, and anhydride; and R is an aromatic or aliphatic group.
- the linker moiety also can be selected from the group consisting of: wherein m is an integer from 1 to 4; n is an integer from 0 to 4; R is independently selected from the group consisting of —H, -Me, -Et, -Bz, and -tBu; and R 1 and R 2 are independently selected from a hydrogen or a chemical protecting group.
- the linker moiety can be selected from the group consisting of: wherein R 1 and R 2 are selected independently from the group consisting of hydrogen and a chemical protecting group, the chemical protecting group selected from the group consisting of: Boc, Fmoc, CBZ, t-butyl, benzyl, and allyl.
- Converting the precursor MR imaging agent to the MR imaging agent also can include reacting the precursor MR imaging agent with a precursor chelate moiety in order to form a covalent bond between the linker moiety of the precursor MR imaging agent and the precursor chelate moiety, the precursor chelate moiety comprising a plurality of carboxylate precursor groups, the carboxylate precursor groups capable of being transformed into carboxylate moieties; transforming a plurality of the carboxylate precursor groups of the bound precursor chelate moiety to a plurality of carboxylate moieties, the carboxylate moieties capable of complexing a paramagnetic metal ion; and complexing a paramagnetic metal ion to the plurality of carboxylate moieties to produce the MR imaging agent.
- the linker moiety can be covalently conjugated to a precursor chelate moiety, the covalent conjugate comprising a plurality of carboxylate precursor groups, the carboxylate precursor groups capable of being transformed into carboxylate moieties.
- Converting the precursor MR imaging agent to the MR imaging agent also can include transforming a plurality of the covalent conjugate's carboxylate precursor groups into carboxylate moieties, the carboxylate moieties capable of complexing a paramagnetic metal ion; and complexing a paramagnetic metal ion to the plurality of carboxylate moieties to produce the MR imaging agent.
- a covalent conjugate can be selected from the group consisting of: wherein n is an integer from 1 to 4; and R 1 , R 2 , R 3 , R 4 , and R 5 are independently selected from the group consisting of an acetate moiety, a -Me, -Et, or -t-Bu protected acetate moiety, an acetamide moiety, and an acetoxy moiety.
- the covalent conjugate can be:
- Converting the precursor MR imaging agent to the MR imaging agent also can include reacting the precursor imaging agent with a chelate moiety, wherein the chelate moiety contains a paramagnetic metal ion, to form a covalent bond between the chelate moiety and the linker moiety of the precursor MR imaging agent to produce the MR imaging agent.
- a chelate moiety contains a paramagnetic metal ion
- the invention features a contrast agent that includes a metal chelate complex at a —CO 2 R and NHR termini of a biopolymer (e.g., a peptide), wherein R is independently selected from the group consisting of hydrogen, alkyl, aliphatic, and a leaving group.
- the contrast agent can include two metal chelate complexes at the CO 2 R and NHR termini of the biopolymer.
- the biopolymer can have a specific binding affinity for fibrin.
- the peptide can be capable of forming a disulfide bond under non-reducing conditions, and in some embodiments, includes a disulfide bond.
- a contrast agent can have the formula: wherein Chelate represents a metal chelate complex; Linker represents a linker moiety; Linker-subunit represents a linker-subunit moiety; m is independently an integer from 1 to 10; p is independently an integer from 0 to 5; s is independently 0 or 1; R 1 is an amino acid side chain or a derivative thereof, and R 2 is independently a hydrogen or an aliphatic group.
- a contrast agent also can have a structure of any one of structures 4-55.
- the invention features a method for altering the stability of a peptide, the peptide having an N-terminal amine functional group.
- the method includes reacting the peptide with a linker-subunit moiety to form a peptide having a C-terminal amine functional group; and covalently attaching a linker moiety to the peptide's C-terminal amine functional group and N-terminal amine functional group to form a modified peptide.
- the method further can include reacting the modified peptide with a capping moiety to form a covalent bond between the capping moiety and the linker moiety of the modified peptide.
- the method also can include reacting the modified peptide with a precursor chelate moiety to form a covalent bond between the precursor chelate moiety and the linker moiety of the modified peptide, the precursor chelate moiety comprising a plurality of carboxylate precursor groups, the carboxylate precursor groups capable of being transformed into carboxylate moieties.
- the carboxylate moieties capable of complexing a paramagnetic metal ion; a paramagnetic metal ion can be complexed to the plurality of carboxylate moieties.
- the method further can include assaying the stability of the modified peptide or assaying the stability of the unmodified peptide and comparing the stability of said modified peptide to the stability of the unmodified peptide.
- Stability of the modified peptide can be improved relative to the stability of the unmodified peptide (e.g., improved 10-fold, 20-fold, or 30-fold relative to the stability of the unmodified peptide). Stability can be assayed using a rat liver homogenate assay.
- the invention features a modified peptide having the structure: wherein Chelate precursor represents a chelate precursor moiety; Linker represents a linker moiety; Linker-subunit represents a linker-subunit moiety; m is independently an integer from 1 to 10; p is independently an integer from 0 to 5; s is independently 0 or 1; R 1 is an amino acid side chain or a derivative thereof, and R 2 is selected from the group consisting of H and an aliphatic group.
- the invention features a modified peptide having the structure: wherein Linker represents a linker moiety; Linker-subunit represents a linker-subunit moiety; p is independently an integer from 0 to 5; s is independently 0 or 1; R 1 is an amino acid side chain or a derivative thereof, and R 2 is selected from the group consisting of H and an aliphatic group.
- Method of making an MR imaging agent also are featured that include reacting a peptide having an N-terminal amine functional group with a linker-subunit moiety to form a modified peptide having an amine functional group on both its N-terminus and C-terminus, or reacting a peptide having a C-terminal carboxylate functional group with a linker-subunit moiety to form a modified peptide having a carboxylate functional group on both its C-terminus and N-terminus; and converting the modified peptide to the MR imaging agent.
- Converting the modified peptide to the MR imaging agent can include covalently attaching a chelate moiety to the modified peptide, wherein the chelate moiety contains a paramagnetic metal ion, to produce the MR imaging agent. Converting the modified peptide to the MR imaging agent also can include covalently linking a linker moiety to a chelate moiety to form a covalent conjugate, wherein the chelate moiety contains a paramagnetic metal ion; and reacting the covalent conjugate with the modified peptide to form the MR imaging agent. Suitable paramagnetic ions are described above.
- the invention features a method of making an MR imaging agent that includes covalently binding an amino acid residue to a linker-subunit moiety to form a C-terminal end of a peptide, wherein the linker-subunit moiety is covalently attached to a resin; synthesizing a peptide on the resin from the covalently bound C-terminal end to an N-terminal residue of the peptide, the N-terminal residue comprising an N-terminal amine functional group; cleaving the peptide from the resin to produce a C-terminal amine functional group of the modified peptide; converting the modified peptide to the MR imaging agent.
- Converting the modified peptide to the MR imaging agent can include covalently attaching a chelate moiety to the modified peptide, wherein the chelate moiety contains a paramagnetic metal ion, to produce the MR imaging agent. Converting the modified peptide to the MR imaging agent also can include covalently linking a linker moiety to a chelate moiety to form a covalent conjugate, wherein the chelate moiety contains a paramagnetic metal ion; and reacting the covalent conjugate with the modified peptide to form the MR imaging agent. Suitable paramagnetic ions are described above.
- FIG. 1 provides the chemical structures of non-natural amino acids.
- FIG. 2 depicts the relaxivities per Gd at 20 MHz, 35° C. in Tris buffered saline (TBS) or 10 mg/ml fibrin in TBS.
- FIG. 3 depicts the accumulation of a contrast agent in the thrombus.
- FIG. 4A is an image of a thrombus.
- FIG. 4B is an image of a thrombus with black blood.
- the term “chemical protecting group” or “protecting group” means any chemical moiety temporarily covalently bound to a molecule throughout one or more synthetic chemistry steps in a reaction sequence to prevent undesirable reactions.
- Common protecting group strategies are described in “Protecting Groups in Organic Synthesis, Third Ed.” by P. Wuts and T. Greene, ⁇ 1999 John Wiley & Sons, Inc.
- the term “leaving group” means any chemical moiety that is displaced by a nucleophile in a nucleophilic substitution or sequence of addition-elimination reactions.
- a molecule comprising a leaving group may be isolated or it may be formed in situ as a transient intermediate in a chemical reaction.
- aliphatic describes any acyclic or cyclic, saturated or unsaturated, branched or unbranched carbon compound, excluding aromatic compounds.
- alkyl includes saturated aliphatic groups, including straight-chain alkyl groups (e.g., methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, nonyl, decyl, etc.), branched-chain alkyl groups (isopropyl, tert-butyl, isobutyl, etc.), cycloalkyl (alicyclic) groups (cyclopropyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl), alkyl substituted cycloalkyl groups, and cycloalkyl substituted alkyl groups.
- straight-chain alkyl groups e.g., methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, nonyl, decyl,
- alkyl further includes alkyl groups, which can further include oxygen, nitrogen, sulfur or phosphorous atoms replacing one or more carbons of the hydrocarbon backbone.
- a straight chain or branched chain alkyl has 6 or fewer carbon atoms in its backbone (e.g., C 1 -C 6 for straight chain, C 3 -C 6 for branched chain), and more preferably 4 or fewer.
- preferred cycloalkyls have from 3-8 carbon atoms in their ring structure, and more preferably have 5 or 6 carbons in the ring structure.
- C 1 -C 6 includes alkyl groups containing 1 to 6 carbon atoms.
- alkyl includes both “unsubstituted alkyls” and “substituted alkyls,” the latter of which refers to alkyl moieties having substituents replacing a hydrogen on one or more carbons of the hydrocarbon backbone.
- substituents can include, for example, alkenyl, alkynyl, halogen, hydroxyl, alkylcarbonyloxy, arylcarbonyloxy, alkoxycarbonyloxy, aryloxycarbonyloxy, carboxylate, alkylcarbonyl, arylcarbonyl, alkoxycarbonyl, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, alkylthiocarbonyl, alkoxyl, phosphate, phosphonato, phosphinato, cyano, amino (including alkyl amino, dialkylamino, arylamino, diarylamino, and alkylarylamino), acylamino (including alkylcarbonylamino, arylcarbonylamino, carbamoyl and ureido), amidino, imino, sulfhydryl, alkylthio, arylthio, thiocarboxylate, sul
- Cycloalkyls can be further substituted, e.g., with the substituents described above.
- An “arylalkyl” moiety is an alkyl substituted with an aryl (e.g., phenylmethyl (benzyl)).
- alkyl also includes the side chains of natural and unnatural amino acids.
- n-alkyl means a straight chain (i.e., unbranched) unsubstituted alkyl group.
- alkenyl includes aliphatic groups that may or may not be substituted, as described above for alkyls, containing at least one double bond and at least two carbon atoms.
- alkenyl includes straight-chain alkenyl groups (e.g., ethylenyl, propenyl, butenyl, pentenyl, hexenyl, heptenyl, octenyl, nonenyl, decenyl, etc.), branched-chain alkenyl groups, cycloalkenyl (alicyclic) groups (cyclopropenyl, cyclopentenyl, cyclohexenyl, cycloheptenyl, cyclooctenyl), alkyl or alkenyl substituted cycloalkenyl groups, and cycloalkyl or cycloalkenyl substituted alkenyl groups.
- alkenyl further includes alkenyl groups that include oxygen, nitrogen, sulfur or phosphorous atoms replacing one or more carbons of the hydrocarbon backbone.
- a straight chain or branched chain alkenyl group has 6 or fewer carbon atoms in its backbone (e.g., C 2 -C 6 for straight chain, C 3 -C 6 for branched chain).
- cycloalkenyl groups may have from 3-8 carbon atoms in their ring structure, and more preferably have 5 or 6 carbons in the ring structure.
- C 2 -C 6 includes alkenyl groups containing 2 to 6 carbon atoms.
- alkenyl includes both “unsubstituted alkenyls” and “substituted alkenyls,” the latter of which refers to alkenyl moieties having substituents replacing a hydrogen on one or more carbons of the hydrocarbon backbone.
- substituents can include, for example, alkyl groups, alkynyl groups, halogens, hydroxyl, alkylcarbonyloxy, arylcarbonyloxy, alkoxycarbonyloxy, aryloxycarbonyloxy, carboxylate, alkylcarbonyl, arylcarbonyl, alkoxycarbonyl, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, alkylthiocarbonyl, alkoxyl, phosphate, phosphonato, phosphinato, cyano, amino (including alkyl amino, dialkylamino, arylamino, diarylamino, and alkylarylamino), acylamino (including alkylcarbonylamino, arylcarbonylamino, carbamoyl and ureido), amidino, imino, sulfhydryl, alkylthio, arylthio, thiocarboxylate,
- alkynyl includes unsaturated aliphatic groups analogous in length and possible substitution to the alkyls described above, but which contain at least one triple bond and two carbon atoms.
- alkynyl includes straight-chain alkynyl groups (e.g., ethynyl, propynyl, butynyl, pentynyl, hexynyl, heptynyl, octynyl, nonynyl, decynyl, etc.), branched-chain alkynyl groups, and cycloalkyl or cycloalkenyl substituted alkynyl groups.
- alkynyl further includes alkynyl groups that include oxygen, nitrogen, sulfur or phosphorous atoms replacing one or more carbons of the hydrocarbon backbone.
- a straight chain or branched chain alkynyl group has 6 or fewer carbon atoms in its backbone (e.g., C 2 -C 6 for straight chain, C 3 -C 6 for branched chain).
- C 2 -C 6 includes alkynyl groups containing 2 to 6 carbon atoms.
- aryl includes groups, including 5- and 6-membered single-ring aromatic groups that may include from zero to four heteroatoms, for example, benzene, phenyl, pyrrole, furan, thiophene, thiazole, isothiaozole, imidazole, triazole, tetrazole, pyrazole, oxazole, isooxazole, pyridine, pyrazine, pyridazine, and pyrimidine, and the like.
- aryl includes multicyclic aryl groups, e.g., tricyclic, bicyclic, such as naphthalene, benzoxazole, benzodioxazole, benzothiazole, benzoimidazole, benzothiophene, methylenedioxyphenyl, quinoline, isoquinoline, napthridine, indole, benzofuran, purine, benzofuran, deazapurine, or indolizine.
- aryl groups e.g., tricyclic, bicyclic, such as naphthalene, benzoxazole, benzodioxazole, benzothiazole, benzoimidazole, benzothiophene, methylenedioxyphenyl, quinoline, isoquinoline, napthridine, indole, benzofuran, purine, benzofuran, deazapurine, or indolizine.
- aryl groups having heteroatoms in the ring structure may also be referred to as “aryl heterocycles,” “heterocycles,” “heteroaryls,” or “heteroaromatics.”
- An aryl group may be substituted at one or more ring positions with substituents.
- DTPA refers to a chemical compound comprising a substructure composed of diethylenetriamine, wherein the two primary amines are each covalently attached to two acetyl groups and the secondary amine has one acetyl group covalently attached according to the following formula:
- X is a heteroatom electron-donating group capable of coordinating a metal cation, preferably O ⁇ , OH, NH 2 , OPO 3 2 ⁇ , or NHR, or OR wherein R is any aliphatic group.
- DTPE tert-butoxy
- DOTA refers to a chemical compound comprising a substructure composed of 1,4,7,11-tetraazacyclododecane, wherein the amines each have one acetyl group covalently attached according to the following formula:
- NOTA refers to a chemical compound comprising a substructure composed of 1,4,7-triazacyclononane, wherein the amines each have one acetyl group covalently attached according to the following formula:
- DO3A refers to a chemical compound comprising a substructure composed of 1,4,7,11-tetraazacyclododecane, wherein three of the four amines each have one acetyl group covalently attached and the other amine has a substituent having neutral charge according to the following formula:
- R 1 is an uncharged chemical moiety, preferably hydrogen, any aliphatic, alkyl group, or cycloalkyl group, and uncharged derivatives thereof
- R 1 is an uncharged chemical moiety, preferably hydrogen, any aliphatic, alkyl group, or cycloalkyl group, and uncharged derivatives thereof
- the carbon atoms of the indicated ethylenes may be referred to as “backbone” carbons.
- the designation “bbDTPA” may be used to refer to the location of a chemical bond to a DTPA molecule (“bb” for “back bone”).
- bb(CO)DTPA-Gd means a C ⁇ O moiety bound to an ethylene backbone carbon atom of DTPA.
- chelating ligand may be used to refer to any polydentate ligand which is capable of coordinating a metal ion, including DTPA (and DTPE), DOTA, DO3A, or NOTA molecule, or any other suitable polydentate chelating ligand as is further defined herein, that is either coordinating a metal ion or is capable of doing so, either directly or after removal of protecting groups, or is a reagent, with or without suitable protecting groups, that is used in the synthesis of a contrast agent and comprises substantially all of the atoms that ultimately will coordinate the metal ion of the final metal complex.
- chelate refers to the actual metal-ligand complex, and it is understood that the polydentate ligand will eventually be coordinated to a medically useful metal ion.
- telomere binding affinity refers to the capacity of a contrast agent to be taken up by, retained by, or bound to a particular biological component to a greater degree than other components. Contrast agents that have this property are said to be “targeted” to the “target” component. Contrast agents that lack this property are said to be “non-specific” or “non-targeted” agents.
- the specific binding affinity of a binding group for a target is expressed in terms of the equilibrium dissociation constant “Kd.”
- open coordination site refers to a site on a metal ion that is generally occupied by a water or solvent molecule.
- the term “purified” refers to a peptide that has been separated from either naturally occurring organic molecules with which it normally associates or, for a chemically-synthesized peptide, separated from any other organic molecules present in the chemical synthesis.
- the polypeptide is considered “purified” when it is at least 70% (e.g., 70%, 80%, 90%, 95%, or 99%), by dry weight, free from any other proteins or organic molecules.
- peptide refers to a chain of amino acids that is about 2 to about 75 amino acids in length (e.g., 3 to 50 amino acids).
- biopolymer refers to a polymeric substance that is naturally formed in a biological system. Certain biopolymers can be constructed from a defined set of building subunits and with common functionalities linking the subunits, e.g., a peptide is usually constructed from a set of amino acids (both natural and non-natural) with amide bonds linking the subunits.
- multimer for purposes herein is defined as a contrast agent or a subunit thereof comprising at least two covalently bonded chelates or synthetic precursors thereof.
- natural amino acid refers to one of the twenty most common occurring amino acids. Natural amino acids modified to provide a label for detection purposes (e.g., radioactive labels, optical labels, or dyes) are considered to be natural amino acids. Natural amino acids are referred to by their standard one- or three-letter abbreviations.
- non-natural amino acid refers to any derivative of a natural amino acid including D forms, and ⁇ and ⁇ amino acid derivatives. It is noted that certain amino acids, e.g., hydroxyproline, that are classified as a non-natural amino acid herein, may be found in nature within a certain organism or a particular protein.
- stable refers to compounds that possess stability sufficient to allow manufacture and which maintains the integrity of the compound for a sufficient period of time to be useful and safe for the purposes detailed herein. Typically, such compounds are stable at a temperature of 40° C. or less, in the absence of moisture or other chemically reactive conditions, for at least a week. Combinations of substituents and variables envisioned by this invention are only those that result in the formation of stable compounds.
- target binding and “binding” for purposes herein refer to non-covalent interactions of a contrast agent with a target. These non-covalent interactions are independent from one another and may be, inter alia, hydrophobic, hydrophilic, dipole-dipole, pi-stacking, hydrogen bonding, electrostatic associations, or Lewis acid-base interactions.
- capping moiety refers to a chelate, organic dye, contrast agent, thrombolytic, or stabilizing moiety.
- Suitable stabilizing moieties are biologically inert, i.e., does not have biological activity.
- the present invention relates to MRI, optical, and radionuclide contrast agents that include a targeting polymer (e.g., peptide) in which both the N- and C-terminal amino acids are each conjugated, either directly or via an optional intervening linker-subunit and linker, to at least one chelate of a paramagnetic (for magnetic resonance imaging) or radioactive (for radionuclide imaging) metal ion or an optical dye (for optical imaging).
- a targeting polymer e.g., peptide
- the linker or linker-subunit may be branched and therefore allow for multiple chelates or dyes to be attached to each end of the peptide, i.e. a multimer.
- the compounds of this invention may contain one or more asymmetric carbon atoms and thus may occur as racemates and racemic mixtures, single enantiomers, diastereomeric mixtures and individual diastereomers. All such isomeric forms of these compounds are expressly included in the present invention.
- Each stereogenic carbon may be of the R or S configuration unless specifically designated otherwise.
- the specific compounds exemplified in this application may be depicted in a particular stereochemical configuration, compounds having either the opposite stereochemistry at any given chiral center or mixtures thereof are also envisioned. It should be understood that the compounds of this invention may adopt a variety of conformational and ionic forms in solution, in pharmaceutical compositions and in vivo. Although the depictions herein of specific preferred compounds of this invention are of particular conformations and ionic forms, the disclosure of the invention is not so limited.
- Novel peptide-based multimers of the present invention offer several advantages as targeted contrast agents.
- chelate represents a metal chelate complex
- p is independently an integer from zero to five
- s is independently one or zero
- R 1 is any amino acid side chain including side chains of non-natural amino acids
- R 2 is any aliphatic group or hydrogen
- n is an integer from 3 to 50 inclusive.
- R 1 and R 2 may be taken together to form a ring structure (including proline and substituted versions thereof). Linkers, if present, may be different.
- Metal ions preferred for MRI include those with atomic numbers 21-29, 39-47, or 57-83, and, more preferably, a paramagnetic form of a metal ion with atomic numbers 21-29, 42, 44, or 57-83.
- Particularly preferred paramagnetic metal ions are selected from the group consisting of Gd(III), Fe(III), Mn(II and III), Cr(III), Cu(II), Dy(III), Tb(III and IV), Ho(III), Er(III), Pr(III) and Eu(II and III).
- Gd(III) is particularly useful.
- Gd is meant to convey the ionic form of the metal gadolinium; such an ionic form can be written as GD(III), GD3+, gado, etc., with no difference in ionic form contemplated.
- radionuclides 90 Y, 99m Tc, 111 In, 47 Sc, 67 Ga, 51 Cr, 177m Sn, 67 Cu, 167 Tm, 97 Ru, 188 Re, 177 Lu, 199 Au, 203 Pb, and 141 Ce are particularly useful.
- Metal complexes with useful optical properties also have been described. See, Murru et al., J. Chem. Soc. Chem. Comm. 1993, 1116-1118.
- lanthanide chelates such as La(III), Ce(III), Pr(III), Nd(III), Pn(III), Sm(III), Eu(III), Gd(III), Tb(III), Dy(III), Ho(III), Er(III), Tm(III), Yb(III) and Ln(III) are suitable. Eu(III) and Tb(III) are particularly useful.
- Metal chelates should not dissociate to any significant degree during the imaging agent's passage through the body, including while bound to a target tissue. Significant release of free metal ions can result in toxicity, which would generally not be acceptable.
- m is 2, n, s, R 1 , and R 2 are defined as above, and the Linker moiety comprises:
- the “Chelate” is preferably bb(CO)DTPA.Gd.
- m is 2, n, s, R 1 , and R 2 are defined as above, and the linker moiety comprises:
- the “Chelate” moiety can be bb(CO)DTPA.Gd.
- optical contrast agents contemplated by the invention may be illustrated by the formula:
- R 1 is any amino acid side chain including non-natural amino acid side chains
- R 2 is any aliphatic group or hydrogen.
- R 1 and R 2 taken together form a ring structure (including Pro and derivatives thereof.
- the linker moieties can be different.
- the optical dye may be an organic dye or an appropriate metal chelate.
- Organic dyes suitable for optical imaging have been described and include, for example, fluorescent porphyrin and fluorescent phthalocyanines [see, e.g., U.S. Pat. No. 5,641,878], particulate materials [see, e.g., WO 96/23524], and polymethine dyes [see, e.g., WO 97/13490].
- Commonly used optical organic dyes are fluorescein, rhodamine [see, e.g., Kojima H, et al., Anal. Chem. 73, 1967-1973 (2001)], tetramethylrhodamine [e.g., Anal. Biochem. 223, 39 (1994)], and Texas red [e.g., Proc. Natl. Acad. Sci. USA 85, 3546 (1988)]. Fluoroscein and luminescent lanthanide chelates are particularly useful.
- the peptide moiety of the contrast agents of the present invention can exhibit specific binding for a biological target and function as a point of attachment for one or more chelates at each terminus.
- biological targets are present in a low (e.g., micromolar or less) concentration and are inefficiently imaged using existing monomeric gadolinium complex MRI contrast agents.
- the peptide-based multimeric MRI contrast agents according to the instant invention provide a much higher concentration of the agent at the target as well as high relaxivity to make imaging of these targets possible.
- the peptide-based multimeric radionuclide contrast agents of the invention may deliver more radionuclides to targets so that imaging can be further improved.
- targeting creates an increased concentration of the imaging agent at the site to be imaged and increases the relaxivity of MRI contrast agents in the bound state through the RIME effect and also limits local chelate motion by rigidifying the bound peptide.
- Targets for the contrast agents can be in any body compartment, cell, organ, or tissue or component thereof.
- Preferred targets are those that are of diagnostic and therapeutic relevance, i.e., those that are associated with disease states.
- Particularly preferred targets are those in association with body fluids, and particularly those in association with blood, plasma, lymph and fluids of the central nervous system.
- Other preferred targets are proteins and receptors that either exist in high concentration or have a large number of binding sites for certain ligands. Included among such target proteins are enzymes and glycoproteins.
- HSA Human serum albumin
- fibrin are useful targets for MRI contrast agents.
- serum albumin is a preferred target. Since HSA is present at high concentration in serum (approximately 0.6 mM) and binds a wide array of molecules with reasonably high affinity, it is a preferred target plasma protein for blood pool contrast agents. HSA is a particularly preferred target for cardiovascular imaging; see U.S. patent application No. 08/875,365, filed Jul. 24, 1997, and WO 96/23526.
- fibrin is a preferred target because it is present in all clots and it can be targeted without interfering with the normal thrombolytic process.
- target binding moieties that include fibrin-binding peptides, see PCT Patent Application WO 01/09188.
- protein targets include, but are not limited to, alpha acid glycoprotein, fibrinogen, collagen, platelet GPIIb/IIIa receptor, chemotactic peptide receptor, somatostatin receptors, vasoactive intestinal peptides (VIP) receptor, bombesin/Gastrin release peptide receptor, and integrin receptors.
- VIP vasoactive intestinal peptides
- Suitable peptides for use in the invention include those capable of specifically binding to the targets identified above. Included among such peptides are RGD-containing peptides targeting platelet GPIIb/IIIa receptor for thrombus imaging, chemotactic peptides targeting white blood cells for infection/inflammation imaging, Octreotide and P-829 peptide targeting somastatin receptors for tumor imaging, vasoactive intestinal peptides (VIP) targeting VIP receptor for tumor imaging, bombesin analogs targeting bombesin/Gastrin release peptide receptor for tumor imaging, and RGD-containing peptides targeting the integrin ⁇ v ⁇ 3 (vitronectin receptor) for tumor imaging.
- RGD-containing peptides targeting platelet GPIIb/IIIa receptor for thrombus imaging
- chemotactic peptides targeting white blood cells for infection/inflammation imaging
- Octreotide and P-829 peptide targeting somastatin receptors for tumor imaging
- any peptide with an affinity for a biological target may be used in a contrast agent of the invention.
- the peptide may be linear or cyclic.
- insoluble lipophilic peptides are considered unsuitable for pharmacological use, but such peptides may be suitable according to the invention because addition of hydrophilic metal chelates to the two termini of the peptide may increase solubility.
- the peptides have between 3 to 50 amino acids (e.g., 3 to 30, 3 to 20, 3 to 15, 5 to 30, 5 to 20, 5 to 15, 10 to 12 amino acids in length).
- Suitable amino acids include natural and non-natural amino acids.
- Amino acids with many different protecting groups appropriate for immediate use in the solid phase synthesis of peptides are commercially available.
- the following non-natural amino acids or amino acid derivatives may be constituents of the peptide targeting group of the invention (common abbreviations in parentheses, see FIG.
- Stereochemistry of amino acids may be designated by preceding the name or abbreviation with the designation “ D ” or “d” or “ L ” or “l” as appropriate. Additionally, ⁇ N-alkylated amino acids may be employed, as well as amino acids having amine-containing side chains (such as Lys and Orn) in which the amine has been acylated or alkylated.
- Peptides of the invention can include the general formula P* -Y*—X 1 * -L* (SEQ ID NO:1), wherein P* is a proline or a non-natural derivative of proline, Y* is a tyrosine or a non-natural derivative thereof, X 1 * is glycine or aspartic acid, or a non-natural derivative of glycine or aspartic acid, and L* is leucine or a non-natural derivative thereof.
- at least one of P*, Y*, X 1 *, or L* is a non-natural derivative of the respective amino acid.
- X 1 * can be glycine or aspartic acid
- L* can be leucine
- at least one of P* or Y* can be a non-natural derivative, such as hydroxyproline or a tyrosine substituted at the 3 position with F, Cl, Br, I, or NO 2 .
- a peptide of the invention also can include the general formula X 1 —X 2 —C—P* -Y* - X 3 —L—C—X 4 —X 5 —X 6 (SEQ ID NO:2), wherein P* is a proline or a non-natural derivative thereof, Y* is a tyrosine or a non-natural derivative thereof, X 1 is W, Y, F, S, Bip, Hx, Dpr, Cy, Gu, Ad, Hfe, 3-Pal, 4-Pal, DopaMe2, nTyr, dW, dF, F(3/4*), or Y(3*).
- F(3/4*) can be a phenylalanine substituted at either the 3 or the 4 position with a moiety such as CH 3 , CF 3 , NH 2 , CH 2 NH 2 , CN, F, Cl, Br, I, Et, or Ome.
- Y(3*) can be a tyrosine substituted at the 3 position with a moiety such as F, Cl, Br, I, and NO 2 .
- X 2 can be E, H, dE, S, H(Bzl), 2-Pal, Dpr, or Th;
- X 3 can be G or D;
- X 4 can be H, F, Y, or W;
- X 5 can be I, L, V, N, Bpa, Bal, Hfe, Nle, Tle, Nval, Phg, Cha, Taz, Fua, Th, 4-Pal, or F(3/4*), wherein F(3/4*) is a phenylalanine substituted at either the 3 or the 4 position with a moiety such as CF 3 , Et, iPr, or OMe;
- X 6 can be N, Q, I, L, or V, or not present.
- X 1 , X 2 , X 5 , P*, and Y* is a non-natural derivative of an amino acid.
- P* can be proline and Y* can be a non-natural derivative of tyrosine substituted at the 3 position with a moiety such as F, Cl, Br, I, or NO 2 .
- P* can be a non-natural derivative of proline such as 4-hydroxyproline and Y* can be tyrosine.
- Such peptides can form a disulfide bond under non-reducing conditions.
- a peptide that can bind fibrin includes the general formula C-P* - Y*—X 1 —L—C (SEQ ID NO:3), wherein X 1 is G or D, P* is proline or its non-natural derivative 4-hydroxyproline; Y* is tyrosine or a non-natural derivative of tyrosine substituted at the 3 position with a moiety such as F, Cl, Br, I, or NO 2 . Typically, at least one of P* or Y* is a non-natural derivative of the respective amino acid.
- the peptide can have the following sequences: W-dE-C-P(4-OH)-Y(3-Cl)-G-L-C-W-I-Q (SEQ ID NO:4), Y-dE-C-P(4-OH)-Y(3-Cl)-G-L-C-Y-I-Q (SEQ ID NO:5), Y-dE-C-P(4-OH)-Y(3-Cl)-G-L-C-W-I-Q (SEQ ID NO:6), W-dE-C-P(4-OH)-Y(3-Cl)-G-L-C-Y-I-Q (SEQ ID NO:7), W-dE-C-P(4-OH)-Y(3-Cl)-D-L-C-W-I-Q (SEQ ID NO:8), Y-dE-C-P(4-OH)-Y(3-Cl)-D-L-C-W-I-Q (S
- peptides having the sequence set forth in Table 1 were synthesized (structure confirmed by mass spectrometry), cyclized, and assayed for affinity to the DD(E) fragment of fibrin. Each peptide was found to have a Kd ⁇ 10 ⁇ M (“-” indicates truncation). TABLE 1 Kd( ⁇ M) vs.
- a peptide also can have the general formula C-D-Y-Y-G-T-C-X 10 (SEQ ID. NO:17), wherein X 10 is n(decyl)G, n(4-PhBu)G, MeL, Bpa, Bip, Me-Bip, F(4*), F(3-Me), F(3, 4-difluoro), Amh, Hfe, Y(3, 5-di-iodo), Pff, 1Nal, d1Nal, or MeL, wherein F(4*) is a phenylalanine substituted at the 4 position with a moiety such as Et, CF 3 , I, or iPr.
- X 10 is n(decyl)G, n(4-PhBu)G, MeL, Bpa, Bip, Me-Bip, F(4*), F(3-Me), F(3, 4-difluoro), Amh, Hfe,
- a peptide can include additional residues, X 1 , P*, and/or X 11 to provide the general formula: C-D-Y-Y-G-T-C-X 10 -X 11 (SEQ ID. NO:18) or X 1 -P*-C-D-Y-Y-G-T-C-X 10 -X 11 (SEQ ID. NO:26), wherein X 1 is any natural or non-natural amino acid, P* is proline or a non-natural derivative thereof, and X 11 is D, dD, ⁇ D, Inp, Nip, Me-D, Cop, or Cmp.
- a peptide can have the sequence of L-P-C-D-Y-Y-G-T-C-n(Decyl)G-dD (SEQ ID NO:19), L-P-C-D-Y-Y-G-T-C-n(Decyl)G-D (SEQ ID NO:20), L-P-C-D-Y-Y-G-T-C-Bip-D (SEQ ID NO:21), L-P-C-D-Y-Y-G-T-C-Bip-dD (SEQ ID NO:22), L-P-C-D-Y-Y-G-T-C-MeL-Inp (SEQ ID NO:23), L-P-C-D-Y-Y-G-T-C-MeL-Cmp (SEQ ID NO:24), or L-P-C-D-Y-Y-G-T-C-MeBip-D (SEQ ID NO:25).
- Peptides having the formula of SEQ ID NO:26 were synthesized (structure confirmed by mass spectrometry) according to standard synthesis methods, such as those disclosed in WO 01/09188 or in WO 01/08712, and assayed for affinity to the DD(E) fragment of fibrin. Each peptide was found to have a Kd ⁇ 10 ⁇ M (Table 2). TABLE 2 X 01 X 10 X 11 L n(Decyl)G dD L n(Decyl)G D L MeL Inp L Bip D L Bip dD L Me-Bip D L MeL Cmp L Bip D L L D Cha Bip D
- the ability of the peptides to bind a target such as HSA or fibrin can be assessed by known methodology.
- affinity of the peptide for fibrin can be assessed using the DD(E) fragment of fibrin, which contains subunits of 55 kD (Fragment E) and 190 kD (Fragment DD).
- the DD(E) fragment can be biotinylated and immobilized via avidin to a solid substrate (e.g., a multi-well plate). Peptides can be incubated with the immobilized DD(E) fragment in a suitable buffer and binding detected using known methodology. See, for example, WO 01/09188.
- linker-subunits and linkers are used to covalently attach capping moieties such as chelates, thrombolytics, and other groups to the two ends of a peptide.
- a linker-subunit moiety can (i) convert the functionality of either the C-terminus carboxylate to an amine functional group or the N-terminus amine to a carboxylate functional group; or (ii) provide a spacer moiety or group between the peptide terminus and the linker, if present, or capping group.
- a peptide can be reacted with a linker-subunit to form a modified peptide having a C-terminal amine functional group and a N-terminal amine functional group.
- a peptide can be reacted with a linker-subunit to form a modified peptide having a N-terminal carboxylate functional group and a C-terminal carboxylate functional group.
- a peptide in another embodiment, can be synthesized from a C-terminal linker-subunit that is bound to a resin, whereby upon cleaving the peptide from the resin, a peptide having a C-terminal amine functional group is produced.
- a linker-subunit can be used as a spacer group and not to change the terminus functional group.
- a linker-subunit may have multiple functional groups for attachment of linker moieties or capping moieties.
- linker-subunit Many types of reactions can be used, including acylation, reductive amination, nucleophilic displacement reactions, urea formation, thiourea formation, and chemoselective ligation in chemically conjugating the linker-subunit to the peptide, linker, and/or capping moieties.
- One advantage of using a linker-subunit is to create similar functional groups on the peptide, thereby facilitating subsequent synthesis.
- the linker moiety can be used to covalently attach one or more capping moieties to the peptide terminus.
- the linker may be branched or unbranched and may comprise multiple functional groups for precursor chelate and chelate attachment.
- the chemical structure of the linker may affect the physical and pharmacological properties of the contrast agent, such as affinity, stability, blood half-life, relaxivity, and plasma protein binding.
- Linkers may be substituted with alkyl, aryl, alkenyl, or alkynyl groups.
- Linkers, if present, at each termini typically are relatively small and rigid for MRI contrast agents.
- a linker can have a molecular weight less than about 350 (e.g., less than about 200).
- the C-terminus carboxylate of a peptide may be converted to an amine functional group with a linker-subunit (e.g., a diamine synthon) to form a peptide having an amine functional group on each end of the peptide to which the remaining linker moiety can be attached.
- linker-subunit e.g., a diamine synthon
- Examples of such peptides modified to have a C-terminal amine function group are:
- n 1 to 4.
- linker-subunits may be employed as spacer groups at the N-terminal amine functional group:
- ⁇ N-alkylated amino acids may be employed, as well as amino acids having amine-containing side chains (such as Lys and Orn) in which the amine has been acylated or alkylated as in the following examples:
- n is an integer from 0 to 3
- R is any aliphatic or aromatic group
- LG is a leaving group such as OH, activated ester, halide, and anhydride.
- linker-subunits include the following:
- n is independently 1 or 2
- R is any aliphatic or aromatic group
- LG is a leaving group such as OH, activated ester, halide, and anhydride.
- linker moieties that are useful when following an amide bond construction strategy in which a peptide molecule has two terminal amine groups include the following: wherein each m is independently an integer from 1 to 4, n is independently an integer from 0 to 4 inclusive, LG is a leaving group, and R′ or R′′ are independently hydrogen or a chemical protecting group.
- a linker moiety also may have branch points for attachment of more than two chelates.
- a linker that includes a carbonyl with a leaving group LG for example, a carboxylic acid or an activated ester
- LG for example, a carboxylic acid or an activated ester
- the following carbonyl-based linker reagents may be appropriate for introducing three or more amine functional groups:
- LG is a leaving group (e.g., —OH, activated ester such as pentafluorophenol (Pfp), N-hydroxysuccinimide (NHS), N-hydroxysulfosuccinimide sodium salt (NHSS), 2-thioxothiazolidin-1yl, or hydroxybenzotriazole (HBT) and R 1 and R 2 are preferably independently hydrogen or a chemical protecting group (e.g., Boc, Fmoc, CBZ, t-butyl, benzyl, or allyl).
- Pfp pentafluorophenol
- NHS N-hydroxysuccinimide
- NHSS N-hydroxysulfosuccinimide sodium salt
- HBT 2-thioxothiazolidin-1yl
- R 1 and R 2 are preferably independently hydrogen or a chemical protecting group (e.g., Boc, Fmoc, CBZ, t-butyl, benzyl, or allyl).
- an amine functional group at the N-terminus of a peptide may be converted to an N-terminus carboxylate functional group by reaction with a cyclic acid anhydride (linker-subunit moiety) thereby producing a modified peptide with a N-terminal carboxylate functional group:
- linker-subunits that can be used to convert an N-terminal amine to a carboxylate functional group include:
- R is any aliphatic or aromatic group.
- both terminal carboxylates in the above examples may be simultaneously reacted with an amino group on a linker moiety as shown below to form a precursor MR imaging agent.
- the precursor MR imaging agent is a peptide molecule derivatized with linkers at both termini thru amide bonds:
- R is hydrogen or an appropriate chemical protecting group, such as methyl, ethyl, benzyl, or t-butyl.
- the protecting groups can be removed and chelating or precursor chelating moieties can be attached through standard methods, for example, amide bond formation.
- linker reagents may be appropriate to introduce three or more amine functional groups:
- R 1 and R 2 are independently hydrogen or a chemical protecting group such as OS, Boc, Fmoc, CBZ, tbutyl, benzyl, or allyl.
- Linker strategies that involve formation of amide bonds are useful because they typically are compatible with the protecting groups on the peptide.
- the peptide, linker, and linker-subunits may be covalently attached to each other by formation of other bond types (nucleophilic displacement, reductive amination and thiourea formation, for example).
- the linkers may also have effects on the properties of the contrast agents such as affinity, pharmacokinetic properties, stability in vivo, and relaxivity.
- a covalent conjugate that includes both a linker moiety and a chelating or chelating precursor moiety can be reacted directly with a peptide with appropriate terminal functionality.
- a covalent conjugate capable of reacting with terminal carboxylate groups follows:
- R 1 , R 2 , R 3 , R 4 , and R 5 are independently an acetate group, acetamide group, or an acetoxy group.
- R 1 , R 2 , R 3 , R 4 , and R 5 are independently an acetate group, acetamide group, or an acetoxy group.
- An example of a covalent conjugate useful for converting a modified peptide with carboxylate functional groups at the two termini to a precursor imaging agent has the following structure:
- LG is a leaving group, wherein R 1 , R 2 , R 3 , R 4 , and R 5 are independently an acetate group, acetamide group, or an acetoxy group.
- a particularly useful covalent conjugate for synthesizing a multimer contrast agent has the following structure, hereinafter “Synthon #1”:
- chelate refers to bb-DTPA-Gd(III).
- structures 15 and 16 are similar to 32 except for different N-terminal linker-subunits.
- the experimental results show that a linker can affect the relaxivity, as well as other characteristics of a contrast agent of the invention.
- Chelating moieties are chelating ligands complexed with metal ions. These chelating moieties contain a synthetic moiety capable of forming a point of attachment to the linker, linker-subunit, and/or modified peptide. One or more chelating moieties may be covalently conjugated to the functional group at each terminus of the modified peptide. In one embodiment, the chelate is attached to a linker-subunit. In another embodiment, the chelate is attached to a linker moiety. In other embodiments, the chelate may be conjugated with a linker moiety to form a covalent conjugate before attaching the covalent conjugate to the modified peptide.
- Precursor chelating moieties are chelating ligands that have not been complexed with metal ions.
- Chelating ligands may have protecting groups or may be precursors to chelating ligands.
- Precursor chelating moieties have a synthetic moiety capable of forming a point of attachment to the linker, linker-subunit, and/or modified peptide.
- Precursor chelating moieties can be converted into chelating moieties by complexing with a metal ion.
- One or more precursor chelate moieties may be covalently conjugated to the functional group at each terminus of the modified peptide.
- the precursor chelate can be attached to a linker-subunit.
- the precursor chelate is attached to a linker moiety.
- the precursor chelate may be conjugated with a linker moiety to form a covalent conjugate before attaching the covalent conjugate to the modified peptide.
- Precursor chelate moieties and chelate moieties according to the invention can have any of the following structures:
- X is a heteroatom electron-donating group capable of coordinating a metal cation, such as O ⁇ , OH, NH 2 , OPO 3 2 ⁇ , NHR, or OR, wherein R is any aliphatic group; R 1 is an uncharged chemical moiety, selected from hydrogen, any aliphatic, alkyl group, or cycloalkyl group, or uncharged substituted versions thereof (e.g.
- Y is a synthetic moiety (e.g., capable of forming a point of attachment, or being the point of attachment, to the functional group of the modified peptide, linker, and/or linker-subunit either directly or with an intervening carbonyl, methylene, methylene-oxygen, thiocarbonyl).
- Moieties with (chelate moiety) or without (precursor chelate moiety) a coordinated metal ion may be used.
- chelating ligands may be used in contrast agents of the invention.
- Such chelating ligands include, but are not limited to, derivatives of DTPA, DOTA, NOTA, and DO3A.
- metal chelates such as gadolinium diethylenetriaminepentaacetate (DTPA.Gd), gadolinium tetraamine 1,4,7,10-tetraazacyclododecane-N,N′,N′′,N′′′-tetraacetate (DOTA.Gd) and gadolinium 1,4,7,10-tetraazacyclododecane-1,4,7-triacetate (DO3A.Gd) are particularly useful.
- Particularly useful chelates include bb(CO)DTPA.Gd.
- Other metals may be substituted for Gd(III) in MRI applications.
- Examples of functionalized chelates that have been synthesized for the purpose of preparing multimeric chelates include pNCS-Bz-DTPA [Martin, V., et al. Bioconjugate Chem. 6,616-23, 1995] and Gd(4-NCS-phenyl)-amino-carbonylmethyl-DO3A [Ramachandran, R. et al., Invest. Rad. 1998, 33(11), 779-797].
- a reagent that includes a chelating ligand with a backbone carbonyl group for connecting to an amine functional group or a linker-subunit or linker, wherein “LG” is a leaving group (e.g., an activated ester) and R represents a group which may be easily cleaved to form O ⁇ (-OtBu, e.g. a carboxylate ester) thereby forming a carboxylate with the neighboring carbonyl group:
- LG is a leaving group (e.g., an activated ester)
- R represents a group which may be easily cleaved to form O ⁇ (-OtBu, e.g. a carboxylate ester) thereby forming a carboxylate with the neighboring carbonyl group:
- the present invention also relates to intermediates useful in the synthesis of contrast agents for MRI according to the following formulae:
- R 1 , R 2 , R 3 , R 4 , and R 5 may be any protected or unprotected acetyl ligand suitable for forming a chelate of a paramagnetic metal with an appropriate formation constant, including the following:
- LG is a “leaving group” and represents —OH and ester forms thereof including, NHS esters, pentafluorophenol, and other activated esters.
- LG is —OH
- R 1 , R 2 , R 3 , R 4 , and R 5 are CH 2 CO 2 O t Bu, hereinafter “Synthon #3”, and has the following structure:
- contrast agents of the invention may be used in the synthesis of contrast agents of the invention:
- the present invention also provides methods of manufacturing compounds.
- a novel oxidation reaction permits the facile preparation of Synthon #3, a preferred embodiment of a chelating ligand.
- the synthesis of Synthon #3 can be achieved through two different synthetic routes, both commencing with hydroxymethyl-diethylenetriamine.
- One route involves a two synthetic step sequence (alkylation, followed by oxidation) and the other involves a six-step process (protection, oxidation, esterification, deprotection, alkylation and hydrogenolysis). Both produce Synthon #3 in high chemical and optical purity (vide Examples, below).
- U.S. Pat. No. 5,637,759 discloses a synthesis of Synthon #1 from 2,3-diaminopropionic acid and aza-lysine by a selective hydrolysis protocol with sodium thiophenoxide. The method disclosed herein avoids the use of this toxic reagent.
- a targeting peptide can be synthesized with or without a C-terminal linker-subunit, typically using solid phase peptide synthesis.
- a protected linear peptide may be cyclized in solution or on the resin.
- Unprotected peptide may also be cyclized in solution or on resin.
- a C-terminal linker-subunit may be conveniently derived from the solid phase synthesis resin and an N-terminus linker or N-terminal linker-subunit can be coupled to the peptide during the solid phase synthesis.
- the linker-subunit-chelate precursor moieties were coupled to the peptide.
- Radionuclide compounds of this invention were prepared from ligand precursors using commercially available radionuclides (for example, 99m Tc from Nycomed Amersham Boston cat. #RX-290195, 111 In from NEN Life Science Products cat. # NEZ304, or 153 Gd from NEN Life Science Products cat. # NEZ142) by reaction in aqueous media, typically at pH 4-6 for 1 hour.
- radionuclides for example, 99m Tc from Nycomed Amersham Boston cat. #RX-290195, 111 In from NEN Life Science Products cat. # NEZ304, or 153 Gd from NEN Life Science Products cat. # NEZ142
- an organic dye may be substituted for a chelate precursor.
- test compounds of this invention can be more stable with respect to degradation by endogenous enzymes than the parent peptide (i.e., the peptide without any attached chelates), a peptide with one or more chelates attached to the N-terminus, or a peptide with one or more chelates attached to the C-terminus.
- test compounds can be incubated with rat liver homogenates. After selected intervals, the reactions can be quenched and centrifuged, and the supernatant can be analyzed by liquid chromatography-mass spectrometry to quantitate the amount of compound remaining.
- Compounds of the invention also can bind a target such as human serum albumin or fibrin.
- a target such as human serum albumin or fibrin.
- at least 10% (e.g., at least 50%, 80%, 90%, 92%, 94%, or 96%) of the contrast agent can be bound to the desired target at physiologically relevant concentrations of drug and target.
- the extent of binding of a contrast agent to a target, such as HSA or fibrin can be assessed by a variety of equilibrium binding methods. For example, binding to HSA can be measured by ultrafiltration.
- a fibrin clot may be formed in a well of a microtiter plate and contacted with the targeting group.
- the supernatant is removed by aspiration (the insoluble fibrin remains bound as a gelled clot to the bottom of the well).
- the concentration of unbound targeting group in the supernatant is then measured.
- the concentration of bound contrast agent is determined as the difference between the total targeting group concentration initially present and the unbound targeting group concentration following the binding assay.
- the bound fraction is the concentration of bound targeting group divided by the concentration of total targeting group.
- Compounds of the invention can exhibit high relaxivity as a result of target binding (e.g., to fibrin), which can lead to better image resolution.
- the increase in relaxivity upon binding is typically 1.5-fold or more (e.g., at least a 2, 3, 4, 5, 6, 7, 8, 9, or 10 fold increase in relaxivity).
- Targeted contrast agents having 7-8 fold, 9-10 fold, or even greater than 10 fold increases in relaxivity are particularly useful.
- relaxivity is measured using an NMR spectrometer.
- the preferred relaxivity of an MRI contrast agent at 20 MHz and 37° C.
- Contrast agents having a relaxivity greater than 60 mM ⁇ 1s ⁇ 1 at 20 MHz and 37° C. are particularly useful.
- targeted contrast agents can show an increase in clot uptake.
- Specificity of uptake of fibrin-targeted agents can be determined by comparing the uptake of the agent by blood clots to the uptake by blood. See Example 11 for more details.
- the specificity of fibrin-targeted contrast agents also can be demonstrated using MRI and observing enhancement of clot signal.
- Peptides of the invention can be used to improve therapies for treating thromboembolic disease.
- Current thrombolytic therapy has limitations, including a significant risk of bleeding, failure to restore blood flow, thrombotic reocclusion after cessation of therapy, and a lag between initiation of therapy and clot lysis.
- An improved therapeutic index can be achieved by conjugating a fibrin targeting peptide of the invention to a thrombolytic agent (e.g., a protein thrombolytic such as plasminogen activators of human or bacterial origin).
- a thrombolytic agent e.g., a protein thrombolytic such as plasminogen activators of human or bacterial origin.
- Such conjugates can activate plasminogen locally or increase endogenous levels of tPA.
- a fibrin targeting peptide can be conjugated to human plasminogen activators including recombinant tissue type plasminogen activator (tPA), prourokinase and urokinase (both single and two chain forms), bacterium derived plasminogen activator including streptokinase, staphylokinase, and animal derived plasminogen activators, including vampire bat plasminogen activator.
- fibrin targeting peptides can be conjugated to fibrinolytics such as copperhead snake fibrolase, which exhibits direct fibrinolytic activity. Such enzymes and proteins can be obtained commercially, extracted from natural sources or tissues, or prepared recombinantly.
- compositions of the invention can be linked or fused in known ways, using the same type of linkers discussed above with respect to constructing MRI contrast agents.
- Conjugation to a protein can be achieved by standard chemical techniques including the formation of amide, ester, disulfide, and thioether bonds.
- a fibrin binding peptide can be covalently linked, either directly or through a linker, to a protein by forming an amide bond between the fibrin binding peptide or the linker and the lysine residues on the surface of the protein. These surface lysine residues are usually distant from the enzyme's catalytic site. Therefore, the tethered moieties do not interfere with the enzyme's catalytic activity.
- the ratio of the fibrin targeting peptide to the thrombolytic or fibrinolytic agent can be controlled by adjusting the stoichiometry of the ligation chemistry. Multiple ligation is particularly useful in the case of a moderately strong fibrin binding ligand because higher binding affinity can be realized through the so called “avidity” effect.
- a coupling agent or an activated ester can be used to achieve amide bond formation between the lysine and the fibrin binding moiety or the linker.
- the below scheme shows an example of a hybrid molecule formed by chemical ligation of urokinase to multiple fibrin binding peptides via linker moieties. The number of surface lysine residues and the number of fibrin binding molecules are illustrative.
- the fibrin targeting peptide can be incorporated into the hybrid molecule using recombinant DNA technology.
- peptides of the invention can be linked to a thrombolytic agent with a linker encompassing an enzymatic cleavage site, e.g., an enzymatic cleavage site normally cleaved by enzymes in the coagulation cascade, such as Factor Xa, thrombin, or plasmin cleavage sites, etc.
- the thrombolytic agent is not activated until it is cleaved from the clot binding compositions of the invention at the site of the clot, the risk of unwanted bleeding events at sites distant from the clot would be minimized.
- thrombolytic moieties can be linked to a peptide-targeted multimeric contrast agent such that a clot can be identified, imaged and dissolved.
- Contrast agents prepared according to the disclosures herein may be used in the same manner as conventional MRI contrast agents and are useful for the diagnosis of deep vein thrombosis, pulmonary embolus, coronary thrombosis, carotid and intracranial thrombosis, atrial and ventricular thrombi, aortic arch thrombi, and high risk plaque.
- certain MR techniques and pulse sequences may be preferred to enhance the contrast of the thrombus compared to the background blood and tissues. These techniques include, but are not limited to, black blood angiography sequences that seek to make blood dark, such as fast spin echo sequences and flow-spoiled gradient echo sequences.
- These methods also include flow independent techniques that enhance the difference in contrast due to the T1 difference between contrast-enhanced thrombus and blood and tissue, such as inversion-recovery prepared or saturation-recovery prepared sequences that will increase the contrast between thrombus and background tissues. Methods of preparation for T2 techniques may also prove useful. Finally, preparations for magnetization transfer techniques may also improve contrast with agents of the invention.
- compositions of the invention can be formulated as a pharmaceutical composition in accordance with routine procedures.
- the compounds of the invention can include pharmaceutically acceptable derivatives thereof.
- “Pharmaceutically acceptable” means that the compound or composition can be administered to an animal without unacceptable adverse effects.
- a “pharmaceutically acceptable derivative” means any pharmaceutically acceptable salt, ester, salt of an ester, or other derivative of a compound of this invention that, upon administration to a recipient, is capable of providing (directly or indirectly) a compound of this invention or an active metabolite or residue thereof.
- compositions of this invention are those that increase the bioavailability of the compounds of this invention when such compounds are administered to a mammal (e.g., by allowing an orally administered compound to be more readily absorbed into the blood) or which enhance delivery of the parent compound to a biological compartment (e.g., the brain or lymphatic system) thereby increasing the exposure relative to the parent species.
- Pharmaceutically acceptable salts of the compounds of this invention include counter ions derived from pharmaceutically acceptable inorganic and organic acids and bases known in the art.
- compositions of the invention can be administered by any route, including both oral and parenteral administration.
- Parenteral administration includes, but is not limited to, subcutaneous, intravenous, intraarterial, interstitial, intrathecal, and intracavity administration.
- pharmaceutical compositions may be given as a bolus, as two or more doses separated in time, or as a constant or non-linear flow infusion.
- compositions of the invention can be formulated for any route of administration.
- compositions for intravenous administration are solutions in sterile isotonic aqueous buffer.
- the composition may also include a solubilizing agent, a stabilizing agent, and a local anesthetic such as lidocaine to ease pain at the site of the injection.
- the ingredients will be supplied either separately, e.g. in a kit, or mixed together in a unit dosage form, for example, as a dry lyophilized powder or water free concentrate.
- the composition may be stored in a hermetically sealed container such as an ampule or sachette indicating the quantity of active agent in activity units.
- compositions of this invention comprise the compounds of the present invention and pharmaceutically acceptable salts thereof, with any pharmaceutically acceptable ingredient, excipient, carrier, adjuvant or vehicle.
- a contrast agent is preferably administered to the patient in the form of an injectable composition.
- the method of administering a contrast agent is preferably parenterally, meaning intravenously, intra-arterially, intrathecally, interstitially or intracavitarilly.
- Pharmaceutical compositions of this invention can be administered to mammals including humans in a manner similar to other diagnostic or therapeutic agents.
- the dosage to be administered, and the mode of administration will depend on a variety of factors including age, weight, sex, condition of the patient and genetic factors, and will ultimately be decided by medical personnel subsequent to experimental determinations of varying dosage followed by imaging as described herein.
- dosage required for diagnostic sensitivity or therapeutic efficacy will range from about 0.001 to 50,000 ⁇ g/kg, preferably between 0.01 to 25.0 ⁇ g/kg of host body mass.
- the optimal dose will be determined empirically following the disclosure herein.
- the quantity of material administered will depend on the seriousness of the thromboembolic condition and position and the size of the clot.
- the precise dose to be employed and the mode of administration can be decided according to the circumstances by the physician supervising treatment.
- dosages of the combined composition/thrombolytic agent conjugate will follow the dosages that are routine for the thrombolytic agent alone, although the improved affinity for fibrin/clot binding added by the compositions disclosed herein may allow a decrease in the standard thrombolytic dosage.
- thrombolytics contemplated for use in this therapy are as follows: Streptokinase 1-3 megaunits over 30 minutes to 3 hrs Anistreplase 30 units; 2-5 minute injection tPA (wild-type) 50-150 mg; infusion over up to 6 hrs Two-chain urokinase (40-100 mg); infusion over up to 6 hrs Single-chain urokinase 3-12 megaunits (30-100 mg; infusion (scuPA) over up to 5 hrs Hybrid plasminogen 20-100 mg; injection or infusion activators and derivatives Muteins of plasminogen 10-100 mg; injection or infusion activators
- the peptide with linker-subunit moiety bound to C-termin us (P-[linker-subunit moiety]).
- the unprotected peptide was prepared using standard Fmoc strategy and a diaminotrityl resin.
- the peptide was cyclized using thallium trifluoroacetate on the resin or in solution. After being cleaved from the resin, the unprotected peptide was purified by RP-HPLC (C-18 column, H 2 O/CH 3 CN/TFA).
- Linker Moiety To a solution of Boc-Dpr(Boc)-OH.DCHA (1 eq.) and pentafluorophenol (1.2 eq.) in dichloromethane was added PS-carbodiimide (1.2-1.5 eq.). The mixture was shaken for 3-5 h at room temperature. After LC-mass results indicated the reaction was complete, the resin was removed by filtration and the solvent was evaporated under reduced pressure to give the crude Linker Moiety (Boc-Dpr(Boc)-OPft (N- ⁇ -Boc-N- ⁇ -Boc-L-diaminopropionic acid pentafluorophenyl ester, 356-128) as a white foam.
- Precursor MR Imaging Agent To a solution of P-[linker-subunit moiety] (1 eq.) and the Linker Moiety ⁇ Boc-Dpr(Boc)-Opft ⁇ (2.2 eq.) in DMF was added DIPEA (4-6 eq.). The mixture was stirred overnight at room temperature. After LC-mass results indicated the reaction was complete, the solvent was removed under reduced pressure. The crude product was then stirred in a mixture of TFA, water and anisole (90%/5%/5%) at room temperature for 3 h.
- Precursor Chelate Moiety DOTAGA-Opft. To a solution of DOTAGA-OH (1 eq.) and pentafluorophenol (1.2 eq.) in dichloromethane was added PS-carbodiimide (1.2-1.5 eq.). The mixture was shaken for 3-5 h at room temperature. After LC-mass results indicated the reaction was complete, the resin was removed by filtration and the solvent was evaporated under reduced pressure to give the crude Precursor Chelate Moiety as a white foam.
- the crude product was then stirred in a mixture of TFA, phenol, methylsulfonic acid, anisole and dichloromethane (90%/2.5%/2.5%/2.5%/2.5%) for 15 min. at room temperature. Diethyl ether was added and a white precipitate formed and was collected as the crude product.
- the crude product was reacted with GdCl 3 .H 2 O in deionized water to form the crude MR imaging agent, which was purified using RP-HPLC (C-18 column, Ethanol/50 mmol AcONH 4 ). Appropriate fractions were combined and the ethanol removed under reduced pressure, and then the combined fractions were treated with sodium acetate for salt exchange. After lyophilization the excess salts were removed using reverse-phase chromatography on a Waters Sep-Pak® C-18 cartridge with water and ethanol:water (50:50) eluants. Appropriate fractions were combined, the ethanol removed under reduced pressure, and the solution was lyophilized to give the desired peptide MR imaging agent as a white solid.
- Hydroxymethyl-diethylenetriamine of the indicated stereochemistry trihydrochloride (25.15 g) (optically pure starting material: Syn. Comm. 29(14), 2377-2391 (1999), racemic starting material: Coll. Czech. Chem. Comm. 34, 630-634 (1969)) was dissolved in a deionized water/1,4-dioxane mixture and the pH of the solution was adjusted to between 8 and 9 with aqueous sodium hydroxide. Di-tert-butyl dicarbonate (3.5 equiv.) was dissolved in dioxane and added between 10 and 20° C. The reaction mixture was stirred between 12 and 20 hours at room temperature.
- BOC-protected triamine (29.94 g) was dissolved in acetonitrile.
- Phosphate buffer consisting of 21.6 g NaH 2 PO 4 , 21.6 g Na 2 HPO 4 and enough deionized water to produce a 500 mL volume, was added (300 mL), followed by 2,2,6,6-tetramethylpiperidinyl-1-oxy (TEMPO) (0.07 equiv.). The mixture was stirred vigorously and warmed to 35° C.
- TEMPO 2,2,6,6-tetramethylpiperidinyl-1-oxy
- the mixture was stirred vigorously and warmed to 35° C.
- Sodium chlorite (2.0 equiv.) was dissolved in deionized water (100 mg/ml). The sodium chlorite solution and bleach (0.02 equiv., approx.
- 0.25% aqueous sodium hypochlorite were added while maintaining a constant temperature. After addition of oxidant, the reaction was stirred for 24 hours. Additional TEMPO (0.07 equiv.) was added and the reaction mixture was stirred for 24 hours. The reaction was cooled to room temperature. Water was added and the pH was adjusted to 8 with 2.0 N aqueous NaOH. A cold solution of aqueous sodium sulfite was added (300 mL) while maintaining a constant pH. The solution was extracted with a small volume of methyl tert-butyl ether and set aside. The aqueous layer was acidified to pH 3-4 with 2.0 N aqueous HCl and extracted with two small volumes of methyl tert-butyl ether.
- the carboxylic acid starting material (178 g) was dissolved in dry DMF. Cesium carbonate (2.0 equiv.) was added, and the solution was stirred for 30 minutes. Benzyl bromide (1.1 eq.) was added dropwise at room temperature. The reaction mixture was stirred under an inert atmosphere for 18 hours. The reaction mixture was diluted with water and extract twice with ethyl acetate. The organic layers were combined and washed sequentially with saturated sodium bicarbonate and sodium chloride solutions. The organic layer was concentrated to an oil (270 g) which was purified by silica gel chromatography using ethyl acetate:hexane.
- the BOC-protected triamine (250 g) was stirred in a solution of 1:1 acetonitrile:4 N aqueous HCl and allowed to stir for approximately 2.0 hours. The acetonitrile was removed in vacuo and the remaining solution was lyophilized to provide a residue that was immediately dissolved in DMF and diisopropylamine (a sufficient amount to raise the pH to 8). Tert-Butyl bromoacetate was added (12.0 equiv.). After the addition was complete, the reaction mixture was warmed to 50° C. and stirred for 18 hours. Upon completion of reaction the volume of the reaction mixture was doubled by the addition of water, after which it was extracted twice with ethyl acetate.
- the peptides have been prepared by solid-phase synthesis.
- the linkers and resins are selected depending on the type of the peptides to be synthesized (e.g., the functional group required at the C-terminus, the protected or unprotected peptide) and the synthetic method to be used (e. g. Fmoc or BOC chemistry, manual or automated synthesis, the continuous flow or batch reactor).
- the synthetic method to be used e. g. Fmoc or BOC chemistry, manual or automated synthesis, the continuous flow or batch reactor.
- a protected-amino acid is attached to the different resins such as HMPB resins, 2-chlorotritylchloride resin and SUSRIN resin.
- a diamine in the synthesis of a peptide with an amino group at the C-terminus, a diamine can be attached to a trityl resin.
- the polystyrene (PS) resins can be used for batch synthesis, while polyethyleneglycol (PEG) modified resins are suitable for continuous flow and batch synthesis.
- PEG polyethyleneglycol
- Many trityl PS resins including 1,3-bis-(aminomethyl)-benzene trityl PS resin are commercially available. If the required trityl PS resin is not available, a similar procedure as described for PEG resins can be used to attach a diamine to a trityl PS resin.
- trityl alcohol resin 25 g, NovaSyn TGT resin, NovaBiochem
- trityl alcohol resin 25 g, NovaSyn TGT resin, NovaBiochem
- a hydrogenation vessel is charged with the above compound, 10% palladium on carbon, ethyl acetate, and triethylamine. The vessel is purged with nitrogen then hydrogen. The mixture is shaken for 24 hours under a hydrogen atmosphere (50 psi). The vessel is purged with nitrogen and the mixture is filtered through Celite®, and the filtrate is concentrated under reduced pressure to give the product as an oil.
- Methyl-2-(bromomethyl)-acrylate (1.00 g, 5.6 mmol, 1.0 eq.) dissolved in acetonitrile (20 mL) was added drop-wise with stirring at room temperature to a solution of benzylamine (1.83 mL, 16.8 mmol, 1.5 eq.) in anhydrous acetonitrile (10 mL). After 16 hours, ether (100 mL) was added, and the white solid (benzylamine hydrobromide) was filtered. The filtrate was concentrated under reduced pressure to give 1.90 g of a crude oil. The oil was dissolved in ethyl acetate (150 mL) and washed with H 2 O and NaCl brine.
- Diamine (1.44 g) was reacted with di-tert-butyl dicarbonate (3.22 g, 14.8 mmol, 1.05 eq.) in dioxane/aqueous Na 2 CO 3 at solution 0° C. for 1 hour and then room temperature for 18 hours.
- the aqueous portion was extracted with ethyl acetate, dried over MgSO 4 and concentrated under reduced pressure to give a crude oil that was purified by flash chromatography (hexanes:ethyl acetate) to give 1.86 g (80%) of the desired.
- 1 H NMR 300 MHz, CDCl 3 ): ⁇ 1.40 (s, 18H), 2.66 (s, 1H), 3.27-3.47 (m, 4H), 5.42 (s, 1H).
- the mixture was filtered through the reaction vessel and the filtrate was collected.
- the pH of the combined filtrate was adjusted to approximately 8 with triethylamine, and the solution was concentrated under vacuum to an oil.
- the white solid was filtered and rinsed with water and diethyl ether.
- the solid was dried by suction filtration, taken up in DMF and diluted with acetonitrile.
- the solution was cooled in an ice bath and was treated with 1.5 g of thallium trifluoroacetate for 2.0 hours.
- the pH of the solution was adjusted with triethylamine to pH 8 and then concentrated under vacuum. Water was added to the oil and the resulting precipitate was collected by suction filtration.
- Diisopropylethylamine was added dropwise until the pH measured 9
- diisopropylethylamine was added dropwise until the pH measured 9.
- the mixture was stirred at room temperature for two hours. Additional pre-activated Synthon #2 (with diisopropylcarbodiimide, diisopropylethylamine, and HOBt) was added in one portion.
- Precursor MR imaging agent (1 g) was reacted with one equivalent of GdCl 3 .6H 2 O in distilled deionized water with the pH adjusted to ca. 6 by the addition of 1 M NaOH.
- the gadolinium complex was purified by reverse phase chromatography (Waters Sep-Pak® C-18) using distilled deionized water and 50:50 (v:v) methanol:water eluent. Appropriate fractions were combined and the methanol removed under reduced pressure at 50° C. and lyophilized to give 811 mg of the MR imaging agent.
- the peptide may be cyclized on a resin as illustrated in the following Scheme:
- Precursor MR imaging agent was reacted with one equivalent of GdCl 3 .6H 2 O in deionized water (pH 6, NaOH).
- the gadolinium chelate was purified using reverse-phase chromatography on a Waters Sep-Pak® C-18 cartridge with water and methanol:water 50:50 eluant. Appropriate fractions were combined and the methanol removed under reduced pressure at 50° C. and lyophilized to give the desired MR imaging agent.
- Table 3 provides mass spectrometry data confirming each of the compounds. See the detailed description for the structure of each of the compounds.
- Scheme X shows a general example wherein two identical optical dyes are added to the same peptide.
- the peptide 1 (177 mg, 0.10 mmol) and 5-carboxytetramethylrhodamine succinimidyl ester A (111 mg, 0.21 mmol) are dissolved in dichloromethane (20 mL) and DMF (20 mL). Diisopropylethylamine is added dropwise until the pH measures 9. The mixture is stirred for overnight and then the solvents are removed under reduced pressure. The residue is purified by silica-gel flash column chromatograph (eluants:dichloromethane/methanol) to give compound 2A.
- 3B is synthesized using the peptide 1 (177 mg, 0.10 mmol) and 5-carboxyfluorescein succinimidyl ester B (99.4 mg, 0.21 mmol).
- 3C is synthesized using the peptide 1 (177 mg, 0.10 mmol) and Texas Red®-X succinimidyl ester C (172 mg, 0.21 mmol).
- the extent of binding of a contrast agent according to the present invention to a target, such as HSA or fibrin, can be assessed by a variety of equilibrium binding methods.
- binding to HSA can be measured by ultrafiltration.
- the contrast agent is mixed with 4.5% weight/volume HSA in a pH 7.4 buffer.
- the sample is loaded into a commercially available centrifugation apparatus equipped with a 30 kDa molecular weight cutoff filter (Millipore Ultrafree MC Low Binding Regenerated Cellulose 30 KDa mol. wt. cutoff catalog # UFC3LTK00), permeable to the targeting group, but not to HSA.
- a small portion (5-10%) of the sample volume is filtered by centrifugation at 2000 ⁇ g for 20 min through the cutoff filter, and the concentration of unbound targeting group in the sample is measured in the filtrate.
- a fibrin clot may be formed in a well of a microtiter plate and contacted with the targeting group. After an incubation time sufficient to establish equilibrium, the supernatant is removed by aspiration (the insoluble fibrin remains bound as a gelled clot to the bottom of the well). The concentration of unbound targeting group in the supernatant is then measured.
- the concentration of bound contrast agent is determined as the difference between the total targeting group concentration initially present and the unbound targeting group concentration following the binding assay.
- the bound fraction is the concentration of bound targeting group divided by the concentration of total targeting group.
- rat liver homogenate which contains both intra- and extracellular enzymes and represents a particularly harsh chemical environment for peptide bonds.
- Freshly prepared rat liver homogenate (630 ⁇ L) was placed in a glass test tube and incubated at 37° C. in a water bath for 4 minutes.
- To the rat liver homogenate at 37° C. was added 70 ⁇ L of a 1 mM solution of test compound.
- time points 0, 5, 15, 30, and 60 minutes a 100 ⁇ L aliquot of the reaction mixture was removed and mixed with 100 ⁇ L of methanol in a microfuge tube to quench the reaction. The quenched reaction mixture was centrifuged for 3 minutes at 10,000 rpm to pellet the precipitated protein.
- the supernatant was analyzed by LC-MS to quantitate the amount of test compound remaining by comparing the area of the single ion MS peak to that of a series of standards.
- the MRI contrast agents of the present invention were evaluated for relaxivity using a Bruker NMS-120 Minispec NMR spectrometer operating at 0.47 Tesla (20 MHz H-1 Larmor frequency) and 37° C. or a Konig-Brown relaxometer (20 MHz, H-1 Larmor frequency) operating at 35° C.
- T1 of water protons was determined by an inversion recovery pulse sequence using the instrument's software.
- Relaxivity was determined by measuring the T1 of multiple solutions of the target (for example, homodisperse gels of freshly polymerized fibrinogen, 10 mg/mL) containing zero, 20, 30, and 40 ⁇ M Gd(III), respectively. The samples are incubated at 37° C. for at least 15 minutes to ensure temperature equilibration before the T1 measurement is performed.
- the Gd(III) content of the samples is determined by inductively coupled plasma-mass spectrometry (ICP-MS).
- the relaxivity (per Gd(III) ion) is determined by plotting the relaxation rate (1/T1) in s ⁇ 1 versus the Gd(III) concentration in mM. The slope of a linear fit to the data gives the relaxivity.
- the relaxivity of the compounds in the absence of target is also determined in an analogous manner, except there is no target present.
- Compounds of the invention show increased relaxivity upon binding to fibrin ( FIG. 2 ) as compared with the relaxivity in the absence of biological target.
- the uptake of a contrast agent into a thrombus was determined by the following method: A 600 g guinea pig (Hartley male) was anesthetized. An incision was made in the abdomen and the inferior vena cava (IVC) isolated and the vessel was allowed to recover for 10 minutes. A 1 cm portion of the IVC was clamped and human thrombin (50 ⁇ L, 4 units) was injected into the vessel to promote thrombus formation. The lower clamp was opened and closed allowing partial blood flow to the segment. After 2-3 minutes the clips were removed. The thrombus was allowed to age in the animal for 30 minutes.
- IVC inferior vena cava
- the contrast agent compound 32 at a dose of 2 ⁇ mol/kg and trace radiolabeled with 70 ⁇ Ci of 111 In, was injected via the jugular vein.
- a non-specific control comprising Gd(DTPA) at a dose of 2 ⁇ mol/kg mixed with 70 ⁇ Ci 99m TcDTPA was injected via the jugular vein.
- the blood sample was weighed and counted using a Packard Cobra II gamma counter. The thrombus was also weighed and counted.
- Radiolabeling with 111 In was performed in advance: An appropriate radiochemical amount of 111 InCl 3 (New England Nuclear) was added to the fibrin targeted contrast agent. The pH was adjusted to 4 by addition of 1 M HCl. The sample was heated at 45° C. for 1 hour. The pH was adjusted to neutral by addition of 1 M NaOH. The labeled agent compound 32 was >95% pure by ⁇ -detected HPLC.
- Fibrin-specific agents show a marked increase in clot uptake.
- FIG. 3 shows that an agent, compound 32, is accumulating in the thrombus. There is specific clot uptake compared to 99m TcDTPA and there is a higher concentration of the agent in the thrombus than in the surrounding blood.
- clot uptake also can be demonstrated using MRI.
- the procedure for in vivo imaging of a thrombus with an agent is as follows: A 600 g guinea pig (Hartley male) is anesthetized. An incision is made in the throat and one of the jugular veins isolated. A 1 cm section of the jugular vein is isolated with vascular clamps. Freshly drawn blood from the animal (50 ⁇ L) is mixed with human thrombin (50 ⁇ L, 4 units) and is injected into the clamped segment of the vein. Four minutes after injection, the clamps are removed and the thrombus is allowed to age for 30 minutes.
- a 2.5 kg female New Zealand White rabbit was anesthetized with a cocktail of Ketamine (50 mg/kg), Aceapromazine (2.5 mg/kg), and Rompon (5 mg/kg) and anesthesia maintained with sodium pentobarbital (approx. 35 mg/kg as needed).
- An i.v. catheter 24 g was placed into the ear vein and the ear artery. The jugular vein and carotid artery were isolated. A stenosis was created in the carotid artery by placing an 18 g needle on top of the vessel and then suturing it into place with 3-0 suture. The needle was then removed. A 5 mm portion of the artery was then segmented off distally to the stenosis with microvascular clips.
- the artery was then crushed twice along the 5 mm section.
- the proximal vascular clip was released to allow blood flow into the section for ca. 3 sec.
- the clip was reapplied and artery was crushed twice again along the 5 mm section.
- the clips were removed.
- a 5 mm segment of the jugular vein was isolated with microvascular clips.
- a thrombus was created by injecting 100 ⁇ L of a 3.7 units of thrombin, 0.06 M CaCl 2 , rabbit whole blood mixture. After 4 minutes, the clips were removed.
- the thrombi were allowed to age for 50 minutes.
- a 1.0 mL solution of the thrombus targeted agent (Structure III, 5 mM, 2 ⁇ mol/kg) was administered via the ear vein.
- Chemical fat saturation was applied as well as 40 mm spatial inferior and superior saturation bands.
- a second MRI data set was acquired using the same parameters with the addition of 40 mm spatial inferior and superior saturation bands to generate a “black blood” image.
- FIG. 4A shows the maximum intensity projection (MIP) of the first data set.
- the blood vessels are partially enhanced from time of flight effects.
- FIG. 4B shows the MIP of the second data set where the signal from in-flowing blood was suppressed (black blood) by the use of superior and inferior saturation bands.
- the identification of the stationary target (a thrombus) through use of the targeted contrast agent is clearly facilitated.
- NovaSyn TGR resin (0.20 mmol/g, 100 mg, 20 ⁇ mol) was washed with NMP/ether/NMP.
- the peptide was assembled by the standard solid phase method using the PyBOP/HOBt/DIEA activation. After the coupling of the final amino acid residue, the resin bound peptide was treated with a solution of piperidine in DMF (20% by volume, 2.0 mL) for 10 minutes to remove the Fmoc protecting group.
- the resin was washed thoroughly with NMP/ether/NMP, and was treated with a solution of fluorascein-5-isothiocyanate (23.4 mg, 60 ⁇ mol) and diisopropylethylamine (11.6 mg, 15.7 ⁇ L, 90 ⁇ mol) in DMF (1.5 mL) for 12 hours.
- the resin was washed thoroughly (NMP/ether/NMP), and treated with a solution of TI (TFA) 3 (18.7 mg, 34.5 ⁇ mol) in DMF (1.5 mL) at 4° C. for three hours.
- the resin was washed after this treatment, and treated with a cocktail of TFA/TIS/water (95/2.5/2.5, 2.0 mL) for two hours.
- N-terminal labeling of the peptides with optical probes can modulate the binding affinity of the optical contrast agents.
- Kd's were observed (Table 6): TABLE 6 Compound Fluorophore Kd J Fluorescein 0.06 L Tetramethylrhodamine 2.0 N 4-Methoxycoumarin 0.2
- Fibrin targeted urokinase is prepared according to the following procedure.
- a fibrin binding peptide with a Gly-Gly dipeptide linker is prepared according to solid phase procedures.
- the N-terminus of the peptide is blocked with an acetyl group, and the C-terminal carboxylic acid is converted to a succinamidal active ester.
- Direct chemical ligation is achieved by mixing urokinase and the activated peptide in appropriate proportions in an aqueous buffer and gently agitating the solution for 30 minutes.
- Fibrin targeted urokinase can be purified by HPLC. Binding to fibrin can be assessed. Compound 1 binds fibrin selectively versus fibrinogen.
- the rabbit jugular vein model of Collen et al. ( J. Clin. Invest. 1983, 71, 368-376) is used for thrombolysis assays.
- Compound (2 mg/kg) is administered by infusion of a bolus (consisting of 20% of the total dose) over 1 min. along with a heparin bolus (300 units/kg) over 1 min. The remainder of the dose is continuously infused over the next 60 min. and heparin (60 units/kg/hr) is continuously infused over the next 180 min.
- the animals are sacrificed, and clots analyzed.
- Compound 1 is more potent in clot lysis than scuPA alone.
- At 3 hr. with 2 mg/kg of compound 1 there is less consumption of fibrinogen and ⁇ 2-antiplasmin, relative to equivalent doses of scuPA alone, demonstrating that compound 1 was more fibrin specific than scuPA alone.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Radiology & Medical Imaging (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Optics & Photonics (AREA)
- Physics & Mathematics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Analytical Chemistry (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Magnetic Resonance Imaging Apparatus (AREA)
Abstract
Description
- This application is a continuation of U.S. application Ser. No. 11/098,665, filed Apr. 4, 2005, which is a continuation of U.S. application Ser. No. 10/209,183, filed Jul. 30, 2002, now abandoned, which claims priority to U.S. Provisional Application Ser. No. 60/308,721, filed Jul. 30, 2001, and is related to co-pending U.S. application Ser. No. 10/209,172, filed Jul. 30, 2002, now U.S. Pat. No. 6,991,775, and to co-pending U.S. application Ser. No. 10/786,791, filed Feb. 25, 2004, all of which are incorporated herein by reference in their entirety.
- This invention relates to contrast agents for diagnostic imaging, and more particularly to peptide-targeted, multimeric contrast agents, wherein a peptide functions as a targeting group and a point of attachment for one or more chelates at both the amino and carboxy termini of the peptide.
- Diagnostic imaging techniques, such as magnetic resonance imaging (MRI), X-ray, nuclear radiopharmaceutical imaging, ultraviolet-visible-infrared light imaging, and ultrasound, have been used in medical diagnosis for a number of years. Contrast media additionally have been used to improve or increase the resolution of the image or to provide specific diagnostic information.
- To be effective, the contrast media must interfere with the wavelength of electromagnetic radiation used in the imaging technique, alter the physical properties of tissue to yield an altered signal, or, as in the case of radiopharmaceuticals, provide the source of radiation itself. MRI and optical methods are unique among imaging modalities in that they yield complex signals that are sensitive to the chemical environment. While the signal from X-ray or radionuclide agents remains the same whether agents are free in plasma, bound to proteins or other targets, or trapped inside bone, certain contrast agents for MRI and optical imaging will have different signal characteristics in differing physiological environments. It is important that the contrast agent be sufficiently sensitive and present at high enough concentration so that signal changes can be observed.
- Complexes between gadolinium or other paramagnetic ions and organic ligands are widely used to enhance and improve MRI contrast. Gadolinium complexes increase contrast by increasing the nuclear magnetic relaxation rates of protons found in the water molecules that are accessible to the contrast agents during MRI (Caravan, P., et al., R. B. Chem. Rev. 99, 2293 (1999)). The relaxation rate of the protons in these water molecules increases relative to protons in other water molecules that are not accessible to the contrast agent. This change in relaxation rate leads to improved contrast of the images. In addition, this increase in relaxivity within a specific population of water molecule protons can result in an ability to collect more image data in a given amount of time. This in turn results in an improved signal to noise ratio.
- Imaging may also be performed using light, in which case an optical dye is chosen to provide signal. In particular, light in the 600-1300 nm (visible to near-infrared) range passes relatively easily through biological tissues and can be used for imaging purposes. The light that is transmitted through, or scattered by, reflected, or re-emitted (fluorescence), is detected and an image generated. Changes in the absorbance, reflectance, or fluorescence characteristics of a dye, including an increase or decrease in the number of absorbance peaks or a change in their wavelength maxima, may occur upon binding to a biological target, thus providing additional tissue contrast. In some situations, for example the diagnosis of disease close to the body surface, UV or visible light may also be used.
- A need persists for contrast agents that can deliver sufficient concentrations of the imaging moiety to the target to improve the sensitivity of the imaging process as well as contrast agents that have a sufficient half-life in vivo.
- The invention is based on peptides and peptide-targeted multimeric contrast agents for MR, optical, and radionuclide imaging, wherein a single peptide can function both as a targeting group and a point of attachment for one or more chelates at both the N- and C-termini, either directly or via an optional intervening linker. Surprisingly, contrast agents of the invention maintain binding affinity for biological targets such as fibrin and high relaxivity. Agents of the invention have a sufficient half-life following in vivo administration such that effective imaging studies can be performed.
- In one aspect, the invention features purified peptides that include the amino acid sequence: P*-Y*-X1*-L* (SEQ ID NO:1), wherein P* is a proline or a non-natural derivative thereof, Y* is a tyrosine or a non-natural derivative thereof, X1* is G or D or a non-natural derivative of G or D; L* is a leucine or a non-natural derivative thereof, and wherein at least one of P*, Y*, X1*, and L* is a non-natural derivative of the respective amino acid. X1* can be G or D and L* can be leucine. In some embodiments, P* is proline or 4-hydroxyproline, and Y* is tyrosine or a non-natural derivative of tyrosine substituted at the 3 position with a moiety selected from the group consisting of F, Cl, Br, I, and NO2. Compounds of the invention can include such peptides linked to a thrombolytic agent.
- In another aspect, the invention features purified peptides that include the amino acid sequence X1-X2-C-P*-Y*-X3-L-C-X4-X5-X6 (SEQ ID NO:2), wherein: P* is a proline or a non-natural derivative thereof, Y* is a tyrosine or a non-natural derivative thereof, X1 is selected from the group consisting of W, Y, F, S, Bip, Hx, Dpr, Cy, Gu, Ad, Hfe, 3-Pal, 4-Pal, DopaMe2, nTyr, dW, dF, F(3/4*), and Y(3*), wherein F(3/4*) is a phenylalanine substituted at either the 3 or the 4 position with a moiety selected from the group consisting of CH3, CF3, NH2, CH2NH2, CN, F, Cl, Br, I, Et, and OMe, and wherein Y(3*) is a tyrosine substituted at the 3 position with a moiety selected from the group consisting of F, Cl, Br, I, and NO2; X2 is selected from the group consisting of E, H, dE, S, H(Bzl), 2-Pal, Dpr, and Th; X3 is selected from the group consisting of G and D; X4 is selected from the group consisting of H, F, Y, and W; X5 is selected from the group consisting of I, L, V, N, Bpa, Bal, Hfe, Nle, Tle, Nval, Phg, Cha, Taz, Fua, Th, 4-Pal, and F(3/4*), wherein F(3/4*) is a phenylalanine substituted at either the 3 or the 4 position with a moiety selected from the group consisting of CF3, Et, iPr, and OMe; X6 is selected from the group consisting of N, Q, I, L, and V, or X6 is not present; and wherein at least one of X1, X2, X5, P*, and Y* is a non-natural derivative of an amino acid. For example, P* can be proline or 4-hydroxyproline, and Y* can be tyrosine or a non-natural derivative of tyrosine substituted at the 3 position with a moiety selected from the group consisting of F, Cl, Br, I, and NO2. The purified peptides can be capable of forming a disulfide bond under non-reducing conditions and can have specific binding affinity for fibrin. In some embodiments, the peptides include a disulfide bond. Compounds of the invention can include such peptides linked to a thrombolytic agent.
- The invention also features purified peptides having an amino acid sequence selected from the group consisting of W-dE-C-P(4-OH)-Y(3-Cl)-G-L-C-W-I-Q (SEQ ID NO:4), Y-dE-C-P(4-OH)-Y(3-Cl)-G-L-C-Y-I-Q (SEQ ID NO:5), Y-dE-C-P(4-OH)-Y(3-Cl)-G-L-C-W-I-Q (SEQ ID NO:6), W-dE-C-P(4-OH)-Y(3-Cl)-G-L-C-Y-I-Q (SEQ ID NO:7), W-dE-C-P(4-OH)-Y(3-Cl)-D-L-C-W-I-Q (SEQ ID NO:8), Y-dE-C-P(4-OH)-Y(3-Cl)-D-L-C-Y-I-Q (SEQ ID NO:9), Y-dE-C-P(4-OH)-Y(3-Cl)-D-L-C-W-I-Q (SEQ ID NO:10), W-dE-C-P(4-OH)-Y(3-Cl)-D-L-C-Y-I-Q (SEQ ID NO:11), F(4-OMe)-H-C-P(4-OH)-Y(3-Cl)-D-L-C-H-I-L (SEQ ID NO:12), Y-H-C-P(4-OH)-Y(3-Cl)-G-L-C-W-I-Q (SEQ ID NO:13), W-dE-C-P-Y(3-Cl)-G-L-C-W-I-Q (SEQ ID NO:14), W-dE-C-P(4-OH)-Y-G-L-C-W-I-Q (SEQ ID NO:15), and F-H-C-P-(4-OH)-Y(3-Cl)-D-L-C-H-I-L (SEQ ID NO:16). The peptides can be capable of forming a disulfide bond under non-reducing conditions, and in some embodiments, the peptides include a disulfide bond. The peptides can have specific binding affinity for fibrin. Compounds of the invention can include such peptides linked to a thrombolytic agent.
- In some embodiments, P* is proline; Y* is tyrosine; X1 is selected from the group consisting of W, Y, F, S, Bip, Hx, Dpr, Cy, Gu, Ad, Hfe, 3-Pal, 4-Pal, DopaMe2, nTyr, dW, dF, F(3/4*), and Y(3*), wherein F3/4* is a phenylalanine substituted at either the 3 or the 4 position with a moiety selected from the group consisting of CH3, CF3, NH2, CH2NH2, CN, F, Cl, Br, I, Et, and OMe, and wherein Y3* is a tyrosine substituted at the 3 position with a moiety selected from the group consisting of F, Cl, Br, I, and NO2; X2 is selected from the group consisting of dE, H(Bzl), 2-Pal, Dpr, and Th; X3 is selected from the group consisting of G and D; X4 is selected from the group consisting of H, F, Y, and W; X5 is selected from the group consisting of I, L, V, N, Bpa, Bal, Hfe, Nle, Tle, nVal, Phg, Cha, Taz, Fua, Th, 4-Pal, and F(3/4*), wherein F3/4* is a phenylalanine substituted at either the 3 or the 4 position with a moiety selected from the group consisting of CF3, Et, iPr, and Ome, wherein at least one of X1, X2, or X5 is a non-natural amino acid derivative; and X6 is selected from the group consisting of N, Q, I, L, and V, or X6 is not present. Such peptides can be capable of forming a disulfide bond under non-reducing conditions, and in some embodiments, the peptides include a disulfide bond. The peptides can have specific binding affinity for fibrin.
- In other embodiments, the invention features purified peptides that include the amino acid sequence: C-P*-Y*-X1-L-C (SEQ ID NO:3), wherein X1 is G or D, P* is proline or its non-natural derivative 4-hydroxyproline; and Y* is tyrosine or a non-natural derivative of tyrosine substituted at the 3 position with a moiety selected from the group consisting of F, Cl, Br, I, and NO2; provided that at least one of P* or Y* is a non-natural derivative of the respective amino acid. The purified peptides can be capable of forming a disulfide bond under non-reducing conditions and can have specific binding affinity for fibrin. In some embodiments, the peptides include a disulfide bond. Compounds of the invention can include such peptides linked to a thrombolytic agent.
- The invention also features purified peptides that include the amino acid sequence: C-D-Y-Y-G-T-C-X10 (SEQ ID. NO:17), wherein X10 is selected from the group consisting of n(decyl)G, n(4-PhBu)G, MeL, Bpa, Bip, Me-Bip, F(4*), F(3-Me), F(3,4-difluoro), Amh, Hfe, Y(3,5-di-iodo), Pff, 1Nal, d1Nal, and MeL, wherein F(4*) is a phenylalanine substituted at the 4 position with a moiety selected from the group consisting of Et, CF3, I, and iPr. Purified peptides can include the amino acid sequence C-D-Y-Y-G-T-C-X10-X11 (SEQ ID. NO:18), wherein X11 is selected from the group consisting of D, dD, βD, Inp, Nip, Me-D, dC, Cop, and Cmp. For example, a peptide can have the follow amino acid sequences: L-P-C-D-Y-Y-G-T-C-n(Decyl)G-dD (SEQ ID NO:19), L-P-C-D-Y-Y-G-T-C-n(Decyl)G-D (SEQ ID NO:20), L-P-C-D-Y-Y-G-T-C-Bip-D (SEQ ID NO:21), L-P-C-D-Y-Y-G-T-C-Bip-dD (SEQ ID NO:22), L-P-C-D-Y-Y-G-T-C-MeL-Inp (SEQ ID NO:23), L-P-C-D-Y-Y-G-T-C-MeL-Cmp (SEQ ID NO:24), or L-P-C-D-Y-Y-G-T-C-MeBip-D (SEQ ID NO:25). The purified peptides can be capable of forming a disulfide bond under non-reducing conditions and can have specific binding affinity for fibrin. In some embodiments, the peptides include a disulfide bond. Compounds of the invention can include such peptides linked to a thrombolytic agent.
- In another aspect, the invention features a method of making an MR imaging agent. The method includes reacting a peptide having an N-terminal amine functional group with a linker-subunit moiety to form a modified peptide having both a C-terminal amine functional group and N-terminal amine functional group; covalently attaching a linker moiety to the C-terminal amine functional group and to the N-terminal amine functional group to form a precursor MR imaging agent; and converting the precursor MR imaging agent to the MR imaging agent. The linker-subunit moiety can be selected from the group consisting of:
wherein n is an integer from 1 to 4; m is an integer selected 1 to 12; and R is an aliphatic or aromatic group. The linker moiety can be selected from the group consisting of
wherein m is an integer from 1 to 4; n is an integer from 0 to 4; LG is a leaving group; and R′ and R″ independently are selected from the group consisting of hydrogen and a chemical protecting group. - The linker moiety also can be selected from the group consisting of:
wherein LG is a leaving group; and R1 and R2 independently are selected from the group consisting of hydrogen and a chemical protecting group. The LG can be selected from the group consisting of —OH, activated ester, halide, and anhydride. The activated ester can be selected from the group consisting of pentafluorophenol (Pfp), N-hydroxysuccinimide (NHS), N-Hydroxysulfosuccinimide Sodium Salt (NHSS), 2-Thioxothiazolidin-1yl, and hydroxybenzotriazole (OBT). The halide can be selected from the group consisting of F, Cl, Br, and I. The chemical protecting group can be selected from the group consisting of Boc, Fmoc, CBZ, t-butyl, benzyl, and allyl. - Converting the precursor MR imaging agent to the MR imaging agent can include reacting the precursor imaging agent with a precursor chelate moiety to form a covalent bond between the precursor chelate moiety and the linker moiety of the precursor MR imaging agent, the precursor chelate moiety comprising a plurality of carboxylate precursor groups, the carboxylate precursor groups capable of being transformed into carboxylate moieties; transforming a plurality of the carboxylate precursor groups of the bound precursor chelate moiety to a plurality of carboxylate moieties, the carboxylate moieties capable of complexing a paramagnetic metal ion; and complexing a paramagnetic metal ion to the plurality of carboxylate moieties to produce the MR imaging agent. The precursor chelate moiety can be selected from the group consisting of:
wherein Y is a synthetic moiety capable of forming a covalent bond with the attached linker moiety, and wherein each X, independently, is an O− or an O− precursor so that X, upon conversion to O−, is capable of forming a carboxylate moiety with its adjacent carbonyl, and R1 is an uncharged chemical moiety, an aliphatic, alkyl group, or cycloalkyl group, or uncharged substituted versions thereof. The synthetic moiety can be selected from the group consisting of a carboxylic acid, activated ester, acid halide, anhydride, alkyl halide, isocyanate, and isothiocyanate, and wherein the O− precursor is selected from the group consisting of —OH, —OMe, OEt, OtBu, Obenzyl, and O-allyl. The precursor chelate moiety also can be selected from the group consisting of:
wherein LG is a leaving group selected from the group consisting of —OH, activated ester, halide, and anhydride, and wherein each R, independently, is an O− or an O− precursor selected from the group consisting of OH, —O-Me, O-Et, O-tBu, O-benzyl, and O-allyl, so that R, upon conversion to O−, is capable of forming a carboxylate moiety with its adjacent carbonyl. - The precursor chelate moiety also can be selected from the group consisting of:
wherein n is an integer from 1 to 4; R is selected from the group consisting of a negative charge and a negative charge precursor capable of being transformed into a negative charge; and X is a chemical leaving group selected from the group consisting of —Cl, —Br, —I, -MsO, -TsO, and -TfO. - the percursor chelate moiety can be selected from the group consisting of:
wherein R is selected from the group consisting of a negative charge and a negative charge precursor capable of being transformed into a negative charge; and X is a chemical leaving group selected from the group consisting of —Cl, —Br, —I, -MsO, -TsO, and -TfO. The negative charge precursor is selected from the group consisting of —H, -Me, -Et, -t-Bu, -benzyl, and -allyl. - In some embodiments, the linker moiety can be covalently conjugated to a precursor chelate moiety, the covalent conjugate comprising a plurality of carboxylate precursor groups, the carboxylate precursor groups capable of being transformed into carboxylate moieties. Converting the precursor MRI imaging agent to the MR imaging agent can include transforming a plurality of the covalent conjugate's carboxylate precursor groups into carboxylate moieties, the carboxylate moieties capable of complexing a paramagnetic metal ion; and complexing a paramagnetic metal ion to the plurality of carboxylate moieties to result in the MR imaging agent. The paramagnetic metal ion can be selected from the group consisting of: Gd(III), Fe(III), Mn(II and III), Cr(III), Cu(II), Dy(III), Tb(III and IV), Ho(III), Er(III), Pr(III), Eu(II) and Eu(III). Gd(III) is a particularly useful paramagnetic ion.
- The covalent conjugate can be selected from the group consisting of
wherein n is an integer from 1 to 4; LG is a leaving group selected from the group consisting of —OH, activated ester, halide, and anhydride; and R1, R2, R3, R4, and R5 are independently selected from the group consisting of an acetate moiety, a -Me, -Et, or -t-Bu protected acetate moiety, an acetamide moiety, and an acetoxy moiety. - The covalent conjugate also can be selected from the group consisting of:
wherein LG is a leaving group selected from the group consisting of —OH, activated ester, halide, and anhydride; and R1, R2, R3, and R4 are selected from the group consisting of an acetate moiety, a -Me, -Et, or -t-Bu protected acetate moiety, an acetamide moiety, and an acetoxy moiety. -
-
- R is a -tBu group, LG is a leaving group selected from the group consisting of —OH, activated ester, halide, and anhydride.
- Methods of the invention further can include, before covalently attaching a linker moiety to the C- and N-terminal amine functional groups, reacting a linker-subunit with the N-terminal amine functional group of the peptide to produce a derivatized N-terminal amine functional group of the peptide. The linker-subunit can be selected from the group consisting of:
wherein Base is selected from the group consisting of adenosine, guanosine, thymine, and cytosine; LG is a leaving group selected from the group consisting of OH, activated ester, halide, and anhydride; and R is an aliphatic or aromatic moiety. The linker-subunit also can be selected from the group consisting of:
wherein n is independently an integer from 0 to 3; R is an aliphatic or aromatic group; and LG is a leaving group selected from the group consisting of: OH, activated ester, halide, and anhydride. -
- In another aspect, the invention features a method of making a MR imaging agent. The method includes covalently binding an amino acid residue to a linker-subunit moiety to form a C-terminal end of a peptide, wherein the linker-subunit moiety is covalently attached to a resin; synthesizing a peptide on the resin from the covalently bound C-terminal end to an N-terminal residue of the peptide, the N-terminal residue comprising an N-terminal amine functional group; cleaving the peptide from the resin to produce a peptide having a C-terminal amine functional group; covalently attaching a linker moiety to the peptide's C-terminal amine functional group and N-terminal amine functional group to form a precursor MR imaging agent; and converting the precursor MR imaging agent to the MR imaging agent. The method further can include before cleaving the peptide from the resin, covalently attaching a linker-subunit moiety to the N-terminal amino functional group to produce a derivatized N-terminal amine functional group. The linker moiety can be covalently conjugated to a precursor chelate moiety, the covalent conjugate comprising a plurality of carboxylate precursor groups, the carboxylate precursor groups capable of being transformed into carboxylate moieties.
- Converting the precursor MR imaging agent to the MR imaging agent can include reacting the precursor MR imaging agent with a precursor chelate moiety to form a covalent bond between the precursor chelate moiety and the linker moiety of the precursor MR imaging agent, the precursor chelate moiety comprising a plurality of carboxylate precursor groups, the carboxylate precursor groups capable of being transformed into carboxylate moieties; transforming a plurality of the carboxylate precursor groups of the bound precursor chelate moiety to a plurality of carboxylate moieties, the carboxylate moieties capable of complexing a paramagnetic metal ion; and complexing a paramagnetic metal ion to the plurality of carboxylate moieties to produce the MR imaging agent.
- Converting the precursor MRI imaging agent to the MR imaging agent also can include transforming a plurality of the covalent conjugate's carboxylate precursor groups into carboxylate moieties, the carboxylate moieties capable of complexing a paramagnetic metal ion; and complexing a paramagnetic metal ion to the plurality of carboxylate moieties to result in the MR imaging agent. The paramagnetic metal ion can be selected from the group consisting of: Gd(III), Fe(III), Mn(II and III), Cr(III), Cu(II), Dy(III), Tb(III and IV), Ho(III), Er(III), Pr(III), Eu(II) and Eu(III). Gd(III) is a particularly useful paramagnetic metal ion.
- In another aspect, the invention features a method of making a MR imaging agent that includes reacting a peptide having a C-terminal carboxylate functional group with a linker-subunit moiety to form a modified peptide having both a C-terminal carboxylate functional group and an N-terminal carboxylate functional group; covalently attaching a linker moiety to both the N-terminal and C-terminal carboxylate functional groups of the modified peptide to form a precursor MR imaging agent; and converting the precursor MR imaging agent to the MR imaging agent. The linker-subunit moiety can be selected from the group consisting of:
wherein LG is a leaving group selected from the group consisting of OH, activated ester, halide, and anhydride; and R is an aromatic or aliphatic group. The linker moiety also can be selected from the group consisting of:
wherein m is an integer from 1 to 4; n is an integer from 0 to 4; R is independently selected from the group consisting of —H, -Me, -Et, -Bz, and -tBu; and R1 and R2 are independently selected from a hydrogen or a chemical protecting group. -
- Converting the precursor MR imaging agent to the MR imaging agent also can include reacting the precursor MR imaging agent with a precursor chelate moiety in order to form a covalent bond between the linker moiety of the precursor MR imaging agent and the precursor chelate moiety, the precursor chelate moiety comprising a plurality of carboxylate precursor groups, the carboxylate precursor groups capable of being transformed into carboxylate moieties; transforming a plurality of the carboxylate precursor groups of the bound precursor chelate moiety to a plurality of carboxylate moieties, the carboxylate moieties capable of complexing a paramagnetic metal ion; and complexing a paramagnetic metal ion to the plurality of carboxylate moieties to produce the MR imaging agent. The linker moiety can be covalently conjugated to a precursor chelate moiety, the covalent conjugate comprising a plurality of carboxylate precursor groups, the carboxylate precursor groups capable of being transformed into carboxylate moieties.
- Converting the precursor MR imaging agent to the MR imaging agent also can include transforming a plurality of the covalent conjugate's carboxylate precursor groups into carboxylate moieties, the carboxylate moieties capable of complexing a paramagnetic metal ion; and complexing a paramagnetic metal ion to the plurality of carboxylate moieties to produce the MR imaging agent.
- A covalent conjugate can be selected from the group consisting of:
wherein n is an integer from 1 to 4; and R1, R2, R3, R4, and R5 are independently selected from the group consisting of an acetate moiety, a -Me, -Et, or -t-Bu protected acetate moiety, an acetamide moiety, and an acetoxy moiety. The covalent conjugate can be: - Converting the precursor MR imaging agent to the MR imaging agent also can include reacting the precursor imaging agent with a chelate moiety, wherein the chelate moiety contains a paramagnetic metal ion, to form a covalent bond between the chelate moiety and the linker moiety of the precursor MR imaging agent to produce the MR imaging agent. Suitable paramagnetic metal ions are described above.
- In yet another aspect, the invention features a contrast agent that includes a metal chelate complex at a —CO2R and NHR termini of a biopolymer (e.g., a peptide), wherein R is independently selected from the group consisting of hydrogen, alkyl, aliphatic, and a leaving group. The contrast agent can include two metal chelate complexes at the CO2R and NHR termini of the biopolymer. The biopolymer can have a specific binding affinity for fibrin. The peptide can be capable of forming a disulfide bond under non-reducing conditions, and in some embodiments, includes a disulfide bond. A contrast agent can have the formula:
wherein Chelate represents a metal chelate complex; Linker represents a linker moiety; Linker-subunit represents a linker-subunit moiety; m is independently an integer from 1 to 10; p is independently an integer from 0 to 5; s is independently 0 or 1; R1 is an amino acid side chain or a derivative thereof, and R2 is independently a hydrogen or an aliphatic group. A contrast agent also can have a structure of any one of structures 4-55. - In another aspect, the invention features a method for altering the stability of a peptide, the peptide having an N-terminal amine functional group. The method includes reacting the peptide with a linker-subunit moiety to form a peptide having a C-terminal amine functional group; and covalently attaching a linker moiety to the peptide's C-terminal amine functional group and N-terminal amine functional group to form a modified peptide. The method further can include reacting the modified peptide with a capping moiety to form a covalent bond between the capping moiety and the linker moiety of the modified peptide. The method also can include reacting the modified peptide with a precursor chelate moiety to form a covalent bond between the precursor chelate moiety and the linker moiety of the modified peptide, the precursor chelate moiety comprising a plurality of carboxylate precursor groups, the carboxylate precursor groups capable of being transformed into carboxylate moieties. After transforming a plurality of the carboxylate precursor groups of the bound precursor chelate moiety to a plurality of carboxylate moieties, the carboxylate moieties capable of complexing a paramagnetic metal ion; a paramagnetic metal ion can be complexed to the plurality of carboxylate moieties. The method further can include assaying the stability of the modified peptide or assaying the stability of the unmodified peptide and comparing the stability of said modified peptide to the stability of the unmodified peptide. Stability of the modified peptide can be improved relative to the stability of the unmodified peptide (e.g., improved 10-fold, 20-fold, or 30-fold relative to the stability of the unmodified peptide). Stability can be assayed using a rat liver homogenate assay.
- In another aspect, the invention features a modified peptide having the structure:
wherein Chelate precursor represents a chelate precursor moiety; Linker represents a linker moiety; Linker-subunit represents a linker-subunit moiety; m is independently an integer from 1 to 10; p is independently an integer from 0 to 5; s is independently 0 or 1; R1 is an amino acid side chain or a derivative thereof, and R2 is selected from the group consisting of H and an aliphatic group. - In yet another aspect, the invention features a modified peptide having the structure:
wherein Linker represents a linker moiety; Linker-subunit represents a linker-subunit moiety; p is independently an integer from 0 to 5; s is independently 0 or 1; R1 is an amino acid side chain or a derivative thereof, and R2 is selected from the group consisting of H and an aliphatic group. - Method of making an MR imaging agent also are featured that include reacting a peptide having an N-terminal amine functional group with a linker-subunit moiety to form a modified peptide having an amine functional group on both its N-terminus and C-terminus, or reacting a peptide having a C-terminal carboxylate functional group with a linker-subunit moiety to form a modified peptide having a carboxylate functional group on both its C-terminus and N-terminus; and converting the modified peptide to the MR imaging agent. Converting the modified peptide to the MR imaging agent can include covalently attaching a chelate moiety to the modified peptide, wherein the chelate moiety contains a paramagnetic metal ion, to produce the MR imaging agent. Converting the modified peptide to the MR imaging agent also can include covalently linking a linker moiety to a chelate moiety to form a covalent conjugate, wherein the chelate moiety contains a paramagnetic metal ion; and reacting the covalent conjugate with the modified peptide to form the MR imaging agent. Suitable paramagnetic ions are described above.
- In another aspect, the invention features a method of making an MR imaging agent that includes covalently binding an amino acid residue to a linker-subunit moiety to form a C-terminal end of a peptide, wherein the linker-subunit moiety is covalently attached to a resin; synthesizing a peptide on the resin from the covalently bound C-terminal end to an N-terminal residue of the peptide, the N-terminal residue comprising an N-terminal amine functional group; cleaving the peptide from the resin to produce a C-terminal amine functional group of the modified peptide; converting the modified peptide to the MR imaging agent. Converting the modified peptide to the MR imaging agent can include covalently attaching a chelate moiety to the modified peptide, wherein the chelate moiety contains a paramagnetic metal ion, to produce the MR imaging agent. Converting the modified peptide to the MR imaging agent also can include covalently linking a linker moiety to a chelate moiety to form a covalent conjugate, wherein the chelate moiety contains a paramagnetic metal ion; and reacting the covalent conjugate with the modified peptide to form the MR imaging agent. Suitable paramagnetic ions are described above.
- Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention pertains. Although methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, suitable methods and materials are described below. All publications, patent applications, patents, and other references mentioned herein are incorporated by reference in their entirety. In case of conflict, the present specification, including definitions, will control. In addition, the materials, methods, and examples are illustrative only and not intended to be limiting.
- Other features and advantages of the invention will be apparent from the following detailed description, and from the claims.
-
FIG. 1 provides the chemical structures of non-natural amino acids. -
FIG. 2 depicts the relaxivities per Gd at 20 MHz, 35° C. in Tris buffered saline (TBS) or 10 mg/ml fibrin in TBS. -
FIG. 3 depicts the accumulation of a contrast agent in the thrombus. -
FIG. 4A is an image of a thrombus.FIG. 4B is an image of a thrombus with black blood. - Definitions
- Commonly used chemical abbreviations that are not explicitly defined in this disclosure may be found in The American Chemical Society Style Guide, Second Edition; American Chemical Society, Washington, D.C. (1997), “2001 Guidelines for Authors” J. Org. Chem. 66 (1), 24A (2001), “A Short Guide to Abbreviations and Their Use in Peptide Science” J. Peptide. Sci. 5, 465-471 (1999).
- For the purposes of this application, the term “chemical protecting group” or “protecting group” means any chemical moiety temporarily covalently bound to a molecule throughout one or more synthetic chemistry steps in a reaction sequence to prevent undesirable reactions. Common protecting group strategies are described in “Protecting Groups in Organic Synthesis, Third Ed.” by P. Wuts and T. Greene, © 1999 John Wiley & Sons, Inc.
- For the purposes of this application, the term “leaving group” means any chemical moiety that is displaced by a nucleophile in a nucleophilic substitution or sequence of addition-elimination reactions. A molecule comprising a leaving group may be isolated or it may be formed in situ as a transient intermediate in a chemical reaction.
- For the purposes of this application, the term “aliphatic” describes any acyclic or cyclic, saturated or unsaturated, branched or unbranched carbon compound, excluding aromatic compounds.
- The term “alkyl” includes saturated aliphatic groups, including straight-chain alkyl groups (e.g., methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, nonyl, decyl, etc.), branched-chain alkyl groups (isopropyl, tert-butyl, isobutyl, etc.), cycloalkyl (alicyclic) groups (cyclopropyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl), alkyl substituted cycloalkyl groups, and cycloalkyl substituted alkyl groups. The term alkyl further includes alkyl groups, which can further include oxygen, nitrogen, sulfur or phosphorous atoms replacing one or more carbons of the hydrocarbon backbone. In certain embodiments, a straight chain or branched chain alkyl has 6 or fewer carbon atoms in its backbone (e.g., C1-C6 for straight chain, C3-C6 for branched chain), and more preferably 4 or fewer. Likewise, preferred cycloalkyls have from 3-8 carbon atoms in their ring structure, and more preferably have 5 or 6 carbons in the ring structure. The term C1-C6 includes alkyl groups containing 1 to 6 carbon atoms.
- Moreover, the term “alkyl” includes both “unsubstituted alkyls” and “substituted alkyls,” the latter of which refers to alkyl moieties having substituents replacing a hydrogen on one or more carbons of the hydrocarbon backbone. Such substituents can include, for example, alkenyl, alkynyl, halogen, hydroxyl, alkylcarbonyloxy, arylcarbonyloxy, alkoxycarbonyloxy, aryloxycarbonyloxy, carboxylate, alkylcarbonyl, arylcarbonyl, alkoxycarbonyl, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, alkylthiocarbonyl, alkoxyl, phosphate, phosphonato, phosphinato, cyano, amino (including alkyl amino, dialkylamino, arylamino, diarylamino, and alkylarylamino), acylamino (including alkylcarbonylamino, arylcarbonylamino, carbamoyl and ureido), amidino, imino, sulfhydryl, alkylthio, arylthio, thiocarboxylate, sulfates, alkylsulfinyl, sulfonato, sulfamoyl, sulfonamido, nitro, trifluoromethyl, cyano, azido, heterocyclyl, alkylaryl, or an aromatic or heteroaromatic moiety. Cycloalkyls can be further substituted, e.g., with the substituents described above. An “arylalkyl” moiety is an alkyl substituted with an aryl (e.g., phenylmethyl (benzyl)). The term “alkyl” also includes the side chains of natural and unnatural amino acids. The term “n-alkyl” means a straight chain (i.e., unbranched) unsubstituted alkyl group.
- The term “alkenyl” includes aliphatic groups that may or may not be substituted, as described above for alkyls, containing at least one double bond and at least two carbon atoms. For example, the term “alkenyl” includes straight-chain alkenyl groups (e.g., ethylenyl, propenyl, butenyl, pentenyl, hexenyl, heptenyl, octenyl, nonenyl, decenyl, etc.), branched-chain alkenyl groups, cycloalkenyl (alicyclic) groups (cyclopropenyl, cyclopentenyl, cyclohexenyl, cycloheptenyl, cyclooctenyl), alkyl or alkenyl substituted cycloalkenyl groups, and cycloalkyl or cycloalkenyl substituted alkenyl groups. The term alkenyl further includes alkenyl groups that include oxygen, nitrogen, sulfur or phosphorous atoms replacing one or more carbons of the hydrocarbon backbone. In certain embodiments, a straight chain or branched chain alkenyl group has 6 or fewer carbon atoms in its backbone (e.g., C2-C6 for straight chain, C3-C6 for branched chain). Likewise, cycloalkenyl groups may have from 3-8 carbon atoms in their ring structure, and more preferably have 5 or 6 carbons in the ring structure. The term C2-C6 includes alkenyl groups containing 2 to 6 carbon atoms.
- Moreover, the term alkenyl includes both “unsubstituted alkenyls” and “substituted alkenyls,” the latter of which refers to alkenyl moieties having substituents replacing a hydrogen on one or more carbons of the hydrocarbon backbone. Such substituents can include, for example, alkyl groups, alkynyl groups, halogens, hydroxyl, alkylcarbonyloxy, arylcarbonyloxy, alkoxycarbonyloxy, aryloxycarbonyloxy, carboxylate, alkylcarbonyl, arylcarbonyl, alkoxycarbonyl, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, alkylthiocarbonyl, alkoxyl, phosphate, phosphonato, phosphinato, cyano, amino (including alkyl amino, dialkylamino, arylamino, diarylamino, and alkylarylamino), acylamino (including alkylcarbonylamino, arylcarbonylamino, carbamoyl and ureido), amidino, imino, sulfhydryl, alkylthio, arylthio, thiocarboxylate, sulfates, alkylsulfinyl, sulfonato, sulfamoyl, sulfonamido, nitro, trifluoromethyl, cyano, azido, heterocyclyl, alkylaryl, or an aromatic or heteroaromatic moiety.
- The term “alkynyl” includes unsaturated aliphatic groups analogous in length and possible substitution to the alkyls described above, but which contain at least one triple bond and two carbon atoms. For example, the term “alkynyl” includes straight-chain alkynyl groups (e.g., ethynyl, propynyl, butynyl, pentynyl, hexynyl, heptynyl, octynyl, nonynyl, decynyl, etc.), branched-chain alkynyl groups, and cycloalkyl or cycloalkenyl substituted alkynyl groups. The term alkynyl further includes alkynyl groups that include oxygen, nitrogen, sulfur or phosphorous atoms replacing one or more carbons of the hydrocarbon backbone. In certain embodiments, a straight chain or branched chain alkynyl group has 6 or fewer carbon atoms in its backbone (e.g., C2-C6 for straight chain, C3-C6 for branched chain). The term C2-C6 includes alkynyl groups containing 2 to 6 carbon atoms.
- In general, the term “aryl” includes groups, including 5- and 6-membered single-ring aromatic groups that may include from zero to four heteroatoms, for example, benzene, phenyl, pyrrole, furan, thiophene, thiazole, isothiaozole, imidazole, triazole, tetrazole, pyrazole, oxazole, isooxazole, pyridine, pyrazine, pyridazine, and pyrimidine, and the like. Furthermore, the term “aryl” includes multicyclic aryl groups, e.g., tricyclic, bicyclic, such as naphthalene, benzoxazole, benzodioxazole, benzothiazole, benzoimidazole, benzothiophene, methylenedioxyphenyl, quinoline, isoquinoline, napthridine, indole, benzofuran, purine, benzofuran, deazapurine, or indolizine. Those aryl groups having heteroatoms in the ring structure may also be referred to as “aryl heterocycles,” “heterocycles,” “heteroaryls,” or “heteroaromatics.” An aryl group may be substituted at one or more ring positions with substituents.
- For the purposes of this application, “DTPA” refers to a chemical compound comprising a substructure composed of diethylenetriamine, wherein the two primary amines are each covalently attached to two acetyl groups and the secondary amine has one acetyl group covalently attached according to the following formula:
- wherein X is a heteroatom electron-donating group capable of coordinating a metal cation, preferably O−, OH, NH2, OPO3 2−, or NHR, or OR wherein R is any aliphatic group. When each X group is tert-butoxy (tBu), the structure may be referred to as “DTPE” (“E” for ester).
-
- wherein X is defined above.
-
- wherein X is defined above.
- For the purposes of this application, “DO3A” refers to a chemical compound comprising a substructure composed of 1,4,7,11-tetraazacyclododecane, wherein three of the four amines each have one acetyl group covalently attached and the other amine has a substituent having neutral charge according to the following formula:
- wherein X is defined above and R1 is an uncharged chemical moiety, preferably hydrogen, any aliphatic, alkyl group, or cycloalkyl group, and uncharged derivatives thereof The preferred chelate “HP”-DO3A has R1=—CH2(CHOH)CH3.
- In each of the four structures above, the carbon atoms of the indicated ethylenes may be referred to as “backbone” carbons. The designation “bbDTPA” may be used to refer to the location of a chemical bond to a DTPA molecule (“bb” for “back bone”). Note that as used herein, bb(CO)DTPA-Gd means a C═O moiety bound to an ethylene backbone carbon atom of DTPA.
- The terms “chelating ligand,” “chelating moiety,” and “chelate moiety” may be used to refer to any polydentate ligand which is capable of coordinating a metal ion, including DTPA (and DTPE), DOTA, DO3A, or NOTA molecule, or any other suitable polydentate chelating ligand as is further defined herein, that is either coordinating a metal ion or is capable of doing so, either directly or after removal of protecting groups, or is a reagent, with or without suitable protecting groups, that is used in the synthesis of a contrast agent and comprises substantially all of the atoms that ultimately will coordinate the metal ion of the final metal complex. The term “chelate” refers to the actual metal-ligand complex, and it is understood that the polydentate ligand will eventually be coordinated to a medically useful metal ion.
- The term “specific binding affinity” as used herein, refers to the capacity of a contrast agent to be taken up by, retained by, or bound to a particular biological component to a greater degree than other components. Contrast agents that have this property are said to be “targeted” to the “target” component. Contrast agents that lack this property are said to be “non-specific” or “non-targeted” agents. The specific binding affinity of a binding group for a target is expressed in terms of the equilibrium dissociation constant “Kd.”
- The term “relaxivity” as used herein, refers to the increase in either of the
MRI quantities 1/T1 or 1/T2 per millimolar (mM) concentration of paramagnetic ion or contrast agent, which quantities may be different if the contrast agent contains a multiplicity of paramagnetic ions, wherein T1 is the longitudinal or spin-lattice, relaxation time, and T2 is the transverse or spin-spin relaxation time of water protons or other imaging or spectroscopic nuclei, including protons found in molecules other than water. Relaxivity is expressed in units of mM−1s−1. - The term “open coordination site” as used herein refers to a site on a metal ion that is generally occupied by a water or solvent molecule.
- As used herein, the term “purified” refers to a peptide that has been separated from either naturally occurring organic molecules with which it normally associates or, for a chemically-synthesized peptide, separated from any other organic molecules present in the chemical synthesis. Typically, the polypeptide is considered “purified” when it is at least 70% (e.g., 70%, 80%, 90%, 95%, or 99%), by dry weight, free from any other proteins or organic molecules.
- As used herein, the term “peptide” refers to a chain of amino acids that is about 2 to about 75 amino acids in length (e.g., 3 to 50 amino acids).
- As used herein, the term “biopolymer” refers to a polymeric substance that is naturally formed in a biological system. Certain biopolymers can be constructed from a defined set of building subunits and with common functionalities linking the subunits, e.g., a peptide is usually constructed from a set of amino acids (both natural and non-natural) with amide bonds linking the subunits.
- The term “multimer” for purposes herein is defined as a contrast agent or a subunit thereof comprising at least two covalently bonded chelates or synthetic precursors thereof.
- As used herein, the term “natural” or “naturally occurring” amino acid refers to one of the twenty most common occurring amino acids. Natural amino acids modified to provide a label for detection purposes (e.g., radioactive labels, optical labels, or dyes) are considered to be natural amino acids. Natural amino acids are referred to by their standard one- or three-letter abbreviations.
- The term “non-natural amino acid” or “non-natural” refers to any derivative of a natural amino acid including D forms, and β and γ amino acid derivatives. It is noted that certain amino acids, e.g., hydroxyproline, that are classified as a non-natural amino acid herein, may be found in nature within a certain organism or a particular protein.
- The term “stable,” as used herein, refers to compounds that possess stability sufficient to allow manufacture and which maintains the integrity of the compound for a sufficient period of time to be useful and safe for the purposes detailed herein. Typically, such compounds are stable at a temperature of 40° C. or less, in the absence of moisture or other chemically reactive conditions, for at least a week. Combinations of substituents and variables envisioned by this invention are only those that result in the formation of stable compounds.
- The terms “target binding” and “binding” for purposes herein refer to non-covalent interactions of a contrast agent with a target. These non-covalent interactions are independent from one another and may be, inter alia, hydrophobic, hydrophilic, dipole-dipole, pi-stacking, hydrogen bonding, electrostatic associations, or Lewis acid-base interactions.
- The term “capping moiety” refers to a chelate, organic dye, contrast agent, thrombolytic, or stabilizing moiety. Suitable stabilizing moieties are biologically inert, i.e., does not have biological activity.
- Contrast Agents
- In general, the present invention relates to MRI, optical, and radionuclide contrast agents that include a targeting polymer (e.g., peptide) in which both the N- and C-terminal amino acids are each conjugated, either directly or via an optional intervening linker-subunit and linker, to at least one chelate of a paramagnetic (for magnetic resonance imaging) or radioactive (for radionuclide imaging) metal ion or an optical dye (for optical imaging). As further exemplified herein, the linker or linker-subunit may be branched and therefore allow for multiple chelates or dyes to be attached to each end of the peptide, i.e. a multimer. The compounds of this invention may contain one or more asymmetric carbon atoms and thus may occur as racemates and racemic mixtures, single enantiomers, diastereomeric mixtures and individual diastereomers. All such isomeric forms of these compounds are expressly included in the present invention. Each stereogenic carbon may be of the R or S configuration unless specifically designated otherwise. Although the specific compounds exemplified in this application may be depicted in a particular stereochemical configuration, compounds having either the opposite stereochemistry at any given chiral center or mixtures thereof are also envisioned. It should be understood that the compounds of this invention may adopt a variety of conformational and ionic forms in solution, in pharmaceutical compositions and in vivo. Although the depictions herein of specific preferred compounds of this invention are of particular conformations and ionic forms, the disclosure of the invention is not so limited.
- Novel peptide-based multimers of the present invention offer several advantages as targeted contrast agents.
-
- 1. The compounds can deliver two or more capping moieties (e.g., chelates, organic dyes, or thrombolytics) to the target using a single targeting peptide so that sufficient improvement in the tissue contrast will be observed in part because of a meaningful concentration of the imaging moiety around the target.
- 2. The MRI contrast agents of this invention also exhibit a high relaxivity upon binding to the target due to the receptor induced magnetic enhancement (RIME) effect combined with the ability of the peptide to limit the local motion of individual chelates when bound to the target.
- 3. The compounds have a high affinity for one or more targets.
- 4. Since the compounds are relatively easy to synthesize according to the methods described herein and only one peptide per molecule is required, a multiplicity of metal ions or organic dyes may be delivered to a target more economically.
- 5. The compounds of the invention can have higher in vivo stability (i.e., longer half-lives) from diminished enzyme metabolism (e.g., decreased cleavage by peptidases).
- These favorable features of peptide-based multimers according to the present invention make them useful targeted contrast agents.
-
- wherein for each m, independently, 1≦m≦10, chelate represents a metal chelate complex, p is independently an integer from zero to five; s is independently one or zero; R1 is any amino acid side chain including side chains of non-natural amino acids; R2 is any aliphatic group or hydrogen; and n is an integer from 3 to 50 inclusive. Alternately, R1 and R2 may be taken together to form a ring structure (including proline and substituted versions thereof). Linkers, if present, may be different.
- Metal ions preferred for MRI include those with atomic numbers 21-29, 39-47, or 57-83, and, more preferably, a paramagnetic form of a metal ion with atomic numbers 21-29, 42, 44, or 57-83. Particularly preferred paramagnetic metal ions are selected from the group consisting of Gd(III), Fe(III), Mn(II and III), Cr(III), Cu(II), Dy(III), Tb(III and IV), Ho(III), Er(III), Pr(III) and Eu(II and III). Gd(III) is particularly useful. Note that, as used herein, the term “Gd” is meant to convey the ionic form of the metal gadolinium; such an ionic form can be written as GD(III), GD3+, gado, etc., with no difference in ionic form contemplated.
- For radionuclide imaging agents, radionuclides 90Y, 99mTc, 111In, 47Sc, 67Ga, 51Cr, 177mSn, 67Cu, 167Tm, 97Ru, 188Re, 177Lu, 199Au, 203Pb, and 141Ce are particularly useful. Metal complexes with useful optical properties also have been described. See, Murru et al., J. Chem. Soc. Chem. Comm. 1993, 1116-1118. For optical imaging using chelates, lanthanide chelates such as La(III), Ce(III), Pr(III), Nd(III), Pn(III), Sm(III), Eu(III), Gd(III), Tb(III), Dy(III), Ho(III), Er(III), Tm(III), Yb(III) and Ln(III) are suitable. Eu(III) and Tb(III) are particularly useful.
- Metal chelates should not dissociate to any significant degree during the imaging agent's passage through the body, including while bound to a target tissue. Significant release of free metal ions can result in toxicity, which would generally not be acceptable.
-
- The “Chelate” is preferably bb(CO)DTPA.Gd.
-
- The “Chelate” moiety can be bb(CO)DTPA.Gd.
- For the purposes of illustration, one contrast agent contemplated by the instant invention is presented below with the various subunits annotated:
wherein R=amino acid side chains such that the peptide has affinity for a biological target, and m=metal ion (paramagnetic for MRI, radioactive for radionuclide imaging, and fluorescent, luminescent, or absorbant for optical imaging). -
- wherein 1≦m≦10, p is independently an integer from zero to five, n is 3 to 50 inclusive, R1 is any amino acid side chain including non-natural amino acid side chains, and R2 is any aliphatic group or hydrogen. Alternatively, R1 and R2 taken together form a ring structure (including Pro and derivatives thereof. The N- and C-terminal amino acids of the peptide can be conjugated to the optical dye directly or via an optional linker (e.g., p=0 or 1). The linker moieties can be different.
- The optical dye may be an organic dye or an appropriate metal chelate. Organic dyes suitable for optical imaging have been described and include, for example, fluorescent porphyrin and fluorescent phthalocyanines [see, e.g., U.S. Pat. No. 5,641,878], particulate materials [see, e.g., WO 96/23524], and polymethine dyes [see, e.g., WO 97/13490]. Commonly used optical organic dyes are fluorescein, rhodamine [see, e.g., Kojima H, et al., Anal. Chem. 73, 1967-1973 (2001)], tetramethylrhodamine [e.g., Anal. Biochem. 223, 39 (1994)], and Texas red [e.g., Proc. Natl. Acad. Sci. USA 85, 3546 (1988)]. Fluoroscein and luminescent lanthanide chelates are particularly useful.
- Targets and Target Binding Peptides
- The peptide moiety of the contrast agents of the present invention can exhibit specific binding for a biological target and function as a point of attachment for one or more chelates at each terminus. In general, biological targets are present in a low (e.g., micromolar or less) concentration and are inefficiently imaged using existing monomeric gadolinium complex MRI contrast agents. The peptide-based multimeric MRI contrast agents according to the instant invention, however, provide a much higher concentration of the agent at the target as well as high relaxivity to make imaging of these targets possible. Similarly, the peptide-based multimeric radionuclide contrast agents of the invention may deliver more radionuclides to targets so that imaging can be further improved. While not being bound to a particular mechanism, it is thought that targeting creates an increased concentration of the imaging agent at the site to be imaged and increases the relaxivity of MRI contrast agents in the bound state through the RIME effect and also limits local chelate motion by rigidifying the bound peptide.
- Targets for the contrast agents can be in any body compartment, cell, organ, or tissue or component thereof. Preferred targets are those that are of diagnostic and therapeutic relevance, i.e., those that are associated with disease states. Particularly preferred targets are those in association with body fluids, and particularly those in association with blood, plasma, lymph and fluids of the central nervous system. Other preferred targets are proteins and receptors that either exist in high concentration or have a large number of binding sites for certain ligands. Included among such target proteins are enzymes and glycoproteins.
- Human serum albumin (HSA) and fibrin are useful targets for MRI contrast agents. For vascular blood pool imaging, serum albumin is a preferred target. Since HSA is present at high concentration in serum (approximately 0.6 mM) and binds a wide array of molecules with reasonably high affinity, it is a preferred target plasma protein for blood pool contrast agents. HSA is a particularly preferred target for cardiovascular imaging; see U.S. patent application No. 08/875,365, filed Jul. 24, 1997, and WO 96/23526.
- For imaging thrombi, fibrin is a preferred target because it is present in all clots and it can be targeted without interfering with the normal thrombolytic process. For additional details concerning target binding moieties that include fibrin-binding peptides, see PCT Patent Application WO 01/09188.
- Other protein targets include, but are not limited to, alpha acid glycoprotein, fibrinogen, collagen, platelet GPIIb/IIIa receptor, chemotactic peptide receptor, somatostatin receptors, vasoactive intestinal peptides (VIP) receptor, bombesin/Gastrin release peptide receptor, and integrin receptors.
- Suitable peptides for use in the invention include those capable of specifically binding to the targets identified above. Included among such peptides are RGD-containing peptides targeting platelet GPIIb/IIIa receptor for thrombus imaging, chemotactic peptides targeting white blood cells for infection/inflammation imaging, Octreotide and P-829 peptide targeting somastatin receptors for tumor imaging, vasoactive intestinal peptides (VIP) targeting VIP receptor for tumor imaging, bombesin analogs targeting bombesin/Gastrin release peptide receptor for tumor imaging, and RGD-containing peptides targeting the integrin αvβ3 (vitronectin receptor) for tumor imaging.
- In principle, any peptide with an affinity for a biological target may be used in a contrast agent of the invention. The peptide may be linear or cyclic. Ordinarily, insoluble lipophilic peptides are considered unsuitable for pharmacological use, but such peptides may be suitable according to the invention because addition of hydrophilic metal chelates to the two termini of the peptide may increase solubility. For ease of synthesis and cost considerations, it is preferred that the peptides have between 3 to 50 amino acids (e.g., 3 to 30, 3 to 20, 3 to 15, 5 to 30, 5 to 20, 5 to 15, 10 to 12 amino acids in length).
- In the targeting peptides of the invention, a great variety of amino acids can be used. Suitable amino acids include natural and non-natural amino acids. Amino acids with many different protecting groups appropriate for immediate use in the solid phase synthesis of peptides are commercially available. In addition to the twenty most common naturally occurring amino acids, the following non-natural amino acids or amino acid derivatives may be constituents of the peptide targeting group of the invention (common abbreviations in parentheses, see
FIG. 1 ): β-Alanine (β-Ala), γ-Aminobutyric Acid (GABA), 2-Aminobutyric Acid (2-Abu), α,β-Dehydro-2-aminobutyric Acid (Δ-Abu), 1-Aminocyclopropane-1-carboxylic Acid (ACPC), Aminoisobutyric Acid (Aib), 2-Amino-thiazoline-4-carboxylic Acid, 5-Aminovaleric Acid (5-Ava), 6-Aminohexanoic Acid (6-Ahx), 8-Aminooctanoic Acid (8-Aoc), 11-Aminoundecanoic Acid (11-Aun), 12-Aminododecanoic Acid (12-Ado), 2-Aminobenzoic Acid (2-Abz), 3-Aminobenzoic Acid (3-Abz), 4-Aminobenzoic Acid (4-Abz), 4-Amino-3-hydroxy-6-methylheptanoic Acid (Statine, Sta), Aminooxyacetic Acid (Aoa), 2-Aminotetraline-2-carboxylic Acid (Atc), 4-Amino-5-cyclohexyl-3-hydroxypentanoic Acid (ACHPA), para-Aminophenylalanine (4-NH2-Phe), Biphenylalanine (Bip), para-Bromophenylalanine (4-Br-Phe), ortho-Chlorophenylalanine (2-Cl-Phe), meta-Chlorophenylalanine (3-Cl-Phe), para-Chlorophenylalanine (4-Cl-Phe), meta-Chlorotyrosine (3-Cl-Tyr), para-Benzoylphenylalanine (Bpa), tert-Butylglycine (Tle), Cyclohexylalanine (Cha), Cyclohexylglycine (Chg), 2,3-Diaminopropionic Acid (Dpr), 2,4-Diaminobutyric Acid (Dbu), 3,4-Dichlorophenylalanine (3,4-Cl2-Phe), 3,4-Diflurorphenylalanine (3,4-F2-Phe), 3,5-Diiodotyrosine (3,5-I2-Tyr), ortho-Fluorophenylalanine (2-F-Phe), meta-Fluorophenylalanine (3-F-Phe), para-Fluorophenylalanine (4-F-Phe), meta-fluorotyrosine (3-F-Tyr), Homoserine (Hse), Homophenylalanine (Hfe), Homotyrosine (Htyr), 5-Hydroxytryptophan (5-OH-Trp), Hydroxyproline (Hyp), para-Iodophenylalanine (4-I-Phe), 3-Iodotyrosine (3-I-Tyr), Indoline-2-carboxylic Acid (Idc), Isonipecotic Acid (Inp), meta-methyltyrosine (3-Me-Tyr), 1-Naphthylalanine (1-Nal), 2 Naphthylalanine (2-Nal), para-Nitrophenylalanine (4-NO2-Phe), 3-Nitrotyrosine (3-NO2-Tyr), Norleucine (Nle), Norvaline (Nva), Ornithine (Orn), ortho-Phosphotyrosine (H2PO3-Tyr), Octahydroindole-2-carboxylic Acid (Oic), Penicillamine (Pen), Pentafluorophenylalanine (F5-Phe), Phenylglycine (Phg), Pipecolic Acid (Pip), Propargylglycine (Pra), Pyroglutamic Acid (pGlu), Sarcosine (Sar), Tetrahydroisoquinoline-3-carboxylic Acid (Tic), and Thiazolidine-4-carboxylic Acid (Thioproline, Th). Stereochemistry of amino acids may be designated by preceding the name or abbreviation with the designation “D ” or “d” or “L ” or “l” as appropriate. Additionally, αN-alkylated amino acids may be employed, as well as amino acids having amine-containing side chains (such as Lys and Orn) in which the amine has been acylated or alkylated. - Peptides of the invention can include the general formula P* -Y*—X1* -L* (SEQ ID NO:1), wherein P* is a proline or a non-natural derivative of proline, Y* is a tyrosine or a non-natural derivative thereof, X1* is glycine or aspartic acid, or a non-natural derivative of glycine or aspartic acid, and L* is leucine or a non-natural derivative thereof. Typically, at least one of P*, Y*, X1*, or L* is a non-natural derivative of the respective amino acid. For example, X1* can be glycine or aspartic acid, L* can be leucine, and at least one of P* or Y* can be a non-natural derivative, such as hydroxyproline or a tyrosine substituted at the 3 position with F, Cl, Br, I, or NO2.
- A peptide of the invention also can include the general formula X1—X2—C—P* -Y* - X3—L—C—X4—X5—X6 (SEQ ID NO:2), wherein P* is a proline or a non-natural derivative thereof, Y* is a tyrosine or a non-natural derivative thereof, X1 is W, Y, F, S, Bip, Hx, Dpr, Cy, Gu, Ad, Hfe, 3-Pal, 4-Pal, DopaMe2, nTyr, dW, dF, F(3/4*), or Y(3*). F(3/4*) can be a phenylalanine substituted at either the 3 or the 4 position with a moiety such as CH3, CF3, NH2, CH2NH2, CN, F, Cl, Br, I, Et, or Ome. Y(3*) can be a tyrosine substituted at the 3 position with a moiety such as F, Cl, Br, I, and NO2. X2 can be E, H, dE, S, H(Bzl), 2-Pal, Dpr, or Th; X3 can be G or D; X4 can be H, F, Y, or W; X5 can be I, L, V, N, Bpa, Bal, Hfe, Nle, Tle, Nval, Phg, Cha, Taz, Fua, Th, 4-Pal, or F(3/4*), wherein F(3/4*) is a phenylalanine substituted at either the 3 or the 4 position with a moiety such as CF3, Et, iPr, or OMe; X6 can be N, Q, I, L, or V, or not present. Typically, at least one of X1, X2, X5, P*, and Y* is a non-natural derivative of an amino acid. For example, P* can be proline and Y* can be a non-natural derivative of tyrosine substituted at the 3 position with a moiety such as F, Cl, Br, I, or NO2. Alternatively, P* can be a non-natural derivative of proline such as 4-hydroxyproline and Y* can be tyrosine. Such peptides can form a disulfide bond under non-reducing conditions.
- Another example of a peptide that can bind fibrin includes the general formula C-P* - Y*—X1—L—C (SEQ ID NO:3), wherein X1 is G or D, P* is proline or its non-natural derivative 4-hydroxyproline; Y* is tyrosine or a non-natural derivative of tyrosine substituted at the 3 position with a moiety such as F, Cl, Br, I, or NO2. Typically, at least one of P* or Y* is a non-natural derivative of the respective amino acid. For example, the peptide can have the following sequences: W-dE-C-P(4-OH)-Y(3-Cl)-G-L-C-W-I-Q (SEQ ID NO:4), Y-dE-C-P(4-OH)-Y(3-Cl)-G-L-C-Y-I-Q (SEQ ID NO:5), Y-dE-C-P(4-OH)-Y(3-Cl)-G-L-C-W-I-Q (SEQ ID NO:6), W-dE-C-P(4-OH)-Y(3-Cl)-G-L-C-Y-I-Q (SEQ ID NO:7), W-dE-C-P(4-OH)-Y(3-Cl)-D-L-C-W-I-Q (SEQ ID NO:8), Y-dE-C-P(4-OH)-Y(3-Cl)-D-L-C-Y-I-Q (SEQ ID NO:9), Y-dE-C-P(4-OH)-Y(3-Cl)-D-L-C-W-I-Q (SEQ ID NO:10), W-dE-C-P(4-OH)-Y(3-Cl)-D-L-C-Y-I-Q (SEQ ID NO:11), F(4-OMe)-H-C-P(4-OH)-Y(3-Cl)-D-L-C-H-I-L (SEQ ID NO: 12), Y-H-C-P(4-OH)-Y(3-Cl)-G-L-C-W-I-Q (SEQ ID NO:13), W-dE-C-P-Y(3-Cl)-G-L-C-W-I-Q (SEQ ID NO:14), W-dE-C-P(4-OH)-Y-G-L-C-W-I-Q (SEQ ID NO:15), or F-H-C-P-(4-OH)-Y(3-Cl)-D-L-C-H-I-L (SEQ ID NO:16). Such peptides can form disulfide bonds under non-reducing conditions.
- According to standard synthesis methods such as those disclosed in WO 01/09188 or in WO 01/08712, peptides having the sequence set forth in Table 1 were synthesized (structure confirmed by mass spectrometry), cyclized, and assayed for affinity to the DD(E) fragment of fibrin. Each peptide was found to have a Kd≦10 μM (“-” indicates truncation).
TABLE 1 Kd(μM) vs. DD(E) X1 X2 C P(4-OH) Y* X3 L C X4 X5 X6 ≦0.1 F(4-OMe) H C Hyp Y(3-Cl) D L C H I L ≦0.1 F(4-OMe) H C Hyp Y(3-Cl) D L C H I ≦0.1 F(4-OMe) H C Hyp Y(3-I) D L C H Bpa ≦0.1 F H C Hyp Y(3-I) D L C H Hfe ≦0.1 F H C Hyp Y(3-I) D L C H Bpa ≦0.1 Y(3-Cl) H C Hyp Y(3-I) D L C H I ≦0.1 Y D-E C Hyp Y(3-Cl) G L C W I Q ≦0.1 F(4-OMe) H C Hyp Y(3-I) D L C H I L ≦0.1 F(4-OMe) H(Bzl) C Hyp Y(3-Cl) D L C H Bpa ≦0.1 F H C Hyp Y(3-Cl) D L C H I ≦0.1 F(4-OMe) H C Hyp Y(3-I) D L C H I ≦0.1 3Pal H C Hyp Y(3-I) D L C H I ≦0.1 4Pal H C Hyp Y(3-I) D L C H I ≦0.1 F(4-F) H C Hyp Y(3-I) D L C H I ≦0.1 Y(3-I) H C Hyp Y(3-I) D L C H I ≦0.1 F H C Hyp Y(3-I) D L C H I L ≦0.1 F(4-OMe) H C Hyp Y(3-Cl) D L C H Bpa L ≦0.1 F(4-OMe) H C Hyp Y(3-I) D L C H Bpa L ≦0.1 F H(Bzl) C Hyp Y(3-Cl) D L C H I L ≦0.1 1Nal H C Hyp Y(3-I) D L C H I ≦0.1 MTyr H C Hyp Y(3-I) D L C H I ≦0.1 F(4-OMe) H(Bzl) C Hyp Y(3-I) D L C H Bpa ≦0.1 F(4-OMe) H(Bzl) C Hyp Y(3-Cl) D L C H I ≦0.1 F H C Hyp Y(3-I) D L C 3Pal I ≦0.1 F(4-I) H C Hyp Y(3-I) D L C H I ≦0.1 F(4-Br) H C Hyp Y(3-I) D L C H I ≦0.1 F(4-Me) H C Hyp Y(3-I) D L C H I ≦0.1 F(4-CF3) H C Hyp Y(3-I) D L C H I ≦0.1 F(4-CN) H C Hyp Y(3-I) D L C H I ≦0.1 Y(3-NO2) H C Hyp Y(3-I) D L C H I ≦0.1 Y(2-F) H C Hyp Y(3-I) D L C H I ≦0.1 F(4-CH2NH2) H C Hyp Y(3-I) D L C H I ≦0.1 F(4-NH2) H C Hyp Y(3-I) D L C H I ≦0.1 F(34-F2) H C Hyp Y(3-I) D L C H I ≦0.1 DopaMe2 H C Hyp Y(3-I) D L C H I ≦0.1 F(2-OMe) H C Hyp Y(3-I) D L C H I ≦0.1 F(3-Me) H C Hyp Y(3-I) D L C H I ≦0.1 F H C Hyp Y(3-I) D L C H I ≦0.1 F H C Hyp Y(3-I) D L C H F(3-CF3) ≦0.1 F(3-CF3) H C Hyp Y(3-I) D L C H I ≦0.1 F(3-OMe) H C Hyp Y(3-I) D L C H I ≦0.1 Hfe H C Hyp Y(3-I) D L C H I ≦0.1 nTyr H C Hyp Y(3-I) D L C H I ≦0.1 W E C Hyp Y(3-Cl) G L C W I Q ≦0.1 F H C Hyp Y(3-I) D L C H I L ≦0.1 F H C Hyp Y(3-Cl) D L C H I L ≦0.1 F(4-OMe) H(Bzl) C Hyp Y(3-I) D L C H I ≦0.1 F H C Hyp Y(3-I) D L C H Nle ≦0.1 F H C Hyp Y(3-I) D L C H Tle ≦0.1 F H C Hyp Y(3-I) D L C H F(4-CF3) ≦0.1 F H C Hyp Y(3-I) D L C H Bip ≦0.1 F H C Hyp Y(3-I) D L C H F(4-Et) ≦0.1 F H C Hyp Y(3-I) D L C H F(4-OMe) ≦0.1 F H C Hyp Y(3-I) D L C H F(3-OMe) ≦0.1 F(F5) H C Hyp Y(3-I) D L C H I ≦0.1 F H C Hyp Y(3-F) D L C H I L ≦0.1 W E C Hyp Y(3-Cl) G L C W I Q ≦0.2 T D-E C Hyp Y(3-Cl) G L C W I Q ≦0.2 F H C P Y(3-Cl) D L C H I L ≦0.2 Y(26-Me) H C Hyp Y(3-I) D L C H I ≦0.2 W E C Hyp Y(3-Cl) G L C H I Q ≦0.2 D-F D-E C Hyp Y(3-Cl) G L C W I Q ≦0.2 Y E C Hyp Y(3-Cl) G L C Y I Q ≦0.2 W E C Hyp Y(3-Cl) G L C F I Q ≦0.2 H D-E C Hyp Y(3-Cl) G L C W I Q ≦0.2 F H C Hyp Y(3-I) D L C H I L ≦0.2 W E C P Y G L C W I Q ≦0.2 F H C Hyp Y(3-I) D L C H nVal ≦0.2 F H C Hyp Y(3-I) D L C H Phg ≦0.2 F H C Hyp Y(3-I) D L C H F(3-Me) ≦0.2 F H C Hyp Y(3-I) D L C 4Pal I ≦0.2 S D-E C Hyp Y(3-Cl) G L C W I Q ≦0.3 W E C Hyp Y(3-Cl) G L C Y I Q ≦0.3 Y E C Hyp Y(3-Cl) G L C W I Q ≦0.3 F D-E C Hyp Y(3-Cl) G L C W I Q ≦0.3 F H C P Y D L C H I L ≦0.3 F H C Hyp Y(3-I) D L C H I L ≦0.3 F H C Hyp Y D L C H Bpa ≦0.4 F H C Hyp Y(3-Cl) G L C H I L ≦0.4 S(Bzl) H C P Y D L C H I L ≦0.4 H E C Hyp Y(3-Cl) G L C H I Q ≦0.4 F(4-OMe) H C Hyp Y D L C H I L ≦0.4 F H C Hyp Y(3-I) D L C Bpa I ≦0.4 Ad H C Hyp Y(3-I) D L C H I ≦0.5 F H C Hyp Y(3-Cl) F L C H I L ≦0.5 F E C Hyp Y(3-Cl) G L C W I Q ≦0.5 F H C Hyp Y(3-Cl) 2-Nal L C H I L ≦0.5 F H C Hyp Y D L C H I L ≦0.5 Hfe H C Hyp Y D L C H I L ≦0.5 Bip H C Hyp Y D L C H I L ≦0.5 W E C P Y G L C W I Q ≦0.5 F(4-OMe) W C Hyp Y(3-I) D L C H I ≦0.5 F H C Hyp Y(3-I) D L C 2Pal I ≦0.5 F H C Hyp Y(3-I) D L C Taz I ≦0.5 F H C Hyp Y(3-I) D L C Dht I ≦0.5 Gu H C Hyp Y(3-I) D L C H I - A peptide also can have the general formula C-D-Y-Y-G-T-C-X10 (SEQ ID. NO:17), wherein X10 is n(decyl)G, n(4-PhBu)G, MeL, Bpa, Bip, Me-Bip, F(4*), F(3-Me), F(3, 4-difluoro), Amh, Hfe, Y(3, 5-di-iodo), Pff, 1Nal, d1Nal, or MeL, wherein F(4*) is a phenylalanine substituted at the 4 position with a moiety such as Et, CF3, I, or iPr. In some embodiments, a peptide can include additional residues, X1, P*, and/or X11 to provide the general formula: C-D-Y-Y-G-T-C-X10-X11 (SEQ ID. NO:18) or X1-P*-C-D-Y-Y-G-T-C-X10-X11 (SEQ ID. NO:26), wherein X1 is any natural or non-natural amino acid, P* is proline or a non-natural derivative thereof, and X11 is D, dD, βD, Inp, Nip, Me-D, Cop, or Cmp. For example, a peptide can have the sequence of L-P-C-D-Y-Y-G-T-C-n(Decyl)G-dD (SEQ ID NO:19), L-P-C-D-Y-Y-G-T-C-n(Decyl)G-D (SEQ ID NO:20), L-P-C-D-Y-Y-G-T-C-Bip-D (SEQ ID NO:21), L-P-C-D-Y-Y-G-T-C-Bip-dD (SEQ ID NO:22), L-P-C-D-Y-Y-G-T-C-MeL-Inp (SEQ ID NO:23), L-P-C-D-Y-Y-G-T-C-MeL-Cmp (SEQ ID NO:24), or L-P-C-D-Y-Y-G-T-C-MeBip-D (SEQ ID NO:25).
- Peptides having the formula of SEQ ID NO:26 were synthesized (structure confirmed by mass spectrometry) according to standard synthesis methods, such as those disclosed in WO 01/09188 or in WO 01/08712, and assayed for affinity to the DD(E) fragment of fibrin. Each peptide was found to have a Kd≦10 μM (Table 2).
TABLE 2 X01 X10 X11 L n(Decyl)G dD L n(Decyl)G D L MeL Inp L Bip D L Bip dD L Me-Bip D L MeL Cmp L Bip D L L D Cha Bip D - The ability of the peptides to bind a target such as HSA or fibrin can be assessed by known methodology. For example, affinity of the peptide for fibrin can be assessed using the DD(E) fragment of fibrin, which contains subunits of 55 kD (Fragment E) and 190 kD (Fragment DD). The DD(E) fragment can be biotinylated and immobilized via avidin to a solid substrate (e.g., a multi-well plate). Peptides can be incubated with the immobilized DD(E) fragment in a suitable buffer and binding detected using known methodology. See, for example, WO 01/09188.
- N- and C-Terminus Linker-Subunits and Linker
- If present, linker-subunits and linkers are used to covalently attach capping moieties such as chelates, thrombolytics, and other groups to the two ends of a peptide. A linker-subunit moiety can (i) convert the functionality of either the C-terminus carboxylate to an amine functional group or the N-terminus amine to a carboxylate functional group; or (ii) provide a spacer moiety or group between the peptide terminus and the linker, if present, or capping group. In one embodiment, a peptide can be reacted with a linker-subunit to form a modified peptide having a C-terminal amine functional group and a N-terminal amine functional group. In another embodiment, a peptide can be reacted with a linker-subunit to form a modified peptide having a N-terminal carboxylate functional group and a C-terminal carboxylate functional group.
- In another embodiment, a peptide can be synthesized from a C-terminal linker-subunit that is bound to a resin, whereby upon cleaving the peptide from the resin, a peptide having a C-terminal amine functional group is produced. In still another embodiment, a linker-subunit can be used as a spacer group and not to change the terminus functional group. A linker-subunit may have multiple functional groups for attachment of linker moieties or capping moieties. Many types of reactions can be used, including acylation, reductive amination, nucleophilic displacement reactions, urea formation, thiourea formation, and chemoselective ligation in chemically conjugating the linker-subunit to the peptide, linker, and/or capping moieties. One advantage of using a linker-subunit is to create similar functional groups on the peptide, thereby facilitating subsequent synthesis.
- The linker moiety can be used to covalently attach one or more capping moieties to the peptide terminus. The linker may be branched or unbranched and may comprise multiple functional groups for precursor chelate and chelate attachment. The chemical structure of the linker may affect the physical and pharmacological properties of the contrast agent, such as affinity, stability, blood half-life, relaxivity, and plasma protein binding. Linkers may be substituted with alkyl, aryl, alkenyl, or alkynyl groups. Linkers, if present, at each termini, typically are relatively small and rigid for MRI contrast agents. For example, a linker can have a molecular weight less than about 350 (e.g., less than about 200).
-
- The C-terminus carboxylate of a peptide may be converted to an amine functional group with a linker-subunit (e.g., a diamine synthon) to form a peptide having an amine functional group on each end of the peptide to which the remaining linker moiety can be attached. Examples of such peptides modified to have a C-terminal amine function group are:
- Wherein n=1 to 4.
-
-
-
- wherein “Base” is a purine or pyrimidine base (“Ad”=adenosine, “Gu”=guanosine, “Th”=thymine, “Cy”=cytosine) and “LG” is a leaving group such as OH, activated ester, halide, or anhydride.
-
- wherein n is an integer from 0 to 3, R is any aliphatic or aromatic group, and LG is a leaving group such as OH, activated ester, halide, and anhydride.
-
- wherein n is independently 1 or 2, R is any aliphatic or aromatic group, and LG is a leaving group such as OH, activated ester, halide, and anhydride.
- Examples of linker moieties that are useful when following an amide bond construction strategy in which a peptide molecule has two terminal amine groups include the following:
wherein each m is independently an integer from 1 to 4, n is independently an integer from 0 to 4 inclusive, LG is a leaving group, and R′ or R″ are independently hydrogen or a chemical protecting group. - A linker moiety also may have branch points for attachment of more than two chelates. For example, when following an amide bond formation strategy, a linker that includes a carbonyl with a leaving group LG (for example, a carboxylic acid or an activated ester) and three or more protected amines can be reacted with a peptide amine to create a molecule with three or more terminal amines. The following carbonyl-based linker reagents may be appropriate for introducing three or more amine functional groups:
- wherein LG is a leaving group (e.g., —OH, activated ester such as pentafluorophenol (Pfp), N-hydroxysuccinimide (NHS), N-hydroxysulfosuccinimide sodium salt (NHSS), 2-thioxothiazolidin-1yl, or hydroxybenzotriazole (HBT) and R1 and R2 are preferably independently hydrogen or a chemical protecting group (e.g., Boc, Fmoc, CBZ, t-butyl, benzyl, or allyl).
-
-
- wherein R is any aliphatic or aromatic group.
- Subsequently, both terminal carboxylates in the above examples may be simultaneously reacted with an amino group on a linker moiety as shown below to form a precursor MR imaging agent. In this example, the precursor MR imaging agent is a peptide molecule derivatized with linkers at both termini thru amide bonds:
- Specific examples of additional linker moieties useful for producing precursor MR imaging agents terminating with two carboxylates are:
wherein each m is independently 1 to 4 inclusive, n is independently 0 to 4 inclusive (e.g., n=1 or 2), and R is hydrogen or an appropriate chemical protecting group, such as methyl, ethyl, benzyl, or t-butyl. In these examples, following attachment of the linker-subunits, the protecting groups can be removed and chelating or precursor chelating moieties can be attached through standard methods, for example, amide bond formation. -
- wherein R1 and R2 are independently hydrogen or a chemical protecting group such as OS, Boc, Fmoc, CBZ, tbutyl, benzyl, or allyl.
- Linker strategies that involve formation of amide bonds are useful because they typically are compatible with the protecting groups on the peptide. As mentioned above, the peptide, linker, and linker-subunits may be covalently attached to each other by formation of other bond types (nucleophilic displacement, reductive amination and thiourea formation, for example).
- The linkers may also have effects on the properties of the contrast agents such as affinity, pharmacokinetic properties, stability in vivo, and relaxivity.
-
- wherein n=1 to 4, and R1, R2, R3, R4, and R5 are independently an acetate group, acetamide group, or an acetoxy group.
-
- wherein R1, R2, R3, R4, and R5 are independently an acetate group, acetamide group, or an acetoxy group.
-
-
- wherein LG is a leaving group, wherein R1, R2, R3, R4, and R5 are independently an acetate group, acetamide group, or an acetoxy group.
-
-
-
- In this example, “chelate” refers to bb-DTPA-Gd(III).
- The “Linker-subunit” above was varied with the following results (relaxivities per Gd(III) ion were determined at 20 MHz and 35° C., units are mM−1s−1):
N-terminal Relaxivity Relaxivity Fibrin Fibrin Affinity Linker-subunit PBS DD(E) (10 mg/mL) Structure 15 Ki = 4.0 μM11.7 18.7 Structure 16 Ki = 3.4 μM12.6 29.5 Structure 32 Ki = 4.7 μM(direct bond) 12.5 21.6 - As shown above,
structures - Chelating Moieties and Reagents
- Chelating moieties are chelating ligands complexed with metal ions. These chelating moieties contain a synthetic moiety capable of forming a point of attachment to the linker, linker-subunit, and/or modified peptide. One or more chelating moieties may be covalently conjugated to the functional group at each terminus of the modified peptide. In one embodiment, the chelate is attached to a linker-subunit. In another embodiment, the chelate is attached to a linker moiety. In other embodiments, the chelate may be conjugated with a linker moiety to form a covalent conjugate before attaching the covalent conjugate to the modified peptide.
- Precursor chelating moieties are chelating ligands that have not been complexed with metal ions. Chelating ligands may have protecting groups or may be precursors to chelating ligands. Precursor chelating moieties have a synthetic moiety capable of forming a point of attachment to the linker, linker-subunit, and/or modified peptide. Precursor chelating moieties can be converted into chelating moieties by complexing with a metal ion. One or more precursor chelate moieties may be covalently conjugated to the functional group at each terminus of the modified peptide. In one embodiment, the precursor chelate can be attached to a linker-subunit. In another embodiment, the precursor chelate is attached to a linker moiety. In other embodiments, the precursor chelate may be conjugated with a linker moiety to form a covalent conjugate before attaching the covalent conjugate to the modified peptide.
-
- wherein X is a heteroatom electron-donating group capable of coordinating a metal cation, such as O−, OH, NH2, OPO3 2−, NHR, or OR, wherein R is any aliphatic group; R1 is an uncharged chemical moiety, selected from hydrogen, any aliphatic, alkyl group, or cycloalkyl group, or uncharged substituted versions thereof (e.g. alcohols); and Y is a synthetic moiety (e.g., capable of forming a point of attachment, or being the point of attachment, to the functional group of the modified peptide, linker, and/or linker-subunit either directly or with an intervening carbonyl, methylene, methylene-oxygen, thiocarbonyl). Moieties with (chelate moiety) or without (precursor chelate moiety) a coordinated metal ion may be used.
- A variety of chelating ligands may be used in contrast agents of the invention. Such chelating ligands include, but are not limited to, derivatives of DTPA, DOTA, NOTA, and DO3A. For MRI, metal chelates such as gadolinium diethylenetriaminepentaacetate (DTPA.Gd),
gadolinium tetraamine gadolinium - Examples of functionalized chelates that have been synthesized for the purpose of preparing multimeric chelates include pNCS-Bz-DTPA [Martin, V., et al. Bioconjugate Chem. 6,616-23, 1995] and Gd(4-NCS-phenyl)-amino-carbonylmethyl-DO3A [Ramachandran, R. et al., Invest. Rad. 1998, 33(11), 779-797]. For optimal relaxivity properties when bound to a target, it is frequently desirable to minimize chelate motion, and hence, a minimal number of covalent bonds linking the target to the chelating ligand are desirable. Below is an example of a reagent that includes a chelating ligand with a backbone carbonyl group for connecting to an amine functional group or a linker-subunit or linker, wherein “LG” is a leaving group (e.g., an activated ester) and R represents a group which may be easily cleaved to form O− (-OtBu, e.g. a carboxylate ester) thereby forming a carboxylate with the neighboring carbonyl group:
- It has been found that the chemical motif of a carbonyl immediately adjacent to a chelating ligand constitutes a class of high relaxivity MRI contrast agents.
-
-
- wherein P is any protecting group, including benzyl and tert-butyl groups. LG is a “leaving group” and represents —OH and ester forms thereof including, NHS esters, pentafluorophenol, and other activated esters.
-
-
- (vide Syn. Comm. 30, 3755 (2000).)
- The present invention also provides methods of manufacturing compounds. In particular, a novel oxidation reaction permits the facile preparation of
Synthon # 3, a preferred embodiment of a chelating ligand. The synthesis ofSynthon # 3 can be achieved through two different synthetic routes, both commencing with hydroxymethyl-diethylenetriamine. One route involves a two synthetic step sequence (alkylation, followed by oxidation) and the other involves a six-step process (protection, oxidation, esterification, deprotection, alkylation and hydrogenolysis). Both produceSynthon # 3 in high chemical and optical purity (vide Examples, below). - U.S. Pat. No. 5,637,759 discloses a synthesis of
Synthon # 1 from 2,3-diaminopropionic acid and aza-lysine by a selective hydrolysis protocol with sodium thiophenoxide. The method disclosed herein avoids the use of this toxic reagent. - Synthesis of Contrast Agents
- Synthesis of the peptide-based contrast agents may be carried out in the following steps. First, a targeting peptide can be synthesized with or without a C-terminal linker-subunit, typically using solid phase peptide synthesis. For cyclic peptides described herein, a protected linear peptide may be cyclized in solution or on the resin. Unprotected peptide may also be cyclized in solution or on resin. A C-terminal linker-subunit may be conveniently derived from the solid phase synthesis resin and an N-terminus linker or N-terminal linker-subunit can be coupled to the peptide during the solid phase synthesis. Typically, following cyclization, the linker-subunit-chelate precursor moieties were coupled to the peptide. Protecting groups were removed to provide the ligand precursors, and then chelates were prepared. Radionuclide compounds of this invention were prepared from ligand precursors using commercially available radionuclides (for example, 99mTc from Nycomed Amersham Boston cat. #RX-290195, 111In from NEN Life Science Products cat. # NEZ304, or 153Gd from NEN Life Science Products cat. # NEZ142) by reaction in aqueous media, typically at pH 4-6 for 1 hour. In the case of optical contrast agents, an organic dye may be substituted for a chelate precursor.
Structure of Contrast Agents:
Properties of Contrast Agents - Compounds of this invention can be more stable with respect to degradation by endogenous enzymes than the parent peptide (i.e., the peptide without any attached chelates), a peptide with one or more chelates attached to the N-terminus, or a peptide with one or more chelates attached to the C-terminus. To estimate in vivo stability, test compounds can be incubated with rat liver homogenates. After selected intervals, the reactions can be quenched and centrifuged, and the supernatant can be analyzed by liquid chromatography-mass spectrometry to quantitate the amount of compound remaining.
- Compounds of the invention also can bind a target such as human serum albumin or fibrin. For example, at least 10% (e.g., at least 50%, 80%, 90%, 92%, 94%, or 96%) of the contrast agent can be bound to the desired target at physiologically relevant concentrations of drug and target. The extent of binding of a contrast agent to a target, such as HSA or fibrin, can be assessed by a variety of equilibrium binding methods. For example, binding to HSA can be measured by ultrafiltration. For measuring binding to fibrin, a fibrin clot may be formed in a well of a microtiter plate and contacted with the targeting group. After an incubation time sufficient to establish equilibrium, the supernatant is removed by aspiration (the insoluble fibrin remains bound as a gelled clot to the bottom of the well). The concentration of unbound targeting group in the supernatant is then measured. In both methodologies, the concentration of bound contrast agent is determined as the difference between the total targeting group concentration initially present and the unbound targeting group concentration following the binding assay. The bound fraction is the concentration of bound targeting group divided by the concentration of total targeting group.
- Compounds of the invention can exhibit high relaxivity as a result of target binding (e.g., to fibrin), which can lead to better image resolution. The increase in relaxivity upon binding is typically 1.5-fold or more (e.g., at least a 2, 3, 4, 5, 6, 7, 8, 9, or 10 fold increase in relaxivity). Targeted contrast agents having 7-8 fold, 9-10 fold, or even greater than 10 fold increases in relaxivity are particularly useful. Typically, relaxivity is measured using an NMR spectrometer. The preferred relaxivity of an MRI contrast agent at 20 MHz and 37° C. is at least 10 mM−1s−1 per paramagnetic metal ion (e.g., at least 15, 20, 25, 30, 35, 40, or 60 mM−1s−1 per paramagnetic metal ion. Contrast agents having a relaxivity greater than 60 mM−1s−1 at 20 MHz and 37° C. are particularly useful.
- As described herein, targeted contrast agents can show an increase in clot uptake. Specificity of uptake of fibrin-targeted agents can be determined by comparing the uptake of the agent by blood clots to the uptake by blood. See Example 11 for more details. The specificity of fibrin-targeted contrast agents also can be demonstrated using MRI and observing enhancement of clot signal.
- Use of Peptides and Contrast Agents of the Invention
- Peptides of the invention can be used to improve therapies for treating thromboembolic disease. Current thrombolytic therapy has limitations, including a significant risk of bleeding, failure to restore blood flow, thrombotic reocclusion after cessation of therapy, and a lag between initiation of therapy and clot lysis. An improved therapeutic index can be achieved by conjugating a fibrin targeting peptide of the invention to a thrombolytic agent (e.g., a protein thrombolytic such as plasminogen activators of human or bacterial origin). Such conjugates can activate plasminogen locally or increase endogenous levels of tPA. For example, a fibrin targeting peptide can be conjugated to human plasminogen activators including recombinant tissue type plasminogen activator (tPA), prourokinase and urokinase (both single and two chain forms), bacterium derived plasminogen activator including streptokinase, staphylokinase, and animal derived plasminogen activators, including vampire bat plasminogen activator. In addition, fibrin targeting peptides can be conjugated to fibrinolytics such as copperhead snake fibrolase, which exhibits direct fibrinolytic activity. Such enzymes and proteins can be obtained commercially, extracted from natural sources or tissues, or prepared recombinantly.
- The compositions of the invention can be linked or fused in known ways, using the same type of linkers discussed above with respect to constructing MRI contrast agents. Conjugation to a protein can be achieved by standard chemical techniques including the formation of amide, ester, disulfide, and thioether bonds. For example, a fibrin binding peptide can be covalently linked, either directly or through a linker, to a protein by forming an amide bond between the fibrin binding peptide or the linker and the lysine residues on the surface of the protein. These surface lysine residues are usually distant from the enzyme's catalytic site. Therefore, the tethered moieties do not interfere with the enzyme's catalytic activity. Multiple ligation can be achieved in a single step. The ratio of the fibrin targeting peptide to the thrombolytic or fibrinolytic agent can be controlled by adjusting the stoichiometry of the ligation chemistry. Multiple ligation is particularly useful in the case of a moderately strong fibrin binding ligand because higher binding affinity can be realized through the so called “avidity” effect. In particular, a coupling agent or an activated ester can be used to achieve amide bond formation between the lysine and the fibrin binding moiety or the linker. The below scheme shows an example of a hybrid molecule formed by chemical ligation of urokinase to multiple fibrin binding peptides via linker moieties. The number of surface lysine residues and the number of fibrin binding molecules are illustrative. Alternatively, the fibrin targeting peptide can be incorporated into the hybrid molecule using recombinant DNA technology.
- In some embodiments, peptides of the invention can be linked to a thrombolytic agent with a linker encompassing an enzymatic cleavage site, e.g., an enzymatic cleavage site normally cleaved by enzymes in the coagulation cascade, such as Factor Xa, thrombin, or plasmin cleavage sites, etc. The thrombolytic agent is not activated until it is cleaved from the clot binding compositions of the invention at the site of the clot, the risk of unwanted bleeding events at sites distant from the clot would be minimized. Furthermore, thrombolytic moieties can be linked to a peptide-targeted multimeric contrast agent such that a clot can be identified, imaged and dissolved.
- Contrast agents prepared according to the disclosures herein may be used in the same manner as conventional MRI contrast agents and are useful for the diagnosis of deep vein thrombosis, pulmonary embolus, coronary thrombosis, carotid and intracranial thrombosis, atrial and ventricular thrombi, aortic arch thrombi, and high risk plaque. When imaging a thrombus, certain MR techniques and pulse sequences may be preferred to enhance the contrast of the thrombus compared to the background blood and tissues. These techniques include, but are not limited to, black blood angiography sequences that seek to make blood dark, such as fast spin echo sequences and flow-spoiled gradient echo sequences. These methods also include flow independent techniques that enhance the difference in contrast due to the T1 difference between contrast-enhanced thrombus and blood and tissue, such as inversion-recovery prepared or saturation-recovery prepared sequences that will increase the contrast between thrombus and background tissues. Methods of preparation for T2 techniques may also prove useful. Finally, preparations for magnetization transfer techniques may also improve contrast with agents of the invention.
- Compositions of the invention, including peptides, peptides conjugated to thrombolytics, and peptide-targeted multimeric contrast agents, can be formulated as a pharmaceutical composition in accordance with routine procedures. As used herein, the compounds of the invention can include pharmaceutically acceptable derivatives thereof. “Pharmaceutically acceptable” means that the compound or composition can be administered to an animal without unacceptable adverse effects. A “pharmaceutically acceptable derivative” means any pharmaceutically acceptable salt, ester, salt of an ester, or other derivative of a compound of this invention that, upon administration to a recipient, is capable of providing (directly or indirectly) a compound of this invention or an active metabolite or residue thereof. Other derivatives are those that increase the bioavailability of the compounds of this invention when such compounds are administered to a mammal (e.g., by allowing an orally administered compound to be more readily absorbed into the blood) or which enhance delivery of the parent compound to a biological compartment (e.g., the brain or lymphatic system) thereby increasing the exposure relative to the parent species. Pharmaceutically acceptable salts of the compounds of this invention include counter ions derived from pharmaceutically acceptable inorganic and organic acids and bases known in the art.
- Pharmaceutical compositions of the invention can be administered by any route, including both oral and parenteral administration. Parenteral administration includes, but is not limited to, subcutaneous, intravenous, intraarterial, interstitial, intrathecal, and intracavity administration. When administration is intravenous, pharmaceutical compositions may be given as a bolus, as two or more doses separated in time, or as a constant or non-linear flow infusion. Thus, compositions of the invention can be formulated for any route of administration.
- Typically, compositions for intravenous administration are solutions in sterile isotonic aqueous buffer. Where necessary, the composition may also include a solubilizing agent, a stabilizing agent, and a local anesthetic such as lidocaine to ease pain at the site of the injection. Generally, the ingredients will be supplied either separately, e.g. in a kit, or mixed together in a unit dosage form, for example, as a dry lyophilized powder or water free concentrate. The composition may be stored in a hermetically sealed container such as an ampule or sachette indicating the quantity of active agent in activity units. Where the composition is administered by infusion, it can be dispensed with an infusion bottle containing sterile pharmaceutical grade “water for injection,” saline, or other suitable intravenous fluids. Where the composition is to be administered by injection, an ampule of sterile water for injection or saline may be provided so that the ingredients may be mixed prior to administration. Pharmaceutical compositions of this invention comprise the compounds of the present invention and pharmaceutically acceptable salts thereof, with any pharmaceutically acceptable ingredient, excipient, carrier, adjuvant or vehicle.
- A contrast agent is preferably administered to the patient in the form of an injectable composition. The method of administering a contrast agent is preferably parenterally, meaning intravenously, intra-arterially, intrathecally, interstitially or intracavitarilly. Pharmaceutical compositions of this invention can be administered to mammals including humans in a manner similar to other diagnostic or therapeutic agents. The dosage to be administered, and the mode of administration will depend on a variety of factors including age, weight, sex, condition of the patient and genetic factors, and will ultimately be decided by medical personnel subsequent to experimental determinations of varying dosage followed by imaging as described herein. In general, dosage required for diagnostic sensitivity or therapeutic efficacy will range from about 0.001 to 50,000 μg/kg, preferably between 0.01 to 25.0 μg/kg of host body mass. The optimal dose will be determined empirically following the disclosure herein.
- With respect to treatment of thrombolytic conditions, the quantity of material administered will depend on the seriousness of the thromboembolic condition and position and the size of the clot. The precise dose to be employed and the mode of administration can be decided according to the circumstances by the physician supervising treatment. In general, dosages of the combined composition/thrombolytic agent conjugate will follow the dosages that are routine for the thrombolytic agent alone, although the improved affinity for fibrin/clot binding added by the compositions disclosed herein may allow a decrease in the standard thrombolytic dosage. Particular thrombolytics contemplated for use in this therapy (with examples of dose and method of administration) are as follows:
Streptokinase 1-3 megaunits over 30 minutes to 3 hrs Anistreplase 30 units; 2-5 minute injection tPA (wild-type) 50-150 mg; infusion over up to 6 hrs Two-chain urokinase (40-100 mg); infusion over up to 6 hrs Single-chain urokinase 3-12 megaunits (30-100 mg; infusion (scuPA) over up to 5 hrs Hybrid plasminogen 20-100 mg; injection or infusion activators and derivatives Muteins of plasminogen 10-100 mg; injection or infusion activators - The invention will be further described in the following examples, which do not limit the scope of the invention described in the claims.
- Synthesis, characterization, and use of several high relaxivity contrast agent compositions of the invention will be further illustrated in the following examples. The specific parameters included in the following examples are intended to illustrate the practice of the invention, and they do not in any way limit the scope of the invention. Those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, many equivalents to the specific embodiments and methods described herein. Such experiments are intended to be encompassed by the scope of the claims.
- The peptide with linker-subunit moiety bound to C-termin us (P-[linker-subunit moiety]). The unprotected peptide was prepared using standard Fmoc strategy and a diaminotrityl resin. The peptide was cyclized using thallium trifluoroacetate on the resin or in solution. After being cleaved from the resin, the unprotected peptide was purified by RP-HPLC (C-18 column, H2O/CH3CN/TFA).
- Linker Moiety: To a solution of Boc-Dpr(Boc)-OH.DCHA (1 eq.) and pentafluorophenol (1.2 eq.) in dichloromethane was added PS-carbodiimide (1.2-1.5 eq.). The mixture was shaken for 3-5 h at room temperature. After LC-mass results indicated the reaction was complete, the resin was removed by filtration and the solvent was evaporated under reduced pressure to give the crude Linker Moiety (Boc-Dpr(Boc)-OPft (N-α-Boc-N-β-Boc-L-diaminopropionic acid pentafluorophenyl ester, 356-128) as a white foam.
- Precursor MR Imaging Agent: To a solution of P-[linker-subunit moiety] (1 eq.) and the Linker Moiety {Boc-Dpr(Boc)-Opft} (2.2 eq.) in DMF was added DIPEA (4-6 eq.). The mixture was stirred overnight at room temperature. After LC-mass results indicated the reaction was complete, the solvent was removed under reduced pressure. The crude product was then stirred in a mixture of TFA, water and anisole (90%/5%/5%) at room temperature for 3 h. Diethyl ether was added and a white precipitate formed, which was purified by RP-HPLC (C-18 column, H2O/CH3CN/TFA) to give the Precursor MR Imaging Agent (tetrakisamino-peptide as a white solid.
- Precursor Chelate Moiety: DOTAGA-Opft. To a solution of DOTAGA-OH (1 eq.) and pentafluorophenol (1.2 eq.) in dichloromethane was added PS-carbodiimide (1.2-1.5 eq.). The mixture was shaken for 3-5 h at room temperature. After LC-mass results indicated the reaction was complete, the resin was removed by filtration and the solvent was evaporated under reduced pressure to give the crude Precursor Chelate Moiety as a white foam.
- MR Imaging Agent. To a solution of the Precursor MR Imaging Agent (1 eq.) and Precursor Chelate Moiety (4.0 eq.) in DMF was added DIPEA (4.0 eq.). The mixture was stirred overnight at room temperature. After LC-mass results indicated the reaction was complete, the solvent was removed under reduced pressure.
- The crude product was then stirred in a mixture of TFA, phenol, methylsulfonic acid, anisole and dichloromethane (90%/2.5%/2.5%/2.5%/2.5%) for 15 min. at room temperature. Diethyl ether was added and a white precipitate formed and was collected as the crude product.
- The crude product was reacted with GdCl3.H2O in deionized water to form the crude MR imaging agent, which was purified using RP-HPLC (C-18 column, Ethanol/50 mmol AcONH4). Appropriate fractions were combined and the ethanol removed under reduced pressure, and then the combined fractions were treated with sodium acetate for salt exchange. After lyophilization the excess salts were removed using reverse-phase chromatography on a Waters Sep-Pak® C-18 cartridge with water and ethanol:water (50:50) eluants. Appropriate fractions were combined, the ethanol removed under reduced pressure, and the solution was lyophilized to give the desired peptide MR imaging agent as a white solid.
- Similar methods were used to synthesize other MR imaging agents.
-
- Hydroxymethyl-diethylenetriamine of the indicated stereochemistry trihydrochloride (25.15 g) (optically pure starting material: Syn. Comm. 29(14), 2377-2391 (1999), racemic starting material: Coll. Czech. Chem. Comm. 34, 630-634 (1969)) was dissolved in a deionized water/1,4-dioxane mixture and the pH of the solution was adjusted to between 8 and 9 with aqueous sodium hydroxide. Di-tert-butyl dicarbonate (3.5 equiv.) was dissolved in dioxane and added between 10 and 20° C. The reaction mixture was stirred between 12 and 20 hours at room temperature. The reaction mixture was then diluted with water, and extracted with ethyl acetate. The organic extract was extracted sequentially with water, saturated sodium bicarbonate, and saturated sodium chloride solutions. The organic extract was dried over sodium sulfate, filtered, and concentrated under in vacuo to provide an oil which was purified by silica gel chromatography with a mixture of ethyl acetate:hexane. The total yield of purified product was 30.11 g. 1H NMR (300 MHz): 5.18 (d, J=7.9 Hz, 1H), 4.76 (bs, 1H), 3.8-3.0 (m, 10H), 1.47-1.42 (2s, 27H). MS (m/Z): 456.4 [M+Na]+.
-
- BOC-protected triamine (29.94 g) was dissolved in acetonitrile. Phosphate buffer, consisting of 21.6 g NaH2PO4, 21.6 g Na2HPO4 and enough deionized water to produce a 500 mL volume, was added (300 mL), followed by 2,2,6,6-tetramethylpiperidinyl-1-oxy (TEMPO) (0.07 equiv.). The mixture was stirred vigorously and warmed to 35° C. Sodium chlorite (2.0 equiv.) was dissolved in deionized water (100 mg/ml). The sodium chlorite solution and bleach (0.02 equiv., approx. 0.25% aqueous sodium hypochlorite) were added while maintaining a constant temperature. After addition of oxidant, the reaction was stirred for 24 hours. Additional TEMPO (0.07 equiv.) was added and the reaction mixture was stirred for 24 hours. The reaction was cooled to room temperature. Water was added and the pH was adjusted to 8 with 2.0 N aqueous NaOH. A cold solution of aqueous sodium sulfite was added (300 mL) while maintaining a constant pH. The solution was extracted with a small volume of methyl tert-butyl ether and set aside. The aqueous layer was acidified to pH 3-4 with 2.0 N aqueous HCl and extracted with two small volumes of methyl tert-butyl ether. The organic extract was combined with the one previously set aside and concentrated in vacuo. The product was used without purification in
Step 3 below. 1H NMR (300 MHz): 5.8 (bs, 1H), 5.3 (m, 1H), 4.4 (M, 1H), 3.6-3.2 (m, 6H), 1.47-1.43 (2s, 27H). MS (m/Z): 470.2 [M+Na]+. - The carboxylic acid starting material (178 g) was dissolved in dry DMF. Cesium carbonate (2.0 equiv.) was added, and the solution was stirred for 30 minutes. Benzyl bromide (1.1 eq.) was added dropwise at room temperature. The reaction mixture was stirred under an inert atmosphere for 18 hours. The reaction mixture was diluted with water and extract twice with ethyl acetate. The organic layers were combined and washed sequentially with saturated sodium bicarbonate and sodium chloride solutions. The organic layer was concentrated to an oil (270 g) which was purified by silica gel chromatography using ethyl acetate:hexane. 1H NMR (300 MHz): 7.3 (s, 5H), 5.6 and 5.15 (2bs, 1H), 5.1 (s, 2H), 4.5 (bs, 1H), 4.0-4.1 (m, 1H), 3.5-3.2 (m, 6H), 1.45 and 1.4 (2s, 27H). MS (m/Z): 560.3 [M+Na]+.
- The BOC-protected triamine (250 g) was stirred in a solution of 1:1 acetonitrile:4 N aqueous HCl and allowed to stir for approximately 2.0 hours. The acetonitrile was removed in vacuo and the remaining solution was lyophilized to provide a residue that was immediately dissolved in DMF and diisopropylamine (a sufficient amount to raise the pH to 8). Tert-Butyl bromoacetate was added (12.0 equiv.). After the addition was complete, the reaction mixture was warmed to 50° C. and stirred for 18 hours. Upon completion of reaction the volume of the reaction mixture was doubled by the addition of water, after which it was extracted twice with ethyl acetate. The organic extracts were combined and washed sequentially with water, saturated sodium bicarbonate, and saturated sodium chloride solutions. The organic solution was concentrated in vacuo to an oil which was purified by silica gel chromatography using ethyl acetate:hexane. The total yield of purified product was 190 g. MS (m/Z): 809.5 [M+Na]−.
- A stainless steel reactor was charged with benzyl ester (157 g), 10% palladium on carbon (19.8 g) and ethyl acetate and hydrogenated at 45 psi for 12 hours. Filtration through Celite® and concentration in vacuo gave an oil. The oil was dissolved in ethyl acetate/hexanes and purified by silica gel chromatography to provide the DTPA carboxylic acid penta-tert-butyl ester(yield: 82%). MS (m/Z): 719.5 [MH]+. When this reagent is used in the synthesis of contrast agents using other chiral elements, no diastereomers are observed and therefore it is concluded that this material is essentially optically pure to the limit of detection by ordinary proton NMR.
- Alcohol (see Syn. Comm. 29(14), 2377-2391 (1999) for a synthesis from hydroxymethyl-diethylenetriamine) starting material (105.0 g), acetonitrile (1.0 L), phosphate buffer (1.0 L, prepared by dissolving 100 mg of NaH2PO4 and 10 mg of Na2HPO4 into 1.0 mL of water and then adjusting the pH to 4.5 with H3PO4) and TEMPO (7.0 g) were combined and warmed to between 45 and 50° C. A solution consisting of sodium chlorite (29.8 g dissolved in 298 mL of water) and sodium hypochlorite (744 μL) was added to the solution while maintaining a temperature of 45 to 50° C. The reaction mixture was stirred vigorously for 4 to 10 hours. The reaction mixture was cooled to room temperature and two layers were separated. The organic layer was isolated and combined with saturated aqueous sodium chloride and stirred for 15 minutes. The organic layer was isolated and concentrated in vacuo to give an oil (171 g) which was purified by column chromatography using hexane:isopropanol with 0.1% triethylamine throughout to provide 81 g of enriched product as an oil. MS (m/Z): 719.5 [MH]+. The optical purity of material produced by this method did not differ from that above.
- The peptides have been prepared by solid-phase synthesis. In solid-phase synthesis, the linkers and resins are selected depending on the type of the peptides to be synthesized (e.g., the functional group required at the C-terminus, the protected or unprotected peptide) and the synthetic method to be used (e. g. Fmoc or BOC chemistry, manual or automated synthesis, the continuous flow or batch reactor). For example, in the synthesis of a peptide with a carboxylic group at the C-terminus, a protected-amino acid is attached to the different resins such as HMPB resins, 2-chlorotritylchloride resin and SUSRIN resin. On the other hand, in the synthesis of a peptide with an amino group at the C-terminus, a diamine can be attached to a trityl resin. The polystyrene (PS) resins can be used for batch synthesis, while polyethyleneglycol (PEG) modified resins are suitable for continuous flow and batch synthesis. Many trityl PS resins including 1,3-bis-(aminomethyl)-benzene trityl PS resin are commercially available. If the required trityl PS resin is not available, a similar procedure as described for PEG resins can be used to attach a diamine to a trityl PS resin.
- The synthesis of 1,3-bis-(aminomethyl)-benzene trityl resin is discussed as an example. Other diamines can be attached to trityl resin in a similar manner.
-
- First, trityl alcohol resin (25 g, NovaSyn TGT resin, NovaBiochem) was placed in a funnel and washed sequentially with DMF, CH2Cl2, and toluene. After removing all solvent, the material was transferred to a flask equipped with a reflux condenser. Toluene (250 mL) and acetyl chloride (25 mL) were added and the slurry was heated to 70° C. and stirred for 1.0 hour. An additional portion of acetyl chloride (25 ml) was added and the slurry was stirred for 2.0 hours at 70° C. The slurry was filtered and the resin washed sequentially with toluene and CH2Cl2.
- Second, freshly prepared trityl chloride resin and THF (250 mL) was placed in a flask. To the slurry was added 1,3-bis-(aminomethyl)-benzene (10 eq., based on a resin substitution of 0.23 mmol/g) and the mixture was stirred for 18.0 hours at room temperature. The slurry was filtered and the resin was washed sequentially with water, DMF, CH2Cl2, methanol, and CH2Cl2. The resin was dried under vacuo (room temperature, 1-5 mm Hg) to a constant weight (25.4 g). The substitution stoichiometry was conducted using a quantitative ninhydrin procedure.
-
- A solution of cesium carbonate (6.5 g) and water was added to 2,3-bis-tert-butoxycarbonylamino propionic acid (3.04 g) in acetonitrile (25 ml). The mixture was stirred for 40 minutes at room temperature. The solvent was removed under vacuum. DMF (50 ml) was added to the solid residue. A solution of benzyl bromide (1.43 ml) and DMF (5.0 ml) was added over 15 minutes at room temperature. The mixture was stirred for 18 hours, and then the mixture was diluted with ethyl acetate (100 ml) and water (50 ml) and stirred for 15 minutes. The layers were separated and the organic layer was dried over sodium sulfate. The mixture was filtered, and the filtrate was concentrated under vacuum to give an oil (3.6 g). The oil was purified by column chromatography with ethyl acetate/hexane to provide an oil (1.8 g). MS (m/Z): [M+Na]+=417. 1H NMR (300 MHz): 1.4 (s, 9H), 2.4 (m, 2H), 4.4 (m, 1H), 4.8 (m, 1H), 6.5 (m, 1H), 7.3 (m, 5H).
- A solution of 2,3-bis-tert-butoxycarbonylamino propionic acid benzyl ester (1.8 g), 4N aqueous HCl (40 ml), and acetonitrile (50 ml) was stirred for 18 hours at room temperature. The solvent was removed under vacuum, and the mixture was diluted with ethyl acetate (100 ml) and water (50 ml) and stirred for 15 minutes. The layers were separated and the aqueous layer was evaporated to dryness (1.23 g of a foam/syrup). 1H NMR (300 MHz): 3.2-3.5 (m, 2H), 4.2-4.35 (m, 1H), 5.13-5.25 (q, 2H, J=11.8, 3.1 Hz).
- A solution of 2,3-diamino-propionic acid trihydrochloride (6.65 g), bb(CO)DTPE (40.0 g, “
Synthon 3”), HOBt (8.5 g), DIC (9.0 ml), diisopropylethylamine (15.0 ml), CH2Cl2 (400 ml) and DMF (200 ml) was stirred for 48 hours. The mixture was diluted with methylene chloride (500 ml) and water (250 ml), and then stirred for 15 minutes. The layers were separated and the organic layer was washed with saturated sodium carbonate (250 ml), saturated sodium chloride (250 ml) and dried over sodium sulfate. The mixture was filtered and the filtrate was concentrated in vacuo to obtain an oil. The oil was purified by silica gel chromatography using ethyl acetate and hexanes to obtain 28.0 g of material. MS (m/Z): [M+2]+=798; [M+1]+=1595. - Hydrogenation of 2,3-bis-carboxy-DTPA propionic acid benzyl ester (17.0 g) was performed in ethyl acetate/triethylamine (10:3) using 10% palladium on carbon (6.0 g) catalyst for 24 hours at 50 psi. The vessel was purged with nitrogen and the mixture was filtered through Celite®, and concentrated under reduced pressure to give 16.0 g of an oil. MS (m/Z): [M+2]+=753; [M+1]+=1504.
- To a solution of diethylenetriamine (3.16 ml), acetonitrile (700 ml), and diisopropylethylamine (10.4 ml) was added pre-reacted (30 min) bb(CO)DTPE (42.0 g, “
Synthon 3”), HOBt (7.9 g), EDC (11.2 g) and diisopropylethylamine (10 ml) in acetonitrile at room temperature. The reaction was stirred for 16.0 hours and then concentrated under reduced pressure. The oil was combined with ethyl acetate, extracted with water and saturated aqueous sodium chloride and then concentrated. The oil was purified by silica gel column chromatography using hexanes/isopropanol/triethylamine to provide 22.5 g of product. MS (m/Z): [M+H]+=1503. - Benzyl-2-bromoacetate (2.54 g) was added to a solution of the previous amine compound (13.5 g), acetonitrile (200 ml) and sodium carbonate (118 g). The mixture was warmed to 60° C. and stirred for 15 hours. The reaction mixture was cooled to room temperature and concentrated under reduced pressure. Ethyl acetate and water were added, the layers were separated. The organic layer was washed with saturated aqueous sodium chloride, then concentrated under reduced pressure to give an oil (14.5 g). MS (m/Z): [M]+=1651.
-
- To a solution of diethylenetriamine (2.12 g, 20.6 mmol) and triethylamine (30.0 g, 41.3 mmol) in THF (100 mL) was added Boc-ON (10.65 g, 43.3 mmol) at room temperature. The mixture was stirred for overnight. To the mixture was added 700 mL of ether and then extracted with phosphate buffer (pH=3, 100 mmol). The aqueous solution was basified to pH=11 and extracted with dichloromethane. The organic layer was separated and dried over anhydrous sodium sulfate. The salts were filtered and the solvent was removed under the reduced pressure to give the indicated compound as a colorless oil (5.55 g). MS (m/Z): [M+H]+=304.1.
- To a solution of the compound above (1.0 g, 3.30 mmol) in methanol (40 mL) was added benzyl acrylate (1.07 g, 6.59 mmol) at room temperature. The mixture was refluxed for 3 days. The solvent was removed at reduced pressure to give a yellow liquid that contains the indicated compound and benzyl acrylate. MS (m/Z): [M+H]+=466.1.
- To a mixture of the compound above and benzyl acrylate (1.0 g) in dichloromethane (25 mL) was added TFA (13.8 mL) at room temperature. The mixture was stirred for 3 h at room temperature and then to the mixture was added 1N HCl and water. The aqueous layer was separated and lyophilized to give the indicated compound (420 mg) as a sticky solid. MS [m/Z]: [M+H]+=266.2.
- To a solution of the above compound, “
Synthon 3”, HOBt and diisopropylethylamine, in CH2Cl2 and DMF is added DIC. The mixture is stirred for 48 h at room temperature. The mixture is diluted with dichloromethane and water, and then stirred for 15 minutes. The layers are separated and the organic layer is washed with saturated sodium carbonate, saturated sodium chloride and dried over sodium sulfate. The mixture is filtered and the filtrate is concentrated in vacuo to obtain an oil. The oil is purified by silica gel chromatography using ethyl acetate and hexanes to obtain the indicated compound. - A hydrogenation vessel is charged with the above compound, 10% palladium on carbon, ethyl acetate, and triethylamine. The vessel is purged with nitrogen then hydrogen. The mixture is shaken for 24 hours under a hydrogen atmosphere (50 psi). The vessel is purged with nitrogen and the mixture is filtered through Celite®, and the filtrate is concentrated under reduced pressure to give the product as an oil.
- Methyl-2-(bromomethyl)-acrylate (1.00 g, 5.6 mmol, 1.0 eq.) dissolved in acetonitrile (20 mL) was added drop-wise with stirring at room temperature to a solution of benzylamine (1.83 mL, 16.8 mmol, 1.5 eq.) in anhydrous acetonitrile (10 mL). After 16 hours, ether (100 mL) was added, and the white solid (benzylamine hydrobromide) was filtered. The filtrate was concentrated under reduced pressure to give 1.90 g of a crude oil. The oil was dissolved in ethyl acetate (150 mL) and washed with H2O and NaCl brine. The organic layer was dried (MgSO4), and evaporated under reduced pressure. The resulting clear oil was purified by flash chromatography (hexanes:ethyl acetate) to give 1.38 g (79%) of the product. 1H NMR (300 MHz, CDCl3): δ 1.68 (s, 2H), 2.79-2.90 (m, 5H), 3.68 (s, 3H), 3.75 (s, 3H), 7.21-7.32 (m, 10H).
- Methyl 3-(benzylamino)-2-((benzylamino)methyl)-proprionate (2.27 g, 7.3 mmol, 1.0 eq) was dissolved in methylene chloride (20 mL) and 4.0 mL of a 4M solution of HCl in dioxane was added. The solution was stirred at room temperature for 20 minutes and solvents were then evaporated under reduced pressure to give a white powder that was dissolved in 50 mL MeOH. Catalyst (10% Palladium on carbon catalyst, 750 mg) was added at 0° C. under argon and the mixture was shaken at 45 psi H2 for 18 hours, then filtered through Celite®. The product (1.47 g) was isolated following a MeOH was and evaporation under reduced pressure. 1H NMR (300 MHz, D2O): δ 3.25-3.43 (m, 5H), 3.82 (s, 3H).
- Diamine (1.44 g) was reacted with di-tert-butyl dicarbonate (3.22 g, 14.8 mmol, 1.05 eq.) in dioxane/aqueous Na2CO3 at
solution 0° C. for 1 hour and then room temperature for 18 hours. The mixture was then acidified (pH=4) with 0.5N KHSO4 and dioxane was evaporated under reduced pressure. The aqueous portion was extracted with ethyl acetate, dried over MgSO4 and concentrated under reduced pressure to give a crude oil that was purified by flash chromatography (hexanes:ethyl acetate) to give 1.86 g (80%) of the desired. NMR (300 MHz, CDCl3): δ 1.41 (s, 18H), 2.66-2.78 (m, 1H), 3.10-3.27 (m, 2H), 3.50-3.62 (m, 2H), 3.68 (s, 3H), 5.17-5.27 (bt, 2H). - Methyl ester (1.50 g) was dissolved in 15 mL of a 2:1 mixture of THF/H2O. LiOH.H2O (0.95 g) was added at 0° C. The mixture was stirred between 0° C. and room temperature for 44 hours. THF was evaporated under reduced pressure and the aqueous solution was extracted with EtOAc. The aqueous layer was made acidic (pH=3) with 0.5M aqueous KHSO4 and extracted with EtOAc. Combined organic fractions were washed with 30 mL H2O, and dried (MgSO4). Solvents were evaporated under reduced pressure to give 1.32 g (92%) of the product. 1H NMR (300 MHz, CDCl3): δ 1.40 (s, 18H), 2.66 (s, 1H), 3.27-3.47 (m, 4H), 5.42 (s, 1H).
- Acid (1.01 g) was reacted at room temperature with benzyl bromide (0.45 mL) in anhydrous DMF containing Cs2CO3 (2.07 g). DMF was evaporated under reduced pressure and the residue was partitioned between H2O and EtOAc . The organic layer was washed with brine, and dried (MgSO4). Solvent was evaporated under reduced pressure and the residue purified by flash chromatography on silica gel (Hexanes/EtOAc 95:5 to 9:1 to 85:15). Yield 1.16 g (90%). 1H NMR (300 MHz, CDCl3): δ 1.42 (s, 18H), 2.79 (quint, 1H, 5.6 Hz), 3.1-3.3 (m, 2H), 3.5-3.65 (m, 2H), 5.13 (s, 2H), 5.15-5.28 (m, 1H), 7.30-7.40 (m, 5H). MS: 431.15 (M+1).
- Benzyl 3-(BOC-amino)-2-(BOC-aminomethyl)-propionate (1. 15 g) was dissolved in 5 mL 4M HCl solution in dioxane. The mixture was stirred at 0° C. for 6 hours and the dioxane was evaporated under reduced pressure. The residue was tritrated with ether and was filtered to give the unpurified diamine dihydrochloride salt (0.81 g) 1H NMR (300 MHz, MeOD): δ 3.1-3.3 (m, 5H+CHD2OD), 3.55 (s, dioxane), 5.19 (s, 2H), 5.15-5.28 (m, 1H), 7.20-7.40 (m, 5H), MS: 209.00 (M+1)
- Acid (2.00 g, 2.8 mmol, 1.5 eq.) was dissolved in 5 mL anhydrous dichloromethane. The diamine (0.26 g), HOAt (0.32 g), and diisopropylethylamine (0.65 mL) were reacted 0° C. with HATU (0.88 g) for 2 hr. Tris amine resin (0.5 g), isocyanate resin (0.5 g), and HATU (0.42 g) were added and the reaction mixture was stirred for 16 h at room temperature. The resins were filtered and the filtrate was evaporated. The residue was partitioned between H2O and EtOAc. The organic layer was washed with H2O, saturated NaHCO3, and brine (20 mL), and dried (MgSO4). Solvent was evaporated under reduced pressure. The oil was purified by flash chromatography on silica gel (Hexanes/Acetone/Et3N) and gave product (1.13 g). MS: 1607.95 (M+1) and 1629.95 (M+Na).
- Benzyl ester (0.90 g, 0.56 mmol) was dissolved in 30 mL EtOAc and Et3N (1 mL) was added. 10% Palladium catalyst on carbon (0.50 g) was added and the mixture was shaken for 15 h under 45 psi Hydrogen. The catalyst was filtered and the solvents evaporated to give the product (0.82 g). MS: 759.55 (M+2H/2)
-
- Peptide Construction: 3.39 g of the 1,3-bis-(aminomethyl)-benzene trityl NovaSyn TGT resin (measured substitution=0.59 mmol) was placed in a standard peptide column and loaded onto a Peptide Synthesizer. Synthesis was carried out using a standard Fmoc strategy. Capping was carried out after coupling the first amino acid using acetic anhydride, 6% diisopropylethylamine in DMF. When the synthesis was complete, the resin was removed from the column and placed in a reaction vessel. The resin was rinsed once with CH2Cl2 and filtered. The resin was then treated with 1% trifluoroacetic acid in CH2Cl2 and placed on a mechanical shaker for 10 minutes. The mixture was filtered through the reaction vessel and the filtrate was collected. The pH of the combined filtrate was adjusted to approximately 8 with triethylamine, and the solution was concentrated under vacuum to an oil. Following precipitation with water, the white solid was filtered and rinsed with water and diethyl ether. The solid was dried by suction filtration, taken up in DMF and diluted with acetonitrile. The solution was cooled in an ice bath and was treated with 1.5 g of thallium trifluoroacetate for 2.0 hours. The pH of the solution was adjusted with triethylamine to
pH 8 and then concentrated under vacuum. Water was added to the oil and the resulting precipitate was collected by suction filtration. The solid was washed with water and diethyl ether to give 2.7 g of crude modified peptide having a C-terminal amine functional group. An example synthesis of H2N-Leu-Pro-Cys-Asp-Tyr-Tyr-Gly-Thr-Cys-Bip-Asp-CO—NHCH2C6H4CH2NH2 (SEQ ID NO:21) was confirmed by an observed m/Z of 1792.8 [M+Na]+. The modified peptide was purified by preparative HPLC. Fractions of similar purity (98-100%) were combined and lyophilized without neutralization. - Modified peptide (3.2 g) and covalent conjugate (
Synthon # 2 above) (3.95 g) were dissolved in dichloromethane. Diisopropylethylamine was added dropwise until the pH measured 9, and diisopropylcarbodiimide (2 eq.) and HOBt (2 eq.) were added simultaneously to the mixture. After stirring 2 minutes, diisopropylethylamine was added dropwise until the pH measured 9. The mixture was stirred at room temperature for two hours. Additional pre-activated Synthon #2 (with diisopropylcarbodiimide, diisopropylethylamine, and HOBt) was added in one portion. Solvents were removed in vacuo and the residue was dissolved in ethyl acetate, which was washed sequentially with 0.1 N hydrochloric acid, saturated sodium bicarbonate, and saturated aqueous sodium chloride. The organic layer was dried over sodium sulfate, filtered, and concentrated under reduced pressure to obtain a light yellow foam (7.8 g). The foam was dissolved in dichloromethane and purified by flash chromatography (dichloromethane:methanol eluent) to provide a white solid (5.6 g). The white solid was stirred in a mixture of TFA, water, and triethylsilane (90%/5%/5%, 30 ml) at room temperature. The mixture was heated to 40° C. and stirred for 2 hours. The solution was concentrated to a volume between 3-5 ml, then cooled to room temperature. Diethyl ether was added and a white precipitate formed. The mixture was allowed to stir for 10 minutes, and the solids were collected by filtration and washed with diethyl ether. The solids were dried under vacuum providing a white solid (4.0 g). The solid was dissolved in a mixture of water: acetonitrile (20 ml, 4:1 ratio) and purified by Prep HPLC to yield a white solid, precursor MR imaging agent (1.6 g). - Precursor MR imaging agent (1 g) was reacted with one equivalent of GdCl3.6H2O in distilled deionized water with the pH adjusted to ca. 6 by the addition of 1 M NaOH. The gadolinium complex was purified by reverse phase chromatography (Waters Sep-Pak® C-18) using distilled deionized water and 50:50 (v:v) methanol:water eluent. Appropriate fractions were combined and the methanol removed under reduced pressure at 50° C. and lyophilized to give 811 mg of the MR imaging agent.
-
- Each of the following MR imaging agents was synthesized analogously to the methods described above. Peptide, prepared using standard Fmoc strategy and cyclized using thallium trifluoroacetate, was purified by HPLC and reacted with
Synthon # 2, diisopropylethylamine, diisopropylcarbodiimide (2 eq.) and HOBt (2 eq.) in dichloromethane. Solvents were removed in vacuo and the residue was dissolved in ethyl acetate, which was washed sequentially with 0.1 N hydrochloric acid, saturated sodium bicarbonate, and saturated aqueous sodium chloride. The organic layer was dried over sodium sulfate, filtered, and concentrated under reduced pressure to obtain a foam which was purified if necessary by flash chromatography or HPLC. The resulting white solid was stirred in a mixture of TFA, water, and triethylsilane (90%/5%/5%, 30 ml) at room temperature for 2-6 hours. Diethyl ether was added and a white precipitate formed, which was purified by Prep HPLC (CH3CN/H2O/AcONH4) to yield a white solid, precursor MR imaging agent. - Precursor MR imaging agent was reacted with one equivalent of GdCl3.6H2O in deionized water (
pH 6, NaOH). The gadolinium chelate was purified using reverse-phase chromatography on a Waters Sep-Pak® C-18 cartridge with water and methanol:water 50:50 eluant. Appropriate fractions were combined and the methanol removed under reduced pressure at 50° C. and lyophilized to give the desired MR imaging agent. Table 3 provides mass spectrometry data confirming each of the compounds. See the detailed description for the structure of each of the compounds.TABLE 3 MS data of Fibrin-Binding compounds Molecular MS (M + 3H)3+/3 Compound Weight calcd obsd 4 4016.884 1256.49467 1255.66 5 4025.96 1259.52 1259.9 6 4108.014 1286.87133 1284.53 7 4307.336 1353.312 1369.34 8 4076.064 1276.22133 1298.48 9 4233.208 1328.60267 1327.94 10 4221.199 1324.59967 1324.57 11 4142.146 1298.24867 1321.13 12 4123.378 1291.99267 1289.80 13 4325.675 1359.425 1333.3 14 4470.833 1407.811 1407.44 15 4363.362 1371.98733 1393.99 16 4511.483 1421.361 1444.57 17 4169.128 1307.24267 1329.85 18 4503.826 1418.80867 1419.25 19 4387.428 1380.00933 1379.12 20 4305.369 1352.65633 1351.6 21 4419.473 1390.691 1390.53 22 4277.356 1343.31867 1341.04 23 4357.829 1370.143 1370.63 24 4443.644 1398.748 1398.9 25 4448.209 1400.26967 1400.11 26 4326.731 1359.777 1359.9 27 4423.505 1392.035 1392.79 28 4343.375 1365.325 1364.7 29 4342.387 1364.99567 1364.7 30 4313.366 1355.322 1354.9 31 4342.387 1364.99567 1364.8 32 4319.303 1357.301 1357.6 - Each of the following optical contrast agents is synthesized analogously to the methods described above. Scheme X shows a general example wherein two identical optical dyes are added to the same peptide.
- 5-Caroxytetramethylrhodamine-Containing Compound (3A)
- The peptide 1 (177 mg, 0.10 mmol) and 5-carboxytetramethylrhodamine succinimidyl ester A (111 mg, 0.21 mmol) are dissolved in dichloromethane (20 mL) and DMF (20 mL). Diisopropylethylamine is added dropwise until the pH measures 9. The mixture is stirred for overnight and then the solvents are removed under reduced pressure. The residue is purified by silica-gel flash column chromatograph (eluants:dichloromethane/methanol) to give compound 2A.
- To compound 2A is added a solution of TFA, H2O and triethylsilane (ratio: 90/5/5, 5 mL). The mixture is shaken for 3 h at room temperature, and then the reaction mixture solution is poured into 50 mL of ether to precipitate the crude product. After the solvents are separated by centrifugation, the crude product is collected and then purified using reverse-phase HPLC to obtain compound 3A.
- 5-Carboxyfluorescein-Containing Compound (3B)
- In a similar procedure as described in the synthesis of 3A, 3B is synthesized using the peptide 1 (177 mg, 0.10 mmol) and 5-carboxyfluorescein succinimidyl ester B (99.4 mg, 0.21 mmol).
- Texas Red®-X-Containing Compound (3C)
- In a similar procedure as described in the synthesis of 3A, 3C is synthesized using the peptide 1 (177 mg, 0.10 mmol) and Texas Red®-X succinimidyl ester C (172 mg, 0.21 mmol).
- The extent of binding of a contrast agent according to the present invention to a target, such as HSA or fibrin, can be assessed by a variety of equilibrium binding methods. For example, binding to HSA can be measured by ultrafiltration. In a typical binding measurement using ultrafiltration, the contrast agent is mixed with 4.5% weight/volume HSA in a pH 7.4 buffer. The sample is loaded into a commercially available centrifugation apparatus equipped with a 30 kDa molecular weight cutoff filter (Millipore Ultrafree MC Low Binding
Regenerated Cellulose 30 KDa mol. wt. cutoff catalog # UFC3LTK00), permeable to the targeting group, but not to HSA. A small portion (5-10%) of the sample volume is filtered by centrifugation at 2000×g for 20 min through the cutoff filter, and the concentration of unbound targeting group in the sample is measured in the filtrate. - For measuring binding to fibrin, a fibrin clot may be formed in a well of a microtiter plate and contacted with the targeting group. After an incubation time sufficient to establish equilibrium, the supernatant is removed by aspiration (the insoluble fibrin remains bound as a gelled clot to the bottom of the well). The concentration of unbound targeting group in the supernatant is then measured.
- In both methodologies, the concentration of bound contrast agent is determined as the difference between the total targeting group concentration initially present and the unbound targeting group concentration following the binding assay. The bound fraction is the concentration of bound targeting group divided by the concentration of total targeting group.
- Affinity of contrast agents to a soluble fibrin DD(E) fragment was examined as set forth above and is reported in Table 4. The compound numbers provided in Table 4 refer to the structures set forth in the detailed description. This data in multiple determinations has an error frequency of no more than 20% in this biological assay.
TABLE 4 Affinity of Compounds for Fibrin Compound Kd, DD(E), μM 4 33 5 12 6 13 7 12 12 5.0 13 5.1 14 4.9 32 4.7 15 4.0 16 3.5 17 6.2 18 5.9 8 8.6 9 6.1 10 9.6 11 13 27 0.7 28 5.3 29 0.8 30 3.7 19 10 20 1.2 21 9.1 22 3.5 31 0.8 23 0.25 24 0.7 25 5.6 42 0.07 43 0.08 44 0.09 45 0.1 33 0.1 35 0.11 46 0.15 47 0.18 48 0.199 49 0.22 50 0.3 34 0.39 - Stability was assayed using rat liver homogenate, which contains both intra- and extracellular enzymes and represents a particularly harsh chemical environment for peptide bonds. Freshly prepared rat liver homogenate (630 μL) was placed in a glass test tube and incubated at 37° C. in a water bath for 4 minutes. To the rat liver homogenate at 37° C. was added 70 μL of a 1 mM solution of test compound. At
time points ln 2/slope. - The stability data of the below compounds was tested.
Compound 5, which has chelates at both the C- and N-termini of the peptide, had a dramatic increase in half-life resulting from resistance to exopeptidase hydrolysis. A comparable increase in half-life was not achieved through modification of one terminus with chelates, even when the other terminus was capped with an unnatural organic moiety as in, for example, compound 3 (containing a biphenyl group on the N-terminus). -
-
-
- Structure 5: half-life=65 min, both N- and C-termini conjugated to chelates.
- Surprisingly, the above data illustrate that the half-life of a peptide is most significantly increased by the addition of gadolinium chelates to both the C- and the N-termini.
- The MRI contrast agents of the present invention were evaluated for relaxivity using a Bruker NMS-120 Minispec NMR spectrometer operating at 0.47 Tesla (20 MHz H-1 Larmor frequency) and 37° C. or a Konig-Brown relaxometer (20 MHz, H-1 Larmor frequency) operating at 35° C. T1 of water protons was determined by an inversion recovery pulse sequence using the instrument's software. Relaxivity was determined by measuring the T1 of multiple solutions of the target (for example, homodisperse gels of freshly polymerized fibrinogen, 10 mg/mL) containing zero, 20, 30, and 40 μM Gd(III), respectively. The samples are incubated at 37° C. for at least 15 minutes to ensure temperature equilibration before the T1 measurement is performed. The Gd(III) content of the samples is determined by inductively coupled plasma-mass spectrometry (ICP-MS). The relaxivity (per Gd(III) ion) is determined by plotting the relaxation rate (1/T1) in s−1 versus the Gd(III) concentration in mM. The slope of a linear fit to the data gives the relaxivity. The relaxivity of the compounds in the absence of target is also determined in an analogous manner, except there is no target present.
- Compounds of the invention show increased relaxivity upon binding to fibrin (
FIG. 2 ) as compared with the relaxivity in the absence of biological target. - The uptake of a contrast agent into a thrombus (blood clot) was determined by the following method: A 600 g guinea pig (Hartley male) was anesthetized. An incision was made in the abdomen and the inferior vena cava (IVC) isolated and the vessel was allowed to recover for 10 minutes. A 1 cm portion of the IVC was clamped and human thrombin (50 μL, 4 units) was injected into the vessel to promote thrombus formation. The lower clamp was opened and closed allowing partial blood flow to the segment. After 2-3 minutes the clips were removed. The thrombus was allowed to age in the animal for 30 minutes. At this point the contrast agent, compound 32 at a dose of 2 μmol/kg and trace radiolabeled with 70 μCi of 111In, was injected via the jugular vein. Immediately following injection of
agent compound 32, a non-specific control comprising Gd(DTPA) at a dose of 2 μmol/kg mixed with 70 μCi 99mTcDTPA was injected via the jugular vein. After 30 minutes blood was drawn, the animal sacrificed, and the thrombus removed. The blood sample was weighed and counted using a Packard Cobra II gamma counter. The thrombus was also weighed and counted. Counts arising from 99mTc were detected from 128-165 keV while counts arising from the decay of 111In were detected from 390-500 keV. Control experiments with only 99mTc or 111In demonstrated radioactivity arising from 99mTc was negligible at detection energies used for 111In and vice versa. The radioactive decay data were converted to % initial dose per gram of tissue, % ID/g, and the mean of three experiments is presented graphically. Radiolabeling with 111In was performed in advance: An appropriate radiochemical amount of 111InCl3 (New England Nuclear) was added to the fibrin targeted contrast agent. The pH was adjusted to 4 by addition of 1 M HCl. The sample was heated at 45° C. for 1 hour. The pH was adjusted to neutral by addition of 1 M NaOH. The labeledagent compound 32 was >95% pure by γ-detected HPLC. - Fibrin-specific agents show a marked increase in clot uptake.
FIG. 3 shows that an agent,compound 32, is accumulating in the thrombus. There is specific clot uptake compared to 99mTcDTPA and there is a higher concentration of the agent in the thrombus than in the surrounding blood. - Specificity of clot uptake also can be demonstrated using MRI. The procedure for in vivo imaging of a thrombus with an agent is as follows: A 600 g guinea pig (Hartley male) is anesthetized. An incision is made in the throat and one of the jugular veins isolated. A 1 cm section of the jugular vein is isolated with vascular clamps. Freshly drawn blood from the animal (50 μL) is mixed with human thrombin (50 μL, 4 units) and is injected into the clamped segment of the vein. Four minutes after injection, the clamps are removed and the thrombus is allowed to age for 30 minutes. Agent,
compound 32, is injected at a dose of 6 μmol/kg and the throat area of the guinea pig is imaged at 1.5 T using a spoiled gradient method TR=36, TE=5, flip angle=30°. The thrombus appears bright relative to the blood. - A 2.5 kg female New Zealand White rabbit was anesthetized with a cocktail of Ketamine (50 mg/kg), Aceapromazine (2.5 mg/kg), and Rompon (5 mg/kg) and anesthesia maintained with sodium pentobarbital (approx. 35 mg/kg as needed). An i.v. catheter (24 g) was placed into the ear vein and the ear artery. The jugular vein and carotid artery were isolated. A stenosis was created in the carotid artery by placing an 18 g needle on top of the vessel and then suturing it into place with 3-0 suture. The needle was then removed. A 5 mm portion of the artery was then segmented off distally to the stenosis with microvascular clips. The artery was then crushed twice along the 5 mm section. The proximal vascular clip was released to allow blood flow into the section for ca. 3 sec. The clip was reapplied and artery was crushed twice again along the 5 mm section. After 4 minutes, the clips were removed. A 5 mm segment of the jugular vein was isolated with microvascular clips. A thrombus was created by injecting 100 μL of a 3.7 units of thrombin, 0.06 M CaCl2, rabbit whole blood mixture. After 4 minutes, the clips were removed.
- The thrombi were allowed to age for 50 minutes. A 1.0 mL solution of the thrombus targeted agent (Structure III, 5 mM, 2 μmol/kg) was administered via the ear vein. After 10 minutes, the animal was placed inside a General Electric Signa LxCVi 1.5 tesla scanner and a first MRI data set was obtained using a 3D RF spoiled gradient echo sequence (SPGR: TR=39 ms, TE=3.1 ms, flip angle=40 degrees, field of view=8 cm, acquisition bandwith=31.25 kH). Chemical fat saturation was applied as well as 40 mm spatial inferior and superior saturation bands. Immediately following this scan (8 minutes later), a second MRI data set was acquired using the same parameters with the addition of 40 mm spatial inferior and superior saturation bands to generate a “black blood” image.
-
FIG. 4A shows the maximum intensity projection (MIP) of the first data set. The blood vessels are partially enhanced from time of flight effects.FIG. 4B shows the MIP of the second data set where the signal from in-flowing blood was suppressed (black blood) by the use of superior and inferior saturation bands. InFIGS. 4A and 4B , the identification of the stationary target (a thrombus) through use of the targeted contrast agent is clearly facilitated. - NovaSyn TGR resin (0.20 mmol/g, 100 mg, 20 μmol) was washed with NMP/ether/NMP. The peptide was assembled by the standard solid phase method using the PyBOP/HOBt/DIEA activation. After the coupling of the final amino acid residue, the resin bound peptide was treated with a solution of piperidine in DMF (20% by volume, 2.0 mL) for 10 minutes to remove the Fmoc protecting group. The resin was washed thoroughly with NMP/ether/NMP, and was treated with a solution of fluorascein-5-isothiocyanate (23.4 mg, 60 μmol) and diisopropylethylamine (11.6 mg, 15.7 μL, 90 μmol) in DMF (1.5 mL) for 12 hours. The resin was washed thoroughly (NMP/ether/NMP), and treated with a solution of TI (TFA)3 (18.7 mg, 34.5 μmol) in DMF (1.5 mL) at 4° C. for three hours. The resin was washed after this treatment, and treated with a cocktail of TFA/TIS/water (95/2.5/2.5, 2.0 mL) for two hours. The crude peptide was precipitated by adding ether to the cleavage cocktail, and purified by preparative HPLC using a Vydac C-18 column. Structures A-N were formed in this manner and their fibrin DD(E) fragment affinities were determined (Table 5).
TABLE 5 A B C D E F G H I N M L K J Affinity of optical targeted contrast agents to fibrin. Kd (μM) ID Vs. DD(E) Fluor X1 X2 X3 X4 X5 X6 X7 X8 X9 X10 X11 X12 X13 D 0.061 Fluor Ahx W F H Hyp Y(3-I) D L H I J 0.055 Fluor Q W E P Y G L W I Q K 0.06 Fluor W F H P Y D L H I L E 0.09 Fluor Ahx G G F H Hyp Y(3-I) D L H I C 0.097 Fluor Ahx G F H Hyp Y(3-I) D L H I B 0.099 Fluor Ahx F H Hyp Y(3-I) D L H I H 0.119 Fluor K W F H Hyp Y(3-I) D L H I G 0.124 Fluor K G F H Hyp Y(3-I) D L H I I 0.127 Fluor K G G F H Hyp Y(3-I) D L H I A 0.136 Fluor beta-A F H Hyp Y(3-I) D L H I F 0.212 Fluor K F H Hyp Y(3-I) D L H I - N-terminal labeling of the peptides with optical probes can modulate the binding affinity of the optical contrast agents. For example, when comparing fluorescein, 4-methoxycoumarin and tetramethylrhodamine derivatives of the peptide (QWECPYGLCWIQ (SEQ ID NO:27); Kd=3 μM) the following Kd's were observed (Table 6):
TABLE 6 Compound Fluorophore Kd J Fluorescein 0.06 L Tetramethylrhodamine 2.0 N 4-Methoxycoumarin 0.2 - Fibrin targeted urokinase is prepared according to the following procedure. A fibrin binding peptide with a Gly-Gly dipeptide linker is prepared according to solid phase procedures. The N-terminus of the peptide is blocked with an acetyl group, and the C-terminal carboxylic acid is converted to a succinamidal active ester. Direct chemical ligation is achieved by mixing urokinase and the activated peptide in appropriate proportions in an aqueous buffer and gently agitating the solution for 30 minutes.
- Fibrin targeted urokinase can be purified by HPLC. Binding to fibrin can be assessed.
Compound 1 binds fibrin selectively versus fibrinogen. - The rabbit jugular vein model of Collen et al. (J. Clin. Invest. 1983, 71, 368-376) is used for thrombolysis assays. Compound (2 mg/kg) is administered by infusion of a bolus (consisting of 20% of the total dose) over 1 min. along with a heparin bolus (300 units/kg) over 1 min. The remainder of the dose is continuously infused over the next 60 min. and heparin (60 units/kg/hr) is continuously infused over the next 180 min. At 3 hours, the animals are sacrificed, and clots analyzed.
Compound 1 is more potent in clot lysis than scuPA alone. At 3 hr. with 2 mg/kg ofcompound 1, there is less consumption of fibrinogen and α2-antiplasmin, relative to equivalent doses of scuPA alone, demonstrating thatcompound 1 was more fibrin specific than scuPA alone. - It is to be understood that while the invention has been described in conjunction with the detailed description thereof, the foregoing description is intended to illustrate and not limit the scope of the invention, which is defined by the scope of the appended claims. Other aspects, advantages, and modifications are within the scope of the following claims.
Claims (9)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/564,648 US20070185311A1 (en) | 2001-07-30 | 2006-11-29 | Peptide-Based Multimeric Targeted Contrast Agents |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US30872101P | 2001-07-30 | 2001-07-30 | |
US10/209,183 US20030180222A1 (en) | 2001-07-30 | 2002-07-30 | Peptide-based multimeric targeted contrast agents |
US11/098,665 US7927581B2 (en) | 2001-07-30 | 2005-04-04 | Peptide-based multimeric targeted contrast agents |
US11/564,648 US20070185311A1 (en) | 2001-07-30 | 2006-11-29 | Peptide-Based Multimeric Targeted Contrast Agents |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/098,665 Continuation US7927581B2 (en) | 2001-07-30 | 2005-04-04 | Peptide-based multimeric targeted contrast agents |
Publications (1)
Publication Number | Publication Date |
---|---|
US20070185311A1 true US20070185311A1 (en) | 2007-08-09 |
Family
ID=23195121
Family Applications (5)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/209,172 Expired - Lifetime US6991775B2 (en) | 2001-07-30 | 2002-07-30 | Peptide-based multimeric targeted contrast agents |
US10/209,183 Abandoned US20030180222A1 (en) | 2001-07-30 | 2002-07-30 | Peptide-based multimeric targeted contrast agents |
US10/786,791 Expired - Lifetime US7238341B2 (en) | 2001-07-30 | 2004-02-25 | Peptide-based multimeric targeted contrast agents |
US11/098,665 Active 2025-10-11 US7927581B2 (en) | 2001-07-30 | 2005-04-04 | Peptide-based multimeric targeted contrast agents |
US11/564,648 Abandoned US20070185311A1 (en) | 2001-07-30 | 2006-11-29 | Peptide-Based Multimeric Targeted Contrast Agents |
Family Applications Before (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/209,172 Expired - Lifetime US6991775B2 (en) | 2001-07-30 | 2002-07-30 | Peptide-based multimeric targeted contrast agents |
US10/209,183 Abandoned US20030180222A1 (en) | 2001-07-30 | 2002-07-30 | Peptide-based multimeric targeted contrast agents |
US10/786,791 Expired - Lifetime US7238341B2 (en) | 2001-07-30 | 2004-02-25 | Peptide-based multimeric targeted contrast agents |
US11/098,665 Active 2025-10-11 US7927581B2 (en) | 2001-07-30 | 2005-04-04 | Peptide-based multimeric targeted contrast agents |
Country Status (23)
Country | Link |
---|---|
US (5) | US6991775B2 (en) |
EP (1) | EP1420681B1 (en) |
JP (2) | JP4298501B2 (en) |
KR (2) | KR20080100856A (en) |
CN (1) | CN1599577A (en) |
AR (1) | AR036196A1 (en) |
AU (1) | AU2002318931B2 (en) |
BR (1) | BR0211623A (en) |
CA (1) | CA2455638C (en) |
CO (1) | CO5560528A2 (en) |
EA (1) | EA006239B1 (en) |
EC (1) | ECSP044996A (en) |
HU (1) | HUP0402029A3 (en) |
IL (1) | IL160001A0 (en) |
MX (1) | MXPA04000967A (en) |
NO (1) | NO20040402L (en) |
NZ (1) | NZ531338A (en) |
PL (1) | PL368807A1 (en) |
TW (2) | TWI240632B (en) |
UA (2) | UA81226C2 (en) |
WO (1) | WO2003011115A2 (en) |
YU (1) | YU9404A (en) |
ZA (1) | ZA200401606B (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10231993B2 (en) | 2013-06-27 | 2019-03-19 | University Of Washington Through Its Center For Commercialization | Biocompatible polymeric system for targeted treatment of thrombotic and hemostatic disorders |
Families Citing this family (66)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI240632B (en) * | 2001-07-30 | 2005-10-01 | Epix Medical Inc | Purified peptides for peptide-based multimeric targeted contrast agents |
CA2461836A1 (en) * | 2001-10-16 | 2003-04-24 | Epix Medical, Inc. | Detection and treatment of intravascular lesions |
AR047692A1 (en) * | 2003-07-10 | 2006-02-08 | Epix Medical Inc | IMAGES OF STATIONARY WHITE |
JP2008508333A (en) * | 2004-08-05 | 2008-03-21 | ヨハン ウォルフガング ゲーテ−ウニベルジテート フランクフルト アム マイン | Multivalent chelators for modification and organization of target molecules |
DE102004038134B4 (en) | 2004-08-05 | 2013-07-25 | Johann Wolfgang Goethe-Universität Frankfurt am Main | Multivalent chelators for modifying and organizing target molecules, methods for their preparation and their use |
WO2006121889A2 (en) * | 2005-05-06 | 2006-11-16 | Epix Pharmaceuticals, Inc. | Chemical exchange saturation transfer contrast agents |
JP4559922B2 (en) * | 2005-06-21 | 2010-10-13 | 株式会社東芝 | Fluorescent complex and lighting device using the same |
WO2007009058A2 (en) * | 2005-07-13 | 2007-01-18 | Georgia State University Research Foundation, Inc. | Contrast agents and methods for preparing contrast agents |
KR100703593B1 (en) * | 2005-08-08 | 2007-04-06 | 경북대학교 산학협력단 | DTPA-bispicolineamideligands, Gadolinium complexes comprising DTPA-bispicolineamide ligands and method for the preparation thereof |
JP5377965B2 (en) | 2005-09-09 | 2013-12-25 | ジョージア ステート ユニバーシティ リサーチ ファウンデーション、インコーポレイテッド | Targeted contrast agents and methods for targeting contrast agents |
EP1928507B1 (en) * | 2005-09-09 | 2015-11-11 | Georgia State University Research Foundation, Inc. | Targeted contrast agents and methods for targeting contrast agents |
US8986650B2 (en) | 2005-10-07 | 2015-03-24 | Guerbet | Complex folate-NOTA-Ga68 |
EP1940841B9 (en) | 2005-10-07 | 2017-04-19 | Guerbet | Compounds comprising a biological target recognizing part, coupled to a signal part capable of complexing gallium |
WO2007044867A2 (en) * | 2005-10-11 | 2007-04-19 | Huntington Medical Research Institutes | Imaging agents and methods of use thereof |
EP2221385A3 (en) | 2005-10-28 | 2010-12-01 | Life Technologies Corporation | Deubiquination assays |
FI20055653A (en) | 2005-12-08 | 2007-06-09 | Wallac Oy | The labeling reagent |
WO2007073792A1 (en) * | 2005-12-19 | 2007-07-05 | Bayer Schering Pharma Aktiengesellschaft | Process for preparing 4,4- diphenylcyclohexanol |
US20070293656A1 (en) * | 2005-12-29 | 2007-12-20 | Epix Pharmaceuticals, Inc. | Collagen binding peptides |
EP2054514A4 (en) | 2006-08-04 | 2009-11-04 | Univ Georgia State Res Found | Enzyme sensors, methods for preparing and using such sensors, and methods of detecting protease activity |
EP2097507B1 (en) | 2006-12-14 | 2015-05-06 | Georgia State University Research Foundation, Inc. | Analyte sensors and use thereof for detecting analyte activity |
US9814672B2 (en) * | 2007-03-09 | 2017-11-14 | Susan T. Laing | Echogenic vehicle for clinical delivery of plasminogen activator and other fibrin-binding therapeutics to thrombi |
FR2914304B1 (en) | 2007-03-28 | 2012-11-16 | Guerbet Sa | COMPOUNDS FOR THE DIAGNOSIS OF DISEASES ASSOCIATED WITH EXPRESSION OF VCAM. |
FR2914303A1 (en) | 2007-03-28 | 2008-10-03 | Guerbet Sa | COMPOUNDS FOR THE DIAGNOSIS OF APOPTOSIS. |
EP2240206B1 (en) | 2008-01-08 | 2017-03-22 | Lantheus Medical Imaging, Inc. | N-alkoxyamide conjugates as imaging agents |
US20090208421A1 (en) | 2008-02-19 | 2009-08-20 | Dominique Meyer | Process for preparing a pharmaceutical formulation of contrast agents |
US20090236541A1 (en) * | 2008-03-24 | 2009-09-24 | General Electric Company | System and Methods for Optical Imaging |
WO2009146099A2 (en) | 2008-04-02 | 2009-12-03 | Georgia State University Research Foundation, Inc. | Contrast agents, methods for preparing contrast agents, and methods of imaging |
EP2328922A4 (en) * | 2008-08-07 | 2013-01-02 | Ipsen Pharma Sas | Analogues of glucose-dependent insulinotropic polypeptide |
CN102171243A (en) * | 2008-08-07 | 2011-08-31 | 益普生制药股份有限公司 | Analogues of glucose-dependent insulinotropic polypeptide (GIP) modified at N-terminal |
KR20130133104A (en) * | 2008-08-07 | 2013-12-05 | 입센 파마 에스.에이.에스 | Glucose-dependent insulinotropic polypeptide analogues |
AU2009280012B2 (en) * | 2008-08-07 | 2012-12-06 | Ipsen Pharma S.A.S. | Truncated analogues of glucose-dependent insulinotropic polypeptide |
WO2010039861A2 (en) | 2008-09-30 | 2010-04-08 | The Regents Of The University Of Michigan | Dendrimer conjugates |
US9017644B2 (en) | 2008-11-07 | 2015-04-28 | The Regents Of The University Of Michigan | Methods of treating autoimmune disorders and/or inflammatory disorders |
US8864821B2 (en) | 2008-11-26 | 2014-10-21 | Visen Medical, Inc. | Methods and compositions for identifying subjects at risk of developing stent thrombosis |
FR2942227B1 (en) | 2009-02-13 | 2011-04-15 | Guerbet Sa | USE OF BUFFERS FOR RADIONUCLEID COMPLEXATION |
EP2408790A1 (en) | 2009-03-19 | 2012-01-25 | Wyeth LLC | Methods for the preparation of [2-(8,9-dioxo-2,6-diazabicyclo[5.2.0]non-1(7)-en-2-yl)ethyl]phosphonic acid and precursors thereof |
WO2010121133A2 (en) | 2009-04-17 | 2010-10-21 | The General Hospital Corporation | Multimodal imaging of fibrin |
US8877157B2 (en) | 2009-07-08 | 2014-11-04 | Lantheus Medical Imaging, Inc. | N-alkoxyamide conjugates as imaging agents |
WO2011005609A2 (en) * | 2009-07-08 | 2011-01-13 | Mayo Foundation For Medical Education And Research | Imaging gastrointestinal volumes and motility |
US8945508B2 (en) | 2009-10-13 | 2015-02-03 | The Regents Of The University Of Michigan | Dendrimer compositions and methods of synthesis |
US8912323B2 (en) | 2009-10-30 | 2014-12-16 | The Regents Of The University Of Michigan | Multifunctional small molecules |
EP2576502B1 (en) * | 2010-06-01 | 2020-08-05 | Cytiva BioProcess R&D AB | Novel chelator and use thereof |
FR2968562B1 (en) | 2010-12-14 | 2013-01-11 | Guerbet Sa | COMPOUNDS FOR THE DIAGNOSIS OF DISEASES ASSOCIATED WITH MUC5AC EXPRESSION |
FR2968999B1 (en) | 2010-12-20 | 2013-01-04 | Guerbet Sa | CHELATE NANOEMULSION FOR MRI |
US9011816B2 (en) * | 2011-03-25 | 2015-04-21 | Case Western Reserve University | Fibronectin targeting contrast agent |
FR2980364B1 (en) | 2011-09-26 | 2018-08-31 | Guerbet | NANOEMULSIONS AND THEIR USE AS CONTRAST AGENTS |
WO2013085718A1 (en) | 2011-12-08 | 2013-06-13 | The Regents Of The University Of Michigan | Multifunctional small molecules |
FR3001154B1 (en) | 2013-01-23 | 2015-06-26 | Guerbet Sa | MAGNETO-EMULSION VECTORIZED |
US9849201B2 (en) * | 2013-05-03 | 2017-12-26 | Washington University | Homing agents |
EP3027228A4 (en) | 2013-08-01 | 2017-06-07 | Rochester Institute of Technology | Modular imaging agents containing amino acids and peptides |
US10471163B2 (en) | 2013-09-13 | 2019-11-12 | The General Hospital Corporation | Activatable fibrin-binding probes |
GB201322456D0 (en) | 2013-12-18 | 2014-02-05 | Ge Healthcare Ltd | Radiotracer compositions and methods |
WO2015196208A2 (en) | 2014-06-20 | 2015-12-23 | The General Hospital Corporation | Collagen targeted imaging probes |
AU2016258123A1 (en) * | 2015-05-06 | 2018-01-04 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Radiotherapeutic and companion imaging agents to target MC1R |
EP3101012A1 (en) | 2015-06-04 | 2016-12-07 | Bayer Pharma Aktiengesellschaft | New gadolinium chelate compounds for use in magnetic resonance imaging |
US10301358B2 (en) | 2015-06-29 | 2019-05-28 | Collagen Medical, LLC | Collagen imaging compositions |
CN114890941A (en) | 2015-08-13 | 2022-08-12 | 通用医疗公司 | Manganese-based chelate conjugates for MR molecular imaging |
KR102464647B1 (en) | 2016-11-28 | 2022-11-08 | 바이엘 파마 악티엔게젤샤프트 | High Relaxation Gadolinium Chelate Compounds for Use in Magnetic Resonance Imaging |
CN106946926A (en) * | 2017-02-27 | 2017-07-14 | 西北大学 | One kind have multiple tooth ammonia carboxylic class dimer chelating agent and preparation method thereof, using and separating medium |
CA3062538A1 (en) | 2017-05-05 | 2018-11-08 | Fusion Pharmaceuticals Inc. | Igf-1r monoclonal antibodies and uses thereof |
EP3619191A4 (en) | 2017-05-05 | 2020-12-16 | Fusion Pharmaceuticals Inc. | Pharmacokinetic enhancements of bifunctional chelates and uses thereof |
US10093741B1 (en) | 2017-05-05 | 2018-10-09 | Fusion Pharmaceuticals Inc. | IGF-1R monoclonal antibodies and uses thereof |
RU2681318C1 (en) * | 2017-11-24 | 2019-03-06 | Федеральное государственное бюджетное учреждение науки институт биоорганической химии им. академиков М.М. Шемякина и Ю.А. Овчинникова Российской академии наук (ИБХ РАН) | Method of obtaining abm-tgiris-abu immunosuppressor peptide labaled by gd3+ ion |
WO2020007822A1 (en) | 2018-07-02 | 2020-01-09 | Conservatoire National Des Arts Et Metiers (Cnam) | Bismuth metallic (0) nanoparticles, process of manufacturing and uses thereof |
CN113164628A (en) | 2018-11-23 | 2021-07-23 | 拜耳股份有限公司 | Contrast medium preparation and preparation method thereof |
CN111233714B (en) * | 2020-03-18 | 2022-04-08 | 滨海吉尔多肽有限公司 | Preparation method of MAPS polypeptide |
Citations (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4622420A (en) * | 1980-03-18 | 1986-11-11 | The Regents Of The University Of California | Chelating agents and method |
US4659839A (en) * | 1984-10-10 | 1987-04-21 | Mallinckrodt, Inc. | Coupling agents for radiolabeled antibody fragments |
US4678667A (en) * | 1985-07-02 | 1987-07-07 | 501 Regents of the University of California | Macrocyclic bifunctional chelating agents |
US4831175A (en) * | 1986-09-05 | 1989-05-16 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Backbone polysubstituted chelates for forming a metal chelate-protein conjugate |
US4880008A (en) * | 1985-05-08 | 1989-11-14 | The General Hospital Corporation | Vivo enhancement of NMR relaxivity |
US4897255A (en) * | 1985-01-14 | 1990-01-30 | Neorx Corporation | Metal radionuclide labeled proteins for diagnosis and therapy |
US5021236A (en) * | 1981-07-24 | 1991-06-04 | Schering Aktiengesellschaft | Method of enhancing NMR imaging using chelated paramagnetic ions bound to biomolecules |
US5099069A (en) * | 1986-09-05 | 1992-03-24 | Gansow Otto A | Backbone polysubstituted chelates for forming a metal chelate-protein conjugate |
US5223409A (en) * | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
US5246692A (en) * | 1986-09-05 | 1993-09-21 | The United States Of America As Represented By The Secretary Of Health And Human Services | Backbone polysubstituted chelates for forming a metal chelate-protein conjugate |
US5492892A (en) * | 1991-03-08 | 1996-02-20 | Andersen; Thomas T. | Endothelin antagonists |
US5637759A (en) * | 1992-07-30 | 1997-06-10 | The Regents Of The University Of California | Metal-ligating amino acid derivatives for MRI and for peptide synthesis |
US5641878A (en) * | 1991-05-15 | 1997-06-24 | Diatron Corporation | Porphyrin, azaporphyrin, and related fluorescent dyes free of aggregation and serum binding |
US5705143A (en) * | 1994-01-12 | 1998-01-06 | Amersham International Plc | Biological targeting agents |
US5891418A (en) * | 1995-06-07 | 1999-04-06 | Rhomed Incorporated | Peptide-metal ion pharmaceutical constructs and applications |
US6001809A (en) * | 1994-07-11 | 1999-12-14 | Elan Pharmaceuticals, Inc. | Inhibitors of leukocyte adhesion |
US6207858B1 (en) * | 1999-03-03 | 2001-03-27 | Idec Pharmaceuticals Corporation | Regioselective synthesis of DTPA derivatives |
US6342598B1 (en) * | 1998-11-26 | 2002-01-29 | Bracco International B.V. | Amphipatic polycarboxylic chelates and complexes with paramagnetic metals as MRI contrast agents |
US6517814B2 (en) * | 2001-01-09 | 2003-02-11 | Bristol-Myers Squibb Pharma Company | Macrocyclic chelants useful for metallopharmaceuticals |
US6656448B1 (en) * | 2000-02-15 | 2003-12-02 | Bristol-Myers Squibb Pharma Company | Matrix metalloproteinase inhibitors |
US6991775B2 (en) * | 2001-07-30 | 2006-01-31 | Epix Medical, Inc. | Peptide-based multimeric targeted contrast agents |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5001230A (en) | 1988-02-18 | 1991-03-19 | Schering Corporation | T cell activation markers |
GB9111199D0 (en) | 1991-05-23 | 1991-07-17 | Sandoz Ltd | Improvements in or relating to organic compounds |
US5364613A (en) * | 1989-04-07 | 1994-11-15 | Sieving Paul F | Polychelants containing macrocyclic chelant moieties |
US5009069A (en) * | 1990-08-24 | 1991-04-23 | Molini Alberto E | Method of recovering energy from ocean water |
AU683015B2 (en) | 1992-03-13 | 1997-10-30 | Diatech, Inc. | Technetium-99m labeled peptides for imaging inflammation |
ATE237342T1 (en) | 1994-07-11 | 2003-05-15 | Athena Neurosciences Inc | LEUKOCYTE ADHESION INHIBITORS |
TW319763B (en) | 1995-02-01 | 1997-11-11 | Epix Medical Inc | |
GB9502065D0 (en) | 1995-02-02 | 1995-03-22 | Nycomed Imaging As | Contrast media |
AU5752696A (en) | 1995-05-18 | 1996-11-29 | Regents Of The University Of Michigan, The | Dna binding antibodies |
DE19539409C2 (en) | 1995-10-11 | 1999-02-18 | Diagnostikforschung Inst | Contrast agent for near infrared diagnostics |
CA2232245C (en) | 1995-10-17 | 2011-06-07 | Rohm Enzyme Finland Oy | Cellulases, the genes encoding them and uses thereof |
DE122007000021I1 (en) | 1997-04-07 | 2007-05-24 | Genentech Inc | Anti-vefg Antibodies |
IT1291623B1 (en) * | 1997-04-18 | 1999-01-11 | Bracco Spa | PROCEDURE FOR CONJUGATION OF CHELANTS WITH MOLECULES CONTAINING AMINE GROUPS |
EA200200220A1 (en) | 1999-07-29 | 2002-08-29 | Эпикс Медикал, Инк. | AIMING MULTIMERAL VISUALIZING AGENTS WITH A MULTI-CUSCLE BINDING MECHANISM |
TWI290146B (en) | 1999-07-29 | 2007-11-21 | Dyax Corp | Binding moieties for fibrin |
AU780730B2 (en) | 1999-10-01 | 2005-04-14 | Angstrom Pharmaceuticals, Inc. | Diagnostic probes and therapeutics targeting uPA and uPAR |
AU2119101A (en) | 1999-10-22 | 2001-05-08 | Insight Neuroimaging Systems, Llc | Ligand chelated paramagnetic mri contrast agents |
EP1251876A2 (en) * | 2000-01-22 | 2002-10-30 | Epix Medical, Inc. | Magnetic resonance imaging using contrast agents prodrugs bioactivated by enzymatic cleavage |
-
2002
- 2002-07-29 TW TW091116938A patent/TWI240632B/en active
- 2002-07-29 TW TW093136632A patent/TWI284539B/en not_active IP Right Cessation
- 2002-07-30 UA UA2004010709A patent/UA81226C2/en unknown
- 2002-07-30 UA UAA200601920A patent/UA84432C2/en unknown
- 2002-07-30 HU HU0402029A patent/HUP0402029A3/en unknown
- 2002-07-30 EP EP02750374.7A patent/EP1420681B1/en not_active Expired - Lifetime
- 2002-07-30 KR KR1020087026503A patent/KR20080100856A/en active IP Right Grant
- 2002-07-30 IL IL16000102A patent/IL160001A0/en unknown
- 2002-07-30 JP JP2003516355A patent/JP4298501B2/en not_active Expired - Fee Related
- 2002-07-30 EA EA200400241A patent/EA006239B1/en not_active IP Right Cessation
- 2002-07-30 PL PL02368807A patent/PL368807A1/en not_active Application Discontinuation
- 2002-07-30 CA CA2455638A patent/CA2455638C/en not_active Expired - Lifetime
- 2002-07-30 WO PCT/US2002/024261 patent/WO2003011115A2/en active Application Filing
- 2002-07-30 CN CNA028192559A patent/CN1599577A/en active Pending
- 2002-07-30 AR ARP020102880A patent/AR036196A1/en unknown
- 2002-07-30 US US10/209,172 patent/US6991775B2/en not_active Expired - Lifetime
- 2002-07-30 AU AU2002318931A patent/AU2002318931B2/en not_active Ceased
- 2002-07-30 NZ NZ531338A patent/NZ531338A/en not_active IP Right Cessation
- 2002-07-30 MX MXPA04000967A patent/MXPA04000967A/en unknown
- 2002-07-30 YU YU9404A patent/YU9404A/en unknown
- 2002-07-30 BR BR0211623-5A patent/BR0211623A/en not_active IP Right Cessation
- 2002-07-30 US US10/209,183 patent/US20030180222A1/en not_active Abandoned
- 2002-07-30 KR KR10-2004-7001314A patent/KR20040020074A/en active IP Right Grant
-
2004
- 2004-01-29 NO NO20040402A patent/NO20040402L/en not_active Application Discontinuation
- 2004-02-20 CO CO04015097A patent/CO5560528A2/en not_active Application Discontinuation
- 2004-02-25 US US10/786,791 patent/US7238341B2/en not_active Expired - Lifetime
- 2004-02-26 ZA ZA200401606A patent/ZA200401606B/en unknown
- 2004-02-27 EC EC2004004996A patent/ECSP044996A/en unknown
-
2005
- 2005-04-04 US US11/098,665 patent/US7927581B2/en active Active
- 2005-07-27 JP JP2005218096A patent/JP2005314438A/en active Pending
-
2006
- 2006-11-29 US US11/564,648 patent/US20070185311A1/en not_active Abandoned
Patent Citations (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4622420A (en) * | 1980-03-18 | 1986-11-11 | The Regents Of The University Of California | Chelating agents and method |
US5021236A (en) * | 1981-07-24 | 1991-06-04 | Schering Aktiengesellschaft | Method of enhancing NMR imaging using chelated paramagnetic ions bound to biomolecules |
US4659839A (en) * | 1984-10-10 | 1987-04-21 | Mallinckrodt, Inc. | Coupling agents for radiolabeled antibody fragments |
US4897255A (en) * | 1985-01-14 | 1990-01-30 | Neorx Corporation | Metal radionuclide labeled proteins for diagnosis and therapy |
US4880008A (en) * | 1985-05-08 | 1989-11-14 | The General Hospital Corporation | Vivo enhancement of NMR relaxivity |
US4678667A (en) * | 1985-07-02 | 1987-07-07 | 501 Regents of the University of California | Macrocyclic bifunctional chelating agents |
US4831175A (en) * | 1986-09-05 | 1989-05-16 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Backbone polysubstituted chelates for forming a metal chelate-protein conjugate |
US5099069A (en) * | 1986-09-05 | 1992-03-24 | Gansow Otto A | Backbone polysubstituted chelates for forming a metal chelate-protein conjugate |
US5246692A (en) * | 1986-09-05 | 1993-09-21 | The United States Of America As Represented By The Secretary Of Health And Human Services | Backbone polysubstituted chelates for forming a metal chelate-protein conjugate |
US5223409A (en) * | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
US5492892A (en) * | 1991-03-08 | 1996-02-20 | Andersen; Thomas T. | Endothelin antagonists |
US5641878A (en) * | 1991-05-15 | 1997-06-24 | Diatron Corporation | Porphyrin, azaporphyrin, and related fluorescent dyes free of aggregation and serum binding |
US5637759A (en) * | 1992-07-30 | 1997-06-10 | The Regents Of The University Of California | Metal-ligating amino acid derivatives for MRI and for peptide synthesis |
US5705143A (en) * | 1994-01-12 | 1998-01-06 | Amersham International Plc | Biological targeting agents |
US6001809A (en) * | 1994-07-11 | 1999-12-14 | Elan Pharmaceuticals, Inc. | Inhibitors of leukocyte adhesion |
US5891418A (en) * | 1995-06-07 | 1999-04-06 | Rhomed Incorporated | Peptide-metal ion pharmaceutical constructs and applications |
US6342598B1 (en) * | 1998-11-26 | 2002-01-29 | Bracco International B.V. | Amphipatic polycarboxylic chelates and complexes with paramagnetic metals as MRI contrast agents |
US6652834B2 (en) * | 1998-11-26 | 2003-11-25 | Bracco International B.V. | Amphipatic polycarboxylic chelates and complexes with paramagnetic metals as MRI contrast agents |
US6207858B1 (en) * | 1999-03-03 | 2001-03-27 | Idec Pharmaceuticals Corporation | Regioselective synthesis of DTPA derivatives |
US6656448B1 (en) * | 2000-02-15 | 2003-12-02 | Bristol-Myers Squibb Pharma Company | Matrix metalloproteinase inhibitors |
US6517814B2 (en) * | 2001-01-09 | 2003-02-11 | Bristol-Myers Squibb Pharma Company | Macrocyclic chelants useful for metallopharmaceuticals |
US6991775B2 (en) * | 2001-07-30 | 2006-01-31 | Epix Medical, Inc. | Peptide-based multimeric targeted contrast agents |
US7238341B2 (en) * | 2001-07-30 | 2007-07-03 | Epix Pharmaceuticals, Inc. | Peptide-based multimeric targeted contrast agents |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10231993B2 (en) | 2013-06-27 | 2019-03-19 | University Of Washington Through Its Center For Commercialization | Biocompatible polymeric system for targeted treatment of thrombotic and hemostatic disorders |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6991775B2 (en) | Peptide-based multimeric targeted contrast agents | |
AU2002318931A1 (en) | Peptide-based multimeric targeted contrast agents | |
US8048906B2 (en) | Optically pure and enriched isomers of chelating ligands and contrast agents | |
US20070014725A1 (en) | Conjugates of macrocyclic metal complexes with biomolecules and their use for the production of agents for NMR diagnosis and radiodiagnosis as well as radiotherapy | |
US9127130B2 (en) | Polylysine dendrimer contrast agent | |
US7164016B2 (en) | Macrocyclic metal complexes and their use for the production of conjugates with biomolecules | |
JP2003505519A (en) | Targeting multimeric imaging agents through multidentate binding | |
JP2003520255A (en) | Magnetic resonance imaging using contrast agent prodrugs that are bioactivated by enzymatic cleavage | |
US20050201943A1 (en) | Magnetic resonance imaging using contrast agents bioactivated by enzymatic cleavage | |
Pierri et al. | Advances in MRI: Peptide and peptidomimetic‐based contrast agents | |
AU2008201709A1 (en) | Peptide-based Multimeric Targeted Contrast Agents |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: EPIX PHARMACEUTICALS, INC., MASSACHUSETTS Free format text: RELEASE BY SECURED PARTY;ASSIGNOR:SCHERING AKTIENGESELLSCHAFT;REEL/FRAME:022656/0569 Effective date: 20060104 Owner name: EPIX PHARMACEUTICALS, INC., MASSACHUSETTS Free format text: CHANGE OF NAME;ASSIGNOR:EPIX MEDICAL, INC.;REEL/FRAME:022660/0712 Effective date: 20040907 Owner name: SCHERING AKTIENGESELLSCHAFT, GERMANY Free format text: SECURITY AGREEMENT;ASSIGNOR:EPIX MEDICAL, INC.;REEL/FRAME:022660/0692 Effective date: 20030521 Owner name: EPIX MEDICAL, INC., MASSACHUSETTS Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:ZHANG, ZHAODA;AMEDIO, JOHN C.;CARAVAN, PETER D.;AND OTHERS;REEL/FRAME:022656/0490;SIGNING DATES FROM 20020830 TO 20020917 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO PAY ISSUE FEE |